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ABSTRACT
The presence of inhibitory molecules is believed to contribute to the failure of axonal 
regeneration in the adult mammalian CNS. This thesis is focussed on the role of the 
Nogo-66 receptor (NgR), and its ligands, in preventing axonal regeneration, and the use 
of genetically modified herpes simplex virus type-1 (HSV-1) for the disruption of these 
interactions.
The expression of ngr, nogo-66 (i.e. pan-no go), nogo-a and omgp mRNA in the intact 
and injured adult rodent nervous system has been examined by in situ hybridisation. 
Nogo-A expression was investigated by immunohistochemistry. The most significant 
findings were that, although cerebral cortical neurons strongly express ngr, many other 
neurons do not express ngr mRNA; indeed, ngr transcripts were absent from the corpus 
striatum and weakly expressed, if at all, by most spinal cord neurons and most primary 
sensory neurons. In contrast, nogo isoforms were expressed by many types of neuron in 
the CNS and PNS. Nogo-A protein was found to be prominently expressed in growing 
and regenerating axons. It is therefore unlikely that NgR/Nogo interactions can explain 
the general failure of axonal regeneration in the CNS.
Several genetically modified HSV-1 vectors were constructed for the disruption of the 
NgR-ligand interactions. The first of these was constructed for the expression of a 
tagged-secreted form of the NgR antagonist peptide (NEP1-40); but, this was found to 
express poorly both in vitro and in vivo. Additionally, a system for the expression of 
functional shRNA from HSV-1 is reported. As a proof of principle, eGFP expression 
was successfully targeted in a cell line in vitro. Similarly, NgR was also targeted in 
primary cultures of cerebellar granule cells in vitro, but with less effect.
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CHAPTER 1
Introduction
Injured central nervous system (CNS) neurons of some lower vertebrates exhibit a strong 
propensity for regeneration (reviewed by Ferretti et al., 2003), often giving rise to target 
reinnervation and clear functional recovery. In contrast, within the mammalian nervous 
system, only neurons of the peripheral nervous system (PNS) display a clinically useful 
capacity for regeneration and functional restitution. That injured adult mammalian CNS 
neurons demonstrate, at best, an abortive regenerative response is suggestive of an 
evolutionary loss of the capability to recover function after CNS injuries.
There are several hypotheses which currently seek to explain the abortive regenerative 
response that occurs following injury to the mammalian CNS: the intrinsic regenerative 
ability of mature CNS neurons may not be sufficiently strong to allow prolonged axonal 
regeneration (Richardson and Verge, 1986; Chong et al., 1996; Anderson and Lieberman, 
1999); the injured CNS may be deficient in a number of important neurotrophic 
molecules (Berry et al., 1996; Zhang et al., 1998; Bradbury et al., 1999); or, molecules 
inhibitory to axonal regeneration may be present after injury to the CNS (Pasterkamp et 
al., 1999; reviewed by Fawcett and Asher, 1999), or in the intact CNS, especially in 
myelin (reviewed by Schwab, 1996).
AXONAL REGENERATION 
PNS Axonal Regeneration
Neurons which extend axons peripherally have long been known to launch a sustained 
regenerative response to injury. Clinically, this often results in some degree of functional 
recovery, dependent on the severity and nature of the lesion. Nonetheless, this innate 
regenerative process is not entirely without complications, since regenerating axons can
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make pathfinding errors resulting in the incorrect innervation of targets which may, for 
example, manifest in clinical symptoms such as neuropathic pain.
The sequence of events that occurs after axotomy of the peripheral processes of dorsal 
root ganglia (DRG) neurons, or the axons of extrinsic CNS neurons (e.g. ventral spinal 
motor neurons), is well documented. Immediately after axotomy, Wallerian degeneration 
commences (Waller, 1850); this entails the degeneration of the severed distal axons and 
their myelin sheaths, which are phagocytosed by both Schwann cells and macrophages. 
As the axonal and myelin debris is eliminated by this process, the Schwann cells begin to 
proliferate and extend processes longitudinally through the channels formed by columns 
of Schwann cells, known as the bands of Biingner. All axonal regeneration within the 
distal segment of injured nerves occurs through these columns. Schwann cells aid the 
process of axonal regeneration through the synthesis of trophic molecules and membrane- 
bound cell adhesion molecules, such as N-CAM, LI and CHL1 (Nieke and Schachner, 
1985; Tacke and Martini, 1990). Other molecules that have been implicated in the 
process of peripheral axonal regeneration as permissive or stimulatory molecular cues 
include laminin and tenascin-C, both of which are synthesized by Schwann cells and are 
embedded in the basal lamina as extracellular matrix molecules (Salonen et al., 1987; 
Martini et al., 1990). At lesion sites in peripheral nerves Schwann cells act to heal the 
wound, migrating from both proximal and distal stumps to bridge any deficit (Ramon Y 
Cajal, 1928). This is in marked contrast to the behaviour of CNS glia at injury sites 
which are characterized by the loss of astrocytes and oligodendrocytes (Berry et al., 
1999).
CNS Axonal Regeneration
In contrast to the robust axonal regenerative response of axotomized PNS neurons, there 
is at best an abortive regenerative response to mechanical injury by intrinsic CNS 
neurons. The most effective regenerative response by axons in CNS tissue is found in the 
optic nerve and optic tract where a few axons can regenerate a few millimetres beyond 
injury sites (Harvey and Tan, 1992; Campbell et al., 1999), although they never 
regenerate back to their targets in the brain.
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Autologous Nerve Grafts for the Enhancement of CNS Axonal Regeneration
Although almost all intrinsic CNS neurons fail to regenerate after axotomy when left 
untreated, many subclasses exhibit the ability to extend axons if provided with a suitably 
permissive environment. This was first observed by Ramon Y Cajal, and his student 
Tello, following the implantation of a segment of peripheral nerve to the cerebrum. They 
found that axons were often present in the grafted nerve, but were unable to prove to the 
satisfaction of critics that these were derived from CNS neurons. The suspicion that CNS 
axons could regenerate was finally confirmed in a landmark series of experiments 
(Richardson et al., 1980; Benfey and Aguayo, 1982). Using novel retrograde labelling 
techniques to trace the source of axons that had regenerated into peripheral nerve grafts, 
they were able to show definitively that many classes of intrinsic neuron were able to 
grow their axons through the permissive environment provided by the peripheral nerve. 
However, since they had implanted the segments of peripheral nerve in brain or spinal 
cord, there was some suggestion that the CNS axons invading the grafts may not have 
been regenerating axons per se, but collateral sprouts from intact CNS axons. The latter 
was disproved when Berry and colleagues reported that retinal ganglion cells (RGCs) 
were able to regenerate their axons from severed optic nerve into a contiguous peripheral 
nerve graft (Berry et al., 1986). However, the grafting of a segment of peripheral nerve, 
depleted of viable cells by repeated freeze-thaw cycles, to transected optic nerve was 
found to elicit no axonal ingrowth from injured retinal ganglion cells (Berry et al., 1988). 
Presumably, Schwann cells in the Bands of Biingner of peripheral nerve, with which in­
growing axons closely associate (Hall and Berry, 1989), provide an essential stimulus for 
regeneration. However, this alone does not explain why some classes of CNS neuron are 
unable to regenerate axons, even in apparently permissive environments. Purkinje cells 
and corticospinal neurons are just two examples of types of neuron that have consistently 
been found to be refractory to regeneration into environments containing Schwann cells 
(Richardson et al., 1982; Chaisuksunt et al., 2003).
Since peripheral nerves are also composed of other cells - including fibroblasts, 
macrophages and endothelial cells - that might have been contributing to the effect of 
peripheral nerve grafts on the regeneration of CNS axons, some groups examined the
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effects of transplanting purified Schwann cells to the injured CNS (Kromer and 
Combrooks, 1985; Paino and Bunge, 1991; Montero-Menei et al., 1992; Martin et al.,
1996). For the most part, these have shown that suspensions of purified Schwann cells 
administered to the vicinity of axotomized CNS neurons do promote some degree of 
axonal regeneration.
The Enhancement of CNS Axonal Regeneration by Other Types of Cell
Olfactory Ensheathing Glial Cells (OEGCs)
In addition to the Schwann cell, another class of cell that has received much attention in 
recent years for its apparent ability to stimulate axonal regeneration of CNS neurons is 
the olfactory ensheathing glial cell (OEGC). This class of cell is responsible for 
ensheathing the axons of olfactory receptor neurons, which are generated throughout life 
and possess an unusual ability to both grow and regenerate their axons into the CNS 
environment of the olfactory bulb and form functional synapses.
p75NTR immunoaffmity-purified cultures of OEGCs were first transplanted to the injured 
nervous system by Ramon-Cueto and Nieto-Sampedro (1994), who implanted them into 
the dorsal horn of the spinal cord at the level of a dorsal rhizotomy. They reported that 
DRG axons, as detected by Dil labelling and calcitonin gene-related peptide (CGRP) 
immunoreactivity, regenerated through laminae 1-5 of the ipsilateral dorsal horn. A 
series of experiments followed, in which different groups attempted to harness these cells 
for the repair of spinal cord and brain injuries. However, whilst some impressive claims 
have been made (reviewed by Raisman, 2001), other groups have failed to demonstrate 
extensive axonal regeneration into, or within, the CNS after grafting of olfactory 
ensheathing glial cells (Gomez et al., 2003; Riddell et al., 2004). The consensus finding 
is that these cells seem to be, at best, of moderate value in promoting axonal regeneration 
from the corticospinal tracts and are less effective in other systems, although they do 
have a clear, though limited effect on optic nerve regeneration (Li et al., 2003). In the 
spinal cord, at least one group has found Schwann cells to be more effective in eliciting 
regeneration of injured tracts (Takami et al., 2002), although there is some evidence that
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OEGCs may be able to stimulate functional recovery by other means (Ramer et al., 
2004).
The Cell Body Response of Injured PNS and CNS Neurons
Over the past two decades, it has become clear that the expression of certain proteins is 
important for a sustained axonal regenerative response by neurons. The genes encoding 
these proteins have become known as regeneration/growth associated genes and include 
c-jurt, atf3, and gap-43 which are discussed later. There are many other regeneration 
associated genes and intrinsic determinants of axonal regeneration which are not 
addressed here (for review see Caroni, (1997), and for an example of the complexity of 
the response as revealed by microarray analysis see Costigan et al., (2002).
Most of the neuronal perikarya which are induced to regenerate axons into peripheral 
nerve grafts in the CNS are found close to the tip of the graft (Richardson et al., 1980). 
This illustrates an interesting phenomenon -  that axons are better able to regenerate after 
proximal injury than a distal injury, although the likelihood of cell death also increases 
with a proximal axotomy. The distance between cell body and point of axotomy is 
inversely correlated with the induction of expression of regeneration associated genes in 
some classes of neuron. This was first observed in a model of optic nerve transection, in 
which the GAP-43 was only found to be expressed in the retinal ganglion cell layer if the 
lesion was within 3mm of the eye (Doster et al., 1991). Similarly, it has been found that 
regeneration associated genes are strongly upregulated by rubrospinal neurons following 
cervical, but not thoracic, lesions of the rubrospinal tract (Fernandes et al., 1999). The 
notion that the neuronal cell body response to axotomy should vary according to the 
proximity of the axonal lesion to the cell body is somewhat unexpected. However, it may 
be the result of the cumulative input of inhibitory cues from the CNS environment along 
the proximal stump (Zagrebelsky et al., 1998). An alternative argument is that the 
neurons may be maintained in an inert state by the presence of intact collaterals, which 
are more likely to be preserved by a distal axotomy.
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Evaluation of the expression profiles of different subclasses of CNS neurons following 
peripheral nerve graft revealed that those neurons that are unable to regenerate their 
axons, such as Purkinje cells, do not initiate the same robust cell body response to injury 
as those CNS neurons that are able to extend their axons into grafted peripheral nerve 
(Anderson et al., 1998). This is a crucial discovery since it implies that there exists a 
variable degree of inherent neuronal potential for regeneration after injury.
Regeneration Associated Gene Expression in Neurons
For successful axonal regeneration to occur, injured neurons must survive the initial 
insult in sufficient numbers, sprout neurites and subsequently extend axons over long 
distances towards their original target. The expression of the regeneration associated 
genes by axotomized neurons, particularly those with proximal injuries, has been 
reported to be detrimental to cell survival. Overexpression of GAP-43 by motor neurons 
enhances their chances of undergoing cell death in response to peripheral nerve injury 
(Harding et al., 1999). Similarly, c-Jun has been implicated in apoptotic neuronal cell 
death (Ham et al., 1995). Those neurons that appear to be inherently incapable of 
regeneration, e.g. Purkinje cells and corticospinal neurons, and do not upregulate 
regeneration associated genes appear to be resistant (although not immune) to cell death 
after axotomy. In contrast, those subtypes of neuron which appear to be programmed to 
launch a regenerative response after injury, e.g. retinal ganglion cells, exhibit a high rate 
of apoptotic cell death (Villegas-Perez et al., 1993; Berkelaar et al., 1994; Garcia- 
Valenzuela et al., 1994).
c-Jun
C-Jun is a transcription factor that is expressed by many different cell-types, and can 
dimerise either with itself to form homodimers or with other proteins such as JunB, JunD, 
c-Fos or CREB/ATF family members, amongst others, to form heterodimers. Any of 
these dimers constitute an AP-1 transcription factor complex which recognizes the 
consensus sequence TGACTCA (Lee et al., 1987). The c-Jun N-terminal kinase (JNK), a 
member of the MAP kinase superfamily, regulates the activity of c-Jun through the 
phosphorylation of two serine residues within the amino terminal of the protein. In the
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nervous system, c-Jun has been implicated in the cellular response to axotomy, as well as 
the processes of axonal regeneration and apoptosis.
C-Jun is widely expressed throughout the brain during early embryonic development, and 
its expression has been reported to decrease with cellular maturation and differentiation. 
In the adult, basal levels of c-Jun expression persist in many classes of neuron throughout 
the CNS and PNS including spinal motor neurons, neurons of autonomic ganglia and 
DRG neurons (Herdegen et al., 1991; Herdegen et al., 1995; de Leon et al., 1995).
Upregulation of c-Jun expression is readily detected in motor and sensory neurons, after 
peripheral nerve injury (Jenkins and Hunt, 1991), and persists until target-tissue 
reinnervation occurs. This is accompanied by increased JNK activity, which results in 
the phosphorylation and activation of c-Jun (Kenney and Kocsis, 1998). Interestingly, 
Schwann cells in the denervated distal stump also upregulate c-Jun; this is thought to 
occur as a consequence of the loss of axonal contact, since the onset of c-Jun expression 
coincides with the commencement of Wallerian degeneration. In addition, expression 
has been reported to subside with the invasion of regenerating axons (Shy et al., 1996; 
Soares et al., 2001). There has been some suggestion that transforming growth factor 
beta (TGFJ3) may induce phosphorylation of c-Jun in Schwann cells leading to the 
initiation of apoptotic pathways, after nerve injury (Parkinson et al., 2001).
A null mutation of the c-jun gene locus results in an embryonic lethal phenotype in 
homozygous transgenic mice, with most embryos dying at E l2.5. Despite the -/- 
transgenic embryos being grossly anatomically and histologically normal, primary 
cultures of -/- transgenic fibroblasts were found to proliferate considerably more slowly 
than those of wildtype embryos and, furthermore, were found to be less responsive to the 
effects of mitogens (Johnson et al., 1993); together, these findings implicate c-Jun in both 
cell survival and mitogen response pathways. That these knockout animals should die in 
utero has proved a hindrance for regeneration studies; however, Raivich et al. (2004) 
have developed a conditional c-jun null mutant, in which it has been demonstrated that 
peripheral nerve regeneration is impaired. The level of GAP-43 upregulation in
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peripherally axotomized neurons in these transgenic mice was also revealed to be 
considerably lower than in wild-type mice.
In general terms, the upregulation of c-Jun by axotomized intrinsic CNS neurons 
correlates well with their capacity for regeneration of axons into segments of peripheral 
nerve grafted to brain. For example, neurons of the thalamic reticular nucleus and the 
deep cerebellar nuclei which successfully extend axons into peripheral nerve grafts, are 
known to up-regulate c-Jun for prolonged periods (Vaudano et al., 1998; Chaisuksunt et 
al., 2000a). Classes of neuron which fail to regenerate axons into the graft exhibit only 
brief expression of c-Jun. The only neurons which prove to be an exception to this trend 
are those of the substantia nigra pars compacta which, despite successfully regenerating 
axons into nerve grafts to striatum, show only modest signs of c-Jun expression 
(Chaisuksunt et al., 2003). In summary, although many intrinsic CNS neurons that 
regenerate their axons into peripheral nerve grafts show a prolonged upregulation of c- 
Jun, there are some successfully regenerating intrinsic neurons that do not, and some non­
regenerating cells that transiently upregulate c-Jun after injury.
Activated Transcription Factor 3 (ATF3)
ATF3 belongs to the ATF/CREB family of basic-region leucine zipper (bZip)-containing 
transcription factors and can either homodimerise to form complexes that bind ATF/CRE 
consensus TGACGTCA DNA sequence to suppress transcription, or can form 
heterodimers with other members of the ATF/CREB family to form complexes that 
stimulate transcription (reviewed by Hai et al., (1999); Hai and Hartman, (2001)). It has 
been reported that ATF3 can heterodimerise with c-Jun to form a transcription factor 
complex capable of binding the AP-1 consensus sequence (Hai and Curran, 1991), which 
is perhaps not surprising given the homology of their consensus DNA binding sites. The 
upregulation of ATF3 by primary sensory neurons and spinal motor neurons after 
peripheral nerve axotomy is more widespread than that of c-Jun, and correlates even 
better with retrograde labelling than does c-Jun. Tsujino et al. (2000) have suggested that 
ATF3 should be regarded as a neuron-specific marker of injury in the nervous system.
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This, however, is in disagreement with more recent findings (see Chapter 5; Hunt et al., 
2004).
Both c-Jun and ATF3 have been found to be upregulated by all classes of axotomized 
peripheral neurons in which they have been studied. Among intrinsic CNS neurons, there 
are variable patterns of ATF3 expression following axotomy; in general, CNS neurons 
that can successfully regenerate their axons into peripheral nerve grafts, upregulate 
ATF3. As with other regeneration associated genes, ATF3 expression by neurons is 
critically dependent on the site of axotomy. For example, corticospinal neurons 
upregulate ATF3 and c-Jun after intracortical axotomy, but not after axotomy within the 
spinal cord (Mason et al., 2003; Chaisuksunt et al., 2003). The downstream targets of 
ATF3 are for the most part yet to be identified.
Growth-Associated Protein 43 (GAP-43)
Although the neuronal expression of GAP-43 in response to axotomy and the capacity to 
regenerate axons in a permissive environment are not perfectly correlated, no neurons 
have been found to regenerate their axons in vivo without expressing GAP-43. That 
some neurons should upregulate GAP-43 and yet fail to regenerate their axons in a 
permissive environment is probably an indication of an intrinsic deficiency of other 
regeneration associated molecules. Currently, it is the best molecular marker of 
regenerating axons.
GAP-43 is a 43KDa growth associated protein that has been identified as being important 
in both neurite outgrowth (Skene and Willard, 1981) and synaptic plasticity (Routtenberg 
and Lovinger, 1985). It is a membrane- and cytoskeleton-associated molecule that 
localizes to the growth cone during neurite outgrowth, and is thought to participate in 
signal transduction, initiated by axon guidance molecules, which culminate in 
cytoskeletal rearrangements. It is strongly expressed by neurons during development and 
regeneration, and diminishes upon target (re-)innervation (reviewed by Benowitz and 
Routtenberg, 1997). However, it is also detected in presynaptic nerve terminals and 
remains present at low levels throughout adulthood in some classes of neuron that are
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particularly plastic, implying that it is perhaps multifunctional. Interestingly, the gap-43 
promoter sequence contains an AP-1 binding site (Weber and Skene, 1998), suggesting 
that the high-level of gap-43 mRNA detected in many injured neurons may be the result 
of c-Jun transcription factor binding activity, perhaps in conjunction with ATF3.
A number of in vitro studies of GAP-43 function have been reported, most of which 
support the notion that the molecule is important for neurite outgrowth. Targeting the 
protein, Shea et al. (1991) incubated a neuroblastoma cell line with anti-GAP-43 
antibodies, and observed a significant reduction in neurite formation. The PC 12 cell line, 
derived from rat phaeochromocytoma, which upregulates GAP-43 in response to NGF 
and subsequently differentiates and extends axons (Kams et al., 1987; Federoff et al., 
1988), has been used as a model by several groups for assessing the role of GAP-43 in 
neurite elongation. Using antisense oligonucleotides to gap-43 mRNA, Jap Tjoen et al. 
(1992) found neurite outgrowth to be impaired, which was in keeping with an earlier 
study in which GAP-43 overexpression in PC 12 cells was found to result in greater 
neurite extension (Yankner et al., 1990). However, others have reported that a mutant 
PC 12 cell line, deficient in GAP-43, was still able to extend neurites in response to NGF 
and have proposed that its role is not in the initial process of sprouting but the function of 
growth cones and the presynaptic terminal (Baetge and Hammang, 1991). In contrast, 
Aigner and Caroni (1993, 1995), who also used antisense oligonucleotides, observed 
fewer neurites sprouting from primary cultures of chick DRG neurons, and reported that 
the few attendant neurites bore smaller growth cones were more susceptible to retraction 
when presented with inhibitory central nervous system myelin-derived liposomes.
Two strains of gap-43 null mutant mice have been generated (Strittmatter et al., 1995; 
Zhu and Julien, 1999), both of which exhibit similar and significant aberrations in axonal 
pathfmding within the visual system. In the first strain, it was found that only a few 
axons traversed the optic chiasm, and that these had done so randomly. In the second 
strain, axons failed to form synaptic contacts in the lateral geniculate nuclei. Also, in this 
strain, the anterior and hippocampal commissures, as well as the corpus callosum were 
reported absent (Shen et al., 2002). There have been no reports of regeneration
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experiments undertaken on either of these gap-43 null mutant mice, presumably because 
they die within a few weeks of birth. Nonetheless, what these models have revealed is 
that GAP-43 alone is not critical for axonal outgrowth from all classes of neuron but that 
it is also likely to be involved in axon guidance/growth cone motility.
Although, there have been no reports of the state of regeneration in gap-43 knockout 
animals, Caroni and colleagues developed a GAP-43 dominant negative and subsequently 
generated a transgenic animal in which this mutant protein was overexpressed within the 
nervous system (Laux et al., 2000). The rate of regeneration of axotomized peripheral 
nerves was found to be impaired, although complete regeneration and re-innervation of 
target tissues was observed. Conversely, overexpression of GAP-43 in the nervous 
system, results in spontaneous sprouting of neurites at the neuromuscular junction, as 
well as significantly more sprouting of neurites and terminal arborisation following 
axotomy (Aigner et al., 1995).
In wild-type animals, in vivo experiments have revealed a clear correlation between 
upregulation and the duration of GAP-43 expression and the capacity to regenerate axons 
into peripheral nerve grafts in the brain (Vaudano et al., 1995). Those neurons which had 
successfully regenerated axons into the graft -  primarily residing in the thalamic reticular 
nucleus - exhibited prolonged expression of gap-43, compared to those that had failed to 
regenerate. Similarly, neurons of the deep cerebellar nuclei which also successfully 
regenerated axons into grafts to cerebellum showed prolonged expression of gap-43 in 
contrast to those that did not. Purkinje cells, which have never been shown to regenerate 
their axons into nerve grafts, do not even transiently upregulate gap-43 transcript 
expression (Anderson et al., 1998)). However, overexpression of GAP-43 in transgenic 
mice is not sufficient to turn non-regenerating neurons into cells which can regenerate 
axons into peripheral nerve grafts (Buffo et al., 1997; Mason et al., 2000).
Scar and Cavity Formation in the Injured Mammalian CNS
Traumatic CNS lesions result in scarring, which is often accompanied by cavity or cyst 
formation, at the site of injury. These readily discernible physical features were long ago
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recognized as potential physical barriers to axonal regeneration. Subsequent histological 
studies of the scar revealed that one of the defining characteristics of CNS injury sites is 
the presence around the lesion site of hypertrophic glial-fibrillary acidic protein (GFAP) 
immunopositive astrocytes, termed reactive astrocytes (Berry et al., 1996; Zhang et al.,
1997).
Astrocytes
The primary function of reactive astrocytes appears to be in the sealing of the wound 
through their formation of an encapsulating glia limitans (reviewed by Reier and Houle, 
1988). At first, it was thought that the mature scar in which astrocytic processes are 
tightly interwoven was, in itself, a physical deterrent to regenerating axons. However, it 
was noted that frog RGC axons were able to penetrate dense astrocytic scars, indicating 
that the failure of mammalian neurons to do so was probably the result of differences in 
the molecular phenotype of their astrocytes (Reier et al., 1983). Much research has since 
been undertaken to establish if and how reactive astrocytes may participate in preventing 
regeneration.
One of the best models for the study of reactive astrocytes involved dorsal root injury 
(rhizotomy), in which the regenerating central axons of primary sensory neurons can be 
studied as they reach the Dorsal Root Entry Zone (DREZ). The particular value of this 
model lies in its elucidation of the role of reactive astrocytes, in the absence of invading 
meningeal cells, in limiting the extension of otherwise regeneration-competent neurons 
(Carlstedt, 1988). Astrocytes reside throughout the entire CNS, becoming more 
numerous and hypertrophic in response to injury or Wallerian degeneration to give rise to 
glial scar tissue. After dorsal root rhizotomy, the astrocytes of the DREZ of the spinal 
cord hypertrophy and -  although their cell bodies remain in the DREZ -  extend astrocytic 
processes up to 700pm into the basal lamina tubes of the connecting dorsal roots (Zhang 
et al., 2001). Upon contact with astrocytic processes, most regenerating sensory axons in 
the dorsal roots either (i) stop regenerating and form end-bulbs (Carlstedt, 1985; Liuzzi 
and Lasek, 1987), or (ii) are deflected and extended back along the dorsal root towards 
their somata (Zhang et al., 2001). A small population of sensory axons usually manage to
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avoid inhibitory influences and regenerate back into the cord, often along blood vessels 
(Chong et al., 1999). Liuzzi and Lasek suggested that reactive astrocytes express 
molecules serving as ‘stop signals’ for regenerating axons (Liuzzi and Lasek, 1987). 
However, it should be borne in mind that (i) ultrastructurally similar nerve profiles are 
seen in the dorsal roots in contact with Schwann cells (Chong et al., 1999), and (ii) these 
putative molecular cues are not insurmountable and can be overcome by intraspinal 
injection of adeno-associated virus (AAV) expressing NT-3 or NGF to the dorsal hom 
(Zhang et al., 1998; Romero et al., 2001), or even by intrathecal infusion of neurotrophins 
(Ramer et al., 2000).
Further evidence for the significance of the glial scar comes from Davies et al. who 
reported that GFP-expressing adult mouse DRG neurons, atraumatically transplanted to 
the dorsal columns of the adult rodent spinal cord, were capable of extending axons over 
long distances within the spinal dorsal columns that were undergoing Wallerian 
degeneration. The rate of regeneration was recorded at 2mm per day, comparable with 
regenerating peripheral nerves, but the axons were found to be arrested on contact with 
the scar tissue (Davies et al., 1997; Davies et al., 1999). However, this does not preclude 
the involvement of other factors such as myelin-associated inhibitory molecules, which 
may be partly responsible for this observation, as will be discussed later.
One of the most successful and reproducible ways of impeding glial scar formation in the 
injured spinal cord in vivo, has been achieved through the use of low dose X-irradiation 
(Kalderon and Fuks, 1996; Ridet et al., 2000; Zeman et al., 2001). There is some 
disagreement over the dose and the time post-injury at which this is most effective with 
one group claiming that, under the wrong conditions (5-20Gy), the treatment group 
scores were worse than untreated controls in motor performance tasks. On balance, 
although this procedure does not completely eliminate reactive astrocytes from the 
injured spinal cord, it does facilitate axonal regeneration and results in moderate 
improvements in behavioural scoring tasks. Remarkably, it has also been reported that a 
single high-dose of radiation (40Gy) applied to neonatal rodents has such a profound
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effect that organotypic sections of the spinal cord taken from the animals when they have 
reached adulthood are capable of supporting neurite outgrowth (Wilson et al., 2000).
It is difficult to model the glial scar using living astrocytes in vitro. Nonetheless, it is 
generally agreed that cultured immature astrocytes are permissive for neurite outgrowth 
from RGC or neocortical neurons in vitro, and mature astrocytes are not (McCaffery et 
al., 1984; Baehr and Bunge, 1990; Le Roux and Reh, 1995). Using a novel culture 
system, Fawcett et al. (1989) measured the capacity of various ages and subtypes of 
neurons to extend axons through a three-dimensional matrix of purified astrocytes. They 
reported that, although embryonic DRG neurons and retinal ganglion cells were able to 
extend axons through these three-dimensional cultures of astrocytes, adult RGCs and 
postnatal DRG neurons were not able to do so. In contrast, two-dimensional monolayers 
of astrocytes were found to be permissive for neurite outgrowth from all ages of RGC 
and DRG neurons. This is not consistent with the explanation that the molecular 
phenotype of adult astrocytes is inhibitory to axonal growth. Rather, it would appear that 
the three dimensional meshwork of astrocytes in a glial scar either forms an effective 
physical boundary to neurite outgrowth or has a different molecular phenotype from a 
monolayer of astrocytes. This is supported by the in vitro work of Fok-Saeng et al. 
(1995) who examined different astrocytic cell lines, which exhibit varying degrees of 
inhibition of neurite outgrowth, for correlations with expression of putative inhibitory 
chondroitin sulphate proteoglycans (CSPGs); they found no correlation with any given 
molecule, but did report that the most inhibitory astrocytic cell lines were those which 
secreted the most extracellular matrix (ECM). Interestingly, however, it has since been 
shown that the astrocyte cell line, Neu7, which is particularly inhibitory to neurite 
outgrowth in vitro, expresses considerably more NG2 (a cell membrane-associated 
chondroitin sulphate proteoglycan), versican and CS-56 antigen than less inhibitory 
astrocyte cell lines (Fidler et al., 1999). Subsequently, a careful series of experiments 
suggested that NG2 was responsible for the axon-inhibitory nature of the Neu7 cell line. 
To date, NG2 has not been shown to be widely expressed by mature astrocytes in vivo, 
even after CNS injury; although, oligodendrocyte precursor cells have been found to
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express large amounts of NG2 in both the intact and injured CNS (Chen et al., 2002; but 
see also Greenwood and Butt, 2003).
In vitro, it has been shown that cytokines can be used to modulate the ability of cultured 
mature astrocytes to support neurite outgrowth. For example, basic fibroblast growth 
factor (bFGF) together with interleukin-1 can be used to induce a permissive response, 
whilst interferon gamma and TGFp induce a non-permissive response (Fok-Seang et al.,
1998). This is an important observation, since many cytokines are released following 
CNS injury which would be expected to influence the nature of the effect that astrocytes 
have on sprouting axons in vivo.
Meningeal Cells
The inhibitory nature of the scars in damaged CNS tissue cannot be attributed wholly to 
reactive astrocytes. Over the past few years, meningeal cells have received more 
attention since it has become apparent that they secrete large amounts of keratan sulphate 
proteoglycans (Hirsch and Bahr, 1999) as well as collagen IV into the lesion site (Rutka 
et al., 1986; Sievers et al., 1994). They are also important sources of semaphorin 
expression (Pasterkamp et al., 2001; De Winter et al., 2002). Their importance may have 
been long overlooked (reviewed by Morgenstem et al., 2002), as co-cultures of astrocytes 
and meningeal cells have revealed that RGC axons grew almost exclusively over 
astrocytes, either growing around or terminating upon contact with meningeal cells 
(Hirsch and Bahr, 1999).
Extracellular Matrix
The dense collagenous extracellular matrix, a major constituent of the scar tissue, and the 
surrounding basal lamina are also important aspects of the glial scar that together may 
comprise a potentially formidable physical barrier to regenerating axons. Recently, 
attempts to reduce collagen IV deposition through the local administration of the iron- 
chelating agent 2-2’ bipyridine have been shown to augment axonal regeneration into the 
scar in a fimbra-fomix injury model (Stichel et al., 1999), but not in that of the injured 
corticospinal tract (Weidner et al., 1999). This is not surprising in the light of a
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subsequent study that has revealed that 2-2’ bipyridine alone is ineffective at reducing 
scar tissue formation in the spinal cord due to the presence of relatively large numbers of 
infiltrating meningeal cells, which are a major source of collagen IV (Hermanns et al., 
2001).
Scar-Derived Inhibitory Molecules
Scar tissue is the source of a number of putative inhibitory molecules such as 
proteoglycans, tenascins and semaphorins (Meiners et al., 1995; Pasterkamp et al., 1999; 
Niclou et al., 2003). These families of potentially inhibitory molecules have been 
implicated in axon guidance in the developing nervous system (McAdams and McLoon, 
1995; Pearlman and Sheppard, 1996; Powell et al., 1997; Powell and Geller, 1999; 
Joester and Faissner, 2001). The proteoglycans consist of chondroitin sulphate 
proteoglycans (CSPG), keratan sulphate proteoglycans (KSPG), heparan sulphate 
proteoglycans (HSPG) and dermatan sulphate proteoglycans (DSPG) (reviewed by 
Margolis and Margolis, 1994). The proteoglycans are composed of a core protein, linked 
to glycosaminoglycan (GAG) side-chains. Some of the molecules are predominantly 
expressed at the cell-surface, such as CSPGs, whilst others are secreted as extracellular 
matrix molecules, such as KSPGs. Some of these molecules, e.g. CSPGs, are expressed 
by GFAP-immunopositive reactive astrocytes and meningeal cells (McKeon et al., 1991). 
DSPG has been reported to support neuron survival in vitro (Kappler et al., 1997). In 
contrast, CSPG and KSPG, whose expression pattern correlates well with glial scar 
formation after CNS injury (Snow et al., 1990; Krautstrunk et al., 2002), have been 
described as non-permissive, if not inhibitory, to neurite outgrowth in vitro (Rudge and 
Silver, 1990; Snow et al., 1990; Snow et al., 1991). HSPG has been shown to potentiate 
the interaction of Slit2 with Robol, which repels migrating neurons and growing axons 
during development (Hu, 2001); it is strongly expressed by leptomeningeal cells (David, 
1988).
Enzymatic cleavage of the GAG sidechains of CSPG or KSPG has been reported to 
render the core proteins permissive for axon growth (Snow et al., 1990; Fidler et al.,
1999). Using organotypic slice cultures of injured and intact adult rat spinal cord as a
30
substrate, Zuo et al. (1998b) reported that treatment with Chondroitinase ABC permitted 
enhanced neurite outgrowth of cultured embryonic chick DRG neurons. Administration 
of Chondroitinase ABC can promote regeneration in vivo of the nigrostriatal tract (Moon 
et al., 2001) and axons in the spinal cord (Bradbury et al., 2002), at least over short 
distances. Also, the implantation of Chondroitinase ABC soaked gel into the 
subarachnoid space has been shown to promote the regeneration dorsal spinocerebellar 
tract axons into grafts of peripheral nerve in spinal cord (Yick et al., 2000). These results 
appear to question the importance of the inhibitory domains in the core proteins of 
several CSPGs.
Whilst the receptor through which CSPGs exert their inhibitory effect has yet to be 
identified, it is known they are capable of activating RhoA in sensitive neurons (Monnier 
et al., 2003). The intracellular signaling pathway is not entirely clear, but protein kinase 
C (PKC) appears to be necessary for this process (Sivasankaran et al., 2004). 
Additionally, it has been reported that NG2, for example, can prevent the homophilic 
binding of the cell adhesion molecules N-CAM and LI in vitro (Grumet et al., 1993). 
Such homophilic molecular interactions of cell adhesion molecules in the substrate with 
those in neurons are thought to be important for neurite outgrowth, not necessarily 
through their adhesive properties but through the activation of second messenger 
systems; there is evidence that c/s-activation of the FGF receptor may participate in this 
process (reviewed by Walsh et al., 1997). However, regardless of the signaling 
mechanism, it is important to note that (i) regenerating peripheral axons can successfully 
extend through the distal stump of injured sciatic nerve, in which NG2 is strongly 
upregulated (Morgenstem et al., 2003; Jones et al., 2003; Rezajooi et al., 2004), and (ii) 
there is no sign of enhanced axonal regeneration in the injured CNS of NG2 null mutant 
mice (Anderson, unpublished observations).
There are two members of the tenascin family of proteins that have been implicated in the 
regulation of neurite outgrowth: Tenascin-C, and Tenascin-R (which is, in fact, a myelin- 
associated inhibitor of regeneration). Tenascin C has been reported to differentially 
regulate neurite growth depending on whether it is surface-bound, or soluble (Gotz et al.,
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1996; Meiners and Geller, 1997), whilst Tenascin R has been shown to be inhibitory to 
the outgrowth of RGC fibres in vitro (Becker et al., 2000). Following spinal cord injury, 
Tenascin-C expression has been shown to be upregulated in and around the lesion site, 
and is probably synthesized by meningeal cells and reactive astrocytes (Zhang et al., 
1997; Deller et al., 1997). Since Tenascin-C is strongly expressed in injury sites and the 
distal stumps of severed peripheral nerves, it is by no means obvious that its overall 
effects are inhibitory (Martini, 1994).
Cavity Formation
Cavitation frequently occurs in compression and contusion injuries, and - since the latter 
constitute the most common type of spinal cord injury in man - it is perhaps not 
surprising that the structural discontinuity imposed by cavitation and cyst formation often 
represent an additional barrier to axonal regeneration in the injured human spinal cord. 
Although the events that give rise to these structures have not yet been fully elucidated, it 
would appear that they are for the most part due to necrosis and apoptosis (Beattie et al.,
2000). However, it should be noted that species-specific responses may be important; for 
example, in the rat spinal cord contusion model fluid-filled cysts are prominent, whereas 
in the mouse model cavities dense with connective tissue prevail (Inman and Steward, 
2003). A plethora of cells have been detected within cavities including ependymal cells, 
macrophages, Schwann cells, and astrocytes (Wallace et al., 1987; Fitch et al., 1999). In 
contrast, GFAP-immunopositive reactive astrocytes are usually found bordering, but not 
within, the cavities (Farooque et al., 1995). Despite this, regenerating axons have been 
reported to enter the cavity, although their presence is inversely proportional to the 
severity of the lesion (Beattie et al., 1997).
Trophic Factor Deficiency in the Injured Mammalian CNS
Neurotrophic factors are secreted soluble proteins known to be important in nervous 
system development, plasticity and neurotransmission. Their actions range from 
promotion of cell survival, to axon outgrowth and control of cellular morphology. The 
term ‘neurotrophic factor’ is used widely to describe a number of different proteins or 
protein families, such as neurotrophins, glial derived neurotrophic factor family, ciliary
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neurotrophic factor, transforming growth factor beta, platelet derived growth factor, and 
insulin-like growth factors. Only neurotrophins and their receptors will be discussed 
here.
Neurotrophins
Neurotrophins are so called since their biological activity is, for the most part, restricted 
to the nervous system. Members of this family of proteins share common structural 
features, and include nerve growth factor (NGF), brain derived neurotrophic factor 
(BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), neurotrophin-6 (NT-6), and 
neurotrophin-7 (NT-7) (Barde et al., 1982; Leibrock et al., 1989; Maisonpierre et al., 
1990; Hallbook et al., 1991; Ip et al., 1992; Gotz et al., 1994; Lai et al., 1998).
The classic neurotrophic factor hypothesis, based primarily on findings concerning NGF 
and extrapolated to other family members, dictates that target-derived molecules undergo 
retrograde transport as internalized receptor-ligand complexes in neurotrophin-dependent 
CNS and PNS neurons and, ultimately, activate various proteins upon arrival in the cell 
body to elicit a biological response (Thoenen et al., 1988; DiStefano and Curtis, 1994). 
However, it has also become clear within recent years that neither BDNF nor NT-3 abide 
by this conventional hypothesis in that both are found to undergo anterograde transport in 
developing retinal ganglion cells and primary sensory neurons, are stored within vesicles 
in axon terminals, and can be released in an activity-dependent manner (von Bartheld et 
al., 1996).
Nerve Growth Factor (NGF/NTF1)
NGF, the first identified neurotrophin, was isolated from moccasin snake venom and then 
mouse sarcoma tissue more than five decades ago (Levi-Montalcini and Hamburger, 
1951), and was soon shown to be crucial for the survival and maintenance of peripheral 
sympathetic neurons in neonatal rodents (Cohen, 1960). Similarly, it was later 
discovered that prenatal depletion of NGF through the administration of anti-NGF 
antibodies culminates in the loss of developing primary sensory neurons of the dorsal 
root ganglia (Johnson, Jr. et al., 1983). The mechanism of action underlying the role of
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neurotrophins in sympathetic and sensory neuron development and survival has since 
become clear; it is now understood that excessive numbers of sympathetic and primary 
sensory neurons are present during development, and only those that successfully form 
connections with their target tissues and retrogradely transport target-derived 
neurotrophic factors, such as NGF, survive to maturity (Jones and Reichardt, 1990). 
Primary sensory neurons remain sensitive to NGF throughout their lifetime; although the 
molecule is not necessary for the survival of mature cells, it does stimulate neurite 
outgrowth (Lindsay, 1988).
In the adult rodent nervous system, strong expression of NGF transcripts and protein are 
detectable in the intact hippocampus and neocortex (Large et al., 1986); regions 
innervated by NGF-responsive cholinergic neurons of the basal forebrain. NGF is not 
expressed in the intact adult spinal cord (Korsching and Thoenen, 1985), but is 
upregulated by meningeal cells and some Schwann cells of nerve roots close to sites of 
compression or complete transection of thoracic spinal cord. Expression was found to 
peak at 1 day post operation (Widenfalk et al., 2001). In contrast, although NGF is not 
expressed by non-neuronal cells in intact adult peripheral nerve, there is no shortage of 
the molecule in lesioned adult peripheral nerves; NGF is strongly upregulated by 
Schwann cells in the distal stump soon after injury (Heumann et al., 1987). Intriguingly, 
these cells also upregulate p75NTR (Taniuchi et al., 1986). It has been suggested that 
NGF, and similar factors, may be temporarily bound and stored by p75NTR-expressing 
Schwann cells as a stimulatory substrate for regenerating axons as they grow back 
through the distal stump towards their original targets (Sandrock, Jr. and Matthew, 1987).
It has been reported that continuous infusion of NGF to the dorsal spinal cord can 
promote the ingrowth of up to 37% of central processes from primary sensory neurons 
after dorsal root crush, by two weeks post operation (Oudega and Hagg, 1996). These 
ingrowing fibres are typically unmyelinated, small diameter fibres and are 
immunopositive for CGRP (i.e. they are consistent with the profile of a subpopulation of 
DRG neurons known to express the trkA receptor). Furthermore, they were observed 
growing up to a distance of several millimeters within the spinal white matter tracts. In
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contrast, only 3% of primary sensory neurons were reported to penetrate the dorsal root 
entry zone in the untreated injured control animals. Similarly, others have reported that 
continuous intrathecal administration of NGF, or intraspinal injection of AAV expressing 
NGF, supports the regeneration of small diameter, unmyelinated, CGRP immunopositive 
fibres into the spinal dorsal horn following dorsal root crush (Ramer et al., 2000; Romero 
et al., 2001). Critically, none of these studies examined the effects of NGF 
administration after rhizotomy by transection; their employment of a crush model raises 
the possibility that some fibres may have been spared.
Autologous grafts of primary fibroblasts, that have been modified ex vivo to express high 
levels of NGF, have been shown to promote the growth of coerulospinal fibres and 
ventral motor axons, as well as CGRP immunoreactive primary sensory fibres when 
transplanted to the injured spinal cord. Injured corticospinal and raphaespinal fibres did 
not respond to the transplants (Tuszynski et al., 1996). Axons that successfully entered 
these grafts of NGF-secreting fibroblasts were not found to exit them; it has, therefore, 
been suggested that this arrested growth is perhaps due to the axons having arrived at the 
point where the concentration of growth factor is highest, and that a better strategy for 
spinal cord repair might be a system whereby the highest concentration of neurotrophin 
can be sequentially switched to sites downstream of the growing axons (Tuszynski et al., 
1997; reviewed by Jones et al., 2001).
Brain Derived Neurotrophic Factor (BDNF/NTF2)
BDNF has been implicated in a plethora of physiological processes within the developing 
or mature CNS, including neuroprotection (Jones and Reichardt, 1990), chemotaxis 
(Ming et al., 2002), neurotransmission (Yang et al., 2002), long-term potentiation 
(Kovalchuk et al., 2002) and cortical inhibition (Huang et al., 1999). Of course, an 
important factor in nerve injury is cell survival, particularly of neurons; there is quite 
clear evidence that BDNF is one molecule that plays an important role in determining cell 
fate in the nervous system during development, in adulthood, and after injury. There is 
also circumstantial evidence that it may be involved in the progression of insidious 
neurodegenerative diseases.
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Like NGF, BDNF has been shown to exert an anti-apoptotic effect on a subpopulation of 
developing primary sensory neurons; unlike NGF-dependent neurons, however, BDNF- 
dependent neurons never lose their dependence on this molecule which they themselves 
secrete to support their own survival in an autocrine manner (Acheson et al., 1995). 
Developing chick RGCs are also dependent on BDNF for their survival; in vitro, it has 
been established that these neurons begin to become dependent on BDNF at E6, 
becoming completely dependent by El 1 (Rodriguez-Tebar et al., 1989). This timecourse 
corresponds to the onset and completion of target innervation in vivo, and the apoptosis 
of superfluous RGCs. Other cells that have been shown to be dependent on BDNF for 
survival, using the BDNF null mutant mouse, include vestibular and trigeminal sensory 
neurons and a subset of nodose-petrosal ganglion neurons (Conover et al., 1995). In the 
latter case, this would appear to include a subpopulation of afferent neurons that is 
involved in chemosensory regulation in the respiratory system since BDNF -/- mice 
exhibit a severely abnormal breathing pattern (Erickson et al., 1996). Additionally, some 
abnormalities in the morphology and physiology of serotonergic neurons has been 
observed in mice heterozygous for BDNF (Lyons et al., 1999).
Following transection or compression of the adult mammalian optic nerve, retinal 
ganglion cells undergo apoptosis with -95% of the population dying within two months 
after injury. However, intravitreal administration of BDNF after complete transection of 
adult rat optic nerve has been reported to promote a 2.3fold increase in RGC survival at 
three weeks post operation. Unfortunately, this is not a prolonged effect and, by seven 
weeks, RGC survival is comparable to the levels observed in control animals (Mey and 
Thanos, 1993).
There is some circumstantial evidence that BDNF may be involved in at least two 
different neurodegenerative disorders. First, wild-type huntingtin protein has been 
reported to induce expression of BDNF within the cortex, whereas the mutant form of the 
protein -  characteristic of Huntingdon’s disease -  does not (Zuccato et al., 2001). This 
could, in part, explain the degeneration of striatal neurons. Second, BDNF released from 
pre-synaptic terminals is known to be able to regulate the sensitivity of post-synaptic
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target neurons to the effect of dopamine by controlling the expression of the D3 receptor 
in dopamine sensitive neurons (Guillin et al., 2001). Given the abnormal distribution of 
the D3 receptor in Parkinson’s disease, it has been suggested that BDNF may be involved 
in the pathogenesis of the disorder.
In the adult brain, BDNF is expressed by neurons within the hippocampus, amygdala and 
neocortex; targets of the forebrain cholinergic neurons (Emfors et al., 1990; Wetmore et 
al., 1990; Phillips et al., 1990). In spinal cord, it is found only in some neurons of lamina 
VII of the dorsal horn. A subpopulation of adult dorsal root ganglia neurons strongly 
expresses BDNF (Emfors et al., 1990), and these appear to be of varying size. No 
obvious regulation of expression is detectable after compression or complete transection 
of the thoracic spinal cord (Widenfalk et al., 2001). Nonetheless, BDNF is one of the 
molecules that has been found to be upregulated in the spinal cord following treatment 
with the anti-Nogo-A function-blocking antibody, IN-1 (Bareyre et al., 2002). 
Transection of peripheral nerves elicits a strong upregulation of BDNF in the distal 
stump; however, the onset of expression commences after 3 days and peaks several 
weeks post injury (Meyer et al., 1992).
Continuous infusion of BDNF into the dorsal spinal cord after dorsal root crush has been 
reported to promote the growth of primary sensory axons into the ascending spinal white 
matter tracts (Oudega and Hagg, 1999). In contrast, others have found that continuous 
intrathecal infusion of BDNF does not enhance growth of primary sensory axons through 
the dorsal root entry zone, after dorsal root crush (Ramer et al., 2000).
Neurotrophin-3 (NT-3/NTF3)
NT-3 is both a survival and neurite-outgrowth inducing factor of neural crest and 
placode-derived neurons (Kalcheim et al., 1992). It also suppresses myelination within 
developing peripheral nerves, acting as an inhibitory modulator through the trkC 
receptor; myelination commences as expression of NT-3 declines (Cosgaya et al., 2002). 
NT-3 null mutant mice exhibit severe neurological and cardiac abnormalities, and die 
perinatally (Emfors et al., 1994; Tessarollo et al., 1994; Donovan et al., 1996).
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Subpopulations of primary sensory and sympathetic neurons were absent in the 
homozygous mutant. In fact, proprioceptive neurons, muscle spindles and Golgi tendon 
organs could not be found. Interestingly, in the heterozygote, muscle spindles were 
present at half the number found in wild-type controls; this is suggestive of a gene dosage 
effect (Emfors et al., 1994). The causes of lethality in the homozygous mutant are the 
gross anatomical and functional abnormalities that it fosters in the development of the 
heart (Donovan et al., 1996). These include atrial and ventricular septal defects, and 
tetralogy of Fallot. This phenotype is compatible with a lack of survival or migration of 
cardiac neural crest cells.
NT-3 exhibits a very restricted pattern of expression in the adult brain; transcripts are 
primarily detected in the CA1 and CA2 neurons of the hippocampus (Emfors et al., 
1990). NT-3 mRNA is not detectable in adult spinal cord, either before or after 
compression or complete transection of the thoracic spinal cord (Widenfalk et al., 2001).
Importantly, NT-3 is the only neurotrophic factor that has to date been shown to promote 
the growth of injured corticospinal axons (Schnell et al., 1994; Grill et al., 1997). Also, it 
has also been shown to promote the ingrowth of primary sensory fibres after dorsal root 
crush (Oudega and Hagg, 1999).
Other Neurotrophins (NT-4/5, NT-6, and NT-7)
NT-4/5 has not been extensively studied, but is known to be widely expressed in the adult 
rodent CNS (Timmusk et al., 1993). It is also strongly upregulated in the distal stump of 
transected peripheral nerve at two weeks post injury (Funakoshi et al., 1993). NT-6 was 
isolated from Xiphophorus (Gotz et al., 1994), and NT-7 from both Danio rerio and 
Cyprinus carpio (Nilsson et al., 1998; Lai et al., 1998), but no mammalian orthologs of 
these family members have yet been identified.
High-Affinity Neurotrophin Receptors
Neurotrophin signaling occurs through three distinct tyrosine kinase receptors (Trks), the 
so-called high-affinity neurotrophin receptors. NGF binds to TrkA (Kaplan et al., 1991;
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Klein et al., 1991a), BDNF to TrkB (Klein et al., 1991b), and NT-3 to TrkC (Lamballe et 
al., 1991); however, the latter exhibits some promiscuity. The dissociation constants of 
these receptor-ligand interactions are in the order of 10'n nM, consistent with slow-on 
slow-off kinetics. However, all of these neurotrophins are also capable of binding the 
low-affinity neurotrophin receptor, p75NTR.
TrkA
TrkA is a receptor for NGF (Kaplan et al., 1991; Klein et al., 1991a), as well as NT3 
(Cordon-Cardo et al., 1991). However, p75NTR can form a receptor complex with trkA to 
increase the binding affinity for NGF, and also potentiate signal transduction (Hempstead 
et al., 1991). Ligand binding initially effects signal transduction by enhancing the 
phosphorylation of certain tyrosine residues within the intracellular domain of the Trk 
receptor; this mechanism is true for TrkA, B and C. Mutations in the trkA gene have 
been linked to congenital insensitivity to pain with anhidrosis (CIPA)(Smeyne et al., 
1994; Indo et al., 1996; Mardy et al., 1999), and it has, therefore, been implicated in the 
anatomical and physiological development of neurons within the nociceptive and 
thermoregulatory circuits.
TrkB
Both BDNF and NT3, but not NGF, bind to TrkB (Squinto et al., 1991; Klein et al., 
1991b). Using conditional knockouts, it has been revealed that TrkB is essential to the 
development of synaptic specializations of inhibitory GABAergic neurons in cerebellum 
(Rico et al., 2002), and that its absence in neurons of the forebrain results in impaired 
synaptic strengthening in complex learning tasks (Minichiello et al., 1999). The latter 
finding is indicative of an important role in synaptic plasticity and long-term potentiation.
TrkC
Cosgaya et al. (2002) found that p75NTR and TrkC have opposite effects on myelination 
in the peripheral nervous system: BDNF acts through p75NTR to enhance the process, 
whilst NT-3 acts through TrkC to inhibit it. Throughout myelination, the levels of 
expression of TrkC and p75NTR remain constant; however, the level of NT-3 gradually
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diminishes, and the ongoing stimulation of p75NTR by BDNF prevails in its induction of 
the process. On completion of myelination, both neurotrophins and their respective 
receptors are downregulated.
The Low-Affinity Neurotrophin Receptor (p75mR/NGFR/TNFR16) 
p75NTR is a member of the tumour necrosis factor receptor superfamily. Two isoforms of 
p75NTR are known to exist in vivo, both of which localize to the cell membrane. The full- 
length protein contains a 28aa signal peptide, four extracellular cysteine-rich repeat 
domains, a serine/threonine-rich region, a single transmembrane domain, and a 155aa 
cytoplasmic domain (Johnson et al., 1986). In comparison, the short-form lacks three of 
the four extracellular cysteine-rich repeat domains, but shares identical transmembrane 
and intracellular regions to the full-length form. The short-form is incapable of binding 
neurotrophins.
The uncleaved precursor to NGF (proNGF) binds to p75NTR with higher affinity than the 
mature cleaved form, whilst the opposite is true for binding to TrkA. Since the nature of 
the biological activity of the neurotrophins is dependent on their receptor interactions, it 
is clear that the extent of proteolysis of pro-neurotrophins in an important factor when 
considering the role of these proteins in any given context. Importantly, the binding 
affinity and selectivity of each of the neurotrophins to their preferred Trk receptor is 
enhanced with synergistic binding to p75NTR (Hempstead et al., 1991; Bibel et al., 1999). 
In addition to the neurotrophins, p75NTR has also been found to bind numerous other 
proteins including prion protein (Della-Bianca et al., 2001), the A (3-peptide of amyloid 
precursor protein (Yaar et al., 1997), an envelope glycoprotein of the rabies virus 
(Tuffereau et al., 1998), and most recently Nogo receptor (Wong et al., 2002; Wang et al., 
2002a), LINGO-1 (Mi et al., 2004), and Sortilin (Nykjaer et al., 2004).
p75NTR has been implicated in extraordinarily diverse biological processes including the 
induction of apoptosis and, paradoxically, the promotion of cell survival. In order to 
achieve these opposing effects, differential activation of intracellular signaling pathways 
is necessary. p75NTR-dependent apoptosis occurs in response to proNGF binding, and
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leads to the activation of nuclear factor kappa p (Carter et al., 1996). However, it has 
very recently been demonstrated that a p75NTR co-receptor, Sortilin, is necessary for the 
mediation of this response to proNGF binding (Nykjaer et al., 2004). The apoptosis of 
oligodendrocytes, following CNS injury, has been correlated with the expression of 
proNGF (Beattie et al., 2002). Similarly, corticospinal neurons, which express p75NTR 
soon after brain injury, also undergo proNGF induced p7S^^dependent cell death 
(Harrington et al., 2004). However, the expression of Sortilin in either the intact or 
injured nervous system has yet to be reported.
p75NTR also plays an important role in axonal growth through its interaction with Rho 
GTPase. It has been found that neurotrophin signaling through p75NTR decreases Rho 
activation (Yamashita et al., 1999). Conversely, ligand-bound Nogo Receptor signaling 
through p75NTR results in a strengthened interaction with the Rho-GDP dissociation 
inhibitor a  (Rho-GDIa) and the subsequent activation of Rho GTPase (Yamashita and 
Tohyama, 2003). Likewise, the ganglioside receptor for MAG, GTlb, may also signal 
through p75NTR to increase Rho activation in a similar manner (Yamashita et al., 2002).
There are two different reported strains of p75NTR null mutant mice. One lacks exon 3 
(Lee et al., 1992), and the other exon 4 (von Schack et al., 2001). Unfortunately, there 
are complications with both of these strains (reviewed by Barker, 2004). The p75NTR 
exon 3 null mutant has been reported to express a splice variant lacking the cysteine- 
repeat domains 2-4 (von Schack et al., 2001), and the p75NTR exon 4 null mutant 
continues to express a fragment of p75NTR which is capable of activating p75NTR 
signaling pathways (Paul et al., 2004). The p75NTR exon 3 null mutant mice were viable 
and fertile, but exhibited deficits in sensory and sympathetic innervation (Lee et al., 1992; 
Lee et al., 1994). In contrast, the mutant mice, with a deletion of exon 4, possessed a 
more severe phenotype with extensive developmental abnormalities in both the nervous 
system and vasculature (von Schack et al., 2001). Furthermore, the mutation proved 
lethal in up to 40% of homozygous knockouts. It is perhaps not surprising that 
experiments aimed at assessing the effect on axonal regeneration in these mutant animals 
have produced conflicting findings in various experimental models (Walsh et al., 1999;
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Boyd and Gordon, 2001; Gschwendtner et al., 2003; Song et al., 2004). These are 
difficult to interpret in the light of what has been learned about the artifactual gene 
products in the respective strains.
Myelin-Mediated Inhibition of CNS Axonal Regeneration
The hypothesis that CNS myelin breakdown products were involved in the prevention of 
axonal regeneration in adult mammals was first posited by Berry (1982). He pointed out 
that non-myelinated axons in the CNS would regenerate after chemical ablation that did 
not damage nearby myelinated fibres, but not after mechanical axotomy, which always 
damaged some myelinated axons. Since damage to myelinated tracts resulted in the 
degeneration of myelin, he hypothesized that degeneration products of CNS myelin were 
inhibitory to axonal growth. Subsequently the ability of CNS myelin to inhibit neurite 
outgrowth was studied in detail by Schwab and Caroni.
NOGO
In a series of landmark papers Schwab and Caroni demonstrated that CNS myelin and 
oligodendrocytes were non-permissive to axonal growth (Schwab and Caroni, 1988; 
Caroni et al., 1988) and they extracted from CNS myelin, proteins of ~250kDa and 
~35kDa that were both potent inhibitors of neurite outgrowth from both neonatal superior 
cervical ganglion cells and dorsal root ganglion cells. These proteins were termed NI-35 
and NI-250 (Caroni and Schwab, 1988b). A monoclonal antibody IN-1, raised against 
NI-250, reacted with both NI-250 and NI-35 and blocked the inhibitory activity of these 
protein fractions and of myelin (Caroni and Schwab, 1988a). Unfortunately, the epitopes 
recognized by IN-1 have not been published and some doubt remains about the molecules 
with which it reacts (Fournier et al., 2002). IN-1 was subsequently used to induce 
regeneration of injured CNS axons in vivo (Schnell and Schwab, 1993; Schnell et al., 
1994). Schwab’s group eventually succeeded in microsequencing six peptides 
originating from the bovine homolog of NI-250, bNI220 (Spillmann et al., 1998) and 
subsequently used this information to search databases of mammalian genes and 
expressed sequence tags (ESTs), in order to identify a full-length mammalian form of the 
gene, incorporating all six homologous peptide sequences, which was termed nogo (Chen
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et al., 2000). At the same time, the nogo gene was independently identified by two other 
groups (Grandpre et al., 2000; Prinjha et al., 2000). Recently, a leucine-rich, 
glycosylphosphatidylinositol (GPI) -linked cell surface protein of 473 amino acids has 
been identified as a receptor to Nogo (NgR) (Fournier et al., 2001). This molecule binds 
the Nogo-66 loop of the Nogo family of proteins with high affinity and its expression has 
been shown to be sufficient to confer sensitivity to Nogo-66 on otherwise insensitive 
cells (Fournier et al., 2001). Whilst it is clear that other powerful inhibitors of neurite 
outgrowth are present in the injured CNS (Dou and Levine, 1994; Canning et al., 1996; 
Davies et al., 1999; Zhang et al., 2001; Pasterkamp et al., 2001), investigations of NgR 
and its interactions have for the first time clearly elucidated the mechanisms limiting the 
sprouting and regeneration of some axons in the adult mammalian CNS.
The Nogo Gene
The human nogo gene has been localized to chromosome 2pl3-14 by radiation hybrid 
mapping (Yang et al., 2000). Using crude in silica genomic mapping of the cDNA 
sequences of Nogo isoforms, it was found that the gene comprises at least 11 exons (Fig. 
1.1) and putatively gives rise to at least seven different proteins by splice variation 
(Chapter 3; Hunt et al., 2002b) (Table 1.1). However, a detailed analysis of human and 
mouse nogo gene structure (Oertle et al., 2003a), in which 5' capsite RACE PCR was 
undertaken to identify transcription start sites, revealed that the human gene is composed 
of 14 exons whereas the mouse gene is only composed of 11. The additional human 
exons were found to be redundant since they are spliced into mature mRNA transcripts to 
encode 5' untranslated region (UTR); all of the mRNA isoforms, incorporating the newly 
discovered exons (termed ID, IF, and 1G), give rise to the same protein, Rtn-T (note that 
isoforms incorporating lAa and lAb also give rise to Rtn-T; however, these are not 
considered whole exons in their own right and are thought to form a single exon in 
conjunction with 1A). None of the transcripts incorporating exon ID, IF or 1G have 
been identified in vivo (Oertle et al., 2003a).
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Nogo Protein
Nogo (RTN4) is a member of the Reticulon family of genes (the others being RTN1-3) - 
so called because their protein products are largely retained in the endoplasmic reticulum 
of cells. A conserved 3' sequence is present in all forms of Nogo transcript and gives rise 
to the reticulon-type amino acid sequence. Interestingly, the Nogo-66 domain, which 
interacts with the Nogo receptor to cause growth cone collapse, is translated from this 
conserved region. Nogo also has a novel 5' sequence where transcript variation arises 
through alternative splicing.
Of the seven different isoforms that are believed to arise from the nogo gene (Chapter 3; 
Hunt et al., 2002b; Oertle et al., 2003a), only three of these - termed Nogo-A, -B and -C 
(Fig. 1.2.), respectively -  have been considered major isoforms expressed in the adult 
nervous system. Rtn-T is expressed in the testes (Zhou et al., 2002). The minor 
transcripts -  none of which are referred to as Nogo - all have properly aligned open 
reading frames, but there is not yet any experimental evidence that the proteins 
corresponding to the minor transcripts are expressed in vivo.
Human Nogo-A, -B and -C proteins are 1192 amino acids (aa), 373 aa and 199 aa in 
length, respectively. Nogo-A appears as ~190-250kDa band after denaturing SDS- 
PAGE, whereas Nogo-B and -C appear as ~55kDa and ~25kDa bands, respectively. 
Their conformation (i.e. which parts of the molecule are likely to be exposed at the 
surface of cells) has considerable significance for their role as inhibitors of axonal 
regeneration but is still not entirely clear, particularly in the case of Nogo-A. Analysis of 
the primary sequence of Nogo-A, -B and-C reveals that none of the isoforms possesses an 
amino terminal signal sequence which would cause the protein to be directed towards the 
cell surface, whereas all forms of Nogo exhibit a dilysine endoplasmic reticulum (ER) 
retention signal (-KRKAE) within the conserved carboxy terminus (Hunt et al., 2002a).
Chen et al. (2000) reported that Nogo-A has seven N-glycosylation sites and many 
potential O-glycosylation sites. Glycosylation would be expected to be limited to cell 
surface molecules. However, whilst it is true that Nogo-A has multiple potential O-
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glycosylation sites, and seven potential N-glycosylation sites, it should be noted that only 
five of the asparagine residues are positively predicted to bear N-glycosylations and, 
more importantly, because the protein lacks N-terminal signal sequence it will not 
necessarily be processed by the N-glycosylation machinery. The number of 
transmembrane domains determines which parts of Nogo are likely to be exposed at the 
cell surface and, therefore, available for interactions with receptors on other cells. Two 
transmembrane domains are strongly predicted within the conserved C-terminus of Nogo. 
Furthermore, it is generally accepted that Nogo assumes a topology such that the two 
most strongly predicted transmembrane domains are separated by the 66-residue 
extracellular or lumenal loop, called Nogo-66 (Grandpre et al., 2000; Chen et al., 2000; 
Prinjha et al., 2000). Nogo-66 has a specialized role in causing growth cone collapse 
(Fournier et al., 2001). Therefore, it is not surprising that recombinant Nogo-A and 
Nogo-C, which both contain the conserved Nogo-66 loop, have both been reported to 
cause growth cone collapse (Grandpre et al., 2000). The Nogo-A specific N-terminal 
sequence inhibits neurite outgrowth, and also prevents fibroblast spreading (Fournier et 
al., 2001). The active region is believed to be located in the middle of the Nogo-A 
specific domain (Prinjha et al., 2002). Whether the so-called Nogo-A specific domain 
passes through the cell membrane to have an extracellular domain is more contentious, 
but is of considerable significance for its availability to the growth cones of regenerating 
neurons. It is worth noting that Nogo-A does have a weakly predicted transmembrane 
domain in its unique amino terminal sequence (Hunt et al., 2002a).
Another feature thought to be present in both Nogo-A and -B is a proline-rich region 
(Hunt et al., 2002a), which would be a good candidate for involvement in interactions 
with other proteins (Kay et al., 2000). In addition, Oertle et al (2003) have recently 
identified consensus sequences for PEST domains (which can lead to rapid degradation 
of protein), SH3-ligands and WW-ligands (both involved in protein-protein interactions) 
within the so-called Nogo-A specific domain. Nonetheless, Nogo does not have the 
domain architecture of a conventional receptor protein.
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Is Nogo Present at the Cell Surface?
Unless Nogo reaches the surface of cells, it is unlikely to be involved in growth cone 
collapse in non-degenerating tissue. The presence of a C-terminal dilysine ER retention 
signal (-KRKAE) does not mean that all of the protein is necessarily retained in the ER. 
There is growing evidence to show that proteins bearing such sequences are able to 
overcome their ER retention signals to reach the cell surface, despite also lacking a N- 
terminal signal sequence. As pointed out by (Chen et al., 2000), the myelin proteins 
PMP-22 and MAL also possess ER retention signal sequences and yet are able to reach 
the cell surface. The immunocytochemical identification of Nogo-A in oligodendrocyte 
membranes in white matter (Huber et al., 2002; Wang et al., 2002c) confirms that the 
molecule can be found at the surface of these cells, although much is likely to be retained 
in the ER. Of particular interest, is the finding that recombinant Nogo-A, and -B are 
always retained in the ER when transfected into COS cells (Grandpre et al., 2000; Chen 
et al., 2000). This suggests that there must be some cell-specific activity in the regulation 
of Nogo transport, at least in oligodendrocytes, perhaps involving the formation of 
complexes with other proteins that are targeted to the cell surface. Recently, (Pot et al., 
2002) reported that axonal regeneration was inhibited in the peripheral nerves of 
transgenic mice expressing Nogo-A under the control of a P0 promoter. The significance 
of this study is that it is the first to demonstrate that Nogo-A is inhibitory to axonal 
regeneration in vivo, and that recombinant Nogo-A made by Schwann cells can become 
available to receptors on regenerating axons.
The Effects o f  Antibodies to Nogo on Axonal Regeneration In Vivo 
The best evidence that Nogo is involved in limiting axonal regeneration in vivo comes 
from experiments with function-blocking antibodies, particularly IN-1 and its derivatives 
(Caroni & Schwab, 1988b; Rubin et al., 1994), produced by Schwab’s laboratory. Most 
of these experiments involve the corticospinal tracts, whose cell bodies contain very high 
levels of mRNAs for ngr, nogo-66 and nogo-a (Chapters 3 and 4; Hunt et al., 2002; Hunt 
et al., 2003). Also, most of these studies use antibodies produced by hybridomas 
implanted into the cerebral hemispheres and in every case the antibodies may have had 
access to the cell bodies as well as the growth cones of the corticospinal neurons. The
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first such study (Schnell and Schwab, 1990) used a model in which the midthoracic 
spinal cord of young rats was injured, the dorsal and dorsolateral parts of the spinal cord 
being severed. The small ventral tract was presumably intact. Regenerating corticospinal 
axons were found up to 2.6 mm distal to the lesion in controls but up to 11 mm distal in 
IN-1 treated animals. Such axons were mainly in the position of the former corticospinal 
tract. The effects of IN-1 were later shown to be enhanced by implantation of foetal 
spinal cord at the lesion site (Schnell and Schwab, 1993) and more strongly enhanced by 
NT-3 treatment (Schnell et al., 1994) which led to axons apparently regenerating up to 
20mm beyond the lesion. IN-1 treatment was subsequently shown to improve functional 
recovery after such lesions (Bregman et al., 1995), but both the effects on regeneration 
and on functional recovery were reduced if treatment was delayed until 8 weeks after 
lesioning (von Meyenburg et al., 1998). IN-1 also stimulated regeneration of 
corticospinal axons following pyramidotomy (Raineteau et al., 1999). In the later studies 
the regenerating axons were often found in the ascending dorsal columns, lateral columns 
and grey matter, rather than the former corticospinal tract. Although the partial lesion 
models used in these studies do not rule out the possibility that axons beyond the lesion 
are spared fibres or their sprouts (effects on collateral sprouting have been increasingly 
emphasized as the basis of functional recovery in studies using IN-1 in vivo- see below), 
the weight of evidence strongly suggests IN-1 can stimulate the regeneration of some 
corticospinal axons, mainly through intact tissue around incomplete transection lesions. 
It remains to be seen whether regenerated axons are responsible for any part of the 
functional recovery achieved by IN-1 treatment, and whether the antibody is effective 
following complete transections of the spinal cord or compression and contusion injuries 
which closely mimic the lesions found most often in man.
IN-1 has also shown effects on the regeneration of other types of CNS axon. First, it was 
shown that IN-1 treatment (via implanted hybridoma cells) increased the number of 
regenerating septohippocampal axons which re-entered the hippocampus following 
removal of the fimbria/fomix (Cadelli and Schwab, 1991). The axons in IN-1 treated 
animals grew for about 1.5- 4 mm in the hippocampus, significantly further than in 
control animals. However, the identification of the axons by cholinesterase staining, as
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opposed to anterograde tracing, leaves some doubt about their origin. Septal nuclei are 
rare examples of neurons thought to regenerate in response to IN-1 although expressing 
very low levels of ngr mRNA (Chapter 3). It was subsequently shown that IN-1 together 
with BDNF increased regeneration in the visual pathway (after freeze/crush lesions of the 
intracranial optic nerve) of young rats (Weibel et al., 1994). However, the distance 
beyond the lesions at which regenerating axons were detected was only about 1.5 mm. 
Retinal ganglion cells in adult rats show strong ngr mRNA expression (Fournier et al., 
2001; Hunt et al., 2002; Wang et al., 2002a). IN-1 has also been shown to enhance the 
regeneration of the central processes of spiral ganglion neurons in the CNS tissue of the 
auditory nerve, and to produce some functional recovery (Tatagiba et al., 2002). Once 
again, the number of axons regenerating was a small percentage of those injured and the 
distance the axons regenerated was limited to 1.5mm, although this allowed some to enter 
their former target nuclei. It is notable that some regeneration of the auditory axons 
beyond the lesion was seen even without IN-1 treatment.
Regeneration of the central processes of primary afferent (DRG) neurons in vivo does not 
seem to be affected by IN-1 (Oudega et al., 2000). The model used involved a peripheral 
nerve graft in the thoracic spinal cord (which is readily invaded by ascending dorsal 
column axons in animals with a conditioning sciatic nerve injury), so that the issue 
addressed was whether IN-1 could promote regeneration of the sensory axons from the 
graft into the rostral spinal cord. This did not happen. Most DRG neurons express nogo 
(Josephson et al., 2001; Huber et al., 2002; Hunt et al., 2002) but only a minority express 
ngr mRNA (Hunt et al., 2002; Josephson et al., 2002). Thus, although Nogo expression 
is widespread on both neurons and glia, the major effects of IN-1 on axonal regeneration 
in vivo appear to be on neurons which express NgR. However IN-1 does promote the 
regeneration of neonatal DRG neurons into CNS tissue (optic nerves) in vitro (Chen et 
al., 2000).
IN-1 and Axonal Sprouting
IN-1 has significant effects in vivo, other than on axon regeneration: it enhances the 
sprouting of some intact and injured axons and increases the expression of growth
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associated genes by some neurons. Axonal regeneration implies the regrowth of an 
injured axon, usually in the general direction of its original projection. Sprouting 
involves the growth of branches from an axon, either injured or intact, but not the growth 
of such branches to a distant site. Obviously, for injured axons, axonal sprouting is a 
necessary precursor of regeneration. One of the most significant observations on the 
effects of IN-1 in vivo is that it increases sprouting rostral to lesions of corticofugal 
fibres, including ipsilateral corticobulbar and corticospinal axons rostral to a unilateral 
pyramidotomy, contralateral corticospinal axons caudal to a pyramidotomy (Bareyre et 
al., 2002) and corticostriate axons (Kartje et al., 1999). All of these fibres arise from 
neocortical neurons which strongly express NgR and Nogo-A (Chapters 3 and 4). 
Sprouting of corticospinal axons into abnormal territories was even observed in animals 
without axotomy (Bareyre et al., 2002). In the case of unilateral pyramidectomy, the 
recovery of function following IN-1 treatment was not abolished by relesioning the 
pyramid 1mm rostral to the original injury (Z’Graggen et al., 1998). Clearly, IN-1 
induced plasticity, as opposed to regeneration, may be responsible for most of the effects 
of the antibody on functional recovery. Furthermore, IN-1 treatment increased the 
density of monoaminergic fibres in the spinal cord caudal to the lesions (Bregman et al., 
1995; Bareyre et al., 2002). Serotonin has been shown to have important functions in 
motor control (Gerin et al., 1995; Nishimaru et al., 2000; Slawinska et al., 2000; Hains et 
al., 2001). In the cerebellum, IN-1 induces sprouting of uninjured Purkinje cell axons, 
within the cortical grey matter (Buffo et al., 2000). Together, these observations suggest 
that the control of axonal sprouting is an important physiological function of the 
molecule(s) detected by the IN-1 antibody.
IN-1 and the Control o f Growth-Associated Gene Expression
Purkinje cells are renowned for their lack of response to axotomy (Rossi et al., 2001), and 
axotomized Purkinje cells upregulate very few of the growth-associated genes that are 
expressed in neurons that can successfully regenerate axons (Zagrebelsky et al., 1998; 
Chaisuksunt et al., 2000). Application of IN-1 to the cerebellum brings about 
upregulation in both intact and axotomized Purkinje cells of some genes normally 
associated with injury and regeneration in other cells, including the transcription factors
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c-jun, P-Jun and JunD, and NADPH diaphorase (Zagrebelsky et al., 1998). Interestingly, 
granule cells were unaffected by IN-1, although they express NgR (but not Nogo) at least 
as strongly as Purkinje cells. IN-1 increased gap-43 mRNA and protein in the spinal cord 
of rats (Bareyre et al., 2002), although it is not clear which neurons were affected. Spinal 
cord neurons express NgR weakly or not at all, but many express Nogo-66 strongly 
(Chapter 3; Hunt et al., 2002).
OLIGODENDROCYTE MYELIN GLYCOPROTEIN
Oligodendrocyte myelin glycoprotein (OMgp) is a GPI-linked CNS myelin protein which 
has also been shown to induce growth cone collapse and inhibit neurite outgrowth (Kottis 
et al., 2002; Wang et al., 2002b). OMgp was the first major peanut agglutinin-binding 
protein of adult human CNS white matter to be identified, more than a decade ago (Mikol 
and Stefansson, 1988). Its gene is one of three located on the reverse strand within the 
first intron of the neurofibromin gene (Viskochil et al., 1991), the others being EVI2A 
and EVI2B. A translocation event within the neurofibromin gene gives rise to a mutant 
form of the neurofibromin protein, which is no longer able to suppress mitogenesis and 
allows the development of the disease, neurofibromatosis type 1. Because of the unusual 
gene structure, it was considered that OMgp and neurofibromin expression and function 
could be closely related (Viskochil et al., 1991). Subsequently, it was demonstrated that 
OMgp, like neurofibromin, acts as a suppressor of mitogenesis when expressed in 3T3 
fibroblasts (Habib et al., 1998a), apparently by blocking intracellular signalling pathways 
from the activated PDGFa receptor. Recently, Wang et al., (2002b) screened proteins 
released from CNS myelin by phospholipase treatment (i.e. GPI-linked cell surface 
proteins) for the ability to inhibit neurite outgrowth. The only inhibitory protein 
identified in this screen was OMgp.
The OMgp Gene
The human omgp gene spans ~3.0kb of genomic DNA, and is located on chromosome 
17ql 1.2. The omgp gene is comprised of two exons (Fig. 1.1.), with the intron being 
present in the 5' untranslated region (Mikol et al., 1990a; Mikol et al., 1993).
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OMgp Protein
Human OMgp consists of 440aa, has a molecular weight of approximately 110-120kDa 
after post-translational modifications and is held at the cell surface by a GPI linkage. It 
bears an N-terminal signal sequence and a C-terminal hydrophobic stretch of residues 
incorporating a potential cleavage site, consistent with being GPI anchored. The protein 
appears to consist of a cysteine-rich N-terminal LRR flanking domain, followed by five 
LLR domains. Additionally, there is a predicted threonine rich region spanning, where 
post-translational O-glycosylation is likely to occur. Mikol et al. (1990b) reported the 
differential addition of the HNK-1 carbohydrate moiety to OMgp, depending on the 
tissue from which it was derived. Curiously, the HNK-1 antigen is also found on MAG 
and is associated with the preferential regeneration of motor axons in peripheral nerves 
(see below) (Low et al., 1994; Martini et al., 1994).
MYELIN-ASSOCIATED GLYCOPROTEIN (MAG)
MAG (otherwise known as siglec 4a) is a transmembrane protein of the immunoglobulin 
superfamily, found in both PNS and CNS myelin (Martini, 1994), where it plays a role in 
the formation and maintenance of myelin sheaths (Fruttiger et al., 1995; Carenini et al., 
1997; Fujita et al., 1998; Marcus et al., 2002). It was originally shown to promote neurite 
outgrowth from neonatal dorsal root ganglion (DRG) neurons, but was subsequently 
found to inhibit neurite growth from adult DRG cells, cerebellar granule cells and many 
other types of neuron (McKerracher et al., 1994; Mukhopadhyay et al., 1994). It should 
be noted, however, that MAG has been found to stimulate, rather than inhibit neurite 
outgrowth from E l7 mouse spinal cord neurons (Tumley and Bartlett, 1998) and even 
from neonatal cerebellar neurons in one study (Shimizu-Okabe et al., 2001). It may be 
that the effects of MAG, and possibly other inhibitors of neurite outgrowth, depend on 
how cells are isolated and cultured. There is evidence that the levels of cyclic AMP in 
neurons modulate the responses to MAG and are reduced in neurons when they become 
sensitive to MAG (Cai et al., 2001). Cyclic AMP levels are likely to be sensitive to 
differences in culture techniques. Although MAG is generally recognized as a potent 
inhibitor of axonal growth in vitro, the MAG knockout mouse exhibits little or no 
enhancement of axonal regeneration in the spinal cord (Bartsch et al., 1995; but see also
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Li et al., 1996). However, the slow-degenerating mutant mouse provides some evidence 
that MAG can be inhibitory to axonal regeneration in vivo: regeneration is enhanced in 
the sciatic nerves of these mice if the mag gene is inactivated (Schafer et al., 1996). As 
the name siglec suggests, MAG is a sialic acid binding protein, which means that it has 
the potential to bind to a variety of sialylated cell surface molecules. Gangliosides GDI a 
and GTlb have been implicated as putative receptors mediating the neurite-inhibiting 
properties of MAG, but the evidence remains somewhat contradictory (Vinson et al., 
2001; Liu et al., 2002; Domeniconi et al., 2002; Vyas et al., 2002). It has been speculated 
that the MAG-induced clustering of gangliosides into lipid rafts could activate RhoA to 
inhibit neurite growth (McKerracher, 2002). The evidence that the Nogo-66 receptor is 
part of one functional receptor complex for MAG on neurons is strong (see below).
The MAG Gene
The human mag gene consists of 12 exons (Fig. 1.1.), spanning nearly 22kb of genomic 
DNA, and is located on chromosome 19ql3.1. Splice variation generates two isoforms of 
the protein (Salzer et al., 1987). Variant 1 (L-MAG) is transcribed from 11 exons (1-10 
and 12) and translates to a protein of 626aa. Variant 2 (S-MAG) encompasses all 12 
exons but gives rise to a shorter protein, of 582aa, due to introduction of an in-frame stop 
codon in exon 11, thus rendering exon 12 part of the 3' UTR in this transcript.
MAG Protein
There is considerable experimentally-derived documentation of the secondary structure 
and conserved functional domains of the two human variants of MAG. Essentially, both 
proteins are known to retain the same secondary structure and topology, notwithstanding 
the slight variation in the cytoplasmic carboxy terminus. Briefly, MAG is known to 
possess five regions of internal homology that give rise to five immunoglobulin-like 
domains within its extracellular amino-terminus (Salzer et al., 1987). Toward the 
carboxy terminus, in the region of ~510aa — 530aa is a single transmembrane domain. 
This is succeeded by different cytoplasmic carboxy termini, which may give rise to 
functional diversity between isoforms. It has been suggested that the modulation of 
linked carbohydrate moieties might occur during development as a means of regulating
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the function of MAG in myelinogenesis (Pedraza et al., 1991). There is also evidence 
that the HNK-1 carbohydrate is linked to MAG in a highly differential manner in 
Schwann cells supporting motor and sensory nerves of adult mammals (Low et al., 1994). 
HNK-1 has, however, been associated with the enhanced regeneration of motor axons 
rather than growth inhibition (Martini et al., 1992). A soluble form of MAG, capable of 
inhibiting neurite outgrowth from P6 DRG neurons, is released from damaged CNS 
myelin (Tang et al., 2001); soluble MAG constitutes the great majority of the neurite- 
outgrowth inhibiting influence released from such myelin, suggesting that the release of 
Nogo from the cell surface is negligible.
NOGO-66 RECEPTOR
The Nogo-66 receptor (NgR) is a common receptor mediating growth cone collapse in 
response to at least three myelin proteins. Fournier et al. (2001) discovered the Nogo-66 
receptor by transfecting COS-7 cells with clones from a cDNA library from adult mouse 
brain and screening to detect which clones bound a Nogo-66 alkaline phosphatase (AP) 
fusion protein. NgR, a GPI-linked cell surface protein, was shown to be sufficient to 
impart sensitivity to Nogo to otherwise insensitive cells: retinal ganglion cells from E7 
chick embryos, which are otherwise insensitive to the growth-cone collapsing effects of 
Nogo-66, were rendered susceptible to its activity after transduction with a virus 
expressing NgR. The dissociation constant (Kd) of the Nogo-66 interaction with NgR 
expressing COS cells was calculated as 5nM, suggesting that it represents a physiological 
interaction.
Two groups (Liu et al., 2002; Domeniconi et al., 2002) have independently reported that 
NgR is also a functional receptor for MAG. Liu et al. (2002) set out to identify co­
receptors for NgR by screening COS cells transfected with clones from a cDNA library 
with an AP-NgR fusion protein. Of the ten clones which were found to bind AP-NgR, 
six of them were NgR itself. This suggests that NgR may self-associate at physiological 
concentrations, although the Kd for this interaction was subsequently determined as >50 
nM (Liu et al., 2002). This is considerably weaker than NgR-ligand interactions. The 
remaining four clones were all identified as MAG. Immunoprecipitation studies showed
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that NgR does indeed precipitate MAG. Furthermore, gain of function studies 
demonstrated that MAG at nanomolar concentrations is capable of inducing growth cone 
collapse in neurons transfected with NgR. Domeniconi et al. (2002) identified a ~80kDa 
neuronal membrane protein, which they had previously shown to bind MAG, as NgR. 
They showed that the removal of neuronal GPI-linked proteins from rat P4 cerebellar 
granule cells protected them against MAG-mediated inhibition of neurite outgrowth. A 
MAG-Fc fusion protein bound to CHO cells expressing NgR and an AP-NgR fusion 
protein was shown to bind to CHO cells expressing MAG. Using AP-NgR and either 
MAG-expressing Chinese hamster ovary (CHO) cells, or immobilized MAG-Fc, a Kd of 
8nM was calculated for this interaction (cf. Liu et al (2002) who calculated a Kd of 
approximately 20nM for interactions between AP-MAG ectodomain and NgR expressing 
COS cells). MAG-Fc was able to precipitate NgR from various lysates. However, 
Niederost et al. (2002) have recently reported that cerebellar granule cells cultured on 
polylysine respond to both a Nogo-A peptide and MAG even after phospholipase 
treatment. It is not easy to reconcile these apparently conflicting results.
Wang et al. (2002b) showed that NgR was also a functional receptor that allowed OMgp 
to cause growth cone collapse. They screened an expression library and identified NgR 
as a high-affmity OMgp-binding protein. Cleavage of NgR and other GPI-linked 
proteins from the cell surface rendered axons of DRG neurons insensitive to OMgp, 
whereas introduction of exogenous NgR conferred OMgp responsiveness on otherwise 
insensitive neurons. A Kd of 5nM was calculated for the interaction of AP-OMgp with 
NgR-expressing COS-7 cells.
The NgR Gene
The human ngr gene consists of two exons (Fig. 1.1), spanning ~27kb, on chromosome 
22ql 1. There is no evidence of splice variation within this gene.
NgR Protein
Human NgR is a GPI-linked protein, of 473aa, detectable as a ~85kDa band following 
denaturing SDS-PAGE. NgR contains an N-terminal cysteine-rich LRR domain
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(LRR-NT), followed by 8 LRR domains (the first of which is incomplete), and a C- 
terminal cysteine-rich LRR domain (LRR-CT). Wang et al. (2002b) deleted parts of the 
NgR molecule to identify regions important for interactions with Nogo-66 and OMgp. 
The LRR and LRR-CT domains of NgR were required for binding of OMgp, but the 
LRR-CT domain was both required and sufficient for binding of Nogo-66. Nonetheless, 
the OMgp and Nogo-66 competed to occupy their overlapping binding sites. However, 
Fournier et al. (2002) have provided evidence that all of the LRR domains as well as the 
LRR-CT and LRR-NT domains in NgR are apparently required for Nogo-66 binding. 
They also report that the unique C-terminal sequence is required for signal transduction, 
perhaps being involved in direct interactions with co-receptors, and that the GPI linkage 
facilitates efficient signal transduction. The GPI linkage apparently directs NgR to 
become localized in caveolin-positive lipid rafts.
MAG also competes with Nogo-66 for binding to NgR (Domeniconi et al., 2002), but the 
regions in NgR required for binding MAG have not yet been examined by domain 
deletion analysis. The competitive binding suggests that at least part of the LRR-CT 
domain of NgR required for Nogo-66 binding is also necessary for the binding of MAG. 
However, this speculation is complicated by the fact that the NgR antagonist peptide 
NEP1-40 (which competitively inhibits Nogo-66 binding and blocks growth cone 
collapse), does not compete with MAG (Liu et al., 2002). NEP1-40 corresponds to 
residues 1-40 of the Nogo-66 loop (and might better be thought of as Nogo-40). The 
most likely explanation for the absence of competition between MAG and NEP1-40 is 
that MAG competes for the active site on NgR which also recognises residues 41-66 of 
Nogo-66.
NgR Co-Receptors 
p75mR
Since NgR is a GPI-anchored cell surface protein, it is incapable of transmembrane signal 
transduction. Therefore, it must interact with at least one other protein, a signal- 
transducing co-receptor. The first evidence that pTS1^  could potentially be a co-receptor 
for NgR came from the work of Yamashita et al. (2002), who demonstrated that pTS1^
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was necessary for MAG-induced inhibition of neurite outgrowth from adult DRG 
neurons and postnatal cerebellar granule cells. Shortly thereafter, two groups reported 
that p75NTR could indeed function as a signal-transducing co-receptor for NgR (Wong et 
al., 2002; Wang et al., 2002a). The p75NTR signalling was shown to occur in response to 
NgR binding of Nogo-66, MAG or OMgp (Wang et al., 2002a). All regions of the NgR 
protein from the LRR-NT domain to the unique C-terminal region are necessary for 
binding p75NTR.
The p75NTR null mutant mouse has now become a prime target for regeneration 
experiments. However, as described earlier, there is some doubt as to whether the two 
different strains of p75NTR null mutant mouse are complete knockouts. Nonetheless, an 
interesting study of the ability of axons to sprout in the CNS of one of these strains of 
animal was published before the relationship between p75NTR and NgR was known 
(Walsh et al., 1999). Transgenic mice were generated in which NGF was expressed by 
astrocytes in the CNS under the control of the GFAP promoter. Sympathetic axons 
sprouted into the brains of the mice, but many more axons grew into the brain if the 
p75NTR gene was inactivated. It is particularly interesting that the sympathetic axons 
which sprouted into the brain were predominantly found in the white matter. It is not yet 
clear whether the sympathetic neurons which sprouted into the CNS expressed NgR. An 
intriguing possibility is that high concentrations of neurotrophins, which promote axonal 
sprouting and limited regeneration in the CNS (Zhang et al., 1998; Bradbury et al., 1999; 
Walsh et al., 1999), may act via neurotrophin-p75NTR interactions that block NgR 
signalling, rather than through the high affinity (trk) receptors. Neurotrophin binding to 
p75NTR is known to reduce its ability to activate RhoA (Yamashita et al., 1999). 
Alternatively, Trks activated by neurotrophin binding may sequester p75NTR, thus 
effectively inactivating NgR. The structure and biological functions in the nervous 
system of p75NTR have been reviewed recently by Dechant and Barde (2002). A reason 
for caution in the interpretation of the role of p75NTR in NgR signalling is that p75NTR is 
differentially expressed by neurons. For example, it is difficult to detect on some classes 
of neurons, e.g. thalamic reticular nucleus neurons (Vaudano et al., 1998) and most 
neostriatal neurons (Sobreviela et al., 1994); its expression by other neurons is disputed,
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e.g. adult retinal ganglion cells (Hirsch et al., 2000; Ding et al., 2001; but see also 
Sheedlo et al., 2002); and on DRG neurons there is a complete spectrum of strengths of 
pTShrm expressjon (Verge et al., 1992). It may be significant, however, that pTS^11 is 
upregulated by several types of intrinsic CNS neurons after injury, including 
corticospinal neurons (Giehl, 2001) and Purkinje cells (Vaudano et al., 1998), neither of 
which has the capacity to regenerate axons into nerve grafts (Anderson et al., 1998).
LINGO-1
Recently, LINGO-1, a transmembrane LRR-containing protein, was also identified as 
being necessary for NgR signalling (Mi et al., 2004). The authors found that LINGO-1 
co-immunoprecipitated with NgR and pTS*™1, and that the expression of all three 
proteins was necessary, in COS cells, for the activation of RhoA by Nogo-66, MAG or 
OMgp. Of course, this does not necessarily mean that the same is true of neurons.
Analysis of the tissue expression profile of LINGO-1, by northern blot, revealed that the 
transcript was restricted to nervous system tissue. RT-PCR of embryonic and postnatal 
rat brain demonstrated that LINGO-1 expression peaked at PI, and decreased thereafter. 
By in situ hybridisation, it was found that LINGO-1 transcript expression was confined to 
neurons within the nervous system. Likewise, immunohistochemistry was used to show 
that the protein was purely neuronal, and that in the cerebellum LINGO-1 is highly 
expressed in early postnatal cerebellar granule neurons, but that in adulthood it is 
predominantly expressed by Purkinje cells. Interestingly, 10 days after spinal cord injury 
in adult rats, LINGO-1 protein was detected in the injured descending axonal tracts 
rostral to the lesion. Also, RT-PCR of injured spinal cord tissue revealed a five-fold 
increase in LINGO-1 mRNA levels, 14 days post injury. There is only one other report 
of the expression pattern of LINGO-1 (aka LERN1) in the adult nervous system (Carim- 
Todd et al., 2003), which is broadly in agreement with the report of Mi et al. (2004). In 
this study, it was shown by in situ hybridisation, immunohistochemistry and northern blot 
of adult rat brain that LINGO-1 expression was largely restricted to neurons within the 
neocortex and limbic system, that very little expression was present in cerebellum, and 
that none was detectable in intact spinal cord.
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NgR is not the Only Receptor for Nogo-A and MAG
NgR should be an important target for manipulations aimed at improving axonal 
sprouting and regeneration in the CNS, at least in the case of cortical projection neurons 
which express NgR strongly. Nonetheless, there is evidence that functional cellular 
receptors other than NgR exist for these axonal-growth inhibitory molecules. The 
interactions of MAG with gangliosides have been claimed to mediate the inhibition of 
neurite outgrowth (Vinson et al., 2001; Vyas et al., 2002; but see also Domeniconi et al., 
2002), and MAG has trophic effects on oligodendrocytes (Gard et al., 1996), which have 
not yet been shown to express NgR. Of course, the other MAG receptors may mediate 
functions unrelated to growth cone collapse. The N - terminal region of Nogo-A, which 
does not bind to NgR, also has the ability to inhibit neurite outgrowth, as well as 
preventing the spreading of other types of cell (Grandpre et al., 2000; Fournier et al., 
2001; Niederost et al., 2002; Prinjha et al., 2002). Presumably this is mediated by 
another receptor, which must be widely expressed. The possibility that gangliosides may 
also act as receptors for Nogo-A would explain why screening of expression libraries has 
so far failed to identify a receptor protein. Niederost et al. (2002) claim that 
phospholipase treatment, to remove NgR and other GPI-linked cell surface molecules, 
does not block all the inhibitory effects of Nogo-A or MAG on neurite outgrowth from 
cerebellar granule cells grown on polylysine (but the result for MAG contrasts markedly 
with the findings of Domeniconi et al. (2002) and Liu et al., (2002).
NgR Signalling
The first experiments on the intracellular signalling pathways involved in growth cone 
collapse in response to Nogo indicated that calcium release from intracellular stores was 
a critical factor (Bandtlow et al., 1993). MAG also induces a rise in intracellular calcium 
levels in neuronal growth cones (Wong et al., 2002). However, it is not clear whether 
these responses were mediated by NgR, since both Nogo and MAG may have additional 
receptors. More recently it has become widely accepted that pathways leading to growth 
cone collapse in response to CNS myelin converge on (activating) the RhoA GTPase 
(Lehmann et al., 1999; Dergham et al., 2002), and that some point on the pathway is 
susceptible to cyclic AMP levels (Cai et al., 1999; Cai et al., 2001; Cai et al., 2002).
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Inhibition of Racl, which has antagonistic effects on the cytoskeleton to RhoA, may also 
play a part in growth cone collapse (Niederost et al., 2002). How such pathways can be 
made compatible with a calcium response is not clear.
NgR Paralogs
Recently, three groups have reported the cloning of two paralogs of NgR, appropriately 
termed NgR2 and NgR3 (Pignot et al., 2003; Barton et al., 2003; Lauren et al., 2003). 
The expression profiles of these two paralogs are remarkably similar to that of NgR and, 
although their function remains unknown, it would not be surprising if they were found to 
be implicated in the failure of CNS axonal regeneration. However, the issue of whether 
the ligands of NgR also bind the NgR paralogs remains contentious; two groups have so 
far failed to demonstrate that Nogo-66, MAG or OMgp serve as ligands for either of the 
two paralogs (Pignot et al., 2003; Barton et al., 2003), but another group has recently 
presented data indicating that NgR2 binds MAG with greater affinity than NgR 
(Venkatesh et al., 2003). In addition, their data suggest that NgR2 does not bind to 
Nogo-66 or OMgp, but does to bind the NgR signal-transducing co-receptor, p75NTR. 
They were not, however, able to demonstrate any interactions of the NgR ligands (Nogo- 
66, MAG, OMgp) or its co-receptor, p75NTR, with NgR3.
HERPES SIMPLEX VIRUSES
Herpes simplex virus type-1 (HSV-1) is a member of the alpha herpesviridae family, and 
is known to principally underlie the pathogenesis of cold-sores. Its counterpart, HSV-2, 
with which it shares a significant degree of genetic homology, is predominantly 
responsible for the manifestation of genital-sores. Nonetheless, the two viruses and their 
associated pathologies are not mutually exclusive. HSV-1 is endemic within all 
populations, and it has been consistently estimated within recent years that ~65% of the 
American population (>12 years old) are seropositive for the virus (Oliver et al., 1995; 
Rosenthal et al., 1997; Langenberg et al., 1999; Xu et al., 2002). Owing to the propensity 
of the herpes simplex viruses to enter latency in the host organism, it is believed that 
infected individuals are incapable of immunological clearance of the virus and, thus, will
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be carriers for life. Curiously, however, reactivation may occur repeatedly throughout 
the life-span of some infected individuals (recurrent symptomatic episodes), whilst not at 
all in others (life-long subclinical infections). There are many theories that seek to 
explain why this should be so, but these will not be discussed here (reviewed by 
Millhouse and Wigdahl, 2000).
Biology of HSV-1
HSV-1 is a nuclear replicating, dsDNA virus. Its genome comprises 152Kb (Roizman 
and Sears, 1996), and is composed of two unique regions: long ( U l ) ,  and short (Us). 
Each of these possesses short inverted terminal repeat (ITR) sequences at both ends, 
which function to permit linear rearrangement of the genome by inversion between these 
two points. This gives rise to four potential linear arrangements of the HSV-1 genome 
(Jacob et al., 1979). However, during latency, the HSV-1 genome is believed to assume a 
circular episomal structure in which such rearrangements do not occur. Therefore, the 
inversion of the unique regions is believed to arise, for the most part, during the 
replication of the viral DNA when long linear concatamers of genomic DNA are 
synthesized.
HSV-1 consists of an icosahedral capsid, enclosing the viral genome, which is separated 
from a glycoprotein rich envelope by the tegument, a layer rich in proteins -  particularly 
virion protein 16 (VP 16) and virion host shut-off protein (vhs). Viral entry into the cell is 
achieved through interactions of the envelope glycoproteins, of which there are 12 (gB- 
gM), with cell surface receptors. Fusion of the viral and cellular membranes is followed 
by release of the viral capsid into the cytoplasm (Morgan et al., 1968). This is 
accompanied by the concomitant release of the tegument proteins, vhs and VP 16. vhs 
acts immediately to induce host cell translational suppression via the activation of a 
pathway which results in the non-specific degradation of mRNA. In the mean time, the 
capsid is transported to the nucleus (Batterson and Roizman, 1983), where the viral DNA 
is deposited and sets about exploiting the host cell RNA polymerase II in order to effect 
transcription. By this time, VP 16 will also have reached the nucleus where it assumes a 
role in transactivating the HSV-1 IE genes, and can facilitate the entry into a lytic life­
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cycle -  although this appears to be largely influenced by host cell-type. For example, the 
dichotomy is that: either, the virus will enter into a lytic life-cycle, in which it replicates 
to form new infectious viral particles; or, the virus will enter into a latent life-cycle, in 
which the viral DNA forms a circular nuclear episome and effectively remains dormant. 
Although the former is common in epithelial cells, the latter is typical in primary sensory 
neurons. Why this should be so is not yet clear.
In the classic model of primary HSV-1 infection, epithelial cells - especially those of 
non-keratinised mucous membranes - are the first to be infected by virus. In these cells, 
the HSV-1 rapidly undertakes a course of lytic replication. Newly formed infectious viral 
particles, released from lysed epithelial cells, infect the nerve terminals of primary 
sensory neurons that lie within close proximity to the lesion. The viral capsids are 
transported retrogradely along the axons, from the peripheral site of primary infection, 
until they reach the perikarya of the primary sensory neurons; these reside in the dorsal 
root ganglia (DRG).
Once the viral DNA has been deposited in the neuronal nucleus, the virus can either 
undertake another round of lytic replication or it can enter latency, as was mentioned 
earlier. However, HSV is renowned for its predilection to enter latency in primary 
sensory neurons and, although it can periodically reactivate and replicate, it is as a result 
of this property of establishing a life-long infection in these neurons that HSV is 
considered neurotropic.
Nonetheless, HSV-1 can infect a broad spectrum of cell-types both in vivo and in vitro. 
One issue of contention is the identification of those envelope glycoproteins that are 
necessary for membrane attachment to, and uptake by, a target cell. Whilst it is true that 
glycoprotein B (gB), gC and gD have all been implicated in the process, it seems unlikely 
that the same combination will be employed for attachment to all target cells. After all, 
the HSV-1 envelope bears at least 12 different glycoproteins, and in practical terms the 
virus is reasonably pan-tropic. Furthermore, whilst heparan sulfate has been shown 
unequivocally to interact with HSV-1 glycoproteins, enabling membrane attachment
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(WuDunn and Spear, 1989; Shieh and Spear, 1991), there are three structurally unrelated 
protein families that serve as cellular entry receptors for HSV-1 (reviewed by 
Campadelli-Fiume et al., 2000).
HSV-1 Gene Activity in Lytic and Latent Cycles
HSV-1 gene activity can be broadly divided into immediate early (IE), early (E) and late 
(L). There are five IE genes giving rise to infected cell proteins (ICP) 0, 4, 22,27 and 47; 
all of which have all been shown to cause cytopathic effects in vitro (Johnson et al., 
1994).
The onset of IE gene expression is regulated by the tegument protein VP 16, which is 
released into the cytoplasm alongside the capsid following the fusion of virus and cellular 
membranes. This protein subserves two important functions. First, VP 16 is a late gene 
product which is incorporated into newly forming viral particles as an essential structural 
protein within the tegument. Second, upon infection of a target cell, the protein is 
released from the tegument into the cytoplasm and transported to the nucleus by Host 
Cell Factor (HCF) where it transactivates the HSV-1 IE genes (LaBoissiere and O'Hare, 
2000).
VP 16 mediated transactivation of IE genes is achieved via interactions with the cellular 
proteins HCF and Oct-1, both of which recognize and bind to TAATGARAT motifs 
within the promoter sequences of the IE genes. Oct-1 contains both a conventional 
homeodomain that enables DNA-binding at its carboxy terminus, and a bipartite DNA- 
binding domain, known as a POU domain, slightly n-terminal to the former. It is the 
POU domain that is responsible for Oct-1 binding of the TAATGARAT motif. The 
VP16/HCF complex does not dissociate, but binds to the TAATGARAT/Oct-1 complex 
(Preston, 2000), whereupon the c-terminal transactivating domain of VP 16 contacts -  and 
activates - the transcriptional pre-initiation complex at the TATA box.
As was mentioned earlier, VP 16 is also a structural component of the tegument. The 
domains involved in this aspect of its function reside at the n-terminal of the protein.
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Deletion of the structural domains renders the virus incapable of replication. Therefore, 
the n-terminal peptide must be preserved, or complemented in vitro, as it is an absolute 
requirement for the synthesis of infectious viral particles.
Successful transactivation of the IE genes results in the synthesis of five proteins (ICP 0, 
4, 22, 27, and 47). With the exception of ICP47, these are all transcriptional 
transactivators which assist in driving the cascade of gene expression from IE through to 
L, during cycles of lytic replication.
ICPO is a transactivator of IE, E and L genes. It is non-essential for growth in vitro but, if 
deleted, will reduce viral yields (Stow and Stow, 1986; Sacks and Schaffer, 1987). Its 
gene is located in the Ul region and is, therefore, present in two copies. ICPO is a 
promiscuous transactivator of transfected genes (Roizman and Sears, 1996), and has also 
been shown to interact with elongation factor 1 delta and cyclin D3 (Kawaguchi et al., 
1997a; Kawaguchi et al., 1997b).
ICP4 is a transactivator of E and L genes, and a repressor of IE genes. Its gene is present 
in both Us regions, and is essential for replication in vitro (DeLuca et al., 1985). It is 
thought to bind directly to certain DNA motifs as a homodimer (Metzler and Wilcox, 
1985), and brings about transcriptional activation through association with ‘hi-jacked’ 
cellular transcription factors TFIIB and either TFIID or the TATA-binding protein (Smith 
et al., 1993).
ICP22 is a transactivator of L gene expression, but is not essential for virus propagation 
in vitro (Poffenberger et al., 1993; Poffenberger et al., 1994; Rice et al., 1995; Leopardi 
et al., 1997; Bruni and Roizman, 1998).
ICP27 is a transactivator of L genes, and repressor of E genes. It is essential for 
replication in vitro. Also, the protein is known to prevent splicing of primary mRNAs 
(Bryant et al., 2001), favouring HSV-1 genes which for the most part do not contain
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introns. In addition, ICP27 can interact with either ICPO or ICP4 to trans-repress viral 
gene activity (Sekulovich et al., 1988; Mullen et al., 1995; Panagiotidis et al., 1997).
Unlike the other IE genes, ICP47 is not a transactivator of gene expression. Its principal 
role is in the prevention MHC presentation of HSV-1 antigens at the surface of infected 
cells. It does this by targeting the transporters of antigen processing (TAP). These 
proteins normally act by translocating peptide fragments across the ER membrane, but 
are retained inactive in the cytosol following binding by ICP47 (York et al., 1994; Fruh et 
al., 1995; Hill et al., 1995).
ICP6  is the large subunit of the viral ribonucleotide reductase (Preston et al., 1984; 
Bacchetti et al., 1984). It is a late stage IE gene, and is sometimes considered a hybrid 
IE/E gene. Its activation is independent of that of genuine IE genes. A null mutation in 
the ICP6  gene does not impair viral DNA synthesis or viral growth in dividing cells in 
vitro, but does significantly impair viral replication in non-dividing cells (Goldstein and 
Weller, 1988). Nonetheless, viruses lacking only ICP6  are capable of replicating in vivo, 
and will give rise to cutaneous lesions similar to those produced by inoculation with wild- 
type HSV-1 (Turk et al., 1989).
The E genes encode proteins that direct the replication of viral DNA, such as thymidine 
kinase, ICP8  (the major DNA binding protein) and DNA polymerase. The L genes 
encode proteins such as ICP34.5 (the neurovirulence factor), VP 16, vhs and the envelope 
glycoproteins.
During viral replication, concatamers of viral DNA are formed. Inversions of the Us and 
Ul sequence occur before the DNA is cleaved into genomic lengths and packaged into 
capsids. Tegument proteins accumulate around the capsid, which buds through the 
nuclear envelope and acquires envelope glycoproteins in doing so. Infectious viral 
particles are ultimately released by cell lysis.
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After entering into latency, the HSV-1 genome persists in the nucleus of infected neurons 
as circular episomal elements (Mellerick and Fraser, 1987; Deshmane and Fraser, 1989). 
Whilst in latency, the genes required for the viral lytic cycle are switched off. The only 
transcripts produced at this stage of the viral life cycle are the Latency Associated 
Transcripts (LATS) which are encoded for by two identical regions found in the long 
terminal repeat sequences of the viral genome (reviewed by Latchman, 1990; Wagner 
and Bloom, 1997). The LATS are initially 8.5kb, before splicing gives rise to smaller 
RNAs (Wagner et al., 1988; Dobson et al., 1989).
The HSV-1 genome encodes in excess of 80 proteins, more than half of which are 
essential for viral propagation in vitro. The remaining genes are superfluous to virus 
growth in vitro, and have therefore been termed non-essential (Roizman and Sears, 
1996).
HSV-1 as a Tool for Genetic Manipulation
Being neurotropic HSV-1 can, by definition, infect postmitotic cells which is one its most 
noteworthy advantages over other viral vectors commonly used for gene delivery, such as 
retroviruses and adeno-associated viruses (AAV). Unlike lentiviruses, which are also 
able to infect postmitotic cells, the HSV-1 genome does not integrate into the host-cell 
genome, thus eliminating the potential risk of insertional mutagenesis. Furthermore, the 
virus - with a 152Kb genome - can accommodate inserts of up to 35kb, enabling 
multiple-gene delivery. Also, HSV-1 can be grown to high titre as a wild-type virus. 
However, due to the virus’ inherent ability to elicit an immune response, a number of 
gene deletions are necessary. Naturally, this procedure impedes viral replication and 
renders it more difficult to grow.
Wild-type HSV-1 is extremely cytotoxic, and can induce fatal encephalitis if 
administered in sufficiently high doses. For the purposes of gene delivery, a number of 
deletions of essential and non-essential genes are required to attenuate this toxicity. 
Deleting some of the immediate early genes reduces the pathogenicity of the virus. 
However, ICP4 and ICP27 are trans-activators of viral gene expression in both the early
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and late stages. These, therefore, must be present in trans in a complementing cell line 
when growing the virus. Virion protein 16 (VP 16), which induces IE gene expression 
after infection, can be inactivated by a 12bp insertion into its C-terminal transactivating 
domain, preventing it from exerting its transactivational effects over the immediate early 
genes (Ace et al., 1989). Yet, the structural function of VP 16 is preserved, enabling it to 
retain its activity as a tegument protein. Also, non-essential genes, which play no part in 
replication can be deleted to reduce cytopathic effect, e.g. ICP34.5, a neurovirulence 
factor.
POST-TRANSCRIPTIONAL GENE SILENCING (PTGS) AND RNA 
INTERFERENCE (RNAi)
One of the great drawbacks of gene therapy, until recently, has been the limitation of its 
application to diseases which solely demand genetic supplementation. Unlike heritable 
monogenic disorders, which usually require delivery and expression of a functional gene 
to mask the effects of an inactivating mutation in an endogenous gene, some organic and 
acquired diseases require gene-suppression.
Historically, regulation of gene expression was believed to occur uniquely at the level of 
transcription, i.e. whether a gene is or is not transcriptionally active. It has long been 
recognized that DNA methylation, particularly of CpG sequences within promoter 
regions of tissue-specific genes, is one way by which efficient gene silencing can be 
achieved in eukaryotic cells (reviewed by Razin and Riggs, 1980). Originally, it was 
considered that such methylation patterns exert a local effect on chromatin structure, 
rendering the promoter region inaccessible and, therefore, inactive (reviewed by Cedar, 
1988). However, there is now evidence to suggest that methylated DNA within promoter 
regions associates with nucleosomal repressor elements which induce such changes in 
chromatin structure and, thus, abrogate transcriptional activity (reviewed by Razin, 
1998). This epigenetic process underlies genetic imprinting (whereby offspring may 
exhibit differential levels of gene activity on each copy of a given gene, dependent on the 
methylation pattern on that inherited from the mother and that of the father), and may be
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responsible for some heritable genetic defects (reviewed by Holliday, 1987). However, 
so little was known about directing site-specific methylation of target sequences that 
attempts were never made to harness epigenetic manipulation for gene therapy in 
humans.
Almost a decade ago, molecular biologists attempting to enhance petunia flower-colour 
through the introduction of a homologous exogenous transgene reported, contrary to their 
expectation, that the resulting flowers were often completely or partially depigmented 
(Jorgensen et al., 1996). In plants, transgene-induced silencing of endogenous genes can 
be achieved transcriptionally by targeted gene-specific methylation, or post- 
transcriptionally through the targeted degradation of mRNA species (Jones et al., 1999). 
What was first termed co-suppression has ultimately led to the elucidation of the latter 
process, which is now known as post-transcriptional gene silencing (PTGS).
The molecular mechanism underlying this process did not start to become clear until Fire 
et al. (1998) reported that the injection of double-stranded RNA into C.elegans resulted 
in greater levels of silencing than was achieved with injection of either of the constituent 
single stranded RNAs alone. Indeed, so potent was the effect of this dsRNA, that the 
injection of only a few molecules per cell was found to be adequate to effect complete 
silencing of the target gene. Surprisingly, the authors also reported that the silencing 
effect was heritable, being transmitted to the first generation of offspring.
Having previously administered dsRNA by injection into the gut, the same group then 
determined that the same response could be achieved by feeding C.elegans with bacteria 
that had been genetically engineered to express dsRNA to the C.elegans unc-22 gene 
(Timmons et al., 2001). Even soaking the worms in solutions of dsRNA was found to 
successfully effect silencing (Tabara et al., 1998). The ease and simplicity of the latter 
has lead to the method becoming a hugely valuable functional genomic tool for the study 
of nematode worms.
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Gene silencing, mediated by dsRNA delivery, is not restricted to C.elegans and has also 
been successfully applied to D.melangastor using a number of delivery methods. Indeed, 
some landmark discoveries about the mechanism of RNA interference (RNAi) were first 
made with Drosophila embryo lysates. Zamore et al. (2000) showed that not only is 
dsRNA processed to 21-23 nucleotide fragments, as was found earlier by Hamilton and 
Baulcombe (1999) in silenced plants, but also that the target mRNA is cleaved at similar 
intervals throughout the region that corresponds to the exogenous silencing dsRNA.
Although much remains unknown about the precise means by which dsRNA-mediated 
silencing occurs, considerable advances in understanding the process have been made 
over the past few years. At present, it is considered that RNAi can be divided into 
initiator and effector steps. In the former, dsRNA is first processively cleaved in an 
ATP-dependent fashion to 21-23 paired nucleotide fragments by the enzyme Dicer, a 
member of the type III family of ribonucleases which selectively degrade dsRNA. These 
short fragments of dsRNA are further processed to become short interfering RNAs 
(siRNAs), which typically consist of 19-21 paired nucleotides bearing dinucleotide 3' 
overhangs.
The effector step entails the formation of the RNA-induced silencing complex (RISC), 
which is composed of the siRNA in association with numerous proteins. Targeting of 
homologous endogenous transcripts is accomplished through the ATP-dependent 
dissociation of the siRNA strands, with the antisense strand participating in contiguous 
base-pairing interactions with the target molecule. Cleavage occurs approximately 12bp 
from the 3' terminus of the antisense siRNA strand (Nykanen et al., 2001), although the 
identity of the nuclease is not yet known. Interestingly, the stringency of the base-pairing 
of antisense siRNA strand and target mRNA is critical -  a single base mismatch has been 
shown to dramatically reduce, if not completely abolish, silencing activity (Elbashir et al., 
2 0 0 1 c).
Since PTGS is so potent in that the introduction of only a few molecules can be sufficient 
to completely silence gene expression within a single cell, and also in that its effects can
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be heritable, one group has suggested that amplification of the siRNAs in Drosophila can 
occur through what they have termed “random degradative PCR” (Lipardi et al., 2001). 
This model is based on the notion that siRNAs could potentially act as primers, with 
target mRNA as template, and dsRNA as the product which would in turn be 
processively cleaved to form new siRNAs. However, this model requires the existence of 
an RNA-dependent RNA polymerase. Whilst such an enzyme is known to exist in 
C.elegans, for example, which could contribute to the potent activity of dsRNA reported 
by Fire et al. (1998), there is no obvious in silica evidence for an orthologous 
(homologous) gene in Drosophila -  and, yet, for the theory of Lipardi et al. (2001) to be 
correct, a protein of the described function must exist.
The variety of organisms in which dsRNA has been shown to be active in inducing PTGS 
is indicative of its evolutionary importance, since it would appear to have emerged prior 
to the divergence of plants and animals. Why this mechanism evolved in the first 
instance, and why it is so well preserved throughout the eukaryotic kingdom today, 
remain something of a mystery. Nonetheless, it has repeatedly been suggested that this 
mechanism may have evolved as a primitive defence against RNA viruses or transposons, 
thus conferring a survival advantage (Cogoni and Macino, 2000; Hammond et al., 2001).
However, other researchers have posited a more plausible explanation -  PTGS is integral 
to development. Evidence for this comes from the involvement of the C.elegans ortholog 
of Dicer, DCR-1, in generating 22 nucleotide small temporal RNAs (stRNAs) such as lin- 
4 and let-7 from larger stem-loop structures; these stRNAs prevent translation of certain 
proteins during development (Grishok et al., 2001; Hutvagner et al., 2001; Ketting et al., 
2001). Similarly, another species of short RNA molecules termed microRNAs 
(miRNAs), which are typically 22 nucleotides in length, can also be generated from 
larger stem-loop structures through Dicer-mediated cleavage (Lee and Ambros, 2001); 
these too have been implicated in suppressing gene expression.
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RNAi in Mammalian Cells
The PKR Response
Despite the preservation of PTGS across the eukaryotic kingdom, it has been somewhat 
more difficult to harness the potential for gene-specific dsRNA-mediated silencing in 
mammals owing to the recent evolutionary acquisition of a putative antiviral response. 
The introduction of dsRNA longer than approximately 30bp induces non-specific 
translational suppression through (i) the activation of dsRNA-dependent protein kinase 
(PKR), which in turn phosphorylates and inactivates the translation initiation factor, 
eIF2a, and (ii) the activation of RNase L, which non-specifically degrades single­
stranded RNA (Lengyel et al., 1980). Together, these pathways function to shut-down all 
translational activity within an ‘infected’ cell, ultimately leading to cell-death. This, 
presumably, is beneficial to the host since it should in theory result in the elimination of a 
pathogen, such as an RNA virus, at an early stage.
siRNA
Since the introduction of dsRNA of less than 30 nucleotides in length does not activate 
the PKR response in mammalian cells, the obvious way to achieve gene silencing in 
mammals was through the introduction of siRNAs, instead of long dsRNA. Transfection 
of cultured mammalian cells with siRNAs revealed that, although complete gene 
silencing seems unattainable, at least 90% knockdown of mRNA and protein can be 
achieved with the best siRNAs (Elbashir et al., 2001a). However, the reason why so 
many siRNAs have been shown to be relatively inefficient, or indeed completely 
ineffective, in mammalian cells is not entirely clear. The most recent theory is that of 
strand bias, in which either the sense or antisense strand may preferentially associate with 
RISC (Schwarz et al., 2003; Khvorova et al., 2003). This process appears to be 
dependent on the nature of the nucleotide composition of the respective strands.
shRNA
It was, originally, convention to administer chemically synthesized siRNAs in gene 
silencing experiments. However, these proved to be expensive and relatively ineffective 
for in vivo delivery. The advent of commercially available kits for in vitro transcription
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of siRNAs considerably lowered the cost of gene silencing experiments, but offered no 
improvement for in vivo delivery. For many researchers, this was a major impediment to 
their use. Nonetheless, it did not take long before several groups reported within a very 
short time-frame that a RNA polymerase III dependent promoter, either U6  or HI, could 
be manipulated for the generation of short-interfering RNAs either by transcription of 
short inverted repeat sequences from different RNA polymerase III dependent promoters 
(Miyagishi and Taira, 2002a), or by RNA polymerase III dependent promoter driven 
transcription of a single hairpin RNA structure (Lee et al., 2002; Paddison et al., 2002a; 
Paul et al., 2002a; Sui et al., 2002b; Yu et al., 2002b), termed short-hairpin RNA 
(shRNA) by Paddison et al. (2002a). These were reported to exhibit a similar level of 
activity to chemically synthesized siRNAs.
Virus-Mediated Delivery o f shRNAs
More recently, numerous groups have reported successfully delivering shRNAs from a 
U6  or HI promoter cassette within different viruses, including lentivirus (Abbas-Terki et 
al., 2002; Dirac and Bernards, 2003; Rubinson et al., 2003; Scherr et al., 2003; Stewart et 
al., 2003; Wiznerowicz and Trono, 2003; An et al., 2003) retrovirus (Brummelkamp et 
al., 2002b) and adenovirus (Shen et al., 2003).
Gene-Specific Methylation in Mammalian Cells
Recently, it has been shown that the gene-specific methylation that can arise in response 
to the introduction of complementary dsRNA in plant cells (Jones et al., 1999), also 
occurs in response to the introduction of siRNA targeted against CpG islands within the 
promotor of interest in mammalian cells (Kawasaki and Taira, 2004; Morris et al., 2004). 
This leads to the silencing of target gene expression at the transcriptional level, as 
opposed to the post-transcriptional gene silencing that is elicited by siRNAs designed 
against the target transcript sequence. Used in conjunction, siRNAs designed against the 
target transcript sequence as well as CpG islands within the target promoter, may result in 
enhanced silencing activity.
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AIMS OF TfflS STUDY
This thesis seeks to assess the likely role of the myelin associated inhibitors of 
regeneration (Nogo, MAG, OMgp) and their common receptor (Nogo Receptor) in the 
failure of axonal regeneration in the CNS. First, in situ hybridization was undertaken to 
record the expression mRNAs encoding ngr, nogo-66 (i.e. all isoforms of nogo), nogo-a 
and omgp in the healthy and injured adult rodent nervous system. This descriptive 
anatomy was necessary to draw basic conclusions about the potential for NgR-ligand 
interactions in vivo, as well as determine whether these molecules would be amenable to 
HSV-1 based gene delivery.
Given the predominantly neuronal expression of nogo-66 and nogo-a transcripts, an 
immunohistochemical study of Nogo-A protein expression in the healthy and injured 
adult rodent nervous system was also undertaken. This was necessary to establish (i) the 
extent to which Nogo-A protein is expressed by neurons in these models, and (ii) whether 
any correlation exists between neuronal expression of the protein and its regenerative 
capacity in vivo. During this study, an incidental observation of ATF3 upregulation by 
non-neuronal cells of transected adult rat sciatic nerve lead to a separate study of ATF3 
expression by these cells in different models of peripheral nerve injury.
In an attempt to ultimately be able to assess the functional interaction of NgR with its 
ligands in vivo, a modified HSV-1 virus was constructed for the expression of a tagged- 
secreted form of the antagonist peptide to NgR, NEP1-40. This has previously been 
shown to disrupt the interaction of NgR with Nogo- 6 6  in vitro, and to promote axonal 
regeneration in vivo (Grandpre et al., 2002). Since the authors reported that intrathecal 
infusion of NEP1-40 by mini-osmotic pump significantly augmented the regeneration of 
injured corticospinal tract axons, after dorsal hemisection of the adult rat thoracic spinal 
cord, it was considered that targeted HSV-1 mediated delivery of NEP1-40 may achieve 
comparable, if not better, regeneration in the injured spinal cord. Furthermore, it was 
thought that such a vector would be of value in the investigation of axonal regeneration in 
regions of the CNS where intrathecally infused peptide would not be expected to
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penetrate sufficiently well to exert its effect, e.g. deep in the spinal cord of animals larger 
than rats.
In addition, with the recent developments in RNAi technology, it was decided that the 
development of an HSV-1 based platform for the delivery of short hairpin RNAs 
(shRNAs) should be attempted. These molecules can be generated by an RNA 
polymerase III dependent promoter in DNA vectors, and possess almost the same level of 
activity as chemically synthesized short interfering RNAs (siRNAs). The establishment 
of such a system in HSV-1 was deemed highly desirable, not least for the in vivo study of 
putative axon-inhibitory molecules and their receptors within the injured nervous system. 
In this study, an HSV-1 vector for the expression of shRNA against eGFP was first 
generated to establish proof of principle. The silencing activity of this vector was 
compared with that of another HSV-1 vector encoding long-hairpin RNA against eGFP, 
which was expected to by-pass the host cell dsRNA dependent protein kinase response 
owing to the function of the HSV-1 protein, ICP34.5. An HSV-1 vector for the 
expression of shRNA against NgR was also constructed, but this was only assessed in 
vitro for NgR silencing activity.
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Figure 1.1.
The gene structure of human nogo (a), omgp (b), mag (c) and ngr (d), respectively. The 
chromosomal locations for these genes are denoted in brackets.
(A) Nogo, H.sapiens (2p14-13)
1 2 3
1—1
9 10 11
1—I- 1
6036Kb 6026Kb 6015Kb
NT_Q26239.7 - H.sapiens Chromosome 2 reference contig.
(B) Oligodendrocyte Myelin Glycoprotein, H.sapiens (17q11.2)
1 2
i   ' i  i
5975Kb 5965Kb 5955Kb
832Kb 833Kb
NT_035420 - H. sapiens Chromosome 17 reference contig.
(C) Myelin Associated Glycoprotein, H.sapiens (19q13.1)
9 10 11
 r
7825Kb 7835Kb
NT_011196 - H.sapiens Chromosome 19 reference contig.
(D) Nogo-66 Receptor, H.sapiens (22q11) 
1
3405Kb 3395Kb
NT_011519 - H.sapiens Chromosome 22 reference contig.
T---
3375Kb
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Figure 1.2.
The transcript structure of the three major iso forms of no go. The 3' striped segments 
denote exons 6-11, and are shared by all three major iso forms. The 5' stippled segment 
(exon 1) is shared by nogo-a and -b. The white segments (corresponding to exons 3 and 
4 of the nogo gene) are specific to nogo-a, but are also present in some minor Nogo 
transcripts (refer to Table 1.1). The black segment (exon 5) is specific to nogo-c. 
Evidently, only nogo-a and -c have specific sequence.
Nogo-A EM
Nogo-B E23 
Nogo-C
1 kJ
_ J1
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Table 1.1. Transcripts from the nogo (reticulon 4) gene
The human nogo gene consists of 14 exons and 8  introns, and gives rise to 12 mRNA 
isoforms which are translated into 7 different proteins. It originally appeared that there 
were 11 exons within the human nogo gene (Hunt et al., 2002) but recently it has been 
reported that there are 14 (Oertle et al., 2003). The mouse nogo gene contains only 11 
exons. The table shows the seven isoforms of Nogo transcript that have been registered 
in Genbank, each of which encodes a different protein with a correctly aligned open 
reading frame. Oertle et al. (2003) have, however, shown that 10 mRNA isoforms, 
translating into 5 different proteins, are present in cDNA libraries from adult tissue. The 
numbers given beneath the exonic sequences correspond to their position within the 
human nogo gene (AY102285), registered in Genbank by Oertle et al. (2003).
* = Exons identified by Oertle et al,. (2003) using 5' capsite RACE PCR. Currently, 
however, there are no independently submitted cDNA sequences nor dbEST submissions 
in Genbank incorporating these sequences.
** = Since the first exon of each of these mRNA isoforms encodes 5' UTR (with the exon 
composition being otherwise identical), they all redundantly give rise to the same protein 
isoform, Rtn-T (986aa) (Zhou et al., 2002).
t  = lAa and lAb are recently discovered exonic sequences (Oertle et al., 2003) that, 
together with 1 A, constitute a single exon.
t  = The first 832 bases of this exon are missing in the Brain my043 cDNA sequence, 
which was originally isolated from foetal brain tissue. It is possible that this cDNA 
sequence is incomplete.
The use of adult human brain, testis, and skeletal muscle cDNA libraries for 5' capsite 
RACE PCR by Oertle et al. (2003) probably explains why they did not detect some Nogo 
mRNA isoforms that were originally isolated from foetal brain tissue (Brain my043 and 
Nogo-A short form cDNAs).
N.B. The human nogo gene has two major promoters; PI gives rise to transcription 
starting at 1A or IB; P2 gives rise to transcription starting at 1C. It has been suggested 
that 4 minor promoters also exist within the nogo gene (P3-6). These are thought to drive 
transcription of the testicular isoforms of Nogo, i.e. all those beginning with lAa, lAb, 
ID, IE, IF or 1G.
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Name
Genbank
Accession
Number
Exon
Predicted
Protein
length
(act)
Hunt et al., 2002
2 3 4 5 6 7 8 9 10 11- - 1 -
Oertle et al., 2003
IE
(5346
-5465)
IF
(5918
-5998)
*
1G
(7657
-7727)
*
2
(26322
-26378)
3
(27057
-29456)
1C
(44188
-44455)
4
(66846
-67053)
5
(71892
-72030)
6
(79807
-79879)
7
(80704
-80750)
8
(80950
-81008)
9
(81373
-82382)
lAa
(3715-
3827)
lAb
(3946
-4116)
1A/  
IB
(3999
-4799)
ID
(4853
-4986)
*
Nogo-A AJ251383 N N Y N N N N Y Y N Y Y Y Y Y Y 1192
Novel isoform 1** AY 123245 Y N N N N N N Y Y N Y Y Y Y Y Y 986**
Novel isoform 2** AY123246 N Y N N N N N Y Y N Y Y Y Y Y Y 986**
Novel isoform 3** AY123247 N N N Y N N N Y Y N Y Y Y Y Y Y 986**
Testis Specific Rtn 
(Rtn-T)** AF333336 N N N N Y N N Y Y N Y Y Y Y Y Y 986**
Novel isoform 4** AY123249 N N N N N Y N Y Y N Y Y Y Y Y Y 986**
Novel isoform 5** AY 123250 N N N N N N Y Y Y N Y Y Y Y Y Y 986**
Nogo-A short form AF320999 N N Y N N N N N Y N Y Y Y Y Y Y 960
Brain my043 AF063601 N N N N N N N N Y* N Y Y Y Y Y Y 647
MGC clone: 15807 
IMAGE:3505850 BC016165 N N Y N N N N Y N N Y Y Y Y Y Y 392
Nogo-B AJ251384 N N Y N N N N N N N Y Y Y Y Y Y 373
Nogo-C AJ251385 N N N N N N N N N Y Y Y Y Y Y Y 199
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CHAPTER 2 
Methods and Materials
MOLECULAR BIOLOGY
Laboratory Materials
Analytical grade laboratory chemicals were purchased from Boehringer Mannheim, 
Gibco-BRL Life Technologies, Merck and Sigma-Aldrich. Standard disposable 
laboratory plasticware was supplied by Greiner.
Custom-made primers for use in PCR primers were synthesized by either Gibco-BRL 
Life Technologies or Sigma-Genosys. All restriction- or modifying- enzymes, as well as 
dNTPs, were purchased from Promega or New England Biolabs.
RNA Extraction
Animal Tissue
The homogenisation of diced tissue was performed with a sonicating probe, set to full- 
power (3x20s, returning samples to ice for lmin between treatments). Samples were 
subsequently incubated for 5mins at room temperature on a shaking platform, before 
being centrifuged at 10 000 x g, 4°C, for lOmins to pellet unwanted cellular debris. The 
supernatant was collected and thoroughly mixed with 0 . 2  volumes of chloroform, before 
being centrifuged at 10 000 x g, 4°C, for 5mins in Phase-Lock tubes (Eppendorf). The 
aqueous layer was removed, mixed with 2  volumes of ice-cold isopropanol, and stored at 
-80°C for at least 1 hour. RNA was pelleted by centrifugation at 10 000 x g, 4°C, 30mins, 
then washed with ice-cold 70% ethanol made with DEPC-treated ddtkO, and centrifuged 
at 10 000 x g, 4°C, for 5mins. The supernatant was discarded, and the pellet left to dry 
under cover at room temperature for 5mins. RNA was re-suspended in a suitable volume 
of DEPC-treated ddH2 0, aliquoted and stored at -80°C.
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Mammalian Cell Lines
Cells cultured in 6 - or 24-well plates were washed in lxHBSS and subsequently lysed in 
an appropriate volume of Trizol reagent (Gibco-BRL Life Technologies). Total RNA 
was extracted as described previously, except that sonication was omitted.
DNasel Treatment o f Extracted RNA
Genomic DNA contamination was eliminated from extracted total RNA samples by 
treatment with DNasel. A commercially available kit was used, as per the 
manufacturer’s instructions (DNA-free; Ambion).
Assessment o f RNA Integrity
lpg of each total RNA sample was resolved on 1%-TAE agarose gel made with DEPC- 
treated ddtLO, and inspected by UV transillumination for the integrity of the ribosomal 
bands.
Mammalian Genomic DNA Extraction
Cultured cells
Genomic DNA was isolated from cultured cells using DNAzol (Gibco-BRL Life 
Technologies), as per the manufacturer’s instructions. Briefly, the culture media was 
discarded and the cell monolayer washed in lx  PBS before an appropriate volume of 
DNAzol was added to lyse the cells. The reagent was collected and mixed by swirling 
with an equal volume of absolute ethanol. The precipitated DNA was washed twice in 
70% ethanol and left to air-dry under cover for 5mins. Samples were resuspended in an 
appropriate volume of 8 mM NaOH overnight on a vertical rotating wheel at 4°C. An 
appropriate volume of 0.1M HEPES was added to neutralise the NaOH, the DNA 
samples were aliquoted and stored at -20°C.
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Reverse Transcription (First-strand DNA synthesis)
First-strand DNA synthesis from total RNA was performed using avian myeloblastosis 
virus reverse transcriptase (AMV-RT; Promega, UK). Briefly, lpg of total RNA was
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mixed with either 500ng of Random primers (Promega, UK) or lpg of oligo(dT)i5 
primers (Promega, UK), and made up to a total volume of 12pl with DEPC-treated 
ddF^O. This sample was incubated at 65°C for lOmins to permit the annealing of 
primers to RNA, and then snap-cooled on ice for 5mins. dNTPs, RNase inhibitor, AMV- 
RT buffer and AMV-RT were added to give a final volume of 20pl (lmg total RNA, 
500ng random hexamers/lpg oligo(dT)i5 , lxAMV-RT buffer, 500pM dNTPs, 20-40U 
RNasin, and 20U of AMV-RT), and incubated at 42°C for 45mins. Samples were placed 
on ice, aliquoted and stored at -20°C for the longterm.
Polymerase Chain Reaction (PCR)
Each PCR amplification of DNA was performed in a total reaction volume of 50pl in a 
0.2ml thin-walled Eppendorf tube. Products were amplified with either the proof-reading 
DNA polymerase, Pfu (template DNA, 400nM Forward Primer, 400nM Reverse Primer, 
200pM dNTPs, lx Pfu buffer, 1.5U Pfu DNA polymerase) or the non-proof-reading 
DNA polymerase, Taq (template DNA, 400nM Forward Primer, 400nM Reverse Primer, 
200pM dNTPs, lx MgCh-free Taq buffer, l-4mM MgCh, 5U Taq DNA polymerase). In 
the latter, the optimal concentration of MgCh was determined experimentally through the 
employment of a range of concentrations. Pfu was always used for cloning, and Taq for 
analytical PCR. Template DNA was (i) single-stranded DNA generated by reverse 
transcription from RNA (~50ng/reaction), (ii) plasmid DNA (l-10ng/reaction), or (iii) 
genomic DNA (~50ng/reaction). Polymerase chain reaction was performed in an 
Eppendorf Mastercycler using a hot-start protocol (i.e. enzyme was added following the 
denaturation of primers and DNA). Typical programme settings comprised denaturation 
at 95°C for lm30s, annealing at 50-65°C (as appropriate) for lm45s, and extension at 
72°C {Pfu) or 74°C {Taq) for a suitable period of time {Pfu amplifies at 500b/min, and 
Taq at lkb/min), for a total of 25-35 cycles.
A-Tailing o f Pfu-Generated PCR Products
Pfu DNA polymerase is proof-reading enzyme (i.e. it possesses 3'->5' exonuclease 
activity), which generates blunt-ended DNA products. In order to adapt P/w-generated 
PCR products for cloning into the pGem T Easy PCR cloning vector (Promega, UK),
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adenine-tails were added by Taq DNA polymerase. Briefly, PCR products were purified 
with GFX columns (Amersham, UK), and then incubated with Taq DNA polymerase (lx  
MgC^-free buffer, 2.5mM MgCb, 200pM dATP, 5U Taq DNA polymerase) for 20mins 
at 70°C.
Taqman® Quantitative PCR
Quantitative PCR was performed using an AB17000 with Taqman® reagents (Applied 
Biosystems). The primers and probe for detection of rat ngr cDNA were custom-made 
by Applied Biosystems. The forward and reverse primers, CGT GGC TTG CAC AGT 
CTT GA and AGG TCC CGG AAG GCA TGT, respectively, were HPLC purified. The 
probe, CGT CTC CTC TTG CAC CAG AAC CAT GTG, possessed a 5' 6 -FAM Fluor 
label. The working concentrations of Taqman® primers and probes were first optimized 
(Fig. 2.1.A and B), as per the manufacturer’s recommendations.
For sample analysis, total RNA was extracted from cultured postnatal rat cerebellar 
granule neurons with Trizol reagent, and treated with DNAfree (Ambion) to degrade 
contaminating genomic DNA. Reverse transcription was performed, as described earlier, 
using random primers. Each sample was analysed in triplicate. Reactions were each 
performed in a total volume of 50pl, containing 50nM of forward primer, 300nM of 
reverse primer, 50nM of 6 -FAM-labelled probe, 25pl of 2x Universal PCR master mix 
(Applied Biosystems) and approximately lng of cDNA. No template controls, and 
standard curves were also included in each analysis. A predetermined assay reagent 
(PDAR) to detect the endogenous control, 18S rRNA, was used for sample normalisation. 
All reactions were singleplex.
Agarose Gel Electrophoresis
1% agarose-TAE gels were always used in resolving DNA samples. 1% w/v agarose was 
made up with lx TAE buffer (0.4M Tris, 0.2M sodium acetate, 20mM EDTA, pH8.3) in 
a Duran bottle, boiled, and left to cool to approximately 50°C before ethidium bromide 
was added to a final concentration of 0.2pg/ml. The solution was poured to an 
appropriate depth in a gel tray containing a comb with suitably sized teeth, and left for
81
45mins to set. DNA samples were mixed with loading buffer (lx  TAE, 50% v/v 
glycerol, 0.025% bromophenol blue) immediately prior to well-loading. For fragment 
size comparison, samples were run against 5pl of 1 kilobase DNA ladder (Gibco-BRL 
Life Technologies, UK).
Preparation of DNA Fragments
DNA Digestion by Restriction Endonuclease
DNA was incubated with the desired restriction endonuclease(s), diluted in a suitable 
buffer, for a minimum of 1 hour at the appropriate temperature. At least 2 units of (each) 
enzyme per microgram of DNA were used in these reactions. Care was taken to ensure 
that glycerol did not exceed 1 0 % of the total reaction volume and, where appropriate, 
other measures were taken to prevent the ‘star-activity’ that is associated with some 
enzymes.
Generation o f  Blunt-Ended DNA
In the absence of compatible restriction sites for subcloning, ‘sticky-ends’ were blunted 
with the modifying enzyme T4 DNA polymerase (Promega, UK). This enzyme 
possesses 5' to 3' polymerase activity for filling-in 5' overhangs, and 3' to 5' exonuclease 
activity for trimming back 3' overhangs. DNA ends were modified in the presence of a 
suitable restriction endonculease buffer and lOOnM dNTPs. 15 units of enzyme were 
added per pg of DNA. The reaction was incubated at room temperature for 10 mins 
before (i) heat inactivation at 80°C for 30mins, or (ii) purification of the DNA with GFX 
columns (Amersham), as per the manufacturer’s instructions.
Isolation and Purification o f  DNA Fragments
Restriction endonuclease-digested, and/or end-modified, DNA samples were mixed with 
an appropriate volume of 6 x loading buffer (30% glycerol, 0.25% bromophenol blue, 
0.25% xylene cyanol) and resolved on a 1% agarose gel, containing 0.2pg/ml ethidium 
bromide. DNA fragments were visualized on a UV transilluminator, at a low power 
setting, and were quickly and carefully excised with a clean scalpel. The DNA fragment 
was subsequently extracted from the gel using the Gene Clean II Gel Extraction Kit (Bio
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101, Vista, Ca, USA) or GFX columns (Amersham) as per the manufacturer’s 
instructions. The purified DNA was ultimately eluted in an appropriate volume of 
autoclaved double-distilled water.
Annealing o f  DNA Oligonucleotides Encoding shRNA
In constructing vectors for the expression of shRNAs, it was necessary to order custom- 
made DNA oligonucleotides corresponding to the sense and antisense strands of the 
desired hairpin construct (see Chapter 8 ). PAGE purified and 5' phosphorylated DNA 
oligonucleotides were purchased from Sigma-Genosys (Pampisford, Cambridgeshire, 
UK) and diluted in DEPC-treated ddFhO to a stock concentration of lOOmM. Adaptor 
DNA (i.e. annealed oligonucleotide DNA for ligation) was prepared by annealing the 
oligonucleotides at a final concentration of lOOpM each in lx annealing buffer (lOx 
annealing buffer = lOOmM Tris-HCl pH7.5, 1M NaCl, lOmM EDTA pH8.0). The 
annealing reaction was incubated in a water-bath at 65°C for lOmins, before being 
transferred to a beaker of 65°C water and left to cool slowly to room temperature. The 
quantity of double-stranded DNA per pi was calculated from the oligonucleotide data 
sheets, and a range of ligations performed in parallel ( l- 1 0 0 ng of adaptor per ligation 
reaction). Samples of annealed oligonucleotide DNA were placed at -20°C for longterm 
storage.
DNA Ligations
Ligation reactions were performed in thin-walled 0.5ml Eppendorf tubes. Reactions 
consisted of an appropriate amount of linearized gel-purified vector (typically ~ 1 0 0 ng), 
an appropriate molar ratio of gel-purified insert (between 1 to 3 copies of insert per copy 
of backbone), lx T4 DNA ligase buffer and 3 units of T4 DNA ligase (Promega, 
Southampton, UK) made up to a final volume of 20pl with autoclaved double distilled 
water. Ligation reactions were either left at room temperature for several hours (‘sticky- 
end’ ligations), incubated at 4°C overnight (for optimal efficiency with the pGem T Easy 
PCR cloning vector system), or incubated in a thermal cycler (‘blunt-end’ ligations). The 
latter were performed in an Eppendorf Thermocycler, in which the samples were 
incubated at 16°C for lmin followed by 37°C for lmin, for 30 cycles. The final step
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comprised 30mins incubation at 22°C. lOjil of the reaction product were used in the 
transformation of 200pl of competent E. coli.
Bacterial Propagation of Plasmid DNA
Bacterial Strains
A number of different bacterial strains of E. coli were used for plasmid cloning:
XL 1-Blue (Stratagene Ltd., Cambridge, UK) -  This is a standard strain of bacteria for the 
propagation of plasmid DNA. These cells were made competent using the calcium 
chloride method (described below) on the day of transformation, and were used 
extensively prior to the acquisition of the TOPIO strain of E.coli. Genotype = recAl 
endAl gyrA96 thi-1 hsdR17 supE44 relAl lac [F’proAB LacF ZAM15, T N 10 (Tef)]
TOPIO (Invitrogen, Paisley, UK) -  This strain of bacteria can be made competent using 
the rubidium chloride method (described below), and subsequently stored longterm at - 
80°C. This was the preferred bacterial strain for routine cloning. Genotype = F  mcrA 
A(mrr-hsdRMS-mcrBC) 08OlacZAM15 AlacX74 deoR recAl araD139 A(ara- leu)7697 
galUgalK rpsL (StrR) endAl nupG
GT116 (Invivogen, San Diego, CA, USA) -  This strain of bacteria was used for the 
propagation of plasmids encoding shRNAs. It lacks the sbcC and sbcD proteins which 
are responsible for the recognition and cleavage of DNA hairpin structures (Connelly et 
al., 1998). Genotype = F  mcrA A(mrr-hsdRMS-mcrBC) &80lacZAM15 AlacX74 recAl 
endAl AsbcC-sbcD
BL21 (DE3) (Novagen, Merck Biosciences Ltd., Nottingham, UK) -  This strain of 
bacteria was used for the expression of Nogo-6 6 -(His)6 . It lacks the bacterial OmpT and 
Lon proteases, which can significantly impair the recovery of intact recombinant protein. 
Furthermore, it is a lysogen (i.e. has phage viral DNA integrated in its genome) of a 
modified XDE3 phage carrying a hybrid transgene encoding bacterial T7 RNA
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polymerase under the control of the IPTG-sensitive lacUVS promoter. Genotype = F  
ompT hsdSB(rB~mB~) gal dcm (DE3)
Propagation o f Bacteria
Master stocks of XL 1-Blue and TOPIO E. coli were stored longterm in 15% glycerol at - 
80°C. Both strains of E. coli were grown in Luria Bertani media (LB media: 1% w/v 
Bacto®-tryptone, 1% w/v NaCl, 0.5% w/v Bacto®-yeast extract), which had been 
autoclaved at 120°C for 20mins at lOlb/square inch prior to use. Inoculates of 
untransformed bacteria from were initially grown in 5ml LB media in the absence of 
selective antibiotic agents at 37°C overnight in a Gallenkamp orbital shaker, set to 
2 0 0 rpm.
XL 1-Blue E. coli were streaked across an LB Agar (2% Bacto®-Agar) plate, containing 
tetracycline at 12.5pg/ml, under sterile conditions. This plate was incubated overnight at 
37°C, and stored for up to 1 month at 4°C. This served as master plate, from which 
individual bacterial colonies could be picked to make competent cells for transformation. 
In contrast, TOPIO bacteria were stored as ready-prepared aliquots of chemically 
competent bacteria at -80°C for up to one year (described later).
Preparation o f Competent Bacteria 
Calcium Chloride Method (used for XL1-Blue)
XL 1-Blue E. coli were made competent using a protocol based on the calcium chloride 
method described by Sambrook and Russell (2001). In short, lOOpl from the 5ml 
overnight culture of untransformed bacteria (described above), was used to inoculate 
100ml of LB media, containing no antibiotic. This was grown to an optical density of 
0.4-0.55 units at 580nm (OD5 8 0), whereupon the bacteria were pelleted by centrifugation 
at 600 xg for lOmins at 4°C. The supernatant was then carefully removed, and the cells 
washed with lOmls of ice-cold lOOmM CaCL. After 30mins on ice, the cells were again 
pelleted under the same centrifugal conditions, the supernatant was removed and the cells 
resuspended in ice-cold lOOmM CaCl2 to a final volume of 4mls. These competent 
bacteria were stored on ice for a maximum of three days.
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Rubidium Chloride Method (usedfor TOPIO and GT116)
An overnight culture of bacteria was diluted 1:100 with 1 xLB and incubated at 37°C, 
200rpm, until an OD5 8 0 /6 0 0 of 0.3-0.8 was obtained. The culture was kept on ice for 
15mins, and then centrifuged at 600 xg, 4°C, for lOmins. Having discarded the 
supernatant, the pellet from 50ml of culture was re-suspended in 20ml of ice-cold RF1 
(lOOmM RbCb, 30mM potassium acetate; lOmM CaCfe, 50mM MnCh, 15% glycerol, 
titrated to pH5.8 with acetic acid), and left on ice for 15mins. The cells were centrifuged 
at 600 xg, 4°C, lOmins, the supernatant discarded, the pellet re-suspended in 2ml of ice- 
cold RF2 (lOmM MOPS, 75mM CaCh, lOmM RbCh, 15% glycerol, titrated to pH6.5 
with KOH) and left on ice for 15mins. Aliquots of 200pl were prepared, snap-frozen in 
liquid nitrogen, and stored at -80°C.
Transformation o f Competent Bacteria
200pl of competent bacteria were transformed through the addition of an appropriate 
volume of extracted plasmid DNA or ligation reaction product. XL 1-Blue or 
TOP10/GT116 E. coli were incubated with DNA on ice for 30mins, or 1 hour, 
respectively. These E. coli were subsequently heat-shocked at 42°C for 90 seconds, or 45 
seconds, respectively. These cells were then incubated on ice for a further 2mins, or 
5mins, respectively. 800pl of LB, pre-warmed to 37°C, was added to each 
transformation. These were then transferred to a Gallenkamp orbital shaker set to 37°C 
and 200rpm for lhour, or 45mins, respectively. The transformed cells were subsequently 
pelleted by centrifugation at 600 xg, room temperature, for lOmins. Having carefully 
removed the supernatant, the cells were resuspended in lOOjil of LB and plated onto LB 
Agar plates containing the appropriate antibiotic (lOOpg/ml ampicillin or 30pg/ml 
kanamycin, dependent on the resistance gene present in the plasmid DNA). Where 
detection of p-galactosidase activity was desirable, e.g. in using the pGem T Easy PCR 
cloning vector, LB Agar additionally contained a final concentration of lOOpg/ml 4- 
chloro, 5-bromo, 3-indolyl-p-galactosidase (X-Gal, Insight Biotechnology, Ltd.), derived 
from a stock of 20mg/ml in dimethyl formamide.
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Bacterial Growth on LB Agar Plates
Bacterial LB Agar plates were incubated at 37°C overnight, to support colony formation, 
and were then stored at 4°C until required.
Extraction of Plasmid DNA
Small Scale (Mini-Prep)
The “mini-prep” DNA extraction method is derived from the alkaline lysis method 
originally described by Bimboim and Doly (1979). Individual colonies of transformed 
bacteria were picked from antibiotic LB Agar plates and were each used to inoculate a 
single 5ml starter preparation of LB media, containing the appropriate antiobiotic 
selective agent (i.e. lOOpg/ml ampicillin, or 30pg/ml kanamycin). Inoculates were 
incubated overnight at 37°C in a Gallenkamp orbital shaker, set to 200rpm. Cells were 
collected from 1.5ml of culture media by centrifugation at 600 xg for lmin, and 
supernatant was removed by aspiration. Pelleted cells were resuspended in lOOpl of 
Solution 1 (50mM Tris-HCl pH7.5, lOmM EDTA pH8 , lOOpg/ml RNase A), lysed by 
addition of 200pl of Solution 2 (200mM NaOH, 1% v/v Triton X-100), and neutralized 
after 5mins by addition of 150pl of Solution 3 (3M NaOAc pH5.5). The lysate was 
centrifuged for 5mins at 600 xg, and the pelleted debris was removed with a hypodermic 
needle hooked at the tip. The DNA was precipitated by addition of 500pl of isopropanol, 
and pelleted by centrifugation for 5mins at 600 xg. The supernatant was carefully 
removed by aspiration and the DNA pellet was washed with 500pl of 70% ethanol. 
Having removed the wash solution, the pellet was left to air-dry under cover at room 
temperature. After approximately lOmins, the DNA pellet was resuspended in 20pl of 
double-distilled water and stored at -20°C.
Large Scale (Midi-Prep)
Midi-Prep plasmid DNA extractions were performed in order to obtain high grade DNA 
for cloning or transfection. Approximately 150ml of LB media, containing the 
appropriate antibiotic selective agent (i.e. lOOpg/ml ampicillin, or 30pg/ml kanamycin), 
were inoculated with 150pl of the residual bacterial culture from one of the initial
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overnight inoculates used in the mini-prep extraction of DNA for restriction digestion 
analysis. Innoculates were grown overnight at 37°C in a Gallenkamp orbital shaker, set 
to 200rpm. Cells from 100ml of culture were pelleted by centrifugation at 600 xg for 
lOmins, at room temperature. Plasmid DNA was subsequently isolated and purified 
using a commercially available Midi-Prep kit (Marligen), according to the manufacturer’s 
instructions. DNA yields varied, dependent on the nature of the plasmid (i.e. whether it 
was a ‘high copy number’ vector), but typically ranged from 300ng-lpg/pl following 
resuspension in 2 0 0 pl autoclaved double-distilled water.
Identification of Positive Bacterial Colonies
Analytical Digestion o f Mini-Prep DNA by Restriction Endonucleases 
Clonal analysis was usually performed by restriction endonuclease digestion of plasmid 
DNA obtained by Mini-Prep extraction. Typically, lOjul of Mini-Prep DNA were 
digested in a total volume of 2 0 pl. 1 0  units of enzyme were included in the reaction with 
a suitable buffer, as indicated by the manufacturer; where two or more enzymes were 
used, care was taken to ensure that (i) a suitable buffer was used to achieve the highest 
enzymatic activity, and (ii) glycerol levels did not exceed 10%. Restriction endonuclease 
digestions were incubated at a suitable temperature for 1-2 hours. Samples were resolved 
on a 1% agarose gel containing 0.2mg/ml ethidium bromide, and visualized on a UV 
transilluminator.
Colony Transfer and Hybridisation with Radiolabelled DNA Probes 
One particularly valuable method for the identification of positive clones, especially in 
the case of double blunt-end ligations in which the insertional efficiency is usually quite 
low, is to screen bacterial colonies with radiolabelled DNA probes.
Colony Transfer
Transfer of bacterial colonies was achieved by gently impressing a circular Hybond N 
nylon membrane on to the surface of an LB Agar plate, and leaving it in place for 2mins. 
A sterile hypodermic needle was used to make asymmetric puncture marks in the 
membrane, and the Agar plate was similarly marked with indelible ink; this served to
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mark the orientation of the membrane on the plate such that it could be easily discerned 
later. The bacterial cells attached to the membrane were lysed are their DNA denatured 
by immersion in denaturing solution (1.5M NaCl, 0.5M NaOH) for 2mins. The filter 
were next immersed in neutralisation solution (2M NaCl, 1M Tris pH5.5) for 2mins, and 
washed in 2xSSC/0.1% SDS for 2mins. The filter then underwent two further washes in 
2xSSC, for 2mins each, before being left to dry under cover for 20mins. The damp 
membrane was placed colony side up and cross-linked two times using a UV Stratalinker 
2400.
Radiolabelling o f DNA Fragments
All fragments of DNA to be used in the analysis of blotted nylon membranes were 
labelled with a[ 3 2P]dCTP by random primer labelling. The method employed was based 
on that originally described by Feinberg and Vogelstein (1983). All probes were labelled 
using Probequant (Amersham). In brief, the gel-purified DNA fragment was transferred 
to a screw-cap Eppendorf tube and heated to 100°C for 5mins, before snap-cooling on 
ice. Each tube in the Probequant kit contains a lyophilized bead of DNA polymerase 
large fragment (Klenow), buffer salts, random primers, dATP, dGTP and dTTP. These 
are resuspended on ice in a defined volume of double-distilled water, before a suitable 
quantity of the denatured DNA was added and mixed by pipetting. 50pCi of a[ P]dCTP 
were added to each reaction under conditions conforming to the UCL regulations for 
radioactivity usage. The reaction mixture was incubated at 37°C for 30mins and was then 
filtered through a G50 Sephadex column (Amersham, UK), according to the 
manufacturer’s instructions, in order to remove unincorporated label. The radiolabelled 
DNA probe was heated for 5mins at 100°C and snap-cooled on ice for 2mins, 
immediately before addition to the hybridisation solution.
Hybridisation
The membranes were pre-hybridized for at least 1 hour at 65°C in Hybaid bottles 
containing 25mls of pre-heated hybridisation solution (6 x SSC, 5x Denhardt’s reagent 
[lOOx Denhardt’s = 2% w/v bovine serum albumin, 2% Ficoll® (type 400), 2% w/v 
polyvinylpyrrolidone], 0.5% w/v SDS in double-distilled water containing 1 OOpg/ml of
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denatured sheared herring sperm DNA). An appropriate quantity of denatured 
a[32P]dCTP-labelled DNA probe was added to the hybridisation solution, and left 
overnight at 65°C to hybridise. The membrane was washed with a series of pre-heated 
wash solutions for 20mins each (2x SSC, 0.1% SDS; 0.5x SSC, 0.1% SDS; O.lx SSC, 
0.1% SDS), before being wrapped in Saranwrap and exposed to film (Kodak X-OMAT) 
in a radioactivity cassette at -80°C. Where necessary, the membrane was re-washed in 
the third solution and again exposed to film.
Screening by PCR
Occasionally, large numbers of colonies were screened by PCR. This was advantageous 
when insertional efficiency was low, and mini-prep DNA extraction on such scale as was 
necessary to identify a positive clone would have been labour-intensive. In these 
instances, colonies were randomly picked from the desired LB Agar plate, and each 
mixed by pipetting in 50pl LB containing the appropriate selective agent, lpl of each of 
these diluted clonal samples was used for PCR, each in a total reaction volume of 50pl.
Phenol:Chloroform:IAA Extraction and Purification of Plasmid DNA
High-purity DNA, free of protein contaminants, was prepared using the standard 
phenol:chloroform:isoamyl alcohol (LAA) method described by Sambrook and Russell 
(2001). This was performed routinely for all samples obtained by midi-prep DNA 
extraction, since it is a recommended treatment for samples that are to be sequenced, as 
well as for plasmids that are to be used in transfection. Linearized plasmids, for use in 
transfection or in vitro transcription of digoxigenin (DIG) labelled riboprobes, were also 
treated in this manner. DNA samples were diluted in 400pl of double-distilled water, and 
mixed thoroughly by inversion with an equal volume of phenol:chloroform:IAA 
(25:24:1), that had been made with pre-equilibrated phenol, pH7.5. Samples were 
centrifuged for 4mins at 10 000 xg, and the aqueous layer was carefully removed and 
retained. This aqueous solution was subject to further treatments with phenol where 
necessary, until no proteinaceous material could be observed at the interface between the 
aqueous and organic layers. The aqueous layer was subsequently mixed thoroughly by 
inversion with an equal volume of chloroform, and centrifuged at 10 000 xg for 4mins to
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separate the aqueous and organic phases. Again, the aqueous layer was removed and 
retained, and subsequently mixed with 3M NaOAc (pH5.5) (O.lx total volume) and ice- 
cold absolute ethanol (2x total volume). The sample was mixed by inversion and placed 
at -80°C for 1 hour, to precipitate the DNA, before undergoing centrifugation at 10 000 
xg, 4°C, for 20mins. The supernatant was removed, and the pelleted DNA sample 
washed with 70% ethanol. Finally, the wash solution was removed and the pellet left to 
air-dry, undercover at room temperature, for approximately lOmins before being 
resuspended in a suitable volume of autoclaved double-distilled water. Linearized 
plasmid for the synthesis of DIG-labelled riboprobes was resuspended in DEPC-treated 
autoclaved double-distilled water.
DNA Sequencing
All plasmid DNA samples for sequencing were subject to phenol:chloroform:IAA 
extraction and spectrophotometry, to ensure that they were submitted at sufficient purity 
(A2 6 0/A2 8 0 greater than 1.8) and at the correct concentration (~100ng/ml). Samples were 
analysed using an ABI automated fluorescent dye sequencing facility (DNA Sequencing 
Facility, Department of Biochemistry, University of Cambridge, UK). SP6, T7 and T3 
sequencing primers were provided by the DNA Sequencing Facility. All other 
sequencing primers were submitted at a concentration of lOpmol/pl, along with the 
relevant plasmid DNA samples.
Bacterial Expression of Recombinant Nogo-66-(His)6
The sequence encoding the growth cone collapsing Nogo-66 loop sequence was 
amplified by RT-PCR from rat brain total RNA, using the primers CCC ATA TGA GGA 
TAT ATA AGG GCG TGA TC and CTC CTC GAG TCA GTG GTG GTG GTG GTG 
GTG CTT CAG GGA ATC AAC TAA ATC. The DNA product was subsequently 
digested with Ndel and Xho\, before in-frame ligation into the same sites within pET28a 
(Novagen). The sequence was verified by automated dye fluorescent sequencing, prior to 
transformation of BL21 ADE3 lysogen bacteria (Novagen). Postive bacterial clones were 
tested for expression of Nogo-66-(His)6 by induction with ImM IPTG for 3 hours. Total 
cellular protein of uninduced and induced cells from each colony was resolved by 20%
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SDS-PAGE. Coomassie staining of the gel was used for comparison of protein fractions 
of uninduced and induced cells. Following identification of expressing colonies, one was 
selected to assess the fractional localization of the induced protein. This was performed 
according to the pET vector system manual (Novagen). Examination of the media, 
periplasmic, soluble and insoluble cytoplasmic fractions revealed that the majority of the 
protein was retained in inclusion bodies (in the insoluble cytoplasmic fraction), as is often 
the case with bacterially-expressed recombinant proteins. The inclusion bodies were 
solubilized in 6M urea for FPLC purification.
FPLC Purification o f Recombinant Nogo-66-(His)6
Histrap columns (Amersham), primed with nickel as per the manufacturer’s instructions, 
were used in conjunction with an FPLC machine (Amersham) to purify Nogo-66-(His)6. 
Briefly, 6M urea containing the induced Nogo-66(His)6 from solubilized inclusion bodies 
was first passed through the nickel primed columns to capture the protein, which was 
ultimately eluted in a solution of 6M urea containing a rising concentration of imidazole 
(0 500mM) over the course of ten minutes. As the protein was eluted from the
columns into 10 x 5ml fractions, at one minute intervals, continuous optical density 
measurements were recorded at an absorbance of 280nm. Samples of each eluted 
fraction, as well as samples of total cell protein from induced and uninduced transformed 
bacteria, were resolved by SDS-PGE. This was performed using a pre-made 12% Bis 
Tris NuPAGE® gel (Invitrogen) with MES buffer, and a broadrange pre-stained SDS- 
PAGE molecular weight standard (Bio-Rad). Bands of protein were visualized with 
Colloidal Coomassie® Stain (Invitrogen).
Extraction and Analysis of Recombinant HSV-1 genomic DNA
Extraction o f Recombinant HSV-1 Genomic DNA
In order to obtain recombinant HSV-1 genomic DNA, complementing cells were 
transduced with replication-incompetent virus (strain = 1764/4-/27in/RLl+/pR19) at an 
MOI of 0.1, and cultured in the presence of 3mM HMBA. Upon observation of complete 
cytopathic effect, typically 48-72hrs after transduction, growth media was removed, the 
cell monolayer washed with HBSS and then lysed with DNAzol (Gibco-BRL Life
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Technologies). Hereafter, the extraction of viral DNA was performed as described 
earlier.
Southern Blot Analysis o f Recombinant Viral DNA 
Sample Preparation and Gel Electrophoresis
Samples of DNAzol extracted recombinant viral DNA, as well as the source viral DNA 
(negative control), and the source shuttle plasmid (positive control) were digested by 
restriction endonucleases. Typically, 1 OOng of each viral DNA, and 20ng of midi-prep 
plasmid DNA, were digested with at least 10 units of each enzyme in a suitable buffer. 
The digestion reactions were made to a final volume of 50pl, and incubated overnight at 
a suitable temperature. Samples were loaded in alternate lanes of a 1% agarose-TAE gel 
and resolved alongside 5pl of lkb DNA ladder (Gibco-BRL Life Technologies). The 
DNA ladder was visualized on a UV transilluminator and photographed against a 
fluorescent ruler for future reference.
DNA Transfer (Southern Blot)
The DNA was first ‘nicked’ by leaving the gel in place on the UV transilluminator for 
2mins, at the highest setting. It was subsequently immersed for 45mins in denaturing 
solution (1.5M NaCl, 0.5M NaOH), briefly washed with double-distilled water, and then 
immersed for at least 30mins in neutralising solution (2M NaCl, 1M Tris pH5.5). An 
inverted gel tray was stood in a shallow tank of 20xSSC (150mM NaCl, 15mM sodium 
citrate pH8.0), and covered by a wick of 3mm Whatman paper (Whatman, Maidstone, 
Kent, UK). The gel was placed face-down on this platform and covered with a piece of 
Hybond N+ nylon membrane, pre-soaked in 6x SSC. Three pieces of 3mm Whatman 
paper, pre-soaked in 20x SCC, were layered on top and gently rolled with a plastic 
pipette to ensure the removal of any air bubbles. Several inches of dry paper towels were 
placed on top, followed by a sheet of glass and a weight. The blotting apparatus was left 
overnight for the DNA to migrate to the nylon membrane by capillary action. The 
membrane was washed briefly in 6x SSC, left under cover to dry for 20mins, and cross- 
linked twice with a UV Stratalinker 2400. Either the membrane was used immediately 
for radioactive analysis, or it was left under cover for a further 20mins to air-dry before
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being placed in storage at 4°C, sandwiched between 3mm Whatman paper and sealed 
with Saranwrap.
Membrane Analysis
Radioactive analysis of the membrane with a[32P]dCTP-labelled DNA probes was 
performed as described previously.
Synthesis of DIG-Labelled Riboprobes for In Situ Hybridisation
In Vitro Transcription
The desired plasmid was first linearized using a suitable restriction endonuclease, and 
then phenol:chloroform:IAA-extracted as described earlier. Synthesis of digoxigenin- 
labelled riboprobe was performed using a commercial digoxigenin (DIG) labelling kit 
(Boehringer Mannheim), as per the manufacturer’s instructions.
RNA Precipitation
The DIG-labelled riboprobe was precipitated by mixing the reaction product with a 0.1 
volume of DEPC-treated 4M LiCl and 2 volumes of absolute ethanol (-20°C), before 
placing at -80°C for at least lhour. The sample was centrifuged at 10 000 xg, 4°C, for 
30mins to pellet the RNA. A single wash of the pellet was performed with 70% ethanol 
(-20°C) made with DEPC-treated ddfhO. The sample was centrifuged at 10 000 xg, 4°C, 
for 5mins and the supernatant discarded. After 5mins of air-drying under cover, the RNA 
pellet was re-suspended in an appropriate volume of either (i) DEPC-treated ddH20 with 
1% v/v RNasin (Promega, Southampton, UK), or (ii) formamide. In the former case the 
sample was first incubated at 37°C for 30mins, prior to aliquoting and storing at -20°C.
Assessment o f Riboprobe Integrity
1 j L t l  of riboprobe was mixed with 2x formaldehyde loading buffer (10% glycerol, 2mM 
EDTA pH8.0, 0.05% w/v bromophenol blue, 0.05% w/v xylene cyanol) and resolved on 
a 1% agarose-MEA gel (1% w/v agarose, lx MEA [lOx MEA = 200mM MOPS, lOmM 
EDTA, 50mM sodium acetate, titrated to pH7.2 with NaOH], 20% v/v formaldehyde) 
without ethidium bromide. Samples were resolved against a DIG-labelled riboprobe of
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known size, for reference, and then transferred to a nylon membrane by northern blotting. 
With the exception of the UV nicking, denaturation and neutralisation steps this was 
essentially the same as described for Southern blotting. The UV cross-linked membrane 
was washed in buffer 1 (lOOmM Tris-HCl, 150mM NaCl pH7.5) for 15mins, blocked 
with modified buffer 2 (1% Boehringer blocking reagent, 0.5% BSA fraction V in buffer 
1) for 30mins, incubated with alkaline phosphatase-conjugated anti-DIG antibodies 
diluted 1:5000 in modified buffer 2 for at least 30mins, washed in buffer 1 for 15mins, 
equilibrated in buffer 3 (lOOmM Tris-HCl, lOOmM NaCl, 50mM MgCL pH9.5) for 
15mins, and developed in darkness for 15mins with buffer 3 containing 0.34mg/ml 4- 
nitroblue tetrazolium chloride (Boehringer), 0.175mg/ml 5-bromo-4-chloro-3s- 
indolylphosphate (Boehringer). The alkaline phosphatase catalysed reaction was 
quenched with buffer 4 (lOmM Tris-HCl, ImM EDTA, pH8.0) for lOmins. Only those 
samples that gave a single sharp band of the correct size were used for in situ 
hybridisation.
TISSUE CULTURE
Health and Safety Category 1 regulations were observed for all work undertaken with 
replication-incompetent HSV-1.
Tissue Culture Materials and Reagents
All tissue culture plastics were purchased from Nunc, CellStar or Sarstedt. Media, 
supplements and other common tissue culture reagents were purchased from Gibco-BRL 
Life Technologies unless otherwise stated.
Mammalian Cell Lines
Unless otherwise stated, full growth medium (FGM) was used in culturing cell lines. 
FGM comprises Dulbecco’s modified Eagle medium (DMEM), 10% v/v foetal calf 
serum, and lOOunits/ml of penicillin and streptomycin. Serum free medium (SFM) was 
used during DNA transfection or viral transduction of cultured cells; it consists of 
DMEM and lOOunits/ml of penicillin and streptomycin.
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Baby Hamster Kidney Cells (BHKs)
Baby Hamster Kidney Cells (clone 13) (Macpherson and Stoker, 1962) were obtained 
from the Imperial Cancer Research Fund, London, UK. These cells were cultured in 
FGM and incubated at 37°C in 5% CO2 . BHKs were passaged by trypsination (0.25% 
trypsin in versene at 37°C, 5% CO2 , for 2-3mins) after a single wash with Hank’s 
Buffered Saline Solution (HBSS) at room temperature. The activity of the trypsin and 
versene solution was quenched by the addition of an appropriate volume of FGM, and the 
resultant cell suspension was used in seeding as desired.
27/12/M:4 (MAM49)
27/12/M:4 are complementing cells, derived from the BHK clone 13 cell line, which have 
been engineered to stably express ICP4 and ICP27 (Thomas et al., 1999). They are 
necessary for the propagation of those recombinant HSV-1 strains lacking functional 
copies of these genes. These cells were cultured in FGM containing 5% v/v tryptose 
phosphate broth, 800mg/ml neomycin (Gibco-BRL Life technologies, Paisley, UK) and 
750mg/ml of zeocin (Cayla, Toulouse, France). 27/12/M4:4 cells were passaged as 
described for the BHK clone 13 cell line. Cells grown for viral infection were done so in 
the absence of neomycin and zeocin.
HT1080
The HT1080 human fibrosarcoma cell line (Rasheed et al., 1974) was obtained from 
ECACC (No. 85111505). These cells were cultured in FGM and incubated at 37°C, in 
5% CO2 . Passaging was performed as described for BHK (clone 13) cells.
PC12
The PC 12 cell line is derived from a rat adrenal phaeochromocytoma (Greene and 
Tischler, 1976), and was obtained from ECACC (No. 88022401). The cell line can be 
reversibly induced to differentiate into a neuronal morphology, characterized by the 
extension of axons, by incubation with the active 2.5S NGFp subunit. PC 12 cells were 
cultured in RPMI1640 media, with 10% foetal calf serum, 2mM glutamine and lx 
penicillin/streptomycin. Cells were not routinely grown on collagen type IV coated
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coverslips, but care was taken not to dislodge cells growing on electrostatically-charged 
TC plastic. To passage the cells, the media was replaced with a small volume of HBSS 
and the cells were dislodged by agitation. The cell suspension was used for seeding as 
desired.
Cell Line Storage
Following trypsination and neutralisation with FGM, cells were pelleted by 
centrifugation at 1 000 xg, for lOmins. The supernatant was discarded and the cells were 
resuspended in ice-cold DMEM containing 20% v/v FCS. A second ice-cold solution of 
DMEM containing 40% FCS and 16% dimethylsulphoxide (DMSO) was added in an 
equal volume. Typically, cells from a 175cm2 flask were resuspended in a total volume 
of lOmls. The suspension of cells was immediately distributed as 1ml aliquots into pre­
labelled ice-cold 2.0ml cryovials; these were quickly wrapped in paper towels, placed in 
a polystyrene container and stored at -80°C overnight. After 24hrs, the frozen cryovials 
were transferred to liquid nitrogen (-180°C) for longterm storage.
To defrost, aliquots of frozen cells were incubated at 37°C and immediately added to 
10ml of FGM. This cell suspension was centrifuged at 1 000 xg for lOmins. The 
supernatant was discarded, and the cell pellet resuspended in 1ml FGM. Resuspended 
cells were seeded into a 25cm2 flask and incubated at 37°C, in 5% CO2 , until confluent.
Transfection with Plasmid DNA
Transient Transfection
Transfections of plasmid DNA were based on the calcium phosphate method originally 
described by Stow and Wilkie (1976). All transfections were performed with 
phenol:chloroform:LAA extracted midi-prep DNA. Cells were cultured in 35mm wells 
such that they would reach 70-80% confluency at the time of transfection. For each 
transfection, two tubes were set up: the first containing 31 pi 2M CaCb, lpg plasmid 
DNA and 20pg of phenol :chloroform:IAA extracted sheared herring sperm DNA; the 
second containing 400pl HEBES transfection buffer (140mM NaCl, 5mM KC1, 0.7mM 
Na2HP0 4 , 5.5mM D-glucose, 20mM Hepes, titrated to pH7.05 with NaOH and sterilized
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through a 0.2pm filter). The contents of the first tube were mixed by slow pipetting, and 
then added drop-wise to second tube whilst gently agitating to mix. The combined 
solution was left for 40mins at room temperature, allowing the DNA to precipitate. The 
FGM was removed from a 35mm well and replaced with transfection mixture. After 1 
hour incubation at 37°C, in 5% CO2 , the well was over-layed with 1ml SFM and returned 
to incubation. 6 hours later all media was removed, the cell monolayer washed twice 
with 2ml FGM, and then shocked for 90s with ice-cold 20% v/v DMSO in HEBES. The 
cells were washed twice with 2ml FGM, and then over-layed with a final volume of 2ml 
FGM before being returned to incubation.
Stable Transfection (Construction o f the eGFP-Expressing BHK Cell Line)
Stable transfection of plasmid DNA was necessary for the construction of the eGFP- 
expressing BHK cell line, termed ‘clone 2B1’. The initial process was essentially the 
same as that described for transient transfection, except that linearized plasmid was used - 
peGFP-Nl (Clontech), linearized with ApalA. Two days following the transfection of 
one 6-well of BHKs, the cells were trypsinized and seeded into 3x 15cm dishes 
(Sarstedt). Selection of transfected cells was achieved through the addition of neomycin 
to a final concentration of 750pg/ml (members of our laboratory have used killing curves 
to demonstrate that this is the minimum required dose to kill all untransfected cells). 
After a further two days of incubation at 37°C, in 5% CO2 , colonies were selected on the 
basis of uniformity and intensity of fluorescence under an inverted fluorescent 
microscope. Selected colonies were picked in a volume of lOOpl using a P200 Gilson 
microtitre pipette, and were subsequently triturated in one well of a 96-well plate. Two 
96-well plates of clones were grown for 2 days under standard incubation conditions and 
then screened by fluorescence microscopy to identify those clones with uniform 
expression of eGFP at moderate/strong intensity. Sixteen clones of cells were scaled up 
for growth in 6-well plates before one clone, termed ‘clone 2B1’, was ultimately 
identified as the most suitable for use in eGFP knock-down experiments. Aliquots of the 
clone 2B1 stable eGFP-expressing cell line were frozen in liquid nitrogen for longterm 
storage, using the method outlined earlier.
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Production of Recombinant Replication-Incompetent HSV-1 vectors
Virus Strain
The replication-incompetent strain of HSV-1 described in this thesis, termed ‘1764/4- 
/27in/RLl+\ was originally derived from the 17syn+ strain (Brown et al., 1973). The 
‘1764’ vector terminology refers to 17syn+ with deletions of both copies of ICP34.5 
(Maclean et al., 1991) as well a 12bp inactivating mutation in the carboxy terminal 
transactivating domain of VP16, termed m l814 (Ace et al., 1989). The ‘4-‘ refers to the 
deletion of both copies of ICP4, whilst both the ‘27in’ and the ’RL1+’ refer to the 
historical deletion and replacement of functional copies of ICP27 and ICP34.5, 
respectively. In summary, this strain of virus lacks both copies of ICP4 and possesses an 
inactivating 12bp insertion in the transactivating domain of VP 16, but otherwise has the 
full complement of HSV-1 genes.
This strain of HSV-1 was propagated on 27/12/M:4 cells grown in FGM supplemented 
with 3mM hexamethylene bisacetamide (HMBA). The 27/12/M:4 cells are 
complementing cell line that stably express ICP4 and ICP27. HMBA compensates for 
the inactivating mutation in the transactivating domain of VP 16.
Homologous Recombination Transfections
Transfections were broadly performed as described above, except that 10-30pg of viral 
DNA was also included in the first tube. Transfected 27/12/M:4 cells were harvested by 
freeze-thawing after 5-7 days, when numerous plaques had become visible by light 
microscopy. Harvested cells were titred in 35mm wells, and the recombination efficiency 
was determined using fluorescence microscopy. Recombinant viral plaques appeared 
white under UV illumination, whilst non-recombinant plaques appeared green.
Purification o f Viral Recombinants by Plaque Selection
Cells were seeded into six 35mm wells and cultured until ~80% confluent. The growth 
media was removed and harvested transfection product was serially diluted 1:2 with 
SFM, such that a final volume of 500pl could be applied per well. 500pl of undiluted 
harvested transfection product was added to the first well, with the five serial dilutions
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being added to the remaining wells. After lhour of incubation at 37°C, in 5% CO2 , the 
wells were overlayed with 2ml of media consisting of one part 1.6% w/v 
carboxymethycellulose and two parts FGM, with HMBA added to a final concentration 
of 3mM. The cells were incubated at 37°C, in 5% CO2 , for two days before recombinant 
plaques were identified and picked under the 520nm light wavelength of an inverted 
fluorescent microscope. When a pure recombinant population had been selected, i.e. 
when no eGFP-expressing cells could be identified, a single plaque was picked and used 
to infect a 35mm well of 80% confluent cells, as described above (except that no CMC 
was used in over-laying the cells, only FGM containing 3mM HMBA). After 3 days of 
incubation, under standard conditions, the well was harvested by freeze-thawing and 
retained as the master stock; a small volume was used for virus propagation, and the 
remainder was stored in liquid nitrogen.
Production o f High Titre Stocks o f Recombinant HSV-1
27/12/M:4 cells were cultured in a 35mm well until ~90% confluent, and were 
subsequently infected with an appropriate volume of virus from the master stock, as 
described previously. However, after the 1 hour incubation at 37°C, in 5% CO2 , the cells 
were over-layed with 2ml FGM containing 3mM HMBA. The cells were incubated until 
complete cytopathic effect (CPE) had been observed, typically 2-3 days post 
transduction, whereupon the cells were harvested by freeze-thawing. The propagation of 
the virus was gradually scaled-up in 25cm2, 80cm2 and 175cm2 flasks. At least ten 
175cm2 flasks, infected at an MOI of 0.1, and harvested by freezing upon observation of 
CPE were used to obtain a high titre stock of virus. Their contents were pooled after 
defrosting, and were centrifuged at 600 xg, 4°C, for 45mins to pellet cellular debris. The 
supernatant was collected and filtered through 5.0pm (Whatman, Maidstone, UK) and 
0.45pm filter disks (Gelman Life Sciences, Ann Arbor, Michigan, USA). The filtered 
virus-containing media was transferred to Beckman centrifuge bottles, and centrifuged at 
12 000 xg, 4°C, for 2hrs. The supernatants were discarded and the virus pellets were 
resuspended under sterile conditions in no more than 500pl combined total volume. The 
virus suspension was transferred to an autoclaved glass sonicating vial, sealed, and 
subjected to sonication in a water bath (three 20s bursts were each interrupted by a lmin
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incubation on ice). The virus suspension was subsequently aliquoted in 50pl to pre­
labelled chilled cryovials, which were transferred to liquid nitrogen for storage. The 
virus titre was determined using the standard assay of virus titre, described below.
Assay o f  Viral Titre
27/12/M:4 cells were seeded into six 35mm wells and cultured until 70-80% confluent. 
A range of 1:10 serial dilutions of virus suspension in SFM were prepared in a 96 well 
plate, and those ranging from lxlO'9 to lxlO^ml of the original virus suspension were 
used to infect each cell monolayer in a total volume of 500pl SFM. After 1 hour of 
incubation at 37°C, in 5% CO2 , the media was removed and the cells were over-layed 
with 2ml of media comprising one part 1.6% w/v carboxymethylcellulose (CMC) and 2 
parts FGM (1:2), with HMBA added to a final concentration of 3mM. The cells were 
incubated for 48hrs at 37°C, in 5% CO2 , and the number of plaques per well, as 
determined by fluorescence microscopy, was used to calculate the viral titre of the 
original virus suspension. Titres are given as plaque forming units (pfu) per ml.
Primary Cultures of Mammalian Cells
Dissociated Cultures o f Mouse/Rat Embryonic Cortical Neurons 
The brains of four pups from each of three litters were carefully dissected to separate the 
cerebral cortices from the ganglionic eminence in artificial cerebral spinal fluid (ACSF: 
25mM KC1, 2mM KH2PO4 , 25mM HEPES, 37mM D-Glucose, lOmM MgSC>4 , 175mM 
sucrose, 0.5mM CaCh, lx penicillin-streptomycin, pH7.4). The cortices were incubated 
in 0.05% trypsin with lOOug/ml Dnasel in DMEM:F12 for 15 minutes at 37°C. 
Trypsinisation was quenched by addition of DMEM:F12 containing 10% FCS for 5mins 
at 37°C. The excised cortical tissue was then triturated with a fire-polished Pasteur 
pipette until no cellular aggregates were visible. The homogenous cellular suspension 
was subsequently pelleted by centrifugation at 1 000 xg for 3mins. The supernatant was 
discarded and the pellet was resuspended in growth media (DMEM:F12, 2mM L- 
glutamine, lx penicillin-streptomycin, with 1:50 dilution of B-27). Cells were plated out 
on 13mm poly-L-lysine:laminin coverslips at a density of l-2million cells per millilitre 
and left for 30 minutes at 37°C to attach. Following attachment, the cells were overlaid
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with growth media, and incubated at 37°C with 5% CO2 . The media was changed daily. 
After 3 days in vitro (DIV), the cells were fixed in 4% paraformaldehyde (PFA) in PBS 
for twenty minutes, and rinsed in PBS prior to immunohistochemistry.
Preparation o f Poly-L-Lysine:Laminin Coated Coverslips
13mm glass coverslips were immersed in concentrated chromic sulphuric acid overnight, 
rinsed in tap water for several hours, and stored in 70% EtOH. As required, these were 
place in 24-wells under sterile conditions, and left to dry in a tissue culture hood. lOOpl 
aliquots of poly-L-lysine:laminin solution (1 Opg/ml: 1 Opg/ml), made up in sterile ddEhO, 
were added per coverslip. Having been left to dry out overnight in a tissue culture hood, 
the coverlslips were rinsed three times with sterile ddH2 0  prior to use.
Dissociated Cultures o f Rat Postnatal Cerebellar Granule Neurons 
The cerebellar corices were carefully dissected from the brains of 6 P8 Sprague-Dawley 
rats and collected in a Petri-dish containing ice-cold HBSS, where the meninges were 
removed. The tissue was diced into smaller pieces and incubated in 0.05% trypsin with 
lOOpg/ml DNasel in DMEM:F12 for 15mins at 37°C. The solution was carefully 
removed by aspiration, and the segments of tissue washed with HBSS. A solution of 
DNasel, pre-warmed to 37°C, was added (0.1% DNase I, 13.75mM glucose in BME) and 
trituration was performed with a fire-polished Pasteur pipette. The cellular suspension 
was diluted with 2 volumes of ice-cold HBSS, and then placed on ice for 5mins to allow 
the debris to settle. The supernatant was carefully layered on to an ice-cold Percoll 
cushion (40.5% Percoll in HBSS) and centrifuged at 1200 xg, 4°C, for 20mins to separate 
the neuronal and non-neuronal cell-types. The HBSS, the non-neuronal cells at the 
interface, and most of the Percoll was carefully aspirated, leaving the neuronal cell pellet 
in a small volume of residual Percoll. These cells were resuspended in HBSS and 
centrifuged at 80 xg, 4°C, for lOmins. The supernatant was discarded, the cell pellet re­
suspended in culture medium (BME, 2mM glutamine, 1.5M glucose, 2M KC1, heat- 
inactivated FCS [57°C, 30mins], lx penicillin and streptomycin), and the cellular 
suspension again centrifuged at 80 xg, 4°C, for lOmins. Finally, the cell pellet was again 
re-suspended in culture medium and the cellular density determined using a
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haemocytometer. Cells were diluted appropriately and plated on poly-L-omithine coated 
coverslips at a density of 1 x 106cells/13mm well. Cultures were incubated at 37°C, in 
5% CO2 . After 24hrs, cytosine arabinoside was added to a final concentration of lOpM.
Preparation o f Poly-L-Ornithine Coated Coverslips
13mm glass coverslips were removed from storage in absolute ethanol, placed in 24- 
wells under sterile conditions, and left to air-dry. The sterile stock solution of poly-L- 
omithine (lOmg/ml) was diluted to a final concentration of lOpg/ml in autoclaved dH20. 
1.5ml of the working stock was added per 24-well, and incubated for 2 hours at 37°C. 
The poly-L-omithine solution was subsequently removed and the wells washed twice 
with 1.5ml autoclaved dt^O. The coverslips were then left to dry in situ in a sterile 
environment. Plates containing coated coverslips were either used on the day of 
preparation, or were stored at 4°C for up to three days.
Protein Extraction and Analysis
Standard Protein Extraction from Cultured Cells
Growth media was removed from cultured cells, and the monolayer washed twice with lx 
PBS. Cells were lysed in an appropriate volume of lx protein sample buffer (5% P- 
mercaptoethanol, 50mM Tris-HCl pH8.9, 6% v/v glycerol, 2% w/v SDS and 0.005% w/v 
bromophenol blue), heated to 95°C and snap-frozen at -20°C until required. Samples 
were again boiled prior to resolution by SDS-polyacrylamide gel electrophoresis.
SDS-PAGE
SDS-PAGE was essentially performed as described by Sambrook and Russell (2001). 
Gels were prepared in a vertical gel electrophoresis separation system, with resolving gel 
layer typically containing 20% acrylamide (20% acrylamide in 375mM Tris HC1 pH 8.8, 
0.1% w/v SDS, 0.1% ammonium persulphate, and 20pl TEMED in a total volume of 
50mls), although this was dependent on the size of the protein of interest. The stacking 
gel contained 5% acrylamide (5% acrylamide in 0.125mM Tris pH6.8, 0.1% w/v SDS, 
0.1% ammonium persulfate, and lOpl TEMED in a total volume of lOmls). Protein 
samples were mixed with sample buffer and resolved at a constant current (35mA per
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gel), with variable voltage, in lx running buffer (25mM Tris, 250mM glycine, 0.1% w/v 
SDS, pH8.3). Electrophoresis was continued until the proteins of interest had migrated to 
the middle of the resolving gel, as determined by reference to the Rainbow molecular 
weight markers (Amersham).
Staining o f SDS-PAGE Gels with Coomassie R250
Gels were carefully removed from the electrophoresis system. The stacking gel was cut 
off with a sharp scalpel and discarded, whilst the resolving gel was immersed in solution
1 (2% w/v Coomassie Brilliant Blue R250, 25% v/v isopropanol, 10% v/v glacial acetic 
acid) and left under gentle agitation for 30mins. The gel was then transferred to solution
2 (2% w/v Coomassie Brilliant Blue R250, 10% v/v isopropanol, 10% v/v glacial acetic 
acid) and left under gentle agitation for at least an hour. Having been fixed and stained, 
the gel was then transferred to a de-staining solution (15% methanol, 7.5% glacial acetic 
acid) to remove the unbound dye. The gel was left under gentle agitation until bands of 
stained protein had become clearly visible against an unstained background, a process 
typically requiring at least four hours.
Transfer o f Proteins to Nitrocellulose Membranes (Western Blot)
Resolved proteins were transferred from SDS-PAGE gels to Hybond C nitrocellulose 
membranes using the wet transfer method, originally described by Towbin et al. (1992). 
The SDS-PAGE gel, a nitrocellulose membrane and six appropriately sized pieces of 
3mm Whatman paper (Whatman International Ltd., Maidstone, Kent, UK) were pre­
soaked in transfer buffer (50mM Tris, 180mM glycine, 0.1% w/v SDS and 20% v/v 
methanol) and assembled in the Trans-Blot™ apparatus (Bio-Rad, Hemel Hempstead, 
Herts, UK), as instructed by the manufacturer. The transfer was conducted at a constant 
ampage, with variable voltage, either (i) overnight at 20mA, 4°C, or (ii) for 2hrs at 70mA, 
4°C.
Immunodetection o f Proteins on Western Blots
Nitrocellulose membranes were incubated for lhr with blocking solution (5% w/v Marvel 
in lx PBS). Primary antibody, raised against the protein of interest, was diluted in the
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blocking solution to suitable final concentration, and was incubated with the membrane 
for 2 hrs. Three lOmin washes were performed with PBS-T (lxPBS, 0.1% Tween-20), 
before the horse radish peroxidase (HRP) conjugated goat anti-IgG secondary antibody 
(Dako) was applied (diluted 1:1000 in blocking solution). After 1 hour of incubation, the 
nitrocellulose membrane was again washed 3x lOmins with PBS-T. Enhanced 
Chemiluminescence reagent (ECL; Amersham) was used, as per the manufacturer’s 
instructions. The membrane was quickly wrapped in Sarawrap and placed in a cassette 
under film (Kodak X-OMAT). Films were developed after varying exposure times (30s 
to 30mins) to visualise immunodetected proteins.
Equalisation o f Protein loading in Western Blot Analysis
Sample protein concentrations were determined with RcDc reagent (Biorad), as per the 
manufacturer’s instructions. The optical density of each sample was measured and 
compared against the values obtained from the standard curve (known concentrations of 
albumin), in order to calculate sample protein concentration. 20pg of sample protein was 
used for western blotting, unless stated otherwise.
Immunocytochemistry
27/12/M:4 cells and BHKs were grown on sterile uncoated 13mm glass coverslips, 
primary cultures of embryonic or postnatal cortical neurons on poly-L-lysine:laminin 
coated coverslips (prepared as described earlier), and primary cultures of post-natal 
cerebellar granule neurons on poly-L-omithine coated coverslips.
Fixation of cells was performed by removing tissue culture media and adding an 
appropriate volume of 4% PFA in 0.1M phosphate buffer, prewarmed to 37°C. Cells 
were incubated with fixative at 37°C, in 5% CO2 , for lOmins, and then washed two times 
with an appropriate volume of lx PBS. Coverslips were stored, immersed in lx PBS, at 
4°C. Immunoreaction was performed broadly in the same manner as described for slide- 
mounted tissue sections, except that coverslips were placed culture side up on strips of 
Parafilm mounted on glass slides.
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Flow Cytometry
Cells cultured in 6-wells were trypsinized in lOOjul 0.25% trypsin in versene for 5mins at 
37°C, in 5% CO2 , before neutralisation with 400pl of the appropriate FCS containing 
growth media. Cells were pelleted at 1 000 xg, for lOmins at 4°C, and resuspended in 
lOOpl ice-cold HBSS. Fixation was achieved by adding four volumes of fixative (4% 
PFA in 0.1M PB), and incubating for 5mins under standard conditions. Samples were 
again pelleted at 1 000 xg, for lOmins at 4°C, and resuspended in 400|lx1 HBSS. Samples 
were transferred to FACs vials and stored on ice until analysed using a Beckton- 
Dickinson FACS Calibur.
ANIMAL EXPERIMENTATION 
Animals
All animals were housed by UCL Biological Services in standard polypropylene cages, 
under an illumination cycle of 12 hours light and 12 hours darkness, with access ad 
libitum to food pellets and water.
Rats
Sprague-Dawley and Lewis rats were supplied by UCL Biological Services and Charles 
River, respectively. Adult rats, used in the experiments described herein, typically 
weighed 200-300g.
Mice
Balb/c mice were supplied by UCL Biological Services, as were ICR mice.
Animal Surgery
All animal surgery was performed under licence, and in accordance to the regulations of 
the UK Home Office and the UCL Animal Ethics Committee.
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Sterilisation o f Surgical Equipment
All Surgical instruments, drapes and swabs were routinely sterilized by autoclave, for 
20mins at 120°C.
Anaesthesia
Anaesthesia was initially induced by delivery of 1.5% oxygen, 3% nitrous oxide and 4% 
Halothane (Fluothane, ICI) to an anaesthetic chamber. Subsequently, the animal was 
prepared for surgery and transferred to the operating area where anaesthesia was 
administered via a scavenging nose cone. The level of Halothane was reduced to 1.5-2% 
once the animal had become deeply anaesthetised, as indicated by the loss of toe-pinch 
reflex.
Animal Preparation
Veterinary hair clippers were used to shave the appropriate areas prior to surgery. These 
areas were also wiped clean with alcoholic swabs (70% EtOH) before the animals were 
rested on a heated pad in the operating bay. The scavenging nose cone for anaesthetic 
delivery was immediately attached, and the animal covered with a sterile drap.
Surgical Procedures
A Zeiss operating microscope was used in performing most surgical procedures. 
Transection o f the Rodent Corticospinal Tract
Animals were deeply anaesthetised and the skin incised along the midline of the neck. 
The trapesius muscles and postaxial musculature were separated along the midline and 
the vertebral column identified. A laminectomy of the C6 vertebra was performed with 
malleus scissors. The dura was opened and the dorsal columns severed with 
microsurgical forceps, as deep as the central canal, thus severing both the ascending 
dorsal columns and the dorsal corticospinal tracts. The musculature was repaired with 
silk sutures and the skin closed with Michel clips. N.B. This procedure was performed 
by Prof. P.N. Anderson.
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Transection o f the Rodent Sciatic Nerve
A skin incision, parallel and caudal to the femur, was made in the left thigh, and the 
underlying muscles were exposed. The muscles were separated by blunt diossection and 
the left sciatic nerve located. Transection of the nerve was performed at mid-thigh level 
with microsurgical scissors. The skin was closed with Michel clips. N.B. This procedure 
was usually performed by Prof. P.N. Anderson.
Transection o f the Dorsal Root (Rhizotomy)
A  left hemilaminectomy was performed at the L2 vertebra and the dura opened. The L3 
and L4 dorsal roots were identified by their large diameter and transected with 
microsurgical scissors. The cut ends were reanastomosed with a single 10/0 suture. The 
dura was closed with 10/0 sutures, the musculature repaired with silk sutures and the 
skin closed with Michel clips. N.B. This procedure was performed by Prof. P.N. 
Anderson.
Crush o f the Rodent Optic Nerve
The scalp of deeply anaesthetised Sprague-Dawley rats was opened along the midlne and 
the left orbit along its superor margin. The optic nerve was located in its dural sheath and 
the sheath opened with microsurgical sutures. The optic nerve was then crushed 1-2 mm 
behind the eye, avoiding damage to the ophthalmic artery. N.B. This procedure was 
performed by Prof. P.N. Anderson.
Autologous Graft o f Peripheral Nerve to Rodent Thalamus
Adult female Sprague-Dawley rats, weighing 180-250g at the time of implantation, 
received peripheral (tibial) nerve grafts to the thalamus. The rats were anaesthetised with 
Halothane, nitrous oxide and oxygen mixture. The scalp was opened and a bur hole 
made in the left parietal bone and the dura opened. Segments approximately 1.5cm long 
of the left tibial nerve were removed and one end implanted through the craniotomy into 
the left thalamus, using a glass micropippette, to co-ordinates (2.3mm posteror to bregma, 
2.6mm lateral to the midline and to a depth of 6mm) taken from the atlas of Paxinos and 
Watson (1986). The graft was fixed to the skull surrounding the craniotomy with
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cyanoacrylate glue (Histoacryl, B. Braun, Germany). The distal end of the graft was left 
lying on the surface of the skull. The scalp was closed with Michel clips. This procerure 
was performed by Dr. G. Campbell and Prof. P.N. Anderson.
Autologous Graft o f Peripheral Nerve to Rodent Cerebellum
These were performed in a similar manner to the grafts in thalamus, except that the bur 
hole was made in the left occipital bone and the graft implanted with its proximal end in 
the region of the cerebellar deep nuclei (co-ordinates: 11.3mm posterior to bregma, 3mm 
lateral to midline and 6mm deep). N.B. This procedure was performed by Dr. M.R.J. 
Mason.
Microinjection o f Replication-Incompetent HSV-1
The cervical spinal cord of deeply anaesthetised Lewis rats was exposed as described 
above. An opening in the pia was made with a fine needle along the line of the dorsal 
root attachment point. A Hamilton needle approximately 300pm external diameter was 
lowered to a depth of 1.5 mm into the cord through the opening in the pia and allowed to 
sit in place for a minute. Two microlitres of HSV-1 suspension was then injected over a 
period of 15 minutes. The needle was withdrawn after a further 5 minutes, the dura 
closed and the wound closed in layers. N.B. This procedure was performed by Prof. P.N. 
Anderson.
Post-Operative Care
After surgery, animals were placed in an incubator, attended until they had regained full 
consciousness, and then transferred to cages.
Harvesting of Animal Tissues
All animals, operated or unoperated, were culled in accordance to Schedule 2 regulations 
of the UK Home Office. All animals were overdosed with Halothane, except those neo­
natal animals used for establishing primary cultures; these were decapitated.
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For RNA Extraction
Organs or tissues were immediately dissected, and removed to a sterile Petri Dish, 
containing ice-cold DEPC-treated lxPBS, where they were first rinsed and then diced 
into small pieces with a sterile scalpel blade. Diced tissue was collected and immersed in 
an appropriate volume of ice-cold Trizol reagent (Gibco-BRL). RNA was subsequently 
extracted as described previously.
For In Situ Hybridisation
Organs were immediately removed, trimmed as necessary, and transferred to pre-labelled 
Peel-A-Way moulds (Polysciences, inc.) containing a small volume of Tissue-Tek. 
Organs were suitably oriented and then completely immersed in Tissue-Tek. Samples 
were quickly embedded in crushed dry-ice, and left to freeze. Fresh-frozen samples were 
wrapped in Parafilm, and stored at -20°C.
For Immunohistochemistry
Organs or tissues were usually prepared as described above for in situ hybridisation. 
However, it was sometimes necessary to transcardially perfuse a freshly killed animal 
with 4% paraformaldehyde (PFA) in 0.1M Phosphate Buffer (PB). After perfusion, 
organs and tissues were removed to 4% PFA in 0.1M PB to post-fix for an appropriate 
length of time (assumed tissue penetration of 2mm/hour). Organs and tissues were 
cryoprotected by immersion in 30% sucrose in lx PBS, 4°C, at least overnight or until no 
longer buoyant.
HISTOCHEMISTRY 
Non-Radioactive In Situ Hybridisation
The greatest effort was taken to ensure that all solutions and glassware used up to and 
throughout the high-stringency washing phase remained RNase-free. Solutions were 
either treated with DEPC (0.1% v/v DEPC overnight, and then autoclaved) or made using 
DEPC-treated d d ^ O  and molecular-grade reagents. Glassware was always washed with 
a strong detergent, such as D90, and rinsed with DEPC-treated ddH20 prior to use.
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Preparation o f Silanised Slides
Twinfrost slides were distributed in racks and immersed in 10% D90 in tap water for 2 
hours, before they were washed with tap water for 20mins, followed by distilled water for 
several minutes. The slides were treated with acid-alcohol for 15mins, washed in 
distilled water for several minutes, autoclaved at 120°C, and later placed in an oven at 
60°C until completely dry. Once removed, and left to cool to room temperature, the 
slides were immersed for 5mins in a solution of 6% 3-aminopropyltriethoxy-silane made 
up with 100% acetone. Immersions of 2x 2mins in 100% acetone and 2x 2mins in 
distilled water were performed. Having been left to air-dry, the slides were stored in 
closed containers until required.
Fixation and Permeabilisation o f Tissue
10pm fresh-frozen sections were cut, using a Bright cryostat, and thaw-mounted onto 
silanised slides. These were placed in Coplin jars containing fixative (4% PFA in PBS), 
and stored overnight at 4°C. Three 5min washes in lxPBS (made from DEPC-treated 
lOx PBS) were performed, and the sections were subsequently immersed in 70% ethanol 
for 5mins. For longterm storage at 4°C, sections were sequentially dehydrated in 80% 
ethanol for 5mins, followed by absolute ethanol in which they remained; for processing, 
these sections were sequentially rehydrated using the same concentrations of ethanol in 
descending order. The 70% ethanol was removed, the sections washed 2x 5mins in 
DEPC-treated ddH20, immersed in 0.1M HC1 for lOmins, washed 2x lOmins in lxPBS, 
immersed in 0.1M triethanolamine (pH8.0) containing 0.25% acetic anhydride for 
20mins, and again washed 2x 5mins in lx PBS. Finally, sections were sequentially 
dehydrated in ascending concentrations of ethanol (70%, 80%, and 95%) for 5mins each, 
before being removed and allowed to air-dry for several minutes.
Pre-Hybridisation
PAP grease-pen (Dako) was used to encircle all of the sections on each of the slides, 
before they were transferred to an incubation chamber humidified with PBS:Formamide 
(1:1) soaked strips of 3mm Whatman paper (Whatman, Maidstone, Kent, UK). Equal 
volumes of prehybridisation buffer and de-ionised formamide (Fluka) were mixed (50%
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formamide, 25mM EDTA, 50mM Tris HC1 pH7.6, 2.5X Denhardt’s reagent, 0.25mg/ml 
tRNA, 20mM NaCl) and applied to sections. The incubation chamber was sealed with 
parcel tape and incubated at 37°C on a level platform for at least 5 hours, if not overnight.
Hybridisation
Equal volumes of hybridisation buffer (20mM Tris-HCl pH7.5, ImM EDTA, lx 
Denhardt’s reagent, 0.5mg/ml tRNA, 0.1 mg/ml poly A RNA, 0.1M DTT, 10% dextran 
sulphate) and deionised formamide were mixed, and the relevant cRNA probe added at 
an appropriate concentration (typically 2-6pl/ml). The solution was mixed thoroughly by 
inversion and incubated in a waterbath at the desired hybridisation temperature (55- 
65°C). One at a time, the slides were removed from the incubation chamber and the pre­
hybridisation solution was replaced with pre-warmed hybridisation solution. The 
incubation chamber was sealed with parcel tape and incubated overnight at the desired 
hybridisation temperature, on a level platform.
High-Stringency Washing
The slides were loaded into a Coplin jar and immersed in room temperature 0.2x SSC 
(diluted from 20x SSC) for 2mins. Subsequently, the slides were washed 3x 20mins with 
0.1xSSC/50% formamide, pre-heated to an appropriate temperature (55-60°C). For the 
duration of the high-stringency washes, the Coplin jar was incubated in a waterbath at the 
same temperature. Finally, the slides were rinsed in room temperature 0.2xSSC for 
lOmins.
Development
Buffer 1 (lOOmM Tris-HCl, 150mM NaCl pH7.5; diluted from lOx buffer 1) was used to 
equilibrate the sections for lOmins. They were then blocked in modified buffer 2 (1% 
Boehringer blocking reagent, 0.5% BSA fraction V in buffer 1) for 30mins. In the 
meantime, alkaline phosphatase conjugated anti-DIG monoclonal antibody was diluted 
1:1500 in an appropriate volume of modified buffer 2. One at a time, the slides were 
placed in an incubation chamber and overlayed with the antibody-containing solution. 
The chamber was sealed with parcel tape and incubated overnight at 4°C on a level
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platform. The slides were loaded into a Coplin jar, washed 2x 15mins in buffer 1, and 
equilibrated for 2mins in buffer 3 (lOOmM Tris-HCl, lOOmM NaCl, 50mM MgCb 
pH9.5). Slides were replaced in the incubation chamber and overlayed with buffer 3 
containing 0.34mg/ml 4-nitroblue tetrazolium chloride (Boehringer), 0.175mg/ml 5- 
bromo-4-chloro-3s-indolylphosphate (Boehringer), and 0.25mg/ml levamisol (Sigma). 
The incubation chamber was sealed and the sections left to develop in darkness and at 
room temperature for at least 12 hours. Upon microscopic visualisation of the cellular 
accumulation of the chromogen, the alkaline phosphatase catalysed reaction was 
quenched by lOmins immersion of the slides in buffer 4 (lOmM Tris-HCl, ImM EDTA, 
pH8.0). These were washed in distilled water for several minutes, and then left under 
cover in a slide rack to air-dry overnight. The slides were immersed 2x 2mins in 
Histoclear and subsequently mounted in DPX under glass coverslips.
Note that, for all new riboprobes, a range of conditions were tested beginning with low 
hybridisation temperature and excess probe. The temperatures were gradually increased 
and the quantity of probe reduced, until the best results were achieved. At the same time, 
the specificity of each antisense probe was verified by comparison to its respective sense 
probe, which was hybridized under identical conditions. No signal, above the 
background level observed in sections hybridized with antisense probe, was observed in 
sections hybridized with sense probe.
Radioactive In Situ Hybridisation (Radiolabelled DNA Oligonucleotides)
Radiolabelling o f 45-mer DNA Oligonucleotides
45-mer antisense and sense DNA oligonucleotides were labelled with S (Dupont NEN) 
using terminal deoxytransferase (Promega). Levels of probe radioactivity were measured 
with a scintillation counter to ensure counts were greater than 200 000 disintegrations per 
million (DPM) per 400pg of 35S-labelled DNA oligonucleotide. Labelled DNA 
oligonucleotides were stored at -20°C, in 20mM DTT.
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Slide-Mounted Tissue Preparations
Tissue sections for radioactive in situ hybridization were cut, mounted, fixed, and 
dehydrated as described for the non-radioactive ISH procedure.
Hybridisation
Two nanograms of labelled probe were used per milliliter of hybridization buffer (50% 
formamide, 4x SSC, pH 7, 25mM sodium phosphate pH 7, ImM sodium pyrophosphate, 
5x Denhardt’s solution, herring sperm DNA, 0.1 mg/ml polyadenylic acid, 0.1 g/ml 
dextran sulfate, 20mM DTT). For competitive cold controls, unlabelled 45-mer 
oligonucleotides were added to a concentration of 200 ng/ml hybridization buffer, 
inclusive of 2 ng/ml of the respective radioactive probe. One hundred microliters of 
hybridization mixture containing relevant probes was added per slide. Incubation of 
slides was carried out in sealed chambers moistened with 2x SSC and 50% formamide. 
Hybridization was performed at 42°C overnight.
High-Stringency Washing and Exposure to Radiographic Film
Four times 30-min high-stringency washes of the sections were performed using lx SSC 
at 58°C. The sections were subsequently rinsed in 0.1 x SSC at room temperature, before 
being dehydrated in 70% ethanol and 95% ethanol, for 1 min each. Sections were air- 
dried for 30 min and exposed to Biomax MR film (Kodak) for 3-6 days.
Emulsion Dipping
Slides were dipped in a 1:1 ratio of K.5 emulsion (Ilford) and 0.5% glycerol at 42°C and 
allowed to dry. Slides were transferred light-tight boxes, containing silica gel, and stored 
at 4°C for 14 days, before undergoing development. Slides were developed for 2mins in 
D19 (Kodak), rinsed in water, and fixed in Hypam (Ilford) for 4mins. The slides were 
then immersed in water for several hours before being stained with thionine, dehydrated, 
immersed in Histoclear, and coverslipped with DPX.
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Immunohistochemistry
Slide-Mounted Tissue Preparations
20pm fresh-frozen sections were cut with a Bright cryostat and thaw-mounted on to 
Superfrost Plus slides.
Post-Fixation
As a preliminary examination of antigen sensitivity to fixation, different methods of 
tissue-section fixation were employed for newly-acquired antibodies: 30s immersion in -  
20°C methanol; lOmins immersion in -20°C methanol:acetone (1:1); 25mins immersion 
in 95% ethanol/5% acetic acid at 4°C; ~45mins immersion in 4% PFA in lxPBS. Some 
sections were also processed without fixation. However, unless stated otherwise, tissue 
sections were post-fixed with 4% PFA.
Immunochemistry
Sections were immunoreacted in an incubation chamber, containing strips of 3mm 
Whatman paper moistened with lx PBS. A PAP-grease pen was used to outline slide- 
mounted sections before they were rinsed several times in lx PBS prior to incubation for 
30mins at RT in blocking solution (0.1M PBS, 5% NGS, 0.5% Triton-X 100). The 
samples were then incubated with primary antibodies, diluted appropriately in blocking 
solution, overnight at RT. Several washes with lx PBS were performed, and the sections 
incubated with fluorophore-conjugated secondary antibodies, diluted in lx  PBS, for two 
hours at RT. Again, several washes with lx PBS were performed, and the sections 
stained with bisbenzimide (2.5pg/ml) for 7 minutes. Several more washes with lx PBS 
were performed, and the sections coverslipped under DABCO medium (90% glycerol, 
10% 0.1M PBS, 2.5% DABCO (Sigma)) and sealed with nail-vamish. Control sections, 
which were not incubated with primary antibodies, were used to ensure signal specificity. 
Slides were stored in darkness at 4°C.
Primary Antibodies
Details of the primary antibodies that were used in this thesis are listed in Table 2.1.
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Secondary Antibodies
Tetramethylrhodamine-conjugated goat anti-mouse IgG monoclonal antibody (Molecular 
Probes) and Alexa-Fluor conjugated goat anti-rabbit IgG monoclonal antibody 
(Molecular Probes) were each used at a dilution of 1:400 in lx PBS. Secondary 
antibodies were applied either alone or together in lx PBS, as necessary. Both secondary 
antibodies were adsorbed against rat serum before being applied to primary antibody- 
treated sections of rat tissue; briefly, the diluted secondary antibodies were incubated in 
10% rat serum (Sigma) at 37°C, 30mins, and then passed through a 0.45pm filter disk 
prior to application.
Digital Image Capture and Analysis
Immunohistochemically reacted samples were excited, viewed and photographed under a 
Zeiss Axioplan II microscope, and also a Leica TCS SP confocal laser scanning 
microscope where appropriate. Prior to image-capture with the confocal microscope, the 
power of the laser, pinhole, offset and gain were optimized to eliminate cross-talk. A 
sequential series of images was captured, with those from a single optical plane being 
compared directly for the assessment of antigen co-localisation. Standard light 
microscopy for the alkaline phosphatase reacted BCIP-NBT chromogen was undertaken 
with the Zeiss Axioplan II. Digital images captured with the Zeiss Axioplan II 
microscope were initially processed with Openlab image analysis software. All images 
were finally processed in Adobe Photoshop 5.0.
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Figure 2.1.
The optimisation of concentrations of Taqman® primers to ngr (A), and Taqman® 5* 6- 
FAM labelled probe to ngr (B), for their subsequent use in quantitative PCR.
A
Forward and Reverse Primer Concentration (nM)
B
~  30
28
>  26 n n n n n
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NgR Taqman Probe Concentration (nM)
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Table 2.1.
Details of the primary antibodies that have been used in work reported in this thesis.
Antibody Name Type
Working
Dilution Supplier
anti-Nogo-A, 
clone 6D5
Mouse monoclonal IgG 
(raised against purified 
recombinant Nogo-A 
specific peptide)
1:20
Kindly provided by 
Dr.R.K. Prinjha, 
Glaxosmithkline pic., 
Harlow, UK.
anti-Neurofilament
200KDa Rabbit polyclonal
1:20 Sigma
anti-NG2 Rabbit polyclonal 1:10 000
Kindly provided by 
Dr. W.B. Stallcup, The 
Burnham Institute,
La Jolla, California, USA.
anti-GFAP Rabbit polyclonal 1:400 Dako
anti-GFAP Mouse monoclonal 1:600 Dako
anti-ATF3 Rabbit polyclonal 1:800 Santa Cruz
anti-SlOO Mouse monoclonal 1:3000 Sigma
anti-p75NTR Mouse monoclonal 1:100 Sigma
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CHAPTER 3
Expression of mRNA for the Nogo-66 Receptor and its Ligand, 
Nogo-66, in the Intact and Regenerating Nervous System
INTRODUCTION
The hypothesis that myelin breakdown products could be inhibitory to axonal 
regeneration was first posited by Martin Berry following the observation that mechanical, 
but not chemical, ablation of axons prevented regeneration (Berry, 1982). In the late 
1980s, his theory was substantiated by Pico Caroni and Martin Schwab, who successfully 
isolated two fractions of myelin, NI-250 and NI-35, that were inhibitory to DRG and 
SCG neurite outgrowth in vitro (Caroni and Schwab, 1988b). They subsequently raised a 
monoclonal IgM antibody against NI-250, popularly termed IN-1, which recognized both 
NI-250 and NI-35 (Caroni and Schwab, 1988a). This antibody was successfully used in 
numerous in vivo studies to enhance axonal regeneration from different types of injured 
CNS neurons (Schnell and Schwab, 1990; Cadelli and Schwab, 1991; Weibel et al., 1994; 
Bregman et al., 1995; Merkler et al., 2001; Tatagiba et al., 2002). However, more than a 
decade elapsed before the gene encoding the inhibitory components of these fractions 
was independently identified by three different groups (Grandpre et al., 2000; Chen et al., 
2000; Prinjha et al., 2000); Schwab’s group micro-sequenced fragments of the bovine 
ortholog of NI-250, bNI-220 (Spillmann et al., 1998), and used the derivative degenerate 
nucleotide sequences to screen databases of gene sequences and expressed sequence tags 
(ESTs) to identify the gene, which they ultimately termed no go.
The nogo gene was originally thought to give rise to three major isoforms through 
alternative splicing; Nogo-A, -B and -C. The carboxy termini of the Nogo isoforms are 
conserved and share significant sequence identity, as well as predicted structural identity, 
with a family of proteins known as Reticulons (the others being RTN1-3). Nogo is also
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known as Reticulon 4 (RTN4). Although the function of this family of proteins remains 
largely unknown, they have earned their name through their propensity to localize in the 
endoplasmic reticulum (ER); all isoforms of Nogo possess a dilysine ER retention signal 
in their conserved carboxy termini. Although the precise topology of Nogo-A remains a 
contentious issue, it is widely agreed that the conserved carboxy termini of the Nogo 
isoforms contain two large transmembrane domains and a unique 66-residue 
lumenal/extracellular loop structure (termed Nogo-66).
Fournier et al. (2001) used alkaline-phosphatase tagged Nogo-66 to screen for potential 
receptors by expression cloning of a cDNA library in COS cells. A positive clone 
encoding a protein of 473 amino acids was identified. Sequence analysis revealed that 
the protein was predicted to be GPI-linked, with seven leucine rich repeat (LRR) 
domains, a carboxy terminal LRR domain (LRR-CT) and a unique carboxy terminal 
sequence. Importantly, it was demonstrated that the transduction of naive E7 chick 
retinal ganglion cells with recombinant HSV-1, for the expression of NgR, was necessary 
and sufficient to confer sensitivity to Nogo-66 in both neurite outgrowth inhibition and 
growth cone collapse assays.
In addition to the Nogo-66 loop, it has been shown that myelin associated glycoprotein 
(MAG) and oligodendrocyte myelin glycoprotein (OMgp) are also functional ligands of 
NgR (Liu et al., 2002; Domeniconi et al., 2002; Wang et al., 2002b). The mechanism of 
NgR-activated transmembrane signalling is not yet entirely clear, but may in part occur 
through the recruitment of the low affinity neurotrophin receptor, p75NTR (Wong et al., 
2002; Wang et al., 2002a). However, owing to obvious discrepancies in the expression 
profiles of NgR and p75NTR, as well as the absence of enhanced axonal regeneration in 
the injured descending and ascending spinal tracts of the p75NTR null mutant mouse 
(Song et al., 2004), it is widely believed that another signal-transducing co-receptor for 
NgR may exist. Very recently, it has been reported that a novel transmembrane protein, 
LINGO-1, potentiates NgR-activated signal transduction through p75NTR; LINGO-1 is 
apparently incapable of signal transduction in the absence of p75NTR, but is markedly 
upregulated following CNS injury (Mi et al., 2004).
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This chapter details the expression pattern of ngr mRNA in the intact and injured adult 
rodent nervous system, as well as that of the various nogo transcripts which encode the 
Nogo-66 ligand. Autologous peripheral nerve grafts to thalamus and cerebellum were 
performed in order to determine whether there was a correlation between the intrinsic 
ability of different classes of CNS neurons to extend axons into a peripheral graft and ngr 
mRNA expression.
Within the nervous system, the expression of ngr mRNA was found to be neuron- 
specific; however, it is differentially expressed by specific classes of neurons. In 
comparison, nogo-66 mRNA is expressed by both neurons and glia within the intact 
CNS, but is expressed more widely by neurons than ngr. No correlation could be found 
between the ability of CNS neurons to extend axons into peripheral nerve grafts and ngr 
mRNA expression.
SUMMARY OF METHODS 
Animals
Twelve unoperated female Sprague-Dawley rats and 2 unoperated C57 black mice were 
used in these experiments. Sixteen operated rats were also used. In 7 rats, a segment of 
autologous tibial nerve was grafted to the thalamus. These animals were killed at 3 
(n=l), 14 (n=4), and 16dpo (n=2). In 3 rats, an autologous tibial nerve was grafted to the 
cerebellum, with the proximal end in the region of cerebellar deep nuclei. These animals 
were killed at 3 (n=l) and 28dpo (n=2). In 6 rats, the left sciatic nerve was transected. 
These animals were all killed at 3dpo.
Non-Radioactive In Situ Hybridisation
Cloning o f Mouse Ngr
5' and 3' segments of mouse ngr (GenBank Accession No. AF283462) were cloned by 
PCR from a mouse single-stranded DNA library, using the proofreading polymerase Pfu. 
For the 5' segment (bases 135-561), the primers ATC GCT CGA GGA AGC CGC TTC 
CAG TGC CCG AC and ACT GAA GCT TGC CGT GGA ACG TGG TAG GGT CC
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incorporating a Xhol and Hindlll restriction endonuclease site, respectively, were used. 
For the 3' segment (bases 784—1760), the primers ATC GCT CGA GAG TCT TGA 
CCG CCT CCT CTT and ACT GAA GCT TCC CGG AAC CCT GTA AAC ATG 
incorporating a Xhol and Hindlll site, respectively, were used.
Cloning o f Rat Nogo-66
The nogo-66 domain of rat nogo-a (GenBank Accession No. AJ242961; bases 3328- 
3525) was cloned from a rat single-stranded DNA library by PCR using Pfu polymerase. 
The primers ATC GCT CGA GAG GAT ATA TAA GGG CGT GAT C and ACT GAA 
GCT TCT TCA GGG AAT CAA C TA AAT C incorporating a Xhol and Hindlll site, 
respectively, were used.
Cloning o f Rat 3' Nogo Region
The 3' region of rat nogo-a (GenBank Accession No. AJ242961; bases 3222-3801) was 
cloned from a rat single-stranded DNA library by PCR using Pfu polymerase. The 
primers ACT GCT CGA GGG TGG TTG GTG CCA GCT TAT and ATC GAA GCT 
TCA CCC CCG TAA TCA AGT GAG incorporating a Xhol and Hindlll site, 
respectively, were used. All PCR products were ligated into the pSP72 vector (Promega) 
in the same orientation between the Xhol and Hindlll sites. Sequences were verified 
using the ABI prism system.
Synthesis o f DIG-Labelled Riboprobes
In all cases, ^ol-linearized plasmid was used in conjunction with T7 RNA polymerase 
for the in vitro transcription of antisense DIG-labelled riboprobes. Conversely, Him1III- 
linearized plasmid was used with SP6 RNA polymerase for the synthesis of the sense 
DIG-labelled riboprobes. Antisense and sense cRNA probes labelled with DIG were 
generated according to the manufacturer’s recommendations using an RNA labelling kit 
(Boehringer Mannheim, Germany).
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Radioactive In Situ Hybridisation
The antisense and sense 45-mer DNA oligonucleotides to nogo-66, TGA ATG GGT 
GGC CTT CAT CTG ATT TCT GGA TAG CCT GGA TCA CGC and GCG TGA TCC 
AGG CTA TCC AGA AAT CAG ATG AAG GCC ACC CAT TC, respectively, were 
used in the radioactive in situ (as described in Chapter 2).
RESULTS
The two distinct non-overlapping DIG-labelled sense riboprobes to mouse ngr mRNA 
gave no signal (Fig. 3.l.A), whilst the complimentary antisense riboprobes generated an 
identical expression profile (Fig. 3.1.D,E). Furthermore, this pattern of expression was 
found to be the same in both mouse and rat tissue. Confirming the previous report 
(Fournier et al., 2001), ngr mRNA was found to be expressed exclusively in grey matter.
ngr mRNA Expression in the Unoperated Nervous System
All layers of the neocortex showed strong staining, including large cells consistent with 
being pyramidal projection neurons (Fig. 3.1.B). No signal was detected in the 
neostriatum, despite strong expression in the adjacent neocortical tissue (Fig. 3.1.C and 
Fig. 3.2.A), ngr was strongly expressed in neurons of the hippocampus, dentate gyrus, 
piriform cortex and amygdala (Fig. 3.1.C). In the diencephalon, strong expression was 
observed in the medial habenular nuclei and dorsal thalamic nuclei (Fig. 3.1.C-E). There 
was no detectable ngr mRNA expression in thalamic reticular nuclei (TRN), 
hypothalamus, or ventral lateral geniculate nuclei (Fig. 3.1.C and E). In the midbrain, 
moderate expression was found in the red nucleus (Fig. 3.1.F). There was weak 
expression in the substantia nigra pars compacta, and apparently very little in the 
substantia nigra zona reticularis (Fig. 3.1.F). Weaker expression was observed in the 
septal nuclei and basal forebrain neurons (Fig. 3.1.G).
In the cerebellum, the granule cell layer exhibited the strongest expression of ngr mRNA 
(Fig. 3.2.B,C). Purkinje cells exhibited weak/moderate signal, but were best visualized in 
oblique sections through cerebellar cortex (Fig. 3.2.C). Moderate signal was detected in
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the deep cerebellar nuclei, and brainstem nuclei (including reticular nuclei, pontine 
nuclei, nucleus prepositus hypoglossi and vestibular nuclei) (Fig. 3.2.B).
In the spinal cord, there was only low expression of ngr mRNA (Fig. 3.2.D). However, 
expression was comparatively greater in the motor neurons of the ventral horn than the 
secondary sensory neurons of the dorsal horn. Also, there appeared to be a subpopulation 
of 20-30% of DRG neurons that showed low/moderate levels of expression (Fig. 3.2.E); 
the remaining DRG neurons did not express ngr. Similarly, the superior cervical 
ganglion exhibited a similar pattern of expression to DRG, i.e. ngr was only expressed by 
a minority of neurons, and the signal was weak/moderate (not shown).
The thymus was negative for ngr mRNA expression, whilst the heart exhibited relatively 
strong expression (not shown). This is in agreement with previous published findings 
(Fournier et al., 2001). Curiously, in the distal colon, moderate/strong expression of ngr 
was detectable in neurons of the myenteric plexus (Fig. 3.3).
ngr mRNA Expression Following Peripheral Nerve Graft Implantation
Grafting of tibial nerve to thalamus failed to induce expression of ngr mRNA within 
neurons of the TRN, which are particularly adept at innervating nerve grafts (Fig. 3.2.F). 
With the exception of a very slight upregulation of ngr in the dorsal thalamic neurons of 
one animal, this class of neuron also failed to show any consistent change in expression. 
Likewise, implantation of tibial nerve grafts to cerebellum brought about no change in 
baseline expression in the various classes of cerebellar neuron. Deep cerebellar nuclei, 
which have a well documented ability to regenerate axons into nerve grafts (Chaisuksunt 
et al., 2000a), and neurons within the cerebellar cortex, which do not regenerate under 
such conditions, both maintained the moderate levels of ngr expression observed in the 
healthy adult rodent.
Expression of nogo-66 mRNA
Two antisense DIG-labelled riboprobes (to the nogo-66 sequence itself; and to the 3' 
nogo sequence, encompassing nogo-66, and adjacent flanking regions conserved
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throughout all known nogo mRNA species) and one 35S-labelled 45-mer DNA 
oligonucleotide probe set (to the 5' end of the nogo-66 sequence) gave very similar 
patterns of expression (Fig. 3.4.A,D,F). The respective complementary sense probes, and 
competitive cold controls, gave no signal (Fig. 3.4.B,C,E,F).
Contrary to previous reports, transcripts encoding nogo-66 were found to be more 
strongly expressed in grey matter than white (Fig. 3.5.A). Neocortex, hippocampus and 
thalamic nuclei expressed nogo-66 mRNA most strongly (Fig. 3.5.C,D). Neurons of the 
TRN were positive (Fig. 3.5.C). nogo-66 was expressed throughout the neostriatum, but 
most prominently in the larger neurons whose size and distribution matches that of the 
cholinergic intemeurons (Fig. 3.5.A,B). nogo-66 mRNA was also detected in septal and 
vestibular nuclei (Fig. 3.5.E). Moderate expression was detectable in the red nucleus, 
substantia nigra pars compacta and zona reticularis (not shown). In the cerebellum, 
strong expression was detected in Purkinje cells and deep cerebellar nuclei, but not in the 
cerebellar granule cell layer (Fig. 3.5.E,F).
In spinal cord, signal was detected in most neurons, especially in the motor neurons of 
the ventral horn (Fig. 3.6.A,B). There was also sporadic low level expression within the 
white matter of the spinal cord, particularly in the dorsal horns. Strong signal was 
detected from most neurons of the DRG (Fig. 3.6.C). Within the visual system, the 
retinal ganglion cell layer, the outer nuclear layer and the inner nuclear layer all displayed 
moderate to strong expression (Fig. 3.6.E). In the uninjured optic nerve, nogo-66 
transcripts were sporadically present at low/moderate levels in the non-neuronal cells 
(Fig. 3.6.D). Whilst no expression was found in the undamaged adult rat sciatic nerve, a 
clear upregulation of mRNAs encoding Nogo-66 was found in scattered non-neuronal 
cells in the distal stump of the axotomized sciatic nerve, at 3dpo (Fig. 3.7.A-G). This 
upregulation was of greatest intensity in the cells closest to the severed end of the distal 
stump (Fig. 3.7.B). RT-PCR was used to confirm upregulation of nogo-66 transcripts in 
the distal stump, 3dpo (Fig. 3.7.H).
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Expression of nogo-66 transcripts was examined in animals with thalamic grafts. In two 
animals, mild but clear upregulation of these transcripts was found at the graft/brain 
interface (Fig. 3.7.1). However, there was no apparent regulation of expression in any 
defined classes of neuron such as the TRN, which remained positive for nogo-66 
transcripts. Unfortunately, owing to poor cellular preservation of structure in the nerve 
grafts in fresh-frozen sections, it was impossible to discern any regulation of nogo-66 
expression within the graft itself.
DISCUSSION
It has been assumed that Nogo is expressed primarily by oligodendrocytes and that the 
interaction of NgR with its ligands can explain the general failure of axonal regeneration 
in the CNS (reviewed by Filbin, 2003). In this study of the in situ expression of 
transcripts encoding NgR and Nogo-66, it has become clear that nogo-66 transcripts are 
predominantly expressed by neurons and that the NgR-ligand interaction cannot 
universally explain the failure of axonal regeneration in the CNS.
Nogo-66 Receptor
Although the pattern of ngr mRNA expression within the CNS in this study was broadly 
found to concur with that reported by Fournier et al (2001), there is one major difference. 
Cerebellar Purkinje cells gave low to moderate signal for ngr, whilst cerebellar granule 
cells gave decidedly stronger signal. In contrast, Fournier et al (2001) described strings 
of strongly staining Purkinje cells, with little or no signal from cerebellar granule cells. 
Strangely, these results are very similar to those obtained in this study when probing for 
Nogo-66 encoding transcripts in the cerebellum. The initial in situ hybridisation (ISH) 
studies for ngr carried out by Fournier et al (2001) were not exhaustive, which perhaps 
explains why they also did not document the differential expression of ngr in other parts 
of the brain. For example, they did not comment on the striking lack of expression of ngr 
mRNA within the neostriatum nor the low levels in the spinal cord. In their ISH 
experiments, Fournier et al (2001) used a single ~lKb 5' DIG labelled riboprobe. In this 
study, two DIG labelled riboprobes were employed; ~0.5Kb 51 and ~lKb 3' probes were
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generated from distinct non-overlapping sequences. The results obtained from the ISH 
with these two different probes were very similar, implying that the correct profile of ngr 
mRNA expression has been recorded.
Within the nervous system, ngr expression was found to be purely neuronal, being 
strongest in neocortical and hippocampal neurons. This is compatible with studies 
demonstrating that administration of function-blocking antibody against Nogo (mAb IN- 
1) after spinal cord injury in postnatal rats results in augmented sprouting and/or axonal 
regeneration of corticospinal axons (Schnell and Schwab, 1990; Schnell and Schwab, 
1993; Bregman et al., 1995; Raineteau et al., 1999; Bareyre et al., 2002). Conversely, 
ngr is very poorly expressed, if at all, in secondary sensory neurons of the spinal cord. 
Adult DRG neurons - of which only a subpopulation are positive for ngr (20-30% in 
adult rat DRG) - are refractory to treatment with mAb IN-1 following injury to their 
central processes. Attempts to enhance axonal regeneration after injury to the dorsal 
columns (i.e. DRG axons) with mAb IN-1 have proved unsuccessful (Oudega et al., 
2000). However, up to 60% of cultured embryonic DRG growth cones collapse upon 
exposure to soluble Nogo-66; this discrepancy between ngr expression and sensitivity to 
Nogo-66 may be explained by (i) addition of selective trophic agents which alter the 
phenotype of the primary culture (ii) species from which the DRG were obtained (iii) age 
of DRG (iv) a potentially unreliable assay (in so much as growth cones can collapse very 
easily, even in the complete absence of collapsing agents). Interestingly, Purkinje cells 
exposed to mAb IN-1 have been shown to sprout and upregulate growth-associated genes 
c-Jun, JunD, and NADPH Diaphorase (Zagrebelsky et al., 1998; Buffo et al., 2000), 
which is compatible with their expressing NgR, albeit at modest level.
If the interaction of NgR with the Nogo-66 domain of the Nogo family of proteins is an 
absolute determinant of the success of axonal regeneration within the CNS, then one 
would imagine that many classes of neuron devoid of ngr or which only express it at low 
levels, such as primary and secondary sensory neurons, should be capable of a very 
robust regenerative response within CNS tissue given an adequate trophic environment. 
However, there is no evidence to suggest for example, that neostriatal neurons (which
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show no expression of ngr) are especially good at regenerating axons following injury - 
although there is evidence of increased neurite outgrowth following grafting of smooth 
muscle to the neostriatum (Tew et al., 1998). With this in mind, it seems likely that there 
are other factors that have as great or greater a role than NgR ligands in the inhibition of 
axonal regeneration in the injured CNS. Indeed, more likely than not, the success of CNS 
axonal regeneration is likely to be determined multifactorially.
Nogo Family of Proteins
Nogo-66 encoding transcripts were detected by three different probes: 35S-radiolabelled 
45-mer DNA oligonucleotides against the Nogo-66 sequence; DIG labelled riboprobe 
against Nogo-66 sequence; DIG labelled riboprobe against Exons 6-11 of the reticulon 4 
gene (termed 3' Nogo, which encompasses the Nogo-66 sequence -  refer to Table 3.1). 
The profiles obtained using each of these probes were identical. Having performed an 
extensive search of the National Institutes of Health National Centre for Biotechnology 
Information (NCBI) database, seven different Nogo-66 encoding transcripts were 
identified by Open Reading Frame. It is impossible to say which of these isoforms have 
been detected in these ISH experiments, given that the 3' region (Exons 6-11) is perfectly 
conserved throughout all seven transcripts. In spite of this, any of these isoforms should 
in theory be capable of inducing growth-cone collapse through the interaction of their 
identical Nogo-66 domains with NgR (Fournier et al., 2001), provided that the 
subcellular localisation of each is such that this would be mechanically feasible.
Overall, the findings reported herein for the expression of Nogo-66 encoding sequences 
are similar to those of Josephson et al (2001); nogo transcripts were found to be 
expressed in neurons as well as glia -  but, on balance, the expression was predominantly 
neuronal. This is in contrast to earlier reports by Chen et al. (2000), GrandPre et al 
(2000), and Prinjha et al. (2000). Nonetheless, Schwab’s group has since published a 
paper on their ISH and immunohistochemical findings for Nogo expression within the 
nervous system, which described high levels of both nogo-a mRNA and protein in some 
classes of neuron (Huber et al., 2002).
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In addition to the work already published by Josephson et al (2001), in which nogo 
expression was examined in the spinal cord and forebrain, this study has also examined 
nogo-66 in both cerebellum and injured peripheral nerve as well as after peripheral nerve 
graft to thalamus. Curiously, whereas Josephson et al (2001) reported no change in nogo 
regulation following weight drop injury to spinal cord, a moderate but clear upregulation 
at the rim of a peripheral nerve graft to thalamus was observed at 16dpo in this study. 
Naturally, such an upregulation of nogo-66 has the potential to deter NgR-expressing 
neurons from extending axons into the peripheral nerve graft. Neurons from the TRN, 
which are known to grow axons into segments of peripheral nerve grafted to thalamus, 
show no sign of ngr expression but do, however, express nogo transcripts.
Grafting of Peripheral Nerve to Brain
ngr mRNA is strongly expressed by corticospinal and hippocampal neurons -  both of 
which demonstrate little if any ability to regenerate into peripheral nerve grafts implanted 
into the brain (Anderson and Lieberman, 1999). Even when stimulated to regenerate 
with NT-3, corticospinal neurons will not extend axons into peripheral nerve grafts (Blits 
et al., 2000). Likewise, in double transgenic mice overexpressing GAP-43 and LI, axons 
from Purkinje cells turn away from peripheral nerve grafts (Zhang et al, unpublished 
observations). Together, these findings infer that peripheral nerves may harbour 
molecules inhibitory to some types of CNS neuron. Conversely, neurons of the TRN -  
which are devoid of ngr - have a high propensity to extend axons into grafted peripheral 
nerve (Benfey et al., 1985; Morrow et al., 1993; Vaudano et al., 1998) and neurons of the 
substantia nigra pars compacta and basal forebrain, which exhibit only low levels of ngr 
mRNA expression or none at all, are also capable of innervating grafted peripheral nerve 
(Woolhead et al., 1998).
However, there is often no correlation between ngr transcript expression and potential to 
regenerate axons into peripheral nerve grafts. For example, the deep cerebellar nuclei, 
which innervate peripheral nerve grafts very successfully, show moderate to strong 
expression of ngr mRNA (Vaudano et al., 1993; Vaudano et al., 1998; Chaisuksunt et al., 
2000b); though, it is not yet known whether these neurons express the NgR co-receptors,
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p75NTR and LINGO-1, which are necessary for signal transduction. Similarly, most 
neurons of the neostriatum and lateral geniculate nucleus, which do not express ngr 
mRNA, are very poor at regenerating axons into peripheral nerve grafts in the brain 
(Vaudano et al., 1995; Woolhead et al., 1998). That complete absence of ngr mRNA 
expression does not correlate with successful innervation of peripheral nerve grafts, 
implies that other factors have a significant role to play in axonal regeneration and that 
the NgR-ligand interactions alone are not the absolute determinant of regenerative 
success.
Examination of peripheral nerve grafts for expression of nogo-66 was not conclusive, 
owing to the poor quality of the graft in fresh-frozen tissue. However, the observation 
that nogo-66 transcripts are upregulated by non-neuronal cells of the distal stump of 
axotomized peripheral nerve at 3dpo is intriguing, but not unprecedented. Tenascin C 
(Martini, 1994), chondroitin-sulphate proteoglycans (Zuo et al., 1998a; Morgenstem et 
al., 2003; Rezajooi et al., 2004), Sema3A and Sema3F (Scarlato et al., 2003) are also 
upregulated in the injured peripheral nerve. Although the injured peripheral nerve 
regenerates very well, it is clear that the environment in which it achieves this exhibits an 
abundance of inhibitory factors. Why these inhibitory factors are unable to exert a 
greater suppressive influence is not immediately obvious, but is most likely to be due to 
an as yet undefined mechanism of ‘override’ initiated by the presence of large quantities 
of neurotrophins and neurotrophic factors, or indeed by the presence of supportive 
extracellular matrix molecules such as laminin. It is equally plausible that the receptors 
for these ligands in some instances are either absent or downregulated in the regenerating 
neurons.
It should also be noted that, whilst Josephson et al (2001) have failed to detect nogo 
transcripts in uninjured peripheral nerve by in situ hybridization, as was the case in this 
study, Martin Schwab’s group has claimed on two occasions to have detected nogo-b 
transcripts by Northern blot in uninjured sciatic nerve (Chen et al., 2000; Huber et al., 
2002) but closer inspection reveals that the bands presented in both Northern blots are, in
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fact, one and the same. This contrasts with the findings of GrandPre et al (2000), who 
were unable to detect any nogo transcripts in uninjured peripheral nerve by Northern blot.
Neuronal Co-Expression of mRNA Encoding NgR and Nogo-66
The co-expression of ngr and nogo-66 by many types of neuron, including neocortical 
neurons, is quite intriguing. Similarly, a range of human neural and non-neural cell lines 
have been found to express both nogo and ngr mRNA by RT-PCR (Satoh and Kuroda,
2002). All evidence for Nogo-66 based induction of growth cone collapse comes from a 
gain-of-function experiment in which naive embryonic retinal ganglion cells (RGCs), 
transfected with HSV-1 to express NgR, are rendered sensitive to the effects of Nogo-66 
(Fournier et al., 2001). Considering that adult RGCs express both ngr and nogo-66 
transcripts without any obvious abnormalities in neurite outgrowth or growth-cone 
function in vitro, it seems unlikely that the above growth cone collapse observations 
should be correct. That is, at least, until the subcellular location of the proteins is taken 
into consideration; as a GPI anchored protein, NgR localizes to lipid-rafts within the 
membranes of the axons and growth cones (Fournier et al., 2001); whilst Nogo, on the 
other hand, appears to localize primarily to the endoplasmic reticulum owing to its 
carboxy-terminus dilysine ER-retention signal, though a very small fraction of the protein 
has been reported to be expressed in the cell membrane of oligodendrocytes (Oertle et al., 
2003b). Such a distribution of ligand and receptor within the same neuron would be 
expected to limit any interaction intra-neuronally, but not inter-neuronally. Thus, exists 
the possibility that the Nogo-66-NgR interaction has a role, not so much in neurite 
outgrowth inhibition in the injured nervous system, but more so as an axon guidance 
mechanism employed in tract formation during development. Some evidence for this is 
perhaps provided by studies in which the development of corticospinal tract axons in 
early postnatal rats was disrupted by the administration of the IN-1 function-blocking 
antibody (Schwab and Schnell, 1991). Likewise, the intrathecal administration of NEP1- 
40, which antagonizes Nogo-66 binding to NgR, results in significantly enhanced axonal 
outgrowth following corticospinal tract injury; though, more interestingly, these 
regenerating axons appear to navigate ‘blindly’ through the white and grey matter of the 
spinal cord, having lost affinity to their tract of origin (Grandpre et al., 2002). This
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phenomenon could potentially be ascribed to the blocking of the proposed ‘Nogo-66- 
NgR axon guidance mechanism’ described above. A similar theory has been further 
expounded by Raisman, who believes that these interactions could serve as a directional 
influence on axonal elongation, enhancing the growth and regeneration of axons in a 
longitudinal projection (Raisman, 2004). Preliminary evidence for this comes from 
experiments in which E15 mouse hippocampal explants were cultured on substrates of 
Nogo-66 or Nogo-A. It was found that increased fasciculation of outgrowing axons 
occurred on both substrates, but that it was more extensive on a substrate of Nogo-A 
(Mingorance et al., 2004).
The Function of NgR and the Nogo Family of Proteins
Most of the recent findings concerning Nogo and NgR suggest that the initial 
understanding of the Nogo-66-NgR mechanism was hugely oversimplified. The 
attractive model of Nogo functioning principally as a potent myelin associated inhibitor 
of axonal regeneration through its interaction with neuronal NgR has undergone much 
revision, owing to the emergence of numerous lines of evidence which collectively 
indicate a much broader biological role. For example, Nogo-66 encoding transcripts are 
expressed so widely throughout human tissues (Table 3.1) that it seems implausible that 
the various Nogo isoforms do not have diverse functions. Indeed, the Nogo-66 domain, 
which binds NgR, has been shown through yeast-two hybrid studies to interact with three 
mitochondrial proteins (Hu et al., 2002); Nogo-B has been shown to possess pro- 
apoptotic activity (Li et al., 2001) and to interact with AS YIP, otherwise known as 
Reticulon 3 (Qi et al., 2003); Nogo-B has also been implicated in vascular remodeling 
(Acevedo et al., 2004); a testis-specific form of Nogo, Rtn-T, which is the only known 
transcript to contain exon 2, is thought to play a role in testicular development (Zhou et 
al., 2002); and, there is also some evidence that Nogo-A interacts with CASPR at CNS 
paranodes to regulate potassium channel localization during development (Nie et al.,
2003).
In the nervous system, mRNA transcripts encoding Nogo-66 localize predominantly to 
neurons (Josephson et al., 2001; Huber et al., 2002; Hunt et al., 2002b), which is
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indicative of a function quite distinct from that of myelin-mediated inhibition of axonal 
regeneration. Interestingly, these transcripts are only moderately upregulated in a few 
cells at the borders of a site of injury (this study; Hunt et al., 2002b). Other studies have 
reported that mRNAs encoding Nogo family members show no, or only moderate, signs 
of regulation following spinal cord injury (Josephson et al., 2002; Wang et al. 2002). In 
this study, it was also found that Nogo-66 encoding transcripts are upregulated in non­
neuronal cells of the distal stump of axotomized sciatic nerve, especially at the point of 
severance, where clearly they fail to prevent axonal regeneration. However, another 
group has reported that they could not detect any upregulation in the distal stumps of 
transected adult rodent nerve by in situ hybridization (Kim et al., 2003b). From 
preliminary quantitative PCR studies on intact and injured adult rat sciatic nerve, it 
appears that all three major isoforms of nogo are expressed in the intact sciatic nerve -  in 
which they are not detectable by in situ hybridization -  and that some of these are 
upregulated in the distal stumps of injured sciatic nerve within several days of injury (J 
Fabes, Department of Anatomy and Developmental Biology, UCL - personal 
communication). Studies in which either Nogo-A or Nogo-C have been overexpressed 
by Schwann cells in transgenic mice have shown marginally impaired peripheral nerve 
regeneration (Pot et al., 2002; Kim et al., 2003b); therefore, one would imagine that at 
least a small percentage of the endogenously expressed Nogo isoforms would reach the 
cell surface where they would be capable of exerting an inhibitory effect on the 
regenerating peripheral axons, assuming of course that they are expressed by Schwann 
cells.
Northern blot analysis of intact sciatic nerve has produced conflicting results. Whilst 
Schwab’s laboratory has on two occasions published the same blot demonstrating nogo-b 
expression in intact adult rat sciatic nerve (Chen et al., 2000; Huber et al., 2002), 
Strittmatter’s laboratory has not detected any expression of the nogo isoforms (Grandpre 
et al., 2000). By in situ hybridization, at least three groups have failed to detect the 
expression of any of the nogo isoforms in intact nerve (this study; Josephson et al., 2001; 
Hunt et al., 2002b; Kim et al., 2003b). However, as stated earlier, preliminary
133
quantitative PCR appears to show that all three major isoforms of nogo are expressed to 
some extent in intact sciatic nerve.
Somewhat surprisingly, ngr is not regulated after autologous peripheral nerve graft to 
brain (this study; Hunt et al., 2002b) or spinal injury (Josephson et al., 2002). Its 
expression does not correlate with the intrinsic ability of CNS neurons to extend axons 
into grafted peripheral nerve, which indicates that it is not an absolute determinant of 
successful axonal regeneration (this study; Hunt et al., 2002b). The strong expression of 
ngr in other tissues, such as heart (Fournier et al., 2001; Wang et al., 2002c; this study), 
imply that it too is likely to participate in functions unrelated to axonal regeneration. The 
expression of ngr by myenteric neurons also raises some interesting questions, since there 
is no myelin in the enteric system and enteric neurons have no projection to the CNS. 
However, these cells have also been found to express both nogo-a transcripts and protein 
(Chapter 4; Osborne et al., 2004). Whether the two molecules are capable of interacting 
in this system, and what their function may be, remains unknown.
The ngr null mutant mice have so far proved to be something a disappointment. A 
preliminary report suggested neither major phenotypic abnormalities, nor enhanced CST 
regeneration after spinal cord injury (Kim et al., 2003). This perhaps is not surprising 
given that both MAG and Nogo-A can signal in the absence of NgR (Niederost et al., 
2002). However, a slight enhancement in the sprouting of serotonergic fibres in the 
spinal cord was described. It was also reported that the ngr null mutant mice performed 
worse than wild-type control littermates on a Rotarod test, which is used to measure 
learning ability. This is interesting in light of an earlier report which demonstrated 
regulation of hippocampal ngr expression during learning exercises (Josephson et al., 
2002). The most recent report on the ngr null mutant mice claims that corticofugal 
plasticity and the recovery of motor function are enhanced in models of stroke (Lee et al.,
2004).
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Summary
There is no direct correlation between neuronal expression of ngr mRNA in the CNS and 
ability to regenerate axons into peripheral nerve grafts to brain. Nonetheless, the results 
from experiments in which the function-blocking antibody IN-1 was administered to the 
CNS seem to be completely compatible with the findings of this study on the distribution 
of ngr mRNA, as the cells which responded to IN-1 are those which have been found to 
express ngr. Furthermore, it seems increasingly unlikely that the original view of the 
Nogo-66-NgR signaling mechanism being a specific oligodendrocyte-neuron interaction 
is entirely correct. At present, the evidence is suggestive of an additional role in inter­
neuronal signalling, which could potentially have a very important role in axon guidance 
and tract formation during development. In any event, whilst ngr expression is not the 
absolute determinant of success of axonal regeneration within the injured CNS, Nogo is 
still arguably the most potent in vivo inhibitor of axonal regeneration presently known 
and NgR one of the most important gateways for the induction of growth cone collapse 
and neurite outgrowth inhibition. On this premise alone, approaches to knock down 
Nogo/NgR expression or to otherwise disrupt the Nogo-66-NgR interaction should be 
sought and, further, combined with other measures -  such as the provision of 
supplementary neurotrophins - to achieve optimal levels of axonal regeneration of some 
classes of neuron (e.g. corticospinal) within the injured CNS.
CONCLUSION
The distribution of ngr mRNA in situ, both before and after injury, is not consistent with 
its being an absolute determinant of the success of axonal regeneration. Likewise, the 
expression profile of transcripts encoding the NgR ligand, Nogo-66, is indicative of an as 
yet undefined role in neuronal function; that is, in addition to its known role as a myelin- 
associated inhibitor of axonal regeneration.
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Figure 3.1.
A. Cerebellum of adult mouse reacted with sense 3' ngr probe. No signal can be seen; 
compare with Fig 3.2.B. Scale bar = 250pm.
B. Neocortex from an adult mouse hybridized with 5' ngr probe. The pattern of ngr 
signal is very strong in neurons of all layers, but not in glia of the molecular layer or 
subcortical white matter. Scale bar = 500pm.
C. Coronal section through the forebrain of an adult mouse, hybridized for ngr (3' 
probe). Strong ngr signal can be seen in the neocortex and hippocampal formation, 
amygdaloid nuclei (asterisk), medial habenular nucleus (arrow) and in the dorsal 
thalamus (T). The hypothalamus (H) and the small region of neostriatum visible (S) 
show little or no ngr signal, ngr signal is absent from white matter. Scale bar = 1mm.
D.E. Sections through the hippocampal formation and dorsal thalamus (T) from adult 
mice, hybridized with the 5' probe (in D) and the 3' probe (in E). The pattern of ngr 
signal obtained with the two probes is identical. Strong signal can be seen in the 
hippocampus and dentate gyrus and medial habenular nuclei, and in the dorsal thalamus, 
but not in the TRN (between arrows in E) or subcortical white matter, Scale bar = 
500pm.
F. Transverse section through the crus cerebri of an adult rat hybridized with the 3' ngr 
probe. Neurons in the red nucleus (asterisk) show moderate levels of ngr signal but those 
in the substantia nigra pars compacta (arrows) show only very weak signal. Scale bar = 
500pm.
G. Section through the basal forebrain of an adult rat hybridized with the 3' ngr probe 
showing only background levels of signal. The anterior commisures are denoted by 
asterisks. Scale bar = 500pm.
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Figure 3.2.
A. Section through neocortex and neostriatum of an adult rat, hybridized with 3' probe 
Note the virtual absence of ngr signal from the caudatoputamen (asterisk) and the 
subcortical white matter, in contrast to the strong signal from the neocortical neurons. 
Scale bar = 500pm.
B. Section through the cerebellum from an adult rat hybridized with 3' ngr probe. Note 
the strong signal from the granule cell layer (G) and moderate signal from neurons in the 
deep nuclei (asterisk). Scale bar = 500pm.
C. Higher power image of a section through rat cerebellar cortex. The oblique section 
through the cortex allows ngr signal from the Purkinje cells (arrows) to be seen, although 
it is always weaker than that from the granule cell layer. Scale bar = 500pm.
D. Transverse section through the cervical spinal cord from an adult rat hybridized with 
the 3' ngr probe. There is generally little ngr mRNA detectable in the spinal cord 
although motor neurons (arrows) show a distinct but weak signal. Scale bar = 500pm.
E. L5 DRG from an adult rat hybridized with the 3' ngr probe. A subpopulation of 
primary sensory neurons (e.g. at arrows) shows ngr signal. Scale bar = 250pm.
F. Coronal section through the thalamus from a rat 3 days after the implantation of a 
tibial nerve graft (G). Neurons in the TRN (between arrows) still show no ngr signal 
although they are known to regenerate into such grafts. Scale bar = 500pm.
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Figure 3.3.
Longitudinal section of distal colon from adult rat. A and B, Moderate signal for ngr is 
exhibited by neurons of the myenteric plexus. Scale bar = 200pm. This tissue was 
sectioned, reacted and photographed by J. Mills.
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Figure 3.4.
Specificity of nogo probes. Sections through the hippocampal formation and dorsal 
thalamus reacted with 3 antisense probes, and their controls. In A and B sections were 
probed with 35S-labelled antisense Nogo-66 DNA oligonucleotides and viewed with dark 
field illumination. There is strong signal from the labelled probe in A but in B excess 
unlabelled probe has been added as a competitive control to detect non-specific binding. 
In C, S-labelled sense probe has been used and viewed with dark field illumination. 
There is no signal from either of the control sections. In D and E sections were reacted 
with antisense (D) and sense (E) DIG-labelled nogo-66 riboprobes. The section treated 
with sense probe (E) shows no signal. In F and G, sections were reacted with antisense 
(F) and sense (G) DIG-labelled 3' nogo riboprobes. Strong signal is present in the section 
treated with antisense riboprobe (F), but none is present in that treated with the sense 
probe (G). Scale bar = 500pm.
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Figure 3.5.
A. Coronal section through neostriatum from adult rat, reacted with probe for 3' region 
nogo. There is strong signal from many neurons in the neocortex (C) and neostriatum 
(S). There is much weaker signal from the cells in the subcortical white matter (W). 
Scale bar = 500|im.
B. Neostriatum of adult rat reacted with probe for 3' region nogo, showing the strong 
signal from striatal projection neurons and a scattered population of predominantly large 
diameter striatal neurons (arrows). Scale bar = 250pm.
C. Section through the hippocampal formation and thalamus of an adult rat hybridized 
for 3' region nogo. There is strong signal in the hippocampal formation, medial 
habenular nucleus (H), some dorsal thalamic nuclei, and the TRN (indicated by arrows). 
Scale bar = 250pm. Insert shows TRN from adult rat exhibiting strong signal for nogo- 
66 using the radioactive oligonucleotide probe. Scale bar = 500pm.
D. Part of the neocortex from an adult rat, hybridized for 3' region nogo. Note the strong 
signal from neurons in layers 2-6. There is very week signal in the molecular layer (M) 
and weak signal in the subcortical white matter (W). Scale bar = 250pm.
E. Section through the cerebellum and brainstem of an adult rat reacted with the probe to 
3’ region nogo. Strong signal can be detected from Purkinje cells, neurons in the deep 
cerebellar nuclei (D) and vestibular nuclei (V). Scale bar = 1mm.
F. A higher power image of cerebellar cortex from adult rat reacted with the probe to 3' 
region nogo. A line of Purkinje cells (arrows) showing strong signal for nogo can be 
seen, with weak signal from cells in the granule cell layer and background levels in the 
molecular layer (asterisk). Compare with ngr expression in Fig 3.2.B. Scale bar = 250 
pm.
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Figure 3.6.
A. Cervical spinal cord from adult rat reacted with the probe to 3' region nogo. Signal 
can be seen in many neurons in the grey matter, but is strongest in motor neurons. At this 
magnification it is difficult to resolve any signal in white matter. Scale bar = 500pm.
B. Higher power image of cervical spinal cord from adult rat reacted with the probe to 3' 
region nogo. Signal can be seen in many neurons in the grey matter, but is strongest in 
motor neurons (arrowed). Distinct signal is also present in the white matter of the dorsal 
columns (asterisk). Scale bar = 500pm.
C. Lumbar dorsal root ganglia reacted with probe to 3' region nogo. Very strong signal 
is present in primary sensory neurons but not in the Schwann cells. Scale bar = 500pm.
D. Optic nerve from adult rat, reacted with the probe to 3' region nogo. Weak signal can 
be detected in scattered glial cells (arrowed). Scale bar = 100pm.
E. Retina from adult rat, reacted with the probe to 3' region nogo. Strong signal can be 
seen from the ganglion cell layer (R), inner nuclear layer (INL) and the outer nuclear 
layer (ONL). Scale bar = 100pm.
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Figure 3.7.
Detection of nogo in adult rat peripheral nerve.
A,B. Dark field images of distal stump of sciatic nerve 3 days after transection, reacted 
with the radioactive Nogo-66 probe. A low level of signal is present from many cells but 
is strong on scattered cells, particularly near the cut end of the nerve (B). Scale bar = 
500pm.
C. Bright field image of the section seen in Fig 3.7.A. Some cells showing highest levels 
of signal are arrowed. Scale bar = 250pm.
D. Bright field image of contralateral (uninjured) sciatic nerve. No signal for Nogo-66 is 
detectable. Scale bar = 250pm.
E.F. Bright field images of sections of sciatic nerve 3 days after injury (E) and 
contralateral to the injury (F), reacted with the probe to 3' region nogo. Strong signal can 
be seen from scattered cells in the injured nerve (arrows) but not in the intact nerve (F). 
Scale bar = 100pm.
G. Film, after 3 days exposure, showing sections of sciatic nerve from adult rat treated 
with the radioactive probe to Nogo-66. Strong signal is apparent from sections of the 
distal stump of the injured nerve (DS) 3 days after transection, but not from sections of 
the intact nerve (C) which are consequently undetectable in the figure.
H. RT-PCR for nogo-66 from RNA extracted from the distal stump of adult rat sciatic 
nerve, 3 days after transection. A single strong band for Nogo-66 (~0.2Kb) is present 
after 35 PCR cycles. Sample was run against a 1Kb DNA molecular weight marker 
(Gibco BRL) on a 1% agarose gel.
I. In situ hybridization with the probe to 3' region nogo on a section of the thalamus of an 
adult rat 16 days after the insertion of a peripheral nerve graft (G). Increased signal can 
be seen from cells in the thalamus near the graft/brain interface (arrowed). Scale bar = 
500pm.
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Table 3.1.
Splice variants of reticulon 4 containing the nogo-66 coding sequence.
The human reticulon 4 gene has been mapped to chromosome 2pl4-> 13 (Yang et al, 
2000). It comprises 11 known exons and is spread over nearly 80Kb of chromosomal 
DNA. Differential splicing of the gene gives rise to at least seven different mRNAs 
containing the nogo-66 coding sequence. For some of these molecules there are multiple 
encoding sequences deposited in the NCBI database with variations confined to the first 
and last exons -  probably because the sequencing process does not reliably read the ends 
of the transcripts. The dilysine ER retention signal, -KRKAE, is found at the C-terminus 
(Exon 11) of all spice variants. The nogo probes we have used for in situ hybridization, 
to the nogo-66 coding sequence located within exons 6 and 7, and the 3' nogo region 
spanning exons 6-11 have the capacity to detect any of the splice variants listed.
Splice variants containing the nogo-66 coding sequence are widely expressed in normal 
and neoplastic human tissues, implying that this gene is multi-faceted and has functions 
other than inducing neuronal growth cone collapse. Nogo A has a specific domain 
(encoded by exons 3 and 4) which also displays neurite outgrowth inhibitory activity, 
through an unknown mechanism. However, the testis specific reticulon (Rtn-T) is 
translated from a transcript containing these two exons and has been postulated to play a 
role in testicular development.
NIH-MGC: National Institutes of Health - Mammalian Gene Collection project.
NSP -  Neuroendocrine Specific Protein
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EXON 1 2 3  4 5 6 7 8 9  10 11
900Kb 910Kb 920Kb 930Kb 940Kb 950Kb 960Kb 970Kb 980Kb 990Kb
Name
Genbank
Accession
Number
Exon 1 Exon 2 Exon 3 Exon 4 Exon S Exon 6 Exon 7 Exon 8 Exon 9 Exon 10 Exon 11 mRNA
length
Amino
acid
length
Sequence 
submitted by
Source 
(human tissue)
Nogo-A AJ251383 Y N Y Y N Y Y Y Y Y Y 3579 1192 Prinjha et al None specified
Reticulon 4a AF148537 Y N Y Y N Y Y Y Y Y Y 4632 1192 Zhou et al None specified
KIAA0086 AB020693 Y N Y Y N Y Y Y Y Y Y 4053 1192 Ohara et al Adult male brain
Rtn-xL AB040462 Y N Y Y N Y Y Y Y Y Y 4166 1192 Eguchi et al Foetal brain
Testis Specific Rtn (Rtn-T) AF333336 N Y Y Y N Y Y Y Y Y Y 3491 986 Shaetal Adult testis
Nogo-A short form AF320999 Y N N Y N Y Y Y Y Y Y 2883 960 Jin and ju None specified
Brain my043 AF063601 N N N Y N Y Y Y Y Y Y 2481 647 M aoetal Foetal brain
MGC clone: 15807 
IMAGE.3505850 BC016165 Y N Y N N Y Y Y Y Y Y 1784 392 NIK-MGC
Kidney: renal cell
Nogo-B AJ251384 Y N N N N Y Y Y Y Y Y 1122 373 Prinjha et al None specified
Reticulon 4b AF148538 Y N N N N Y Y Y Y Y Y 2235 373 Zhou et al None specified
ASY cell death-inducing gene ABO 15639 Y N N N N Y Y Y Y Y Y 2052 373 Yutsudo Fibroblast
Foocen-m A F132047 Y N N N N Y Y Y Y Y Y 2276 373 Ito and Schwartz Placenta
Rtn-xS AB040463 Y N N N N Y Y Y Y Y Y 1709 373 Eguchi et al Foetal brain
MGC clone;1012S 
IMAGE:3901353 BC010737 Y N N N N Y Y Y Y Y Y 1485 373 NIH-MGC
Pancreas: epitheloid 
carcinoma
MGC clone:13655 
IMAGE:4082756 BC012619 Y N N N N Y Y Y Y Y Y 1654 373 NIH-MGC Brain: glioblastoma
Nogo-C AJ251385 N N N N Y Y Y Y Y Y Y 600 199 Prinjha et al None specified
Reticulon 4C AF087901 N N N N Y Y Y Y Y Y Y 1617 199 Zhou et al None specified
NSPC Homolog AF077050 N N N N Y Y Y Y Y Y Y 1785 199 Song et al Pituitary
NSPC Homolog AF125103 N N N N Y Y Y Y Y Y Y 1798 199 Zhang etal
CD34+ve 
haematopoietic 
stem/progenitor cells
SP1507 Unknown mRNA AF177332 N N N N Y Y Y Y Y Y Y 1700 199 Gu et al None specified
MGC clone: 1239 
IMAGE:3139770 BC001035 N N N N Y Y Y Y Y Y Y 1160 199 NIH-MGC
Placenta:
choriocarcinoma
MGC clone: 14766 
IMAGE:4291127 BC007109 N N N N Y Y Y Y Y Y Y 1079 199 NIH-MGC Skeletal muscle
MGC clone:24257 
IMAGE:3933041 BC014366 N N N N Y Y Y Y Y Y Y 1698 199 NIH-MGC Brain
CHAPTER 4
Nogo-A Expression in the Intact and Injured Nervous System 
INTRODUCTION
Nogo-A is widely considered one of the most inhibitory proteins to axonal regeneration. 
In addition to the Nogo-66 domain, which is present in all Nogo isoforms and has been 
shown to exert neurite outgrowth inhibition through the Nogo-66 Receptor (NgR) 
(Fournier et al., 2001), Nogo-A possesses a unique amino terminus which is also a potent 
inhibitor of neurite outgrowth (Grandpre et al., 2000; Prinjha et al., 2000). This ‘Nogo-A 
specific’ domain is active in the absence of NgR (Niederost et al., 2002). However, 
whilst studies to elucidate a Nogo-A specific receptor have so far proved fruitless, there 
have been numerous studies implicating the Nogo family of proteins, including Nogo-A , 
in ever broader biological processes (Li et al., 2001; Hu et al., 2002; Acevedo et al., 
2004).
(
Within the nervous system, in situ hybridisation studies using pan -nogo antisense 
riboprobes have revealed a widespread distribution of nogo transcripts, both in 
oligodendrocytes and neurons (Chapter 3; Josephson et al., 2001; Huber et al., 2002; 
Hunt et al., 2002b). Furthermore, nogo-a transcripts are also expressed by these cell 
types (Josephson et al., 2001; Huber et al., 2002). That neurons should express nogo-a is 
not in keeping with the notion that Nogo-A functions solely as a myelin associated 
inhibitor of axonal regeneration within the nervous system. Intriguingly, Nogo-A protein 
has been reported to be extensively expressed by CNS and PNS neurons within the 
developing nervous system, prior to the emergence of oligodendrocytes and the onset of 
myelination (Tozaki et al., 2002). It has also been found to be strongly expressed in 
developing muscle (Wang et al., 2002c).
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In situ hybridisation and immunohistochemistry were performed to elaborate on Nogo-A 
expression, particularly by neurons, in the adult rodent nervous system before and after 
injury. Furthermore, localisation of the protein was compared with that in cultured 
embryonic neocortical and adult DRG neurons. Some preliminary observations, 
regarding Nogo-A expression in the developing nervous system and muscle, were also 
made.
SUMMARY OF METHODS 
Animal Models
Twenty operated adult Sprague-Dawley rats were used in these experiments. In 3 rats, 
autologous segments of the left tibial nerve were grafted to the left thalamus. These 
animals were killed at 14 days post operation (dpo). In 8 rats, the left sciatic nerve was 
transected in the thigh, and 2-3mm of the nerve resected to create a gap between the 
proximal and distal stumps. These animals were killed at 4 (n=2), 8 (n=3) and 16dpo 
(n=3). In 6 rats, the dorsal columns of the spinal cord were transected at C6, using 
microsurgical scissors. These animals also underwent a left sciatic nerve transection to 
stimulate the sprouting of dorsal column axons into the lesion site, and were killed at 4 
(n=2), 8 (n=2) and 16dpo (n=2). In 3 rats, the left optic nerve was crushed with 
watchmaker’s forceps. These animals were killed at 4 (n=2) and 14dpo (n=l) days. 
Three unoperated adult Sprague-Dawley rats, and two unoperated P14 male Balb/c mice 
were also used in these experiments. For dissociated adult DRG cultures, three 
unoperated adult Lewes rats were killed. For dissociated embryonic cortical cultures, 
three pregnant ICR mice were killed by dislocation of the neck at 13.5 days post 
conception (E l3.5), and three pregnant Sprague-Dawley rats were each killed at 17 days 
and 19 days post conception (E l7 and E l9). N.B. All observations of Nogo-A 
expression in vivo were derived from Sprague-Dawley rats or Balb/c mice.
Immunohistochemistry
20pm fresh-frozen sections were cut with a Bright cryostat and thaw-mounted on to 
Superfrost Plus slides. As a preliminary examination of antigen sensitivity to fixation,
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different methods of tissue-section fixation were employed: 30s immersion in -20°C 
methanol; lOmins immersion in -20°C methanol:acetone (1:1); 25mins immersion in 95% 
ethanol/5% acetic acid at 4°C; ~45mins immersion in 4% PFA in lxPBS. Some sections 
were also processed without fixation. For all double-labelling immunohistochemistry, 
fixation with 4% PFA was the preferred method. Immunohistochemistry was performed 
as described in Chapter 2.
The following primary antibodies were used in this study: mouse anti-Nogo-A 
monoclonal antibody (clone 6D5; RKP et al., manuscript in preparation; Dupuis et al.,
2002); rabbit anti-neurofilament 200kDa polyclonal antibody (Sigma); rabbit anti-NG2 
polyclonal antibody (kind gift of Dr. W.B. Stallcup, The Burnham Institute, La Jolla, 
California ); rabbit anti-bovine glial fibrillary acidic protein (Dako); rabbit anti-ATF3 
(Santa Cruz). Two secondary antibodies were used: monoclonal tetramethylrhodamine 
conjugated goat anti-mouse (Molecular Probes); monoclonal Alexa-Fluor conjugated 
goat anti-rabbit (Molecular Probes). Both secondary antibodies were adsorbed against rat 
serum prior to use. Control sections, which were not incubated with primary antibodies, 
were used to ensure signal specificity.
SDS-PAGE and Western Blotting
Freshly isolated P8 Sprague-Dawley rat cerebellar granule neurons (a kind gift from 
Laura Facci; prepared as described by Ginham et al., 2001) were homogenized by boiling 
in Laemmli sample buffer (lxlO6 in 200pl). lOpl of lysate was run on a 7.5% Tris- 
glycine polyacrylamide gel (BioRad) adjacent to Rainbow markers (RPN-800, 
Amersham Pharmacia) at 75V. Proteins were electroblotted onto PVDF (BioRad) at 30V 
overnight. The filter was blocked using 5% milk powder (Marvel) in PBS for 90 mins. 
Anti-Nogo-A monoclonal 6D5 conditioned medium was diluted 1 in 20 in 5% milk and 
incubated with the filter for 90 mins. After washing (3x 5mins) with PBS the filter was 
incubated with goat anti-mouse-HRP (BioRad) diluted 1 in 3000 for 90 minutes. The 
filter was washed with four changes of PBS (5 mins each) and then visualized using ECL 
onto Hyperfilm ECL (Amersham Pharmacia). This work was performed by Dr. Rabinder 
Prinjha, Glaxosmithkline pic.
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In Situ Hybridisation
Cloning o f Rat Nogo-A Fragment
A 499bp fragment of Genbank sequence AJ242961 (bases 1517-2015, which correspond 
to part of the ‘Nogo-A specific domain’) was obtained by RT-PCR from adult rat brain 
total RNA. Primers incorporating the internal restriction endonuclease sites Xhol and 
Hindlll were used in the amplification (ACT GCTCGA GAG GAT GCT TCT TTC CCC 
AGT and ATC GAA GCT TAA AAC TGG TGA CGG AGT TGC, respectively). The 
purified DNA product was ligated between these sites in the pcDNA3 vector 
(Invitrogen), and the insert sequence was verified using an automated fluorescent-dye 
sequencing system (Applied Biosystems, UK).
Generation o f DIG-Labelled Riboprobes
Antisense probes were generated by linearisation of the pcDNA3 plasmid with Xhol, 
followed by in vitro transcription with T7 RNA polymerase. Conversely, sense probes 
were generated by linearisation with Hindlll, followed by in vitro transcription with SP6 
RNA polymerase. Antisense and sense cRNA probes labelled with DIG were generated 
according to the manufacturer’s recommendations using an RNA labelling kit 
(Boehringer Mannheim, Germany). In situ hybridisation was performed as described in 
Chapter 2.
RESULTS
Western Blot of P8 Rat Cerebellar Granule Cells with anti-Nogo-A mAb (Fig. 4.1)
Immunoblotting of P8 Sprague-Dawley rat cerebellar granule cell lysate, with the anti- 
Nogo-A monoclonal antibody 6D5, revealed a single strong band of 180KDa. 
Additionally, immunoblotting of cos cell lysate, following transfection with a DNA 
expression vector encoding human Nogo-A, enabled the detection of the same band (not 
shown; RKP et al., in preparation).
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nogo-a mRNA Expression in the Intact Nervous System (Table 4.1)
nogo-a transcripts were expressed widely throughout the nervous system in both white 
and grey matter. In the neocortex many neurons including large pyramidal cells were 
found to express nogo-a, as were many small cells whose morphological appearance 
resembled oligodendrocytes (Fig. 4.2.A). Similarly, cells within the subcortical white 
matter also expressed high levels of nogo-a mRNA. In the neostriatum, cells whose large 
size and scant distribution was consistent with being cholinergic intemeurons were found 
to strongly express the transcript. Lower levels were detectable in many other smaller 
cells within this region (Fig. 4.2.B). In the hippocampus, moderate levels of nogo-a 
expression were found in the CA1-CA4 cells and neurons of the dentate hilus. Very little 
or only background expression was evident in the dentate gyrus (Fig. 4.2.C). Moderate 
levels of nogo-a were present in the red nucleus and substantia nigra pars compacta 
(SNpc) (Fig. 4.2.D).
In the cerebellum, nogo-a transcripts were moderately expressed by small cells within the 
white matter and granule cell layer whose appearance was consistent with being 
oligodendrocytes. Strong expression was also evident in neurons of the cerebellar deep 
nuclei. Interestingly, many Purkinje cells strongly expressed nogo-a, yet some others 
exhibited no expression (Fig. 4.2.E). Only background levels were discernible within the 
granule cell layer, notwithstanding a few larger cells -  thought to be non-granule cell 
neurons -  and smaller presumptive glia. Very strong expression of nogo-a was found in 
neurons of the pontine nuclei (not shown).
In the spinal cord, nogo-a transcripts were most strongly expressed by neurons 
throughout the grey matter, especially within the large motor neurons of the ventral horn 
(Fig. 4.2.F). However, neurons of the superficial dorsal horn exhibited notably lower 
levels of expression. Transcripts were highly expressed by neurons of the dorsal root 
ganglia (DRG), but no discemable expression was observed in either the satellite or other 
non-neuronal cells of the DRG (Fig. 4.2.G). Similarly strong expression was observed in 
neurons of the superior cervical ganglion (Fig. 4.2.H). In the retina, strong expression of 
nogo-a transcripts was readily detectable in the retinal ganglion cell neurons (Fig. 4.2.1).
156
In the distal colon of adult rat, neurons of the myenteric plexus were also found to 
express nogo-a mRNA (Fig. 4.3).
Nogo-A Protein in the Intact Nervous System (Table 4.1)
Since it has previously been reported that different methods of tissue post-flxation affect 
the immunohistochemical detection of Nogo-A (Huber et al., 2002), numerous post- 
fixation methods were examined to verify this claim. Fresh-frozen tissue sections were 
post-fixed with paraformaldehyde, methanol, methanol:acetone (1:1), or acid alcohol, or 
were not post-fixed at all. The pattern of Nogo-A immunohistochemical detection was 
very similar in terms of distribution and relative intensity for all forms of post-fixation 
(as well as none at all), except with acid alcohol. Paraformaldehyde produced the lowest 
background level of signal, whilst methanol or methanol:acetone (1:1) produced the 
strongest cellular signal. In contrast, acid alcohol greatly enhanced white matter 
immunofluorescence and simultaneously decreased the perikaryal signal from both 
neurons and glia. All tissue sections labelled only for Nogo-A were routinely fixed with 
methanol :acetone (1:1), but double-labelled sections were post-fixed with 
paraformaldehyde for compatibility with other examined antigens.
In the neocortex of adult rat, most neurons were only weakly immunoreactive for Nogo- 
A whilst presumptive oligodendrocytes were strongly immunopositive (Fig. 4.4.A). In 
the neostriatum of adult rat, presumptive glia were strongly immunopositive for Nogo-A, 
but moderate immunoreactivity was also detected in large neurons (perikarya > 20pm in 
diameter) whose distribution was consistent with being cholinergic intemeurons (Fig. 
4.2.B, inset). No discemable Nogo-A expression was observed in the perikarya within 
the granule cell layer of the hippocampal formation, but neurons of the dentate hilus were 
immunoreactive for Nogo-A (Fig. 4.2.C, inset). In the cerebral peduncles, both 
presumptive oligodendrocytes and axons were immunopositive for Nogo-A (Fig. 4.4.B). 
In the cerebellum of adult rat, strong immunoreactivity for Nogo-A was detected in the 
neuronal perikarya of the deep nuclei, and in most but not all Purkinje cell perikarya and 
their dendrites (Fig. 4.4.C). Nogo-A could not be detected in the axons of Purkinje cells. 
No obvious nuclear signal for Nogo-A in Purkinje cells, or spinal motor neurons, was
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observed (cf. Jin et al., 2003), but its presence at a lower level than that in the cytoplasm 
could not be definitively excluded. Intriguingly, some Purkinje cell perikarya did not 
exhibit any discernible immunoreactivity for Nogo-A (Fig. 4.4.D). Strong expression of 
the protein was found in numerous other neuronal perikarya throughout adult rat brain, 
including those of the habenular nuclei, the pontine nuclei and the mesencephalic nucleus 
of V (not shown).
In the lumbar spinal cord of adult rat, strong Nogo-A immunoreactivity was detectable in 
neurons throughout the grey matter, especially in motor neurons of the ventral horn (Fig. 
4.4.E). Interestingly, the axons of motor neurons were also found to be Nogo-A 
immunopositve. In cervical spinal cord, some motor neurons in the ventral horn did not 
express Nogo-A (not shown). Strong expression of Nogo-A was observed in the 
presumptive glia, distributed throughout the grey and white matter of both lumbar and 
cervical spinal cord. No co-localisation with NG2 could be demonstrated at either level, 
suggesting that this population of glia does not include oligodendrocyte precursor cells 
(OPCs) (Fig. 4.5.A-C). In the SCG, the perikarya of postganglionic sympathetic neurons 
were strongly immunoreactive for Nogo-A, as were their axons (Fig. 4.4.F). Likewise, 
strong expression of the protein was detected in the perikarya and axons of DRG neurons 
(Fig. 4.4.G). In the intact sciatic nerve of adult rat, immunofluorescent signal for Nogo- 
A was detected in apparently all myelinated axons (Figs. 4.5.D-F), but was particularly 
prominent in bundles of unmyelinated axons (Fig. 4.4.H).
High levels of Nogo-A protein expression were detected in the retinal ganglion cells of 
adult rats (Fig. 4.6.A). However, their axons were much less readily immunoreactive, 
both in the retinal nerve fibre layer and the optic nerve (Fig. 4.6.B-C). Strong expression 
of Nogo-A was found in the perikarya and axons of the ciliary ganglion neurons (Figs.
4.6.C and D).
Nogo-A Expression in the Embryonic and Early Postnatal Nervous System
Nogo-A was found to be expressed throughout the telencephalic wall of embryonic 
mouse forebrain. At El 3.5, the protein appeared to be present in the perikarya of radial
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glia, their processes, as well as tangentially aligned axon-like structures (Fig. 4.7.A). 
However, immunofluorescent signal for Nogo-A did not co-localize with that of 
calretinin, a calcium-binding protein, expressed by preplate neurons. At E l7.5, structures 
reminiscent of radial glia within the cortical plate (CP) were immunopositive for Nogo- 
A, as were corticofugal and corticopetal fibres in the intermediate zone (IZ) (Fig. 4.7.B). 
Sections through E 14 rat hindlimb immunoreacted for Nogo-A and neurofilament 
revealed that developing peripheral nerve, as well as skeletal muscle, express high levels 
of Nogo-A (Fig. 4.8.A-B).
In the neocortex of P14 mouse, Nogo-A was not obviously expressed by neurons, but was 
by presumptive oligodendrocytes (Fig. 4.7.C). In the neostriatum of these animals, 
Nogo-A was not detected in any neuronal perikarya. However, presumptive 
oligodendrocytes, often closely associated with bundles of axons, were strongly 
immunoreactive for the protein (Fig. 4.7.D).
Nogo-A Expression in Cultured Neurons
Dissociated cultures of adult Lewis rat DRG neurons (3 days in vitro; DIV), foetal 
(E13.5) ICR mouse cortical neurons (3DIV) (Fig. 4.6.E-G) and foetal Sprague-Dawley 
rat E l7 and E l9 cortical neurons (3DIV) (not shown) exhibited strong perikaryal Nogo-A 
immunoreactivity. Within the neurites, Nogo-A expression was most marked in the 
growth cones (Figs. 4.6.F-H) arid axonal varicosities. Strong expression was also often 
present at branch points or at sites where axons crossed (Fig.s 4.6.E-H). Intriguingly, 
Nogo-A immunofluorescent signal tended to be detected more distally within the neurites 
than was that of neurofilament (Fig. 4.6.F). Indeed, in the growth cones, most of the 
signal for Nogo-A was localized to the central domain and rarely to the periphery (Fig.
4.6.H); however, it was occasionally detected in some filopodia.
Nogo-A Expression after Peripheral Nerve Injury
Transcripts for nogo-a were not detected in intact adult rat sciatic nerve, nor the proximal 
and distal stumps of transected sciatic nerves at 4, 8 and 16 days post operation (dpo) 
(Figs. 4.9.A-B). However, strong immunofluorescent signal for Nogo-A was present in
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the axons within the proximal stumps at all timepoints. At 4 dpo, axonal sprouts were 
observed at the severed end of the proximal stump (Figs. 4.10.A-B) and, by 8 and 16dpo, 
these were found to have extended distally with many axons having entered the distal 
stump (Figs. 4.10.C-D and 4.11.A-B). The majority of sprouting and regenerating axons, 
identified by neurofilament immunoreactivity, were Nogo-A immunopositive at all 
timepoints after transection. However, the relative expression was variable: the fibres 
which were most prominently immunoreactive for Nogo-A were not always strongly 
immunoreactive for neurofilament, and vice versa (Figs. 4.5.G-I). In fact, the 
regenerating axons exhibited a more patchy immunoreactivity for Nogo-A than they did 
for neurofilament. This was such that the Nogo-A-defined axons were often slightly 
different in shape compared to the neurofilament-defined axons. Clearly, the tips of 
many regenerating axons expressed signal for Nogo-A, but not for neurofilament (Figs. 
4.10.C-F). It would seem, therefore, that Nogo-A may serve as a suitable 
immunohistochemical marker for most regenerating axons in injured peripheral nerve.
At 16dpo, in the tissue bridge between proximal and distal stumps, spontaneously 
generated small striated muscle fibres were found amid the regenerating axons. 
Interestingly, these ectopic muscle fibres were always strongly Nogo-A immunoreactive 
(Figs. 4.11 .A-D), and were often observed in contact with regenerating axons which had 
grown along their surface (Figs. 4.1 l.E-F). Those axons which had come into contact 
with these Nogo-A immunopositive muscle cells exhibited varying degrees of 
immunoreactivity for the protein, but many were found to express high levels of Nogo-A. 
No discernible regulation of Nogo-A expression by axotomized motor or DRG neurons, 
themselves identified by ATF3 immunoreactivity in their nuclei, was observed at 4dpo 
(not shown).
Nogo-A Expression After Peripheral Nerve Implantation into the Thalamus
At 16dpo, in situ hybridisation revealed a strong expression of nogo-a mRNA in a ring of 
cells bordering the tip of a autologous tibial nerve graft in thalamus (Fig. 4.9.C). No such 
pattern of expression was detected contralateral to the graft. Transcripts for nogo-a were 
abundant in the neurons of the thalamic reticular nucleus - which is the source of the
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majority of regenerating axons following peripheral nerve graft to thalamus -  on both the 
grafted and contralateral (i.e. non-regenerating) sides. There was no obvious regulation 
of nogo-a mRNA expression in these regenerating intrinsic CNS neurons.
Nogo-A Expression After Spinal Cord Injury
Dorsal column transection and concomitant sciatic nerve conditioning lesions were 
performed on adult Sprague-Dawley rats to assess transcript and protein expression at 
different timepoints after injury. At 8dpo, a mild upregulation of nogo-a mRNA 
expression was observed in cells bordering a lesion to the dorsal columns of adult rat 
spinal cord (Figs. 4.9.D-E). However, there were far fewer nogo-a-expressing cells 
within the lesion site itself compared to the surrounding spinal cord tissue. In contrast, 
immunohistochemical analysis of Nogo-A expression after dorsal column injury revealed 
a markedly different picture. As early as 4dpo, there was a considerable increase in 
Nogo-A immunoreactivity. This was predominantly detected in neurites at the borders of 
the lesion, especially in axons in the ascending dorsal columns, and also in some 
scattered perikarya. The lesion site was for the most part devoid of Nogo-A 
immunoreactivity (Fig. 4.12.A). Nonetheless, by 8 and 16dpo, Nogo-A could be 
observed in swollen axons within the ascending dorsal columns caudal to the injury, as 
well as in fibres penetrating the lesion site (Figs. 4.12.B and D). Most of these fibres 
were also immunoreactive for neurofilament (Fig. 4.12.C), indicating that these were 
indeed axonal sprouts. No colocalisation of Nogo-A with GFAP orNG2 immunoreactive 
structures could be found (Figs. 4.12.E-F), demonstrating that these penetrating fibres 
were not the processes of astrocytes or NG2 immunopositive glia. Within the lesion site, 
some in-growing Nogo-A positive processes terminated with large rounded 
neurofilament negative structures which were consistent with being retraction bulbs. In 
some instances, confocal microscopic analysis of a single optical plane revealed that 
axons, both in the ascending dorsal columns caudal to the lesion as well as in the lesion 
itself, were immunoreactive for neurofilament and Nogo-A (not shown). At later 
timepoints, some Nogo-A immunoreactive perikarya were identified within the lesion 
sites (not shown), usually near the borders. Similarly, strong upregulation of Nogo-A 
was detected in some neuronal perikarya in the grey matter at the lesion borders.
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Nogo-A Expression After Optic Nerve Crush
At 4dpo, the lesion site could clearly be defined by the relative absence of Nogo-A and 
GFAP immunoreactivity. Conversely, the proximal and distal boundaries of the lesion 
site were further enhanced by an upregulation of Nogo-A expression (Fig. 4.12.G). The 
perikarya of small cells, consistent with being oligodendrocytes, strongly expressed 
Nogo-A. No axonal labelling was readily discernible in the proximal stump of the 
crushed optic nerve, owing to the high level of background signal presumably due to the 
presence of large amounts of myelin (Fig. 4.12.H). Nonetheless, axonal sprouts, 
identified by their neurofilament immunoreactivity, had entered the lesion site from the 
proximal stump. Some of these invading neurites weakly expressed Nogo-A, which was 
visible because of the lower background signal within the lesion site. However, some 
putative axonal sprouts were found to express Nogo-A, but not neurofilament (not 
shown).
DISCUSSION
This study has confirmed many previous reports that Nogo-A is expressed by numerous 
types of neuron. As well as confirming that the protein is expressed by presumptive 
oligodendrocytes, but not astrocytes, it was also demonstrated that it is not expressed by 
NG2 immunopositive glia. Additionally, it was shown that Nogo-A is extensively 
expressed throughout the intact and regenerating axons of the peripheral nervous system. 
Nogo-A is very strongly expressed by unmyelinated axons in peripheral nerves, but 
appears to be expressed with varying degrees of intensity by most, if not all, peripheral 
nerve axons. In vitro dissociated cultures of E l3.5 mouse, as well as E17 and E19 rat, 
neocortical neurons and adult rat DRG neurons exhibited strong expression of Nogo-A, 
most notably in the neuronal perikarya, axonal varicosities and growth cones. In vivo, 
following the transection of adult rat sciatic nerve, regenerating axons were found to 
contain large amounts of Nogo-A, as were ectopic striated muscle fibres that arise 
spontaneously in the tissue bridge between proximal and distal stumps amid the 
regenerating Nogo-A immunoreactive axons.
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In adult rats, which had undergone a dorsal column transection and a concomitant sciatic 
nerve conditioning lesion, many axons sprouting into the spinal dorsal column lesion site 
were found to contain Nogo-A and, moreover, represented the major source of the protein 
within the lesion. In short, a strong expression of axonal Nogo-A appeared to correlate 
well with the ability to regenerate.
Expression of nogo-a mRNA vs. nogo-66 mRNA in the CNS
Transcripts encoding the Nogo-66 ligand are most strongly expressed by neurons, are 
found in presumptive oligodendrocytes and are upregulated around sites of injury to the 
CNS and in distal stumps of peripheral nerves (Chapter 3; Hunt et al., 2002a). In situ 
hybridisation for nogo-a mRNA reveals a broadly similar distribution in the intact 
nervous system, which is consistent with previous reports (Josephson et al., 2001; Huber 
et al., 2002). Nonetheless, it has become clear that the relative expression of nogo-a 
mRNA and nogo-66 mRNA by neurons and glia is different: for example, nogo-a 
expression by glia is much more obvious, and its expression by neurons -  especially 
neocortical neurons -  is less marked than for nogo-66. This implies that neocortical 
neurons express nogo-b or -c  as well. The finding that nogo-a mRNA is expressed by 
myenteric plexus neurons of the distal colon is in keeping with previously reported 
immunohistochemical findings, and is highly suggestive of a neuron-specific function of 
the protein.
Nogo-A Protein Expression in the CNS
This study has confirmed previous reports of Nogo-A expression by many CNS neurons 
(Huber et al., 2002; Tozaki et al., 2002). Nonetheless, there is a clear disparity between 
transcript and protein expression patterns, which is best illustrated by adult rat neocortical 
neurons in which the mRNA is strongly expressed but the protein only weakly so. It may 
be that this phenomenon can be explained by post-transcriptional regulation, or perhaps 
by rapid export of the protein into the axons from the neuronal perikarya. However, there 
is little evidence for the latter since the axons do not appear to contain an abundance of 
Nogo-A. In fact, although in these experiments the corticofugal axons were not 
specifically immunolabelled for Nogo-A expression, only very weak expression was
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evident at best in axons within the cerebral peduncles and dorsal corticospinal tract of the 
spinal cord. Similarly, throughout the whole of the CNS, it was found that intrinsic CNS 
neurons which express Nogo-A in the perikarya show very weak if any labelling of their 
axons. It seems unlikely that this is the result of higher background levels of signal 
detected throughout the CNS, since axons are very easily identifiable in the peripheral 
nervous system (see below). One example of this comes from Purkinje cells, most of 
which show strong perikaryal expression of Nogo-A, as well as weak to moderate 
immunoreactivity in their dendrites but little or no signal in their axons. That Nogo-A is 
expressed strongly in the perikarya of many Purkinje cells, but very weakly or not at all 
in others is also quite intriguing. Several other genes are known to give rise to unusual 
patterns in the cerebellar Purkinje cells, typified by zebrin (Hawkes and Leclerc, 1989; 
Brochu et al., 1990; Gravel and Hawkes, 1990) which is expressed in rows by a series of 
parasagittal stripes. Indeed, this finding warrants further investigation. Contrary to an 
earlier report (Jin et al., 2003), no obvious Nogo-A immunoreactivity was observed in the 
nuclei of Purkinje cells, nor of spinal motor neurons, but this does not exclude the 
possibility that the protein was expressed at much lower levels than were present in the 
neuronal cytoplasm. The glial cells that were found to express Nogo-A did not include 
either NG2+ cells, or astrocytes. The former is noteworthy since oligodendrocyte 
precursors are known to express NG2, whilst mature oligodendrocytes are known to 
express Nogo-A, thus indicating that the onset of Nogo-A expression can be listed with 
other changes in gene expression which mark the phenotypic maturation of this cell 
lineage. This finding has recently been confirmed by Mingorance et al. (2004).
Nogo-A Protein Expression in the PNS
Unlike intrinsic CNS neurons, the majority of neurons which have axons projecting into 
peripheral nerves express high levels of Nogo-A transcripts and protein in their perikarya 
as well as large amounts of the protein in their axons. This is true of spinal motor 
neurons of the ventral horn (wherein Nogo-A is clearly visible even in the intraspinal 
segments of their axons), DRG neurons, postganglionic sympathetic neurons and ciliary 
ganglion neurons. It seems that Nogo-A is expressed at varying degrees in all 
neurofilament-labelled axons of the intact peripheral nerve, although the most intense
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immunofluorescent signal for Nogo-A is found in bundles of unmyelinated axons; these 
would include DRG c-fibres and postganglionic sympathetic fibres. In time, Nogo-A 
may paradoxically prove to be a useful marker of peripheral axons. Nonetheless, the role 
of Nogo-A within neurons of the peripheral nervous system remains something of a 
mystery, not least since it has been reported to be expressed by another type of peripheral 
neuron: that of the colonic myenteric plexus (Osborne et al., 2004).
Nogo-A Expression in the Embryonic and Early Postnatal Nervous System
It was difficult to discern any Nogo-A positive neuronal perikarya within the E l3.5 or 
E l7.5 mouse cortex. Immunoreactivity for calretinin, which is expressed by preplate 
neurons at these developmental timepoints, did not clearly coincide with that of Nogo-A. 
The apparent expression of Nogo-A by radial glia, lately considered a neuronal 
progenitor cell (reviewed by Goldman, 2003), within the embryonic telencephalic wall of 
mouse forebrain requires further investigation and, unfortunately, could not be 
definitively confirmed in this study owing to a lack of appropriate antibodies. Similarly, 
it was impossible to confirm whether the axon-like structures running tangentially 
through the E l7.5 mouse telencephalic wall were indeed corticofugal and corticopetal 
axons, but morphologically they appeared to be such. In the event that these preliminary 
observations should prove correct, it would raise some interesting questions as to the 
nature and extent of Nogo-A involvement in the developing nervous system. This 
potentially commands even greater significance, given the absolute absence of CNS 
myelin throughout this period of cortical development.
Nogo-A Expression in Cultured Neurons
In dissociated cultures of adult Sprague-Dawley rat DRG neurons, and El 3.5 ICR mouse 
neocortical neurons -  as well as E l7 and E19 Sprague-Dawley rat neocortical neurons -  
similar patterns of Nogo-A expression were observed. The strongest expression was 
detected in the perikarya. However, the axons were also rich in Nogo-A, although the 
distribution was somewhat uneven with an obvious accumulation of the protein in axonal 
varicosities, at branch points, at places where axons crossed and in growth cones. This 
pattern is perhaps suggestive of a role in axon growth, guidance and perhaps synapse
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formation (which may account for the very large number of axonal varicosities which 
were observed in these cultures of neocortical neurons). The Nogo-A immunoreactivity 
did not co-localize precisely with that of neurofilament; for example, Nogo-A was 
prominent in the terminal elements of the neurites, including the growth cones, where 
there was little or no signal for neurofilament. This finding may is in agreement with the 
observations made on the expression profiles of regenerating axons in vivo (see below). 
In the cultures of adult DRG neurons, Nogo-A was clearly visible in the central domain 
of large growth cones, as has been previously reported (Tozaki et al., 2002), and was 
reminiscent of the expression pattern of SCG10 - a growth-associated neuronal protein 
which controls microtubule dynamics and enhances neurite outgrowth -  which is also 
localized for the most part to growth cones and perikarya (Di Paolo et al., 1997; Riederer 
et al., 1997; Lutjens et al., 2000). It is important that the extent to which Nogo-A is 
present at the cell surface in neurons, if at all, be investigated thoroughly since this is 
likely to yield some vital clues about the function of neuronal Nogo-A.
Nogo-A Expression after CNS Injury
In this study, three models of CNS injury were examined in adult Sprague-Dawley rats: 
transection of the spinal dorsal columns, autologous tibial nerve graft in thalamus and 
optic nerve crush. In situ hybridisation was performed on injured spinal cord and grafts 
in thalamus. In both cases nogo-a transcripts were obviously upregulated in some cells 
bordering the lesion sites. Immunohistochemistry was performed on injured spinal cord 
and crushed optic nerve, where it was found that signal for Nogo-A was considerably 
higher at the margins, and much lower within the substance, of the lesions.
The finding that Nogo transcripts are downregulated within the lesion site of injured 
spinal cord is congruent with earlier reports (Josephson et al., 2001; Huber et al., 2002; 
Wang et al., 2002c). However, the observation that Nogo expression is increased in some 
cells at the margins of spinal injury sites remains contentious, since only Wang et al. 
(2002) have reported a similar finding whilst Josephson et al (2001) and Huber et al 
(2002) were unable to detect any sign of upregulation of the transcripts around contusion 
and transection sites, respectively. There is no simple explanation for this discrepancy.
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However, in the present study, the protein was also found to be upregulated by some 
neuronal perikarya at the borders of the lesion site.
The ingress of large numbers of Nogo-A immunopositive axons to the spinal cord lesion 
site at 8-16dpo was somewhat unexpected. Most of the penetrating axonal sprouts, as 
identified by neurofilament immunoreactivity, were found to be Nogo-A 
immunopositive. Given that these animals also underwent a conditioning peripheral 
nerve lesion, which is known to enhance the sprouting of ascending axons of DRG 
neurons into a dorsal column lesion site, it is likely that many of these Nogo-A positive 
axons are indeed those of sensory DRG neurons. The strongest immunofluorescent 
signal for Nogo-A was detected in dorsal column axons close to the lesion, which is 
perhaps indicative of the molecule undergoing fast anterograde axonal transport. This 
process often results in an axonal accumulation of protein proximal to the lesion site 
(Banks et al., 1969; Anderson et al., 1978). Some of the axons which had entered the 
lesion sites did not express Nogo-A, and may have been those of local spinal neurons. It 
is certainly true that some types of neuron express little or no Nogo-A. Also, the uneven 
distribution of Nogo-A throughout the axonal shafts in cultured neurons may explain why 
some segments of regenerating axons in vivo were not found to express Nogo-A. In any 
event, the meshwork of Nogo-A positive processes, which may have consisted of fine 
axonal sprouts and/or oligodendrocyte processes, at the lesion borders could pose a 
considerable inhibitory barrier to regenerating axons. This is potentially further 
compounded by presence of significant numbers of interweaving NG2-expressing 
processes. The few Nogo-A positive non-neuronal cells that appeared within the lesion 
site at 16dpo were most probably mature oligodendrocytes, which presumably had 
formed from their precursors which do not express Nogo-A. Surprisingly, at all 
timepoints, the major source of Nogo-A within the lesion sites was always the ingrowing 
Nogo-A-expressing axonal sprouts. What bearing this has on the inhibition of axonal 
regeneration in the injured spinal cord, if any, remains to be seen.
Autologous tibial nerve grafts in thalamus were employed as a model of regeneration, 
since it is well establish that axons of certain classes of intrinsic CNS neurons, e.g. the
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thalamic reticular nucleus (TRN), are particularly adept at regenerating their axons into 
such grafts. In the intact state, or whilst undergoing regeneration, TRN neurons were 
found to express nogo-a transcripts. Clearly, this implies that their expression of nogo-a 
is not detrimental to the regeneration of their axons into grafts of peripheral nerve. Those 
cells which upregulate nogo-a at the borders of a peripheral nerve graft in thalamus have 
yet to be identified, but some exhibited a neuronal morphology. Interestingly, those 
neurons of the dorsal thalamus which successfully regenerate their axons into peripheral 
nerve grafts are usually located within close proximity to the graft. However, it seems 
quite unlikely that all the cells which were seen to upregulate nogo-a around the graft 
were successfully regenerating neurons.
In the experimental model of optic nerve crush, the lesion site was almost completely 
devoid of Nogo-A by 4dpo, which was comparable with spinal cord lesion sites at the 
same timepoint. The increased expression of Nogo-A at the borders of the optic nerve 
lesions may have been in oligodendrocytes or axons. The axonal sprouts found within 
these lesion sites expressed less Nogo-A than was found in sprouting axons in spinal cord 
lesions, and much less than was found in regenerating peripheral axons. This is probably 
because many of the axons that sprout into spinal lesions, following conditioning 
peripheral nerve injuries, are ascending central processes of DRG neurons. These 
neurons strongly express Nogo-A.
Three nogo-a null mutant mice which have been described (Zheng et al., 2003; Simonen 
et al., 2003; Kim et al., 2003c), and the corticospinal tracts of each of these has been 
reported to respond differently to injury. In two of these mutants, regeneration is 
enhanced by varying degrees (Simonen et al., 2003; Kim et al., 2003c), and in the other 
there appears to be no improvement (Zheng et al., 2003). The overt lack of conformity 
between phenotypes is a little troublesome, although some attribute it to the different 
genetic manipulations that were employed and the potential for differential ‘genetic 
compensation’. The initial examination of intact corticospinal tracts in one of these 
knockout models has revealed no obvious anatomical abnormalities (Simonen et al., 
2003). This is surprising in the light of an earlier report that administration of the IN-1
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antibody to postnatal rats disrupts the anatomical development of these tracts (Schwab 
and Schnell, 1991). On the whole, these mutants have been of little assistance in 
clarifying the role of Nogo-A in axonal (re-)growth. One hypothesis must be that 
oligodendrocyte and neuronal Nogo-A have antagonistic effects. In this vein, the 
generation of a conditional neuronal Nogo-A null mutant might yield some interesting 
data.
Nogo-A Expression After Peripheral Nerve Injury
At 4 days after nerve transection, apparently all sprouting axons were Nogo-A 
immunopositive. At 8 and 16dpo, Nogo-A was present in many regenerating axons but 
the intensity of expression was variable. For example, some of the fibres which were 
most strongly immunoreactive for neurofilament, were not for Nogo-A, and vice versa. 
These Nogo-A positive fibres were likely to be axons, not Schwann cell processes, 
because (i) all were emanating from the proximal stump, (ii) some were neurofilament 
positive, (iii) some were myelinated, (iv) no Nogo-A positive cell bodies were identified 
in the outgrowth from the proximal stump, and (v) no nogo-a mRNA signal was detected 
in the proximal stump of injured nerves. Given the pattern of Nogo-A and neurofilament 
in the axons of cultured neurons (see above), it is quite probable that the Nogo-A positive 
but neurofilament negative structures observed at the forefront of the outgrowth from the 
proximal stump were in fact growth cones. That a significant number of neurofilament- 
positive regenerating axons appeared to express little or no Nogo-A is somewhat 
intriguingly, since apparently all axons within the intact nerve express the protein. 
However, in cultures of neurons (see above) the pre-terminal neurites were often found to 
express little Nogo-A -  except at axonal varicosities or points of axonal contact -  lending 
a possible explanation to what has been observed in vivo. Of course, it is equally 
plausible that these regenerating neurofilament-positive but Nogo-A-negative axons may 
be representative of a subpopulation of neurons that is capable of downregulating Nogo- 
A expression in axons following injury. However, in the present study, no obvious 
downregulation of Nogo-A was observed in any DRG neurons or spinal motor neurons of 
the ventral horn, following transection of the peripheral nerve.
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The most important question to arise from this work is whether the Nogo-A expressed by 
peripheral axons has any role in their ability to regenerate. A knowledge of the 
subcellular distribution of the protein, i.e. whether it is present at the axonal surface, as 
well as its topology is likely to assist in answering this. However, it is worth noting that 
regenerating peripheral axons have been shown to be sensitive to the effects of Nogo-A, 
when overexpressed by Schwann cells in peripheral nerves (Pot et al., 2002). This is 
important, since only a subpopulation of motor and sensory neurons express ngr 
transcripts and relatively weakly at that, implying that these neurons may express other 
presently unidentified receptors for Nogo-A (Prinjha et al., 2002).
Considering that increased expression of Nogo-A in adult muscle has been implicated in 
the development of amyotrophic lateral sclerosis (ALS) (Dupuis et al., 2002), it is 
somewhat surprising that ectopic striated muscle fibres - arising in the tissue bridge 
between the proximal and distal stumps of injured peripheral nerve - were strongly 
immunoreactive for Nogo-A. However, since axonal sprouting also occurs in ALS 
(Stalberg et al., 1986) it is possible that these ectopic muscle fibres were responding to 
axonal sprouting by expressing Nogo-A. During development, skeletal muscle has also 
been reported to express Nogo-A (Tozaki et al., 2002; Wang et al., 2002c) but its 
temporal pattern of expression has yet to be correlated with innervation by the developing 
peripheral nervous system. The hypothesis of relationship between excessive axonal 
sprouting and muscular expression of Nogo-A is supported by a recent report that 
denervated muscle also upregulates Nogo-A in wild-type rodents (Magnusson et al.,
2003). However, Dupuis et al. (2002) did not detect any upregulation of Nogo-A in the 
denervated muscles of wild-type animals.
Summary
The present study has confirmed that nogo-a mRNA is expressed by many different 
classes of neuron, but that perikaryal protein expression is not directly proportional, e.g. 
neocortical pyramidal neurons express moderate levels of transcript but relatively little 
protein. After injury, Nogo-A is upregulated by some intrinsic CNS neurons around the 
lesion site. Most, if not all, uninjured neurons with axons in peripheral nerve express
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Nogo-A in both their perikarya and axons. After injury, the majority of regenerating 
peripheral axons are clearly Nogo-A positive. This is also true of axons sprouting into 
CNS lesion sites. There appears, therefore, to be a correlation between axonal expression 
of Nogo-A and high regenerative ability. Despite being considered an inhibitor of axonal 
growth, there remains the possibility that Nogo-A has an alternative role in neurons, 
especially within their axons, that is beneficial to vigorous axonal regeneration.
CONCLUSION
In addition to its well documented expression in oligodendrocytes, Nogo-A is also 
expressed by numerous classes of neuron within the CNS and PNS, both in the intact and 
regenerating nervous system. Although Nogo-A is widely detectable in neuronal 
perikarya, its expression in intrinsic CNS axons of adult mammals is very limited. 
However, the expression of Nogo-A in axons correlates well with axonal regenerative 
potential, and the majority of axons in peripheral nerves continue to express the molecule 
whilst undergoing regeneration.
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Table 4.1.
Neuronal expression of nogo-a mRNA and protein.
Key:-
not detectable 
-/+ very weak
+ weak
++ moderate/strong
+++ very strong
NE not examined
* some, but not all, neocortical neurons were weakly immunoreactive for Nogo-A
** strongest neuronal expression in well-dispersed, large diameter neurons
(indicative of cholinergic intemeurons) 
t  most, but not all, Purkinje cells were found to express Nogo-A
f t  all motor neurons in the lumbar spinal cord expressed nogo-a mRNA and protein,
but some motor neurons in the cervical spinal cord were not immunoreactive for 
Nogo-A (N.B. in situ hybridization was not performed on comparable sections of 
cervical spinal cord)
t  although no immunoreactivity was detected in perikarya in either the inner or
outer nuclear layers, weak expression was present in both the inner and outer 
plexiform layers, presumably in axon terminals (see Fig. 4.6.A)
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nogo-a m RNA Nogo-A p ro te in
A dult r a t  (Sprague-D awley)
Neocortex ++ +
Neostriatum
**++ **+
Hippocampal formation:-
CA1-4 + +
Dentate gyrus l+(vay weak) -
Hilus o f  dentate gyrus ++ ++
Amygdala + -
Piriform cortex + +
Habenular nucleus +++ +++
Thalamic reticular nucleus ++ +
Other thalamic nuclei ++ +
Tuberomammillary nucleus ++ ++
Other hypothalamic nuclei + ++
Substantia nigra ++ +
Oculomotor nucleus ++ ++
Red nucleus ++ ++
Cerebellum:-
Purkinje cells ++*
Granule cell layer - -
Molecular cell layer - -
Deep cerebellar nuclei ++ + +
M esencephalic nucleus V NE ++
Pontine nuclei + + + ++
Spinal motor neurons + + * + + «
Retina:-
Retinal ganglion cells + + + + + +
Inner nuclear layer / + (very weak) J
Outer nuclear layer - J
Superior cervical ganglion + + + +++
Ciliary ganglion NE +++
DRG + + + +++
A dult r a t  (Lewis)
Dissociated DRG neurons in vitro (3DIV) NE +++
P8 r a t  (Sprague-D aw ley)
Cerebellar granule neurons (western blot) NE +++
E17 and  E19 r a t  (Sprague-D awley)
Dissociated cortical neurons in vitro (3DIV) NE +++
P14 m ouse (Balb/c)
Neocortex NE -
Neostriatum NE -
E13.5 m ouse (IC R )
Dissociated cortical neurons in vitro (3DIV) NE +++
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Figure 4.1.
Western blot of P8 Sprague-Dawley rat cerebellar granule neurons. Protein was 
separated on a 7.5% gradient gel and detected with the anti-Nogo-A monoclonal antibody 
6D5. The position of Rainbow molecular weight markers is shown on the left. A single 
strong Nogo-A band of 180kDa is detectable. N.B. Nogo-A was not detected in 
cerebellar granule cells of adult rats by immunohistochemistry, but such cells do express 
Nogo-A in the neonate (Huber et al., 2002).
250 
160
105— ►
7 5 — ►
5 0 — ►  
3 5 — ►  
3 0 — ►
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Figure 4.2.
In situ hybridization for nogo-a mRNA in adult Sprague-Dawley rat tissues.
A. Coronal section through part of the forebrain showing cerebral cortex (asterisk) and corpus 
callosum (cc). Strong signal for nogo-a can be seen in cells of varying sizes in most of the 
cortex, except the molecular layer (m), in the corpus callosum and the underlying fimbria/fomix. 
V indicates lateral ventricle. Scale bar = 200pm.
B. Forebrain, showing the deep layers of cerebral cortex (c), underlying white matter (w) and 
neostriatum (asterisk). Although the level of expression is generally lower in the neostriatum 
than in cortex, scattered large striatal cells (arrows) express very strong signal for nogo-a mRNA. 
Scale bar = 200pm. Inset: immunohistochemistry for Nogo-A in adult rat striatum. Scattered, 
large neuronal perikarya - resembling cholinergic intemeurons -  express the Nogo-A protein. 
Scale bar = 50pm.
C. Part of the dentate gyrus (asterisk) shows very low or background levels of signal but 
scattered neurons (arrowheads) in the hilus express moderate or strong signal for Nogo-A 
mRNA. Scale bar = 100pm. Inset: immunohistochemistry for Nogo-A on adult rat dentate gyrus. 
Scattered neuronal perikarya in the hilus of the dentate gyrus express the Nogo-A protein, whilst 
the granule cells of the dentate gyrus do not. Scale bar = 25pm.
D. Coronal section through part of the midbrain showing strong nogo-a mRNA expression in the 
substantia nigra (indicated by arrows) and red nucleus (asterisk). Scale bar = 200pm.
E. Part of cerebellar cortex showing strong signal for nogo-a mRNA from some Purkinje cells 
(arrowheads) but not from others (regions indicated by arrows). The molecular layer (m) shows 
no signal and the granule cell layer (g) shows background levels except for scattered cells of 
various sizes which may be oligodendrocytes and ectopic Purkinje cells. W indicates white 
matter. Scale bar = 200pm.
F. nogo-a mRNA is strongly expressed in motor neurons in the ventral horn of the lumbar spinal 
cord. Scale bar = 200pm.
G. Neurons in the L5 DRG express strong signal for nogo-a mRNA. The non-neuronal cells in 
the attached dorsal root (r) show no signal. Scale bar = 100pm.
H. Sympathetic neurons in the superior cervical ganglion show strong signal for nogo-a mRNA. 
Scale bar = 200pm.
I. Section through retina showing strong signal for nogo-a mRNA from cells in the ganglion cell 
layer (arrowheads). Scale bar = 100pm.
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Figure 4.3.
A-B nogo-a transcript expression in neurons of the myenteric plexus (arrows). Scale 
bars = 200pm. These sections were prepared and reacted by J. Mills.
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Figure 4.4.
Immunohistochemuistry for Nogo-A in adult Sprague-Dawley rat tissues.
A. Part of motor cortex showing strong Nogo-A immunoreactivity in presumptive 
oligodendrocytes (arrowheads) and weak expression in neurons (arrows). Scale bar = 
100pm.
B. Transverse section through the cerebral peduncle (containing corticofugal axons). 
Nogo-A immunoreactivity can be seen in axons and some presumptive oligodendrocytes. 
Scale bar = 20pm.
C. Cerebellar cortex showing Nogo-A expression in many Purkinje cells and scattered 
small presumptive oligodendrocytes in the granule cell layer (g). The dendrites of 
Purkinje cells (arrowheads) extending into the molecular layer (m) are also labelled. 
Scale bar = 100pm.
D. Higher power image of section through cerebellar cortex, parallel with the Purkinje 
cell layer, showing some Purkinje cell perikarya expressing Nogo-A and others (arrows) 
lacking Nogo-A. Presumptive oligodendrocytes in the granule cell layer (g) are indicated 
by arrowheads. Scale bar = 100pm.
E. Ventral horn of lumbar spinal cord showing strong Nogo-A expression in motor 
neurons and smaller, presumptive oligodendrocytes. Axons in the ventral white matter 
are also Nogo-A positive. Scale bar = 100pm.
F. Superior cervical ganglion showing strong Nogo-A expression in neuronal perikarya, 
as well as axons. Scale bar = 100pm.
G. L5 DRG showing strong Nogo-A expression in all sensory neurons, most larger cells 
displaying a reticular pattern, with the smaller cells exhibiting the most intense 
immunoreactivity. Sensory axons also contain Nogo-A . Scale bar = 100pm.
H. Sciatic nerve in longitudinal section. Although all axons express Nogo-A (see also 
Fig. 4.5.D-F), the bundles of non-myelinated axons (arrows) are the most strongly 
immunoreactive. Scale bar = 50pm.
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Figure 4.5.
Confocal microscope images of single optical planes of spinal cord white matter (A-C), 
intact sciatic nerve (D-F) and regenerating sciatic nerve (G-I) to show the extent of 
colocalisation of NG2 and Nogo-A (A-C) and neurofilament protein and Nogo-A (D-I). 
All images were taken from adult Sprague-Dawley rats. Nogo-A is red.
A. Nogo-A positive cells and fibres in the dorsal column white matter of adult rat spinal
cord. Scale bar =20pm, applies also to B and C.
B. NG2 positive cells and processes in the same optical section.
C. Superimposed images show that although the NG2 positive structures are often close
to the Nogo-A positive structures, the antigens were never colocalized.
D. Nogo-A immunoreactivity in sciatic nerve. Scale bar =20pm, applies also to E and F.
E. Neurofilament immunoreactivity in the same optical section.
F. Superimposed images show that although apparently all neurofilament positive 
structures are immunoreactive for Nogo-A, Nogo-A is strongly expressed by bundles of 
non-myelinated axons which are neurofilament negative (arrows in D,E,F).
G. Nogo-A immunoreactivity in regenerating sciatic nerve, 16dpo. Scale bar = 20pm, 
applies also to H and I.
H. Neurofilament immunoreactivity in the same optical section.
I. Superimposed images show that although all neurofilament positive structures are 
immunoreactive for Nogo-A to varying degrees, a few Nogo-A positive structures (red) 
are not immunoreactive for neurofilament.
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Figure 4.6.
Nogo-A immunofluorescence in adult Sprague-Dawley rat retina and associated nerves (A-D) 
and in cultured neurons (E-H).
A. Section through retina showing strong Nogo-A expression in the ganglion cell layer (RGL) 
(arrowheads) (cf. Fig. 4.2.1). Weak immunoreactivity for Nogo-A is present in the inner and 
outer plexiform layers (IPL and OPL, respectively), but no expression can be detected in 
perikarya of the inner and outer nuclear layers (INL and ONL, respectively). Scale bar = 100pm.
B. Higher power of section through the ganglion cell layer and optic fibre layer, double stained 
for Nogo-A (red) and neurofilament protein (green). The retinal ganglion cell axons are strongly 
immunoreactive for neurofilament and weakly Nogo-A positive, whereas the ganglion cell bodies 
(some arrowed) are strongly Nogo-A positive but neurofilament negative. Scale bar = 100pm.
C. In the optic nerve (Op), retinal ganglion cell axons are difficult to distinguish using Nogo-A 
staining but some presumptive oligodendrocytes can be seen. The perikarya of neurons in the 
adjacent ciliary ganglion (asterisk) are strongly Nogo-A positive. Scale bar = 100pm.
D. Axons (mainly non-myelinated) in the ciliary nerves are strongly Nogo-A positive. Scale bar 
= 50pm.
E. Cultured neurons from E l3.5 ICR mouse cerebral cortex, immunoreacted for Nogo-A (red) 
and neurofilament protein (green), and stained with bisbenzimide to show cell nuclei (blue). 
Nogo-A is concentrated in neuronal cell bodies, sites where neurites cross (arrowhead) and 
axonal varicosities. Scale bar = 50pm.
F. Cultured neurons from E l3.5 ICR mouse cerebral cortex, immunoreacted for Nogo-A (red) 
and neurofilament protein (green), and stained with bisbenzimide, showing Nogo-A at growth 
cones at the ends of neurites (arrowheads) and branch points (arrows). Scale bar = 50pm.
G. Higher magnification images of cultured neurons from El3.5 ICR mouse cerebral cortex, 
showing Nogo-A concentrated at a neurite branch point (arrowhead) and in varicosities (arrows). 
The neurites are not evenly stained for Nogo-A and one of the processes arising at the branch 
point has virtually no label. Scale bar = 10pm.
H. Phase contrast/immunoflouresence image of the terminal parts of a neurite in a culture of 
adult Lewis rat DRG neurons (3DIV). Nogo-A is concentrated in the growth cones and branch 
points. This culture was prepared, immunoreacted and photographed by Dr. G. Campbell. Scale 
bar = 10pm.
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Figure 4.7.
Nogo-A expression in embryonic (A-B) and postnatal (C-D) mouse forebrain.
A. Nogo-A is expressed in the ventricular zone (VZ), in radial glia cells (arrows), as well 
as in the preplate layer (PPL), in early fibres (arrowheads) of the developing cortex at 
E13.5. Note that there is no colocalisation of Nogo-A in calretinin (CalR) positive 
preplate cells (green). Scale bar = 100pm.
B. Nogo-A expression in the fibre systems of the developing cortex at E17.5. LI -  layer 
I; CP -  cortical plate; SP -  subplate; IZ -  intermediate zone. Scale bar = 100pm.
C. Nogo-A is expressed in oligodendrocytes, but not neurons, in P I4 neocortex. Scale 
bar = 20pm.
D. In P14 striatum, immunofluorescent signal for Nogo-A was detected exclusively in 
presumptive oligodendrocytes and their processes amid the bundles of myelinated axons. 
Scale bar = 50pm.
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Figure 4.8.
Nogo-A expression in E l7 rat hindlimb.
A. Immunofluorescent signal for Nogo A (red) was observed in developing rat sciatic 
nerve (n), as well as developing skeletal muscle (m). Scale bar = 200pm.
B. Same field as A, with immunofluorescent signal for neurofilament (green) in 
developing rat sciatic nerve. Scale bar = 200pm.
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Figure 4.9.
In situ hybridization for nogo-a mRNA in injured nervous tissues of adult Sprague- 
Dawley rats.
A and B. Show the absence of signal in the proximal (A) and distal (B) stumps of a 
sciatic nerve 4 days after transection. Scale bar = 50pm.
C. Section through a peripheral nerve graft (g) in the thalamus, 14 days after 
implantation, nogo-a mRNA has been upregulated by cells in the thalamus bordering the 
graft. C indicates a small cavity in the CNS tissue caused by the grafting procedure. 
Scale bar = 200pm.
D. Horizontal section through transected dorsal columns of cervical spinal cord, 8dpo. A 
slight/moderate upregulation of nogo-a transcript expression is observed at the border of 
the lesion (L) by cells within the injured dorsal columns (arrows). Scale bar = 500pm.
E. Parasagittal section through transected cervical dorsal columns spinal cord, 8dpo. A 
slight/moderate upregulation of nogo-a mRNA expression is detected near the borders of 
the lesion (L) at the level of the dorsal columns (arrows), but not elsewhere. Scale bar = 
500pm.
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Figure 4.10.
Severed sciatic nerves, from adult Sprague-Dawley rats showing the proximal stump 
and/or regenerating axons immunoreacted for Nogo-A (red) and neurofilament protein 
(green). The proximal stump is to the left of the image in A-D.
A. Many Nogo-A positive axons are present in the proximal stump at 4dpo, when 
regeneration into the lesion site (L) is minimal. Scale bar = 100pm.
B. At higher magnification it can be seen that Nogo-A positive axons which run parallel 
in the proximal stump (at the left of the image) have sprouted into the lesion site, where 
some end at Nogo-A positive varicosities. Scale bar = 100pm .
C. Nogo-A positive axons regenerating from the proximal stump towards the distal 
stump across the gap, 8dpo. Scale bar = 100pm , also applies to D.
D. The same field immunoreacted for neurofilament protein. Although the images in C 
and D both show large numbers of regenerating axons, many fibres that are neurofilament 
positive contain little Nogo-A and vice versa.
E. Axons at the edge of the outgrowth from the proximal stump 8dpo, immunoreacted 
for Nogo-A. Scale bar = 20pm , also applies to F.
F. The same field immunoreacted for neurofilament protein and Nogo-A, clearly shows 
that some axons are nogo-A positive but neurofilament negative.
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Figure 4.11.
Outgrowth from severed sciatic nerves of adult Sprague-Dawley rats immunoreacted for 
Nogo-A (red) and neurofilament protein (green), 16dpo. The proximal stump is to the 
right of the image.
A. Bundles of Nogo-A positive axons regenerating towards the distal stump have a few 
Nogo-A positive ectopic muscle fibres (asterisk) developing in their midst. Scale bar = 
100pm also applies to B.
B. The same field, double stained for Nogo-A and neurofilament protein. Although 
many regenerating axons are immunoreactive for both Nogo-A and neurofilament the 
antigens are not precisely colocalized within the axons.
C. At higher magnification, Nogo-A positive axons can be seen among and at the surface 
of the muscle fibres (asterisk). Scale bar = 50pm also applies to D.
D. The same field, double stained for Nogo-A and neurofilament protein. Some axons 
are Nogo-A positive but neurofilament negative (arrows).
E. An ectopic muscle fibre (asterisk) is Nogo-A positive and is approached by Nogo-A 
positive axons (arrows). Scale bar = 20pm also applies to F.
F. The same field, double stained for Nogo-A and neurofilament protein. It can be more 
clearly seen that the expression of Nogo-A and neurofilament protein is variable between 
axons. Some axons (arrowheads) are running along the surface of the Nogo-A positive 
muscle fibre.
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Figure 4.12.
Transection injuries of the dorsal columns of the spinal cord (A-F, caudal to the right) 
and crush injuries to the optic nerve (G,H, proximal to the left) of adult Sprague-Dawley 
rats.
A. At 4dpo in a horizontal section stained for Nogo-A, the lesion site (L) lacks 
significant Nogo-A expression but there is some increased immunoreactivity at the 
borders of the lesion. Scale bar = 100pm.
B. By 8dpo there is a further increase in Nogo-A in the injured dorsal column (arrow) 
caudal to the lesion (L), particularly in swollen axons. Some Nogo-A positive fibres are 
present in the lesion. Scale bar = 100pm.
C. At higher magnification the lesion site (L) at 8dpo contains many neurofilament 
positive fibres, presumably including sprouts from the injured dorsal column axons. 
Scale bar = 100pm, also applies to D.
D. The same field as C, immmunoreacted for Nogo-A, shows many Nogo-A positive 
fibres in the lesion site (L) which are not always co-localized with neurofilament protein.
E. At the edge of a lesion in the spinal cord, 16dpo, a meshwork of Nogo-A positive 
fibres (arrowheads) and NG2 positive fibres is present in the grey matter, but the two 
antigens are not co-localized. Scale bar = 100pm.
F. At the edge of a dorsal column lesion in the spinal cord, 8dpo, some GFAP positive 
processes (green) have extended into the lesion site (L) but they are distinct from the red 
Nogo-A positive fibres. Scale bar = 100pm.
G. The crush site of an optic nerve 4dpo, immunoreacted for Nogo-A. There is a modest 
increase in Nogo-A at the boundaries of the lesion (L). Scale bar = 100pm.
H. At higher magnification, Nogo-A positive fibres can be seen sprouting into the lesion 
site (L) of an optic nerve 4dpo. Scale bar =50pm.
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CHAPTER 5
Expression of ATF3 by Glial Cells during Wallerian 
Degeneration: Differential Response of PNS and CNS Glia
(N.B. Although unrelated to the Nogo-66 Receptor and its ligands, the work 
reported within this chapter stemmed from a fortuitous observation of ATF3 
upregulation by non-neuronal cells of injured sciatic nerve; the discovery was made 
whilst using the anti-ATF3 antibody as a comparative control for assessing changes 
in Nogo-A protein expression by peripherally axotomized DRG neurons. In 
addition to contralateral DRG, which was immunoreacted for direct comparison, 
sections of intact and injured sciatic nerve were also immunoreacted as negative 
controls).
INTRODUCTION
Wallerian degeneration is the process by which the nervous system responds to injury 
(Waller, 1850). It occurs in both the PNS and CNS, but differs in numerous respects. 
After transection of a peripheral nerve, Schwann cells within the distal stump rapidly 
begin to proliferate, and haematogenous monocytes infiltrate the damaged tissue. The 
latter differentiate into macrophages, and are responsible for the phagocytotic removal of 
cellular debris and extracellular matrix. This clearance permits the ultrastructural 
remodeling of injured nerve, in that Schwann cell columns (i.e. the bands of Bungner) are 
prepared to receive regenerating axons. The response of non-glial cells in the proximal 
stump of a severed peripheral nerve is somewhat attenuated. Naturally, these proscribed 
cellular responses are governed by significant changes in gene expression (Kubo et al., 
2002; Costigan et al., 2002). Indeed, integral to such changes in gene activity is a class 
of proteins known as transcription factors. These bind directly to specific DNA 
sequences, typically lying within a gene promoter region, and regulate its transcription.
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Often, a single active transcription factor will promote the transcription of a number of 
downstream target genes, some of which may also encode transcription factors; in other 
words, the activity of one transcription factor may regulate the expression of another. In 
the glial cells of the distal stump of injured peripheral nerve, it is known that the 
transcription factors c-jun, c-fos, krox-20 and scip are themselves transcriptionally 
upregulated (Pyykonen and Koistinaho, 1991; Stewart, 1995; Zorick et al., 1996; Soares 
et al., 2001). It is, of course, of particular interest to know which cascades of gene 
expression come under the control of these transcription factors, since it appears that it is 
the response of Schwann cells to nerve injury that enables them to recapitulate their 
ability to promote axonal regeneration. In contrast, their counterparts in the CNS (i.e. 
oligodendrocytes) do not undertake comparable programmes of gene expression during 
Wallerian degeneration, and many of these cells initially die before they repopulate from 
precursors, which may partly explain their failure to promote axonal regeneration after 
injury. Indeed, whereas implanted segments of peripheral nerve, suspensions of 
autologous Schwann cells and synthetic axon guidance channels lined with Schwann 
cells are all known to promote axonal regeneration of some classes of CNS neurons 
(reviewed by Jones et al., 2001), oligodendrocytes are believed to be inhibitory to axon 
outgrowth (reviewed by Yiu and He, 2003). Additionally, the process of Wallerian 
degeneration in the CNS is further complicated by the fact that other types of CNS glia 
(e.g. reactive astrocytes, oligodendrocyte precursor cells, meningeal cells and activated 
microglia), which are abundant in the injured CNS, are also thought to inhibit axonal 
regeneration (Liu et al., 1998; reviewed by Fawcett and Asher, 1999; Chen et al., 2002). 
At the moment, very little is known about the transcriptional control of these cellular 
processes; but, intriguingly, a number of different transcription factors are strongly 
upregulated by peripheral glia, but not CNS glia, during Wallerian degeneration.
ATF3 belongs to the bZip leucine zipper family of transcription factors that bind to 
cAMP and phorbol ester responsive promoters at cAMP response element (CRE) and 
activator protein-1 (AP-1) binding sites (reviewed by Hai and Hartman, 2001). However, 
ATF3 expression is reminiscent of that of c-Jun in injured neurons (Tsujino et al., 2000), 
and has been shown to form functional heterodimers with c-Jun in vitro (Pearson et al.,
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2003). In contrast to ATF3 homodimers, ATF3/c-Jun heterodimers tend to activate rather 
than suppress gene expression through an AP-l-like transcription factor binding site 
(Nilsson et al., 1997).
In the study described here, the expression of ATF3 during Wallerian degeneration in the 
PNS and CNS was examined. Intriguingly, ATF3 was found to be upregulated by PNS 
glia, but not CNS glia, during Wallerian degeneration. Schwann cells in degenerating 
distal stumps of transected peripheral nerve strongly upregulated ATF3; and 
downregulation did not occur if axonal regeneration was prevented by ligation of the 
proximal stump.
SUMMARY OF METHODS
In 20 adult Sprague-Dawley rats the left sciatic nerve was transected in the thigh, and 2- 
3mm of the nerve resected to create a gap between the proximal and distal stumps. These 
animals were killed at 1 (n=4), 4 (n=3), 8 (n=3), 16 (n=3) and 30dpo (n=4). In three of 
the animals with resected nerves the proximal stump was ligated and turned aside to 
prevent axonal regeneration into the distal stump. These rats were killed at 30dpo. In 9 
rats the left sciatic nerve was transected and reanastomosed with 10/0 sutures to allow 
rapid axonal regeneration into the distal stump. These rats were killed at 4 (n=3), 16 
(n=3) and 30dpo (n=3). In 8 rats the left L3-6 dorsal roots were cut using microsurgical 
scissors. The animals were killed at 1 (n=3) and 8 (n=3) and 30dpo (n=2). In 6 rats the 
left optic nerve was crushed with watchmakers’ forceps 2mm from the eyeball. These 
rats were killed at 4 (n=2), 8 (n=2) and 30dpo (n=2). In 6 PI rat pups the left sciatic 
nerve was transected. The animals were killed after 4 (n=3) and 7 dpo (n=3).
Immunofluorescencce Histochemistry
Primary antibodies: rabbit polyclonal anti-ATF3 (Santa Cruz); mouse monoclonal anti- 
neurofilament 200kDa (Sigma); rabbit polyclonal anti-c-Jun (a kind gift of Dr. A. 
Behrens, Cancer Research UK, London, UK); mouse monoclonal anti-bovine glial
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fibrillary acidic protein (Sigma); mouse monoclonal anti-SlOO (Sigma); mouse 
monoclonal anti-p75 (Sigma).
Secondary antibodies: monoclonal tetramethylrhodamine conjugated goat anti-mouse 
(Molecular Probes); monoclonal Alexa-Fluor-conjugated goat anti-rabbit (Molecular 
Probes).
In Situ Hybridisation
In three adult rats, in situ hybridisation was performed on the proximal and distal stumps 
of resected sciatic nerve, as well as a comparable segment of the uninjured contralateral 
sciatic nerve, 8dpo. Dr. M.R.J. Mason undertook this work using digoxygenin-labelled 
antisense and sense riboprobes for ATF3 (Mason et al., 2003).
Statistical Analysis
All sections of injured sciatic nerve for statistical analysis were immunoreacted for 
ATF3, and stained with bisbenzimide (which labels all nuclei). The percentage of ATF3 
immunopositive nuclei were calculated from comparable fields, photographed using a 
x20 objective, from each of three adjacent sections of injured sciatic nerve, per animal. 
These data were collated with those from at least two other animals, depending on the 
injury model and timepoint (see above). The sample mean and the standard error of the 
mean were subsequently calculated. Graphs were generated in Microsoft Excel.
RESULTS
ATF3 Expression in Peripheral Glia
Uninjured Sciatic Nerve
ATF3 immunoreactivity could be detected neither in contralateral sciatic nerves, nor in 
those of unoperated control rats.
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Resected Sciatic Nerve
The resection of adult rat sciatic nerve, in which a 2-3mm segment was excised at the 
level of the thigh, was performed to slow the course of regeneration. In this model, 
ATF3 immunoreactive cells had appeared in the distal stump as early as ldpo, but not in 
the proximal stump. At all time points, the ATF3 immunopositive endoneurial cells 
within the distal stump exhibited strong immunoreactivity peaking at 16dpo 
(Figs.5.1.B,D,F,H and Fig.5.2.B); by 30dpo, the number of ATF3 immunoreactive cells 
showed considerable variability from one animal to another, perhaps reflecting critical 
differences in the extent of regeneration that had occurred. In contrast, the temporal 
pattern of expression of ATF3 by cells within the proximal stump was quite different, but 
expression also peaked at 16dpo (Figs.5.1.A,C,E,G and Fig.5.2.A). Additionally, in 
comparison to the distal stump, ATF3 immunoreactivity in the proximal stump was much 
weaker at any given timepoint (Fig.5.1.A-H and Fig.5.2.A-B).
The size and shape of ATF3 immunoreactive cells was not entirely homogenous, 
suggestive of a mixed population. Furthermore, although there were very rarely any 
immunoreactive cells within the perineurium, a few cells within the epineurium were 
immunoreactive for ATF3 and appeared most often to be associated with the tunica 
adventitia of blood vessels. However, the density of cells within the endoneurium of the 
distal stump, as measured by staining with bisbenzimide, increased on average between 2 
and 3 fold from 4dpo to 16dpo; a period when ATF3 immunoreactivity increased from 
51.41% to 64.37% (Fig. 5.2.B).
ATF3 immunopositive endoneurial cells were often found in contact with regenerating 
axons at later timepoints (Figs. 5.3A, and 5.3B), suggesting that it is not the direct loss of 
axonal contact per se that induces the upregulation of ATF3. Nonetheless, the percentage 
of ATF3 immunoreactive nuclei within the distal stump of resected peripheral nerve 
appears to be inversely correlated with the extent of axonal regeneration (Fig. 5.3C).
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Transection & Reanastomosis vs. Transection & Ligation
To further investigate whether the degree of regeneration could explain the wide variation 
in the percentage of ATF3 immunopositive cells in the distal stump of resected nerve at 
30dpo, transected & reanastomosed as well as transected & ligated sciatic nerve were 
examined.
Reanastomosis of the proximal and distal stump of a transected peripheral nerve is 
beneficial to axonal regeneration. In the transected and reanastomosed adult rat sciatic 
nerve, a small number of neurofilament immunopositive regenerating axons could be 
detected entering the distal stump as early as 4dpo. By 16dpo, there was extensive 
axonal regeneration into the distal stump, although most of these fibres would not have 
re-innervated their original target tissues. By 30dpo, the density of axons within the 
distal stump was very similar to that observed at 16dpo; however, many of these fibres 
were probably completely regenerated. In comparison to the distal stump of resected 
nerve (Fig. 5.2.B), the percentage of ATF3 immunoreactive endoneurial cells in the distal 
stump of transected and re-anastomosed sciatic nerve was notably lower at each 
successive time-point (Fig. 5.2.C and 5.3.D). The proximal stumps contained very few 
ATF3 immunopositive cells in this model (not counted), and these tended to be close to 
the site of reanastomosis.
Ligation of the proximal stump, following transection of the sciatic nerve prevented any 
axonal regeneration. By 30dpo, the percentage of ATF3 immunopositive cells remained 
consistently high (67.92%; Fig. 5.2.C) with average levels exceeding those observed at 
8dpo or 16dpo in the distal stumps of resected sciatic nerve (63.93% and 64.37%, 
respectively; Fig. 5.2.B).
ATF3 mRNA Expression in Resected Sciatic Nerve
Signal for ATF3 mRNA was detected in the distal stumps of resected sciatic nerves at 
8dpo (Fig. 5.3.F), but not in contralateral intact sciatic nerves (Fig. 5.3.E).
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Transected Neonatal Sciatic Nerve
To investigate whether the upregulation of ATF3 by peripheral glia in response to 
Wallerian degeneration was age-specific, the sciatic nerve was transected in PI rat pups 
and examined at 4 and 7dpo. At both time points, large numbers of endoneurial cells 
within the distal stump were immunoreactive for ATF3 (Fig. 5.4). However, the intensity 
of expression was slightly lower than that observed in lesioned adult sciatic nerve.
Schwann Cells Upregulate ATF3 During Wallerian Degeneration 
The majority of ATF3 immunoreactive cells within the distal stump were also 
immunoreactive for the Schwann cell marker, SI00 (Fig. 5.5.A). Furthermore, most 
ATF3 immunopositive cells also expressed pTS^111 (Fig. 5.5.B), which is known to be 
strongly upregulated by Schwann cells during Wallerian degeneration. By phase contrast 
microscopy, ATF3 immunoreactive could be observed within the bands of Bungner 
adjacent to macrophages laden with myelin debris (Fig. 5.5.C). The endothelial cells and 
pericytes of endoneurial blood vessels were very rarely immunoreactive for ATF3 in 
injured adult nerve, except at ldpo when a small number of these cells were found to be 
weakly positive. The ATF3 immunoreactive cells found at the periphery of epineurial 
blood vessels were thought to be Schwann cells, since they also expressed S100.
ATF3 Expression in CNS Glia
Transection o f the Dorsal Root (Rhizotomy)
Rhizotomy was performed to establish whether upregulation of ATF3 is common to both 
peripheral and CNS glia during Wallerian degeneration. Within each dorsal rootlet is a 
small cone of CNS tissue, termed the dorsal root entry zone (DREZ), from which GFAP 
immunopositive astrocytic processes extend following rhizotomy. These processes 
project into the injured adjoining rootlet, and constitute the first CNS tissue to be 
encountered by regenerating primary sensory afferents. Indeed, very few of the axons 
regenerating along the dorsal rootlets actually manage to grow back into the spinal cord; 
the majority arrest at the DREZ, and some axons turn back on themselves (Chong et al., 
1999; Zhang et al., 2001).
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By ldpo, ATF3 immunoreactive cells were present close to the site of transection. By 4 
and 8dpo, when long GFAP immunopositive astrocytic processes were observed 
extending out from the DREZ into the adjoining dorsal rootlets, ATF3 immunoreactive 
cells were present throughout the whole segment of peripheral nerve from the site of 
transection up to the border of the DREZ (Fig. 5.5.D and E). Both the DREZ and the 
rostral spinal dorsal column, which were undergoing Wallerian degeneration, were 
devoid of immunoreactivity for ATF3.
Expression o f c-Jun during Wallerian Degeneration
The pattern of c-Jun immunoreactivity closely resembled that of ATF3 in all injury 
models examined. For example, c-Jun was strongly upregulated by large numbers of 
endoneurial cells in the distal stump of lesioned sciatic nerve, following a similar 
temporal course as ATF3. Also, c-Jun immunopositive cells were present in the distal 
segment of peripheral nerve up to the border of the DREZ following rhizotomy (Fig. 
5.5.F); no c-Jun immunopositive CNS glia were observed either in the DREZ or the 
degenerating rostral spinal dorsal column.
Optic Nerve Crush
There is a considerable degree of axonal sprouting in the proximal stump of adult rat 
optic nerve following crush injury (Zeng et al., 1994), but very little axonal regeneration 
(Campbell et al., 1999).
At all time points examined (4, 8 and 30dpo), both the lesion site and the meninges 
contained some strongly ATF3 immunopositive cells. However, throughout the proximal 
and distal stumps, there were a few very weakly ATF3 immunoreactive cells (Fig. 5.5.G); 
although, this could be the result of non-specific binding of the rabbit antiserum. Many 
putative retinal ganglion cells ipsilateral to the lesion, but not contralateral, were ATF3 
immunopositive at all time-points (Fig. 5.5.H) consistent with a previous study (Takeda 
et al., 2000).
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DISCUSSION
The evidence presented here for the upregulation of ATF3 in the distal stump of 
transected sciatic nerve of adult rat is supported by a previous study (Nagarajan et al., 
2002), in which the distal stump of transected sciatic nerve of adult mouse was examined 
for changes in gene expression using gene chip technology. Analysis of their raw 
microarray data, made publicly available for downloading, shows that ATF3 was 
significantly upregulated. In addition, numerous other genes, already known to be 
upregulated, were also detected in this analysis (Table 5.1).
ATF3 Expression in Schwann Cells in the Injured Peripheral Nerve
ATF3 expression is induced in many endoneurial cells in the injured sciatic nerve, 
including Schwann cells in the distal stump. The duration of expression is prolonged by 
ligation of the proximal stump after transection (30dpo = 67.92%), but reduced by 
reanastomosis of the proximal and distal stumps after transection (30dpo = 3.64%). 
Intermediate values were recorded after resection (30dpo = 31.80%), which slows the 
course of regeneration and leads to a more variable outcome. Intriguingly, it would 
appear that glial expression of ATF3 is negatively regulated by signals derived from 
completely regenerated axons, not by contact of Schwann cells with regenerating axons 
per se. Evidence for this comes from the distal stumps of transected & reanastomosed 
nerve; by 16dpo and 30dpo there was little difference in axonal density, yet ATF3 
immunopositive cells were widespread and often in contact with axons in the former 
(16dpo = 21.10% vs. 30dpo = 3.64%). Similarly, in the distal stump of resected nerve at 
30dpo (31.80%) the axonal density was variable, reflecting the slowed rate of 
regeneration, and many ATF3 immunoreactive cells -  some in contact with axons - could 
be observed.
It is unlikely that the upregulation of ATF3 is a general response to injury, since it is 
neither upregulated in perineurial cells, nor endothelial cells of the endoneurial or 
epineurial blood vessels which would also have been damaged. That the number of cells 
upregulating ATF3, and the strength of expression, was markedly higher in the distal 
stump than the proximal stump at all timepoints is also indicative of a genuine molecular
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process occurring during Wallerian degeneration. Also, given that the ATF3 
immunoreactive nuclei within the distal stump are for the most part found within SI00 or 
p?5 NTR immun0p0Sitive structures, it is reasonable to suggest that the molecule is 
principally expressed by Schwann cells. However, the homogenous appearance of ATF3 
immunoreactive nuclei - in terms of shape, size and intensity of signal -  does not 
preclude the involvement of other cell types.
Differential Expression of ATF3 in PNS and CNS Glia
Rhizotomy elicited ATF3 expression by peripheral glia in the segment of peripheral 
nerve from the site of transection up to the border of the DREZ. In contrast, the CNS glia 
in the DREZ and rostral spinal dorsal column did not express ATF3, despite undergoing 
Wallerian degeneration in response to the death of the very same axons. These 
differences in glial response were strikingly obvious in sections of the ipsilateral DREZ. 
However, direct trauma to the CNS, in the form of an optic nerve crush, evoked a 
somewhat different response. Although strongly immunoreactive cells were detected in 
the lesion site, as well as in the meninges, only very weakly immunoreactive cells could 
be observed in the proximal and distal stumps at any survival time. It is possible that this 
weak immunoreactivity is due to non-specific binding of the rabbit antiserum. 
Nonetheless, the pattern of immunoreactivity is distinct from that observed in the injured 
PNS and strongly suggests that ATF3 is not upregulated in a program of gene expression 
associated with the CNS glial response during Wallerian degeneration. It may, however, 
be upregulated strongly in a few cells at the lesion site and in the meninges as a result of 
direct trauma.
ATF3 and c-Jun Exhibit a Similar Pattern of Expression in Injured Peripheral Nerve
Although no double-labelling experiments were performed owing to the lack of 
compatible antibodies, the pattern of ATF3 expression was very similar to that of c-Jun in 
all models of injury examined. In lesioned peripheral nerve, strong expression of c-Jun 
was observed in endoneurial cells of the distal stump. Likewise, following rhizotomy, c- 
Jun expression was observed in PNS glia residing in the distal segment of the transected 
peripheral nerve root, but not in CNS glia residing in the respective DREZ or
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degenerating spinal dorsal column, all of which were undergoing Wallerian degeneration 
in response to the loss of the same axons. In the injured optic nerve, it is known that c- 
Jun is not upregulated during Wallerian degeneration (Vaudano et al., 1998). It is 
enticing to think that ATF3 and c-Jun may be forming functional heterodimers in 
peripheral glia; ATF3 homodimers tend to be involved in the repression of transcription, 
and ATF3/c-Jun heterodimers in activation. It is not yet clear which genes can be 
regulated by these homo- and/or hetero-dimers but, not surprisingly, it is known that their 
consensus binding sites are slightly different.
Is ATF3 Expression in Schwann Cells Linked to Axonal Regeneration?
Wallerian degeneration is different in PNS and CNS glia and, perhaps with the exception 
of olfactory ensheathing glia (OEG), Schwann cells are the most permissive for axonal 
regeneration. Therefore, it is quite plausible that one of the key reasons why axonal 
regeneration fails in most parts of the CNS is simply because oligodendrocytes, 
astrocytes and microglia do not respond appropriately to injury.
In injured peripheral nerve, there are many changes in gene expression in the distal 
stumps (Kubo et al., 2002). For example, cell adhesion molecules such as N-CAM, LI 
and CHL1 are all upregulated and thought to be beneficial to regeneration (Tacke and 
Martini, 1990; Hillenbrand et al., 1999). Similarly, pTS1'1711 is upregulated by Schwann 
cells and is believed to assist in the process of regeneration by storing neurotrophic 
factors, such as NGF and BDNF, which are also upregulated (Funakoshi et al., 1993). 
Extracellular matrix molecules such as laminin, tenascin-C and collagens are upregulated 
(Eather et al., 1986; Martini et al., 1990; Siironen et al., 1992; Doyu et al., 1993), as well 
as various cytokines (Rotshenker et al., 1992; Curtis et al., 1994; Subang and Richardson, 
2001), although there is some debate about the extent in which these molecules assist in 
regeneration. On the other hand, myelin-associated molecules such as P0 and MAG are 
downregulated (Poduslo, 1984; Gupta et al., 1990); the latter having long been implicated 
in axonal regenerative failure within the CNS. However, it should not be overlooked that 
Schwann cells within the distal stump of transected peripheral nerve also upregulate 
molecules that are believed to be highly inhibitory to axonal regeneration in the injured
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CNS - such as Sema3A, Nogo and NG2 (Hunt et al., 2002b; Scarlato et al., 2003; 
Rezajooi et al., 2004) . Yet, these do not seem to be detrimental to regeneration within 
the peripheral nervous system. There are, of course, a number of potential explanations, 
one of them being that the activity of co-expressed permissive molecules overrides that of 
inhibitory molecules.
ATF3 and Transcriptional Control
ATF3 is also upregulated by many axotomized neurons, and was at first considered to be 
a neuron-specific marker of injury in the nervous system (Tsujino et al., 2000). In vitro, 
it has been shown to act through HSP27 to confer resistance to apoptosis and to promote 
neurite outgrowth (Nakagomi et al., 2003). These are, of course, desirable responses in 
injured neurons; but, protection from apoptosis would presumably be of equal benefit to 
Schwann cells during Wallerian degeneration. That ATF3 and c-Jun share a similar 
pattern of expression in both neurons (Takeda et al., 2000) and Schwann cells following 
axonal injury is suggestive of their controlling molecular responses common to both cell 
types, possibly through the formation of heterodimers. Indeed, CHL1 and GAP43 are 
upregulated by axotomized neurons as well as Schwann cells (Verge et al., 1990; Hall et 
al., 1992; Chong et al., 1994; Zhang et al., 2000). Likewise, pTS*4711 - which is strongly 
expressed by Schwann cells during Wallerian degeneration - is also upregulated by 
axotomized motomeurons (Gschwendtner et al., 2003). Whether these changes in gene 
expression are linked to the activity of upregulated ATF3, either as a homodimer or as a 
heterodimer in conjunction with c-Jun, remains to be seen. Although, in the case of 
GAP-43, it would appear that overexpression of c-Jun alone is insufficient to drive 
transcription of GAP-43 (Carulli et al., 2002), even though its promoter contains an AP-1 
transcription factor binding site (Weber and Skene, 1998).
Summary
ATF3 is widely upregulated by Schwann cells distal to a peripheral nerve transection. Its 
temporal expression pattern appears to be regulated by axonal regeneration and 
reinnervation of target organs: transection & ligation, which prevents peripheral nerve 
regeneration, leads to prolonged ATF3 expression whereas transection & reanastomosis,
208
which expedites regeneration, leads to a shorter course of expression compared to 
transection & resection models, which are designed to slow the course of regeneration. 
Curiously, in contrast to peripheral Schwann cells, CNS glia do not appear to upregulate 
ATF3 during Wallerian degeneration. This differential transcriptional response to 
axotomy may, in part, explain why Schwann cells are one of the most highly supportive 
cell-types for axonal regeneration and are fundamental to the success of regeneration in 
the peripheral nervous system. In time, a fuller understanding of the molecular 
mechanisms that make them so will doubtless prove hugely valuable to the study and 
treatment of CNS nerve injury.
CONCLUSION
Schwann cells, but not CNS glia, express both ATF3 and c-Jun during Wallerian 
degeneration. These transcription factors may participate - perhaps through the formation 
of heterodimers - in regulating cascades of gene activity which ultimately render 
Schwann cells supportive for axonal regeneration.
The principal observation reported in this chapter, that ATF3 is upregulated in the 
endoneurial cells of axotomized peripheral nerve, was also independently discovered by 
M.K.Hossain-Ibrahim. Figure 5.2 incorporates our collective data on the temporal 
expression profile of ATF3 in various models of peripheral nerve injury.
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Figure 5.1.
Resection of adult rat sciatic nerve. ATF3 immunoreactive nuclei (green) are shown in 
the proximal (A,C,E,G) and distal (B,D,F,H) stumps at 4,8,16 and 30dpo, respectively. 
ATF3 expression is stronger and more widespread in the distal stump, than in the 
proximal stump at all timepoints. The main image in C, and the inset image, show 
segments of proximal stump and distal stump, respectively, photographed under 
standardized conditions (exposure, gain and offset). The perineurium (P) is devoid of 
ATF3 immunoreactivity. Scale bars: A,B = 200pm; C-H = 50pm.
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Figure 5.2.
Histograms showing the percentage of ATF3 immunopositive nuclei in the proximal (A) 
and distal stumps (B,C) of injured adult rat sciatic nerves. In the proximal stump after 
resection (A), not only were the number of ATF3 immunopositive nuclei less numerous 
but also more weakly immunoreactive than in the distal stump (B). There is no bar for 
4dpo in A, because so few nuclei were ATF3 immunopositive (<1%). In C, the course of 
ATF3 expression in the distal stump after cut and reanastomosis (C&R) at 8,16 and 
30dpo is compared with cut and ligation (C&L) of the sciatic nerve at 30dpo. In contrast 
to resection (B), in which regeneration is slowed, C&R permits rapid axonal regeneration 
which is associated with a faster downregulation of ATF3 in the distal stump. However, 
when regeneration is prevented by C&L, ATF3 expression in the distal stump remains 
high.
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Figure 5.3.
Sciatic nerves from adult rats. In distal stumps of resected nerves at 30dpo (A, B, and C), 
a considerable degree of variation in both ATF3 immunoreactivity (green) and the 
quantity of axonal regeneration (as determined by heavy chain neurofilament 
immunoreactivity; red) is evident. In some instances, ATF3 immunopositive nuclei and 
regenerating axons are found in close association, suggesting that the presence of 
regenerating axons in the distal stump is not alone sufficient for the immediate 
downregulation of ATF3. In D, the distal stump of cut and reanastomosed sciatic nerve 
is shown at 30dpo, when axonal regeneration is extensive and ATF3 expression has 
declined. By in situ hybridisation, ATF3 mRNA is undetectable in intact sciatic nerve 
(E), but upregulated in the distal stump of resected nerve 8dpo (F). Scale bars = 50pm. 
The sections shown in E and F were prepared and reacted by Dr. M.R. J. Mason.
214
NF200
NF29£
215
Figure 5.4.
The distal stump of a sciatic nerve from a neonatal rat, 5dpo. The nerve was resected at 
PI. Similar to adult rat sciatic nerve, many endoneurial cells strongly express ATF3. 
Scale bar = 50pm.
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Figure 5.5.
PNS glia, but not CNS glia, express ATF3 during Wallerian degeneration. ATF3 (green) 
is expressed in SI00 (red in A) and p75NTR (red in B) immunopositive cells in the distal 
stumps of resected sciatic nerves of adult rat (A = 30dpo; B = 8dpo). C is a double 
exposure showing a phase contrast image and ATF3 immunofluorescence (green) of the 
distal stump of a resected nerve, 4dpo. The ATF3 nuclei are found between the debris­
laden macrophages (asterisk) inside the bands of Bungner (indicated by arrows). D and E 
show the dorsal rootlets of adult rat sciatic nerve, immunoreacted for ATF3 (green) and 
GFAP (red) 8 days after dorsal rhizotomy. The GFAP immunopositive astrocytes which 
characterise the dorsal root entry zone (d) of the spinal cord have long processes 
projecting into the peripheral segment of the rootlets (asterisk). For the most part, ATF3 
expression is confined to the peripheral segment of the rootlets in which Schwann cells 
reside. F shows a dorsal rootlet, 1 day after dorsal rhizotomy, immunoreacted for c-Jun 
(green) and GFAP (red). Note that c-Jun expression is confined to the Schwann-cell 
containing part of the rootlet (asterisk), as is ATF3 (compare with E). G and H are 
images of optic nerve and retina from the same animal, 30 days after a left optic nerve 
crush injury. Both have been immunoreacted for ATF3 (green) and GFAP (red). In G, 
reduced GFAP immunolabelling marks the crush site (L) which also contains some ATF 
immunopositive nuclei. Additionally, some nuclei proximal and distal to the lesion are 
ATF3 immunoreactive, but these are much less numerous and more weakly labelled than 
in injured peripheral nerves. H shows the retina ipsilateral to the optic nerve crush site, in 
which strongly ATF3 immunopositive nuclei are visible in the ganglion cell layer 
(arrowheads). Op = optic nerve head. Scale bars: A-C = 25pm; D = 100pm, E = 50pm; 
F = 100pm; G = 50pm; H = 50pm.
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Table 5.1.
Some of the genes which appear to be upregulated more than five-fold in the distal stump 
of adult rat sciatic nerve at 14d, or 28d, after transection (calculated from the raw 
microarray data made available for downloading by Nagarajan et al. 2002).
Gene name Supporting Evidence
Jun oncogene Stewart, 1995
Tenascin C Martini et al., 1990
Insulin-like growth factor 1 Cheng et al., 1996
ATF3 Hunt et al., 2004
Neuropilin Scarlato et al., 2003
Lectin, galactose binding, soluble 3 
(a.k.a. ga!ectin-3/MAC-2) Reichert et al., 1994
GAP-43 Curtis et al., 1992
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CHAPTER 6
o m g p  mRNA Expression in the Intact and Injured
Nervous System
INTRODUCTION
Oligodendrocyte myelin glycoprotein (OMgp) was first identified in a screen of adult 
human CNS white matter for peanut agglutinin-binding proteins (Mikol and Stefansson, 
1988). It is a GPI-linked leucine rich repeat (LRR) protein that is subject to differential 
post-translational modification with the HNK-1 carbohydrate (Mikol et al., 1990b). The 
function of the molecule remained something of a mystery until recently, when it was 
identified as a functional ligand for the Nogo-66 Receptor (Wang et al., 2002b). Shortly 
afterwards, it was also reported to be the main neurite-outgrowth inhibitor in ‘arretin’, a 
protein fraction extracted from bovine myelin (Kottis et al., 2002).
As its name suggests, OMgp is believed to be a myelin protein. However, there is some 
evidence that it may in fact be predominantly expressed by neurons (Habib et al., 1998c), 
not only by oligodendrocytes as had initially been thought (Mikol and Stefansson, 1988). 
Furthermore, the transient expression of OMgp in 3T3 fibroblasts was found to suppress 
mitogenesis by blocking intracellular signalling pathways from activated PDGFa 
receptor (Habib et al., 1998a). Together, these two studies are suggestive of another role 
for OMgp, possibly as part of a receptor complex on neurons.
Since there is now irrefutable evidence that many of the isoforms of Nogo are expressed 
by adult neurons (Josephson et al., 2001; Huber et al., 2002; Hunt et al., 2002b), and also 
that Nogo-A and NgR are expressed in neurons throughout embryonic development 
(Huber et al., 2002; Josephson et al., 2002; Tozaki et al., 2002; Lauren et al., 2003; Meier 
et al., 2003; Mingorance et al., 2004), it seems plausible that neuron-neuron signalling 
may be occurring through the NgR-ligand interactions. OMgp, being a GPI anchored cell 
surface protein, is of course well located for such cell surface interactions, in contrast to
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the Nogo family of proteins which all contain a carboxy terminal ER-retention signal. 
Since it is also possible that OMgp is a receptor in its own right, intemeuronal NgR- 
OMgp interactions could potentially result in two-way signalling.
The finding of omgp expression by neurons has been given very little attention, especially 
in the context of OMgp-mediated inhibition of axonal regeneration (Wang et al., 2002b; 
Kottis et al., 2002). This is an important issue, not least because NgR is the only protein 
with which OMgp has, to date, been shown to bind. Naturally, there may be other 
proteins with which OMgp interacts; in fact, it would be surprising if there were not, as it 
can alter intracellular signalling in cells in which it is overexpressed. If this finding is 
correct, OMgp would require a signal transducing co-receptor and, presumably, at least 
one ligand. One possibility would be that the soluble form of NgR, cleaved from the cell 
surface by a zinc metalloproteinase (Walmsley et al., 2004), could act as such a ligand for 
OMgp. Though what the function of such a system would be is difficult to say.
Since very little is known about OMgp, it was felt that an investigation of its expression 
pattern in the adult rodent nervous system, by in situ hybridisation, was warranted, not 
least, because the previous report of omgp expression by neurons had yet to be 
confirmed. Furthermore, because the protein appears to modulate PDGFa signalling in 
fibroblasts, it could be of considerable importance in neuronal physiology. In this study, 
in situ hybridisation using both DIG-labelled riboprobes and 35S-labelled 45-mer DNA 
oligonucleotides was performed.
SUMMARY OF METHODS 
Animal Models
Seven unoperated adult Sprague-Dawley rats, and one unoperated Balb/c mouse, were 
used in these experiments. The Balb/c mouse brain, and one Sprague-Dawley rat brain, 
were used for the extraction of total RNA. Three Sprague-Dawley rats received 
autologous peripheral nerve grafts to thalamus, and were culled after 16 days. The 
remaining three rats were used unoperated for in situ hybridisation.
222
Cloning of the Rat omgp Coding Sequence
Rat genomic DNA was isolated from adult Sprague-Dawley rat brain using DNAzol, as 
described in Chapter 2. PCR was performed with the forward and reverse primers, GGC 
TTT GAT GGA ATA TCA G and TAG CAG CAA GTA CCA AGA CA, using the 
proof-reading DNA polymerase, Pfu (Promega). The amplicon was ligated into the PCR 
cloning vector, pGem T Easy (Promega). Two clones were sequenced by automated 
fluorescent dye sequencing.
In Situ Hybridisation with DIG-Labelled Riboprobes
A 540bp fragment of mouse omgp (bases 1096-1635 of Genbank sequence NM_019409) 
was cloned by PCR from total RNA extracted from adult Balb/c mouse brain, using the 
forward primer ACT GCT CGA GTA GTA GCA CTG ATA GGG CTG and the reverse 
primer ACT GAA GCT TGC AAG TAC CAA GAC ATT GTG. The amplicon was 
ligated into pcDNA3 using the Xhol and Hindlll restriction sites, which were also 
contained in the forward and reverse primers, respectively, i/mdlll-linearized plasmid 
was used for the synthesis of DIG-labelled sense riboprobes in conjunction with SP6 
RNA polymerase. Conversely, YM-linearized plasmid was used for the synthesis of 
DIG-labelled antisense riboprobes in conjunction with T7 RNA polymerase. In situ 
hybridisation was carried out as described in Chapter 2. The sense riboprobe produced 
no signal.
Radioactive In Situ Hybridisation
A 35S-labelled 45-mer DNA oligonucleotide, ACT CAT TCC ATC CTG GAG GTG 
AAT AGT TAG AGT TGC AGC TGC TGC (bases 1042-1086 of Genbank sequence 
AY316298), was used for radioactive in situ hybridisation as described in Chapter 2. The 
specificity of binding of this antisense omgp probe was verified by ‘competitive control’, 
in which a mixture of radiolabelled and unlabelled oligonucleotide (in a ratio of 1:100) 
was applied to sections. The absence of radioactive signal in competitive control sections 
was indicative of the high specificity of the antisense probe.
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RESULTS 
Cloning of Rat omgp
In order to perform in situ hybridisation with radiolabelled 45-mer DNA oligonucleotides 
on rat tissue, it was first necessary to obtain the rat omgp coding sequence (CDS) in order 
to design exact-matching probes. At the time that this work was undertaken, the rat omgp 
CDS had not yet been cloned, sequenced and registered in Genbank. Unfortunately, the 
early build of the rat genome, which was publicly accessible through the National Centre 
for Biotechnology Information (NCBI) website (www.ncbi.nih.gov), was fraught with 
sequencing errors. Using the Basic Local Alignment of Sequence Tool (BLAST) to align 
the Genbank approved mouse omgp CDS against the draft rat genome, it became 
apparent that there was a frame shift in the draft rat genomic omgp CDS, and numerous 
nucleotide mismatches (Fig. 6.1). Furthermore, there were no matching rat expressed 
sequence tags (ESTs) deposited in dbEST, therefore preventing the extrapolation of a 
consensus sequence from overlapping ESTs. The cloning of the rat omgp CDS was, 
therefore, required to ensure the design of perfectly complementary 45-mer 
oligonucleotide antisense sequences for radioactive in situ hybridisation. Also, given the 
growing significance of OMgp in axonal regeneration and the common usage of rats as 
experimental models, it was felt that the cloning of the rat omgp CDS and the submission 
of its sequence to a publicly accessible database, such as Genbank, would be of wider 
benefit.
BLAST alignment of the full-length mouse omgp sequence against the draft rat genome 
sequence revealed that the gene structure of omgp is the same in both mouse and rat. 
That is to say that the omgp gene consists of two exons, with the intron being located in 
the 5' untranslated region (UTR) and the CDS being located entirely within the second 
exon. Having obtained the rat genomic sequence corresponding to the mouse omgp CDS, 
a correction was made for the obvious frame-shift, due to the omission of an A at position 
169, to provide a rough prediction of the correct rat omgp CDS.
Regions of complete homology between the mouse full-length omgp cDNA and rat 
genomic sequences, overlying the start codon and flanking the stop codon of the CDS,
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were selected for PCR primer design. Using total RNA extracted from adult Sprague- 
Dawley rat brain tissue, RT-PCR was performed, and the 1.5Kb amplicon cloned into 
pGem T Easy PCR cloning vector (Promega, Southampton, UK). Two clones were 
subsequently submitted for automated fluorescent-dye sequencing, both of which were 
identical (Fig. 6.2).
The cloned sequence was compared by BLAST with the draft rat genomic omgp CDS 
(Fig. 6.3). A single nucleotide mismatch was detected at position 713 (T->C), in addition 
to the obvious sequencing errors in the draft rat genomic omgp CDS. However, 
alignment of the sequencing results with the mouse and human full-length omgp cDNA 
sequences revealed that, in these sequences, the base at position 713 was also T (not 
shown). It was, therefore, assumed that the mismatch was most likely to be due to a 
sequencing error in the draft rat genome database, and not a genuine point-mutation 
arising from RT-PCR. The cloned rat omgp CDS was deposited in Genbank (Accession 
number AY316298). Recently, an updated build of the rat genome has been made 
publicly available, and the replacement genomic contig (Accession Number 
NW_47336.1), which spans the omgp gene, shares 100% sequence identity with the 
cloned rat CDS that was submitted to Genbank as part of this study (Fig. 6.4).
At the level of the nucleotide sequence, the rat omgp CDS is 95% homologous to that of 
mouse, and 90% homologous to that of human. The same percentage homologies apply 
at the level of the amino acid sequence for OMgp (Fig. 6.5).
omgp mRNA Expression in the Intact Adult Rodent Nervous System
By radioactive in situ hybridisation, it was grossly apparent from the radiographic film 
that omgp was strongly expressed in the neocortex, pyriform cortex, hippocampal 
formation, habenular nucleus, some brainstem nuclei, spinal cord grey matter and dorsal 
root ganglia (DRG) (Fig. 6.6.A-F). Moderate signal was also observed in the cerebellar 
cortex (Fig. 6.6.D). Unfortunately, due to a technical problem, silver granule
precipitation was not achieved and the cellular expression could not be examined
microscopically.
225
However, using a DIG-labelled antisense riboprobe to omgp, it was found that both 
neurons and glia expressed omgp transcripts in the neocortex. However, expression of 
the transcript by large pyramidal projection neurons was less prominent than in smaller 
neurons throughout the full thickness of the cortex (Fig. 6.7.A). The overall level of 
expression of omgp by neocortical neurons appeared weaker and less extensive relative to 
nogo-a, nogo-66 and ngr (Fig. 6.7.B-D), but many smaller putative glial cells appeared to 
express the transcripts at low to moderate levels throughout the cortex. Additionally, 
weak to moderate signal for omgp was detected in the glial cells of the subcortical white 
matter. In the neostriatum, omgp mRNA was detectable in both neurons and glia, but 
much more weakly than in neocortex (not shown). In the hippocampal formation, strong 
signal for omgp was observed in the CA1-CA4 pyramidal neurons, and the granule 
neurons of the dentate gyrus (Fig. 6.8.A). In the cerebellar cortex, Purkinje cells were the 
only class of neuron to strongly express omgp, but very weak signal was also observed in 
the granule cell layer (Figs. 6.8.B and C). Strong expression was also observed in 
neurons of the vestibular nuclei (Fig. 6.8.B). Weak expression of omgp by glia was also 
observed throughout the cerebellar white matter.
In the spinal cord, omgp was strongly expressed by neurons in both the dorsal and ventral 
horns (Fig. 6.8.D). Only very weak signal was detectable in glial cells of the spinal white 
matter. Moderate to strong expression was observed in different subpopulations of dorsal 
root ganglia (DRG) neurons (Fig. 6.8.E). The same was true of the postganglionic 
sympathetic neurons of the superior cervical ganglion (SCG) (Fig. 6.8.F). Intact sciatic 
nerve did not appear to express omgp (not shown).
Autologous Peripheral Nerve Graft in Thalamus
No obvious regulation of omgp expression was observed 16d post implantation of 
autologous tibial nerve graft to thalamus, except in one of three animals. In this rat, the 
ventral blade of the dentate gyrus, ipsilateral to the graft, was no longer found to express 
omgp (Fig. 6.9). No other differences were noted.
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DISCUSSION
In Situ Hybridisation for omgp mRNA in the Intact Adult Rodent Nervous System
In the present study, in situ hybridisation was performed to map omgp mRNA expression 
in the intact adult rodent nervous system, using both DIG-labelled riboprobes and 35S- 
labelled DNA oligonucleotides. It was confirmed that expression of omgp mRNA is 
predominantly neuronal (Habib et al., 1998b). Expression was generally higher in the 
spinal cord than brain, with the strongest expression being detected in neurons of the 
spinal grey matter. On the whole, omgp mRNA did not appear to be regulated after CNS 
injury, although this was only assessed using DIG-labelled riboprobes.
Exposure to film of slides hybridized with 35S-labelled DNA oligonucleotides revealed a 
pattern of omgp expression which was grossly consistent with that obtained using DIG- 
labelled riboprobes. However, owing to a technical problem with the process of silver 
granule precipitation, it was not possible to determine the precise cellular expression of 
omgp transcripts using radioactive in situ hybridisation on this occasion. The relatively 
long exposure to film and alkaline-phosphatase development times required with the 
radioactive and DIG approaches, respectively, would seem to indicate that the mRNA is 
likely to be relatively lowly expressed throughout the adult rodent nervous system 
compared to other species of mRNA.
The findings presented herein were broadly consistent with those of a previous study of 
omgp expression, by Habib et a l (1998b) who performed in situ hybridization (ISH) 
using radio-labelled riboprobes. That is to say that the more prominent transcript 
expression was detected in pyramidal neocortical neurons, neurons of pyriform cortex, 
pyramidal neurons of the hippocampus, cerebellar Purkinje cells, brainstem nuclei, and 
spinal cord grey matter, as was reported by Habib et al. (1998b). However, in this study, 
omgp expression in the hypothalamic nuclei could only be described as moderate at best. 
In addition to the tissues examined by Habib et al (1998b), DRG and SCG were also 
examined. Neurons within these ganglia were found to express omgp at moderate to 
strong levels, which presumably reflected different subpopulation expression profiles. 
Furthermore, intact sciatic nerve was not found to express the mRNA.
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omgp mRNA Expression Following Grafting of Peripheral Nerve to Thalamus
No regulation of omgp expression could be detected in CNS neurons following the 
grafting of an autologous segment of tibial nerve to thalamus, except in one animal. In 
this rat, 16dpo, signal for omgp was absent from the ventral blade of the dentate gyrus. 
This was not found in the other two rats, also 16dpo, which may be suggestive of some 
experimental anomaly.
OMgp Protein Expression in the Nervous System
Unfortunately, the absence of a commercially available anti-OMgp antibody meant that 
immunohistochemistry could not be performed as part of this study. However, Habib et 
al (1998b) have performed immunohistochemistry with an affinity-purified polyclonal 
anti-OMgp antibody, which revealed strong staining of the plasma membrane of Purkinje 
cell bodies and of the dendrites projecting into the molecular layer. No staining of the 
cerebellar granule cells was observed, although immunoreactive Purkinje cell axons were 
detected in the granule cell layer and underlying white matter. The perikarya of 
hippocampal pyramidal cells were strongly immunoreactive for OMgp, as were 
corticotectal tract fibres. Some hypothalamic nuclei expressed OMgp protein. 
Widespread immunoreactivity was found in the neocortex, with the strongest labelling in 
layer V. Since these results were at odds with their previous finding using a less specific 
polyclonal antibody (Mikol and Stefansson, 1988), that there was strong OMgp 
immunoreactivity in white matter, Habib et al. (1998b) sought to verify the expression of 
OMgp in oligodendrocytes. They demonstrated OMgp protein was expressed by primary 
cultures of mouse oligodendrocytes but concluded, on the basis of their comprehensive 
immunohistochemical and complementary ISH studies, that expression of OMgp is 
predominantly neuronal within the murine CNS.
Neuronal Expression of OMgp
The available evidence thus suggests that OMgp is principally a neuronal protein with a 
limited amount of OMgp being expressed by oligodendrocytes. The functions of 
neuronal OMgp have not been explored. As with neuronal Nogo, the possibility that 
these ligands interact with neuronal NgR in cis (i.e. at the surface of the same cell)
228
remains open but, considering that OMgp over-expression in NIH3T3 cells suppresses 
mitogenic signalling (Habib et al., 1998a), it is hard to imagine that OMgp does not 
participate in some regulatory signalling mechanism in neurons.
Summary
The predominantly neuronal expression of omgp does not preclude a role for the protein 
as a myelin-associated inhibitor of axonal regeneration, since putative oligodendrocytes 
were also found to express omgp, albeit weakly, throughout the CNS white matter. 
However, this function of OMgp has only been demonstrated in vitro and, based on the 
expression profile, it is unlikely to constitute the sole function of the protein. Another as 
yet undetermined role for OMgp, possibly in neuron-neuron signalling, cannot be 
excluded. Unfortunately, an omgp null mutant mouse has not yet been reported. Such an 
animal would be expected to yield some important information regarding the likely 
function of OMgp. However, it has been found by quantitative PCR of postnatal rat brain 
(Vourc'h et al., 2003a), and also by both northern and western blot of postnatal mouse 
brain (Habib et al., 1998b), that omgp expression is developmentally regulated and peaks 
during the late stages of myelination. Furthermore, it has been reported that primary 
cultures of oligodendrocytes exhibit a similar pattern of omgp expression, prompting the 
authors to suggest that OMgp may have roles in vivo in the arrest of oligodendrocyte 
proliferation, the arrest of myelination or the compaction of myelin (Vourc'h et al., 
2003a). The same group has also detected a coding single nucleotide polymorphism in 
the human omgp gene (OMGP62), which apparently impairs the transport of the protein 
to the cell membrane. This polymorphism was reported to be present in both autistic and 
control populations, but was associated with a lower developmental quotient in the 
autistic subjects (Vourc'h et al., 2003b). Intriguingly, this may be linked to the finding 
that the ngr null mutant mice have impaired learning skills (Kim et al., 2003a).
CONCLUSION
The predominantly neuronal expression of omgp mRNA in the adult rodent nervous 
system raises important questions about the role of OMgp in vivo. This has been
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somewhat overlooked in its recent description as a myelin-associated inhibitor of axon 
regeneration (Wang et al., 2002b). Whilst it is possible that oligodendrocyte OMgp does 
modify axon growth and regeneration through the NgR/p75NTR/LINGO-l receptor 
complex in vivo, it seems unlikely that this is its main physiological role. Indeed, OMgp- 
NgR signalling in a neuron-neuron model is also plausible. Ultimately, however, further 
consideration should be given to the evidence suggesting that OMgp is capable of acting 
as a receptor in its own right.
N.B. Part of the work report in this chapter was carried out in collaboration with an MSc 
student, J. Mills, working under my supervision. In particular, Ms Mills prepared and 
reacted the sections shown in Figs. 6.8.D-F. She also assisted with the cloning of the rat 
omgp CDS.
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Figure 6.1.
Alignment of the mouse omgp cDNA sequence against the draft rat genome. Using 
genomic BLAST, available via the NCBI website, the full-length mouse omgp cDNA 
sequence (Genbank Accession No. BC024757) was used to identify the corresponding 
omgp sequence within the draft rat genome (on contig NW_042664). Numerous single 
base mismatches were apparent, many of which were expected to be evolutionary. There 
was a frame-shift of one nucleotide in the draft rat genomic sequence, which disrupted 
the ORF and was expected to be due to a sequencing error.
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>ref|NW 042664.1|RnlO 210 Rattus norvegicus chromosome 10 WGS supercontig
Length = 1962622
Score = 2769 bits (1440), Expect = 0.0 
Identities = 1613/1697 (95%), Gaps = 11/1697 (0%)
Strand = Plus / Minus
Query: 73 ggctttgatggaatatcagatactgaaaatgtcttcctgcctgttcatccttctgtttct 
1 1 I I 1 1 1 1 1 II 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 III 1 1 1 1 1 1 1 1 1 
ggctttgatggaatatcagatattgaaaatgtcttcctgcctgttcatccttctgtttct
132
Sbjct: 1490171 1490112
Query: 133 cacgcctggcatcttatgcatttgtcctctccagtgtacatgcacagagaggcacaggca 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 11111111111 111 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 
cacgcctggcattttatgcatttgtcctctccaatgtatatgcacagagaggcacaggca
192
Sbjct: 1490111 1490052
Query: 193 tgtggactgttcaggcagaaacttgactacattaccacctggactgcaggagaacattat 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
tgtggactgttcaggcagaaacctgactacattaccacctggactgcaagagaac-ttat
252
Sbjct: 1490051 1489993
Query: 253 acatttaaacctgtcttataaccactttactgatctgcataaccagttaaccccatatac 
1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 II 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 II 1 II II 1 1 1 1 1 1 1 1 
acatttaaacctgtcttataaccactttactgatctgcataaccagttaaccccttatac
312
Sbjct: 1489992 1489933
Query: 313 caatctgagaaccctggatatttcaaacaacaggcttgaaagtctgcctgctcagttacc 
1 1 1 1 1 1 1 1 1 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
caatctgaggaccctggatatttcaaacaacaggcttgaaagtctgcctgcccagttacc
372
Sbjct: 1489932 1489873
Query: 373 tcggtctctctggaacatgtctgctgctaacaacaatattaaacttcttgacaaatctga 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 11111111111 1 1 1 1 1 1 1 1 1 1 II11 111 1111 1 1 1 1 1 1 1 
tcggtctctctggaacatgtctgctgctaacaacaacattaaactacttgacaaatctga
432
Sbjct: 1489872 1489813
Query: 433 tactgcttatcagtggaaccttaaatacctggatgtttctaagaatatgctggaaaaggt 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
492
Sbjct: 1489812 tactgcttatcagtggaaccttaaatacctggatgtttctaagaatatgttggaaaaggt 1489753
Query: 493 tgttctcattaaaaataccctaagaagtctcgaggttcttaacctcagcagtaacaagct
1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 I 1 1 1 1 1 1 1 1 II II
552
Sbjct: 1489752 tgttctcattaaaaataccttaagaagtcttgaggttcttaacctcagcagtaataaact 1489693
Query: 553 ttggacagttccaaccaacatgccttccaaactgcatatcgtgg-acctgtctaataact 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 
ttggacagttccaaccaacatgccttccaaactacatattgtggnacctgtctaataact
611
Sbjct: 1489692 1489633
Query: 612 cactgac-acaaatccttccagggacattaataaacctgacaaatctcacacatctttac 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 II 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
670
Sbjct: 1489632 cactgancacaaatccttccagggacattaataaacctgacaaatctcacacatctttac 1489573
Query: 671 ctgcacaacaataaattcacattcattccagaacagtcttttgaccaacttttgcagttg 
1 1 1 1 1 1 1 1 1 1 1111111 I 1111 1 1 1 1 1 1 1 1 1 1 111111111 1 1 II 1 1 1 1 1111 1 1 1 1 1 
ctgcacaacaataaattcacattcattccagatcagtcttttgaccaactcttgcagttg
730
Sbjct: 1489572 1489513
Query: 731 caagagataactcttcataataacaggtggtcatgtgaccataaacaaaacattacttac 
t111 II 1 1 1 1 1 II 1 II 1 III 1 III 1 1 III 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1
790
Sbjct: 1489512 caagagataactcttcataataacaggtggtcatgtgaccatacacaaaacattacttac 1489453
Query: 791 ttattgaagtgggtgatggaaacgaaagcccatgtgatagggactccttgttctaagcaa 
1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
850
Sbjct: 1489452 tcactgaagtggatgatggaaacaaaagcccatgtgatagggattccttgttctaagcaa 1489393
Query: 851 gtatcctctctaaaggaacagagcatgtaccccacacctcctgggtttacctcaagctta 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1
910
Sbjct: 1489392 gtatcctctctgaaggaacagagcatgtaccccacgcctcccggatttacttcaagctta 1489333
Query: 911 tttactatgagtgagatgcagacagtggacaccattaactctttgagtatggtaactcaa 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
tttactatgagtgagatgcagacagtggacaccattaactctctgagtatggtaactcaa
970
Sbjct: 1489332 1489273
Query: 971 cccaaagtgaccaaaacacccaaacaatatcgaggaaaggaaaccacatttggtgtcact 
II 1 1 1 1 1 1 1 1 I 1 1 1 1 1 1 II 1 II 1 1 1 1 1 II 1 1 1 1 1 1 II 1 1 I 1 1 1 1 1 1 I III 1 1 1 1 
cctaaagtgaccaatatacccaaacaatatcgaggaaaagacaccacatttggtgtcacc
1030
Sbjct: 1489272 1489213
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Query: 1031 ctaagcaaagataccacttttagtagcactgatagggctgtggtggcctacccagaagac 
1111111111 I 1111 111111111111 it 1 1 1 1 1 1 1 1 1 III 1 111111 1 1 1 1 II 1 1
1090
Sbjct: 1489212 ctaagcaaagacaccacttttagtagcactgatagggctctggagccctacccagaagac 1489153
Query: 1091 acacccacagaaatgaccaattcccatgaagcagcagctgcaactctaactattcacctc 
1 1111111II 1 11 111 111 III 1 11 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 111 111 1 1
1150
Sbjct: 1489152 acacccacagaaatgaccagttcacgtgaagcagcagctgcaactctaactattcacctc 1489093
Query: 1151 caggatggaatgagttcaaatgcaagcctcaccagtgcaacaaagtcac-ccccaagccc 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1111 II 1 1 1 1 1 1 II 1
1209
Sbjct: 14B9092 caggatggaatgagttcaaatgcaagcctcaccagtgcagcaaaatc-ctcccca-gcac 1489035
Query: 1210 c-gtgaccctcagcatagctcgtggcatgccaaataacttctctgaaatgcctcgacaaa 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 III 1
1268
Sbjct: 1489034 ctgtgaccctcagcataactagtggcatgccaaataatttctctgaaatgcctcaacaga 1488975
Query: 1269 gcacaaccctcaacttacggagggaagaaaccactgcaaatggaaacactcggccacctt 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 II 1 1 1 II III INI 1 1 1 1 II 1 1
1328
Sbjct: 1488974 gcacaacccttaacttacggagggaagaaacaactgcaaatgtaaagactcagccacctt 1488915
Query: 1329 c-tgcggctagtgcttggaaagtaaatgcctcgctccttttaatgctcaatgctgtggtc 
1 1 1111 1 1 1 11 1 11 1 11111 111111 1 111 11 1 1111 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1
1387
Sbjct: 1488914 cct-cggctagtgcttggaaagtaaatgcctcactccttttaatgctcaatgctgtggtc 1488856
Query: 1388 atgctggcaggctgagggtctgcagtttctgaaacgaaggagaaccttcctccatgatgt 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
atgctggcaggctgagggtctgcagtttctgaaatgaaggagaaccttcctccctgatgt
1447
Sbjct: 1488855 148879S
Query: 1448 acagttggga aaa c - gtgcccc tat eta accagtg atrtc aagc tat a trtatg trairtc a ag
1 1 1 1 11111 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 11111 III 1 1 1 1 11 I 1 1 1 1 1 1 1 1 111 1 1 1 1 1 
acagttgggaaaatag-gcccttatctaaccagtgattcaagctatactatgtattcaag
1506
Sbjct: 1488785 1488737
Query: 1507 aaagccagtcttatatttctgactttgatgtaaatgaagtaatttgtcttaattaaaaga 
1 1 1 1 II 1 1 1 II 1 1 1 1 1 1 1 1 1 II 1 111111111111 111II 11111 1 1 1 1 II 1 1 1 1 1 1
1566
Sbjct: 1488736 aaagccagtattgtatttctgactttgatgtaaatgaagtaacttgtcttaattaaaaga 1488677
Query: 1567 agtgcacaatgtcttggtacttgctgctattttcctgtcttaagtaaaactaatgacttt 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1626
Sbjct: 1488676 agtgcacaatgtcttggtacttgctgctattttcctgtcttaagtaaaactaatgacttt 1488617
Query: 1627 tttttttaatgaaatgttttctttttaaggcttcaacttattgcacaaactataaagagc 
1111 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 111111111 1 1 1 1 1 1 1 1 1 II 1 11 II 11 1 1 1 1 1 1
1686
Sbjct: 1488616 ttttttaaatgaaatgtttcctttttaaggcttcaacttactgcacaaagtataaagagc 1488557
Query: 1687 atctaaactttaatatgtattttatgtatgtttarractgtcaaatgtctgggacaaaata
1 11111II111II1II 1111111111 II1 II 1 1 II 1 1 1 1 I 1 1 1 1 II II 1 1 1 1 1 1 1 1 1 1 1
174 6
Sbjct: 1488556 atctaaactttaatatgtattttatgtatgtttacattgtcaaatgtctgggacaaaata 1488497
Query: 1747 aaaggcctatgctcctg 1763 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
aaaggcctatgctcctg 1488480Sbjct: 1488496
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Figure 6.2.
The cloned rat omgp CDS. The start and stop codons of the 1323bp rat omgp CDS are 
shown in bold type (ATG and TGA, respectively). The sequence selected as an in situ 
hybridisation target for a 35S-labelled 45-mer antisense DNA oligonucleotide is 
highlighted in yellow.
Rat omgp CDS (Genbank Accession No. AY316298)
1 ATGGAATATC AGATATTGAA AATGTCTTCC TGCCTGTTCA TCCTTCTGTT TCTCACGCCT
61 GGCATTTTAT GCATTTGTCC TCTCCAATGT ATATGCACAG AGAGGCACAG GCATGTGGAC
1 2 1  TGTTCAGGCA GAAACCTGAC TACATTACCA CCTGGACTGC AAGAGAACAT TATACATTTA
1 8 1  AACCTGTCTT ATAACCACTT TACTGATCTG CATAACCAGT TAACCCCTTA TACCAATCTG
2 4 1  AGGACCCTGG ATATTTCAAA CAACAGGCTT GAAAGTCTGC CTGCCCAGTT ACCTCGGTCT
3 0 1  CTCTGGAACA TGTCTGCTGC TAACAACAAC ATTAAACTAC TTGACAAATC TGATACTGCT
3 6 1  TATCAGTGGA ACCTTAAATA CCTGGATGTT TCTAAGAATA TGTTGGAAAA GGTTGTTCTC
4 2 1  ATTAAAAATA CCTTAAGAAG TCTTGAGGTT CTTAACCTCA GCAGTAATAA ACTTTGGACA
4 8 1  GTTCCAACCA ACATGCCTTC CAAACTACAT ATTGTGGACC TGTCTAATAA CTCACTGACA
5 4 1  CAAATCCTTC CAGGGACATT AATAAACCTG ACAAATCTCA CACATCTTTA CCTGCACAAC
6 0 1  AATAAATTCA CATTCATTCC AGATCAGTCT TTTGACCAAC TCTTGCAGTT GCAAGAGATA
6 6 1  ACTCTTCATA ATAACAGGTG GTCATGTGAC CATACACAAA ACATTACTTA CTTACTGAAG
7 2 1  TGGATGATGG AAACAAAAGC CCATGTGATA GGGATTCCTT GTTCTAAGCA AGTATCCTCT
7 8 1  CTGAAGGAAC AGAGCATGTA CCCCACGCCT CCCGGATTTA CTTCAAGCTT ATTTACTATG
8 4 1  AGTGAGATGC AGACAGTGGA CACCATTAAC TCTCTGAGTA TGGTAACTCA ACCTAAAGTG
9 0 1  ACCAATATAC CCAAACAATA TCGAGGAAAA GACACCACAT TTGGTGTCAC CCTAAGCAAA
9 6 1  GACACCACTT TTAGTAGCAC TGATAGGGCT CTGGAGCCCT ACCCAGAAGA CACACCCACA
1 0 2 1  GAAATGACCA GTTCACGTGA AGCAGCAGCT GCAACTCTAA CTATTCACCT CCAGGATGGA
1 0 8 1  ATGAGTTCAA ATGCAAGCCT CACCAGTGCA GCAAAATCCT CCCCAGCACC TGTGACCCTC
1 1 4 1  AGCATAACTA GTGGCATGCC AAATAATTTC TCTGAAATGC CTCAACAGAG CACAACCCTT
1 2 0 1  AACTTACGGA GGGAAGAAAC AACTGCAAAT GTAAAGACTC AGCCACCTTC CTCGGCTAGT
12 61 GCTTGGAAAG TAAATGCCTC ACTCCTTTTA ATGCTCAATG CTGTGGTCAT GCTGGCAGGC
1 3 2 1  TGA
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Figure 6.3.
Alignment of the cloned rat omgp CDS against the draft rat genome. The frame-shift 
sequencing error in the omgp CDS of the draft rat genomic contig, NW_042664, is 
highlighted in yellow (corresponding to position 169 of the cloned rat omgp CDS), as are 
two other obvious sequencing errors. Only one unpredictable mismatch, highlighted in 
red (corresponding to position 713 of the cloned CDS), was ultimately found between the 
cloned and draft genomic sequences. Potentially, this could have been due to either a 
sequencing error in the draft rat genome, or a PCR generated point mutation in the cloned 
sequence.
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>ref|NW 042664.1|RnlO 210 Rattus norvegicus chromosome 10 WGS supercontig
Length = 1962622
Score = 2496 bits (1298), Expect = 0.0 
Identities = 1321/1325 (99%), Gaps = 3/1325 (0%)
Strand = Plus / Plus
Query: 1 atggaatatcagatattgaaaatgtcttcctgcctgttcatccttctgtttctcacgcct
1 1 1 1 1 1 1 1 1 1 111111111111111 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 111111 II 1 1 1 1 1 I 
atggaatatcagatattgaaaatgtcttcctgcctgttcatccttctgtttctcacgcct
60
Sbjct: 1490164 1490105
Query: 61 ggcattttatgcatttgtcctctccaatgtatatgcacagagaggcacaggcatgtggac
1111 1 1 1 1 1 1 1 1 1 111111111 1 1 1 1 1 I 1 1 1 II 1 11111111 1 1 1 1 111111 1 1 1 1 1 1 1 1
ggcattttatgcatttgtcctctccaatgtatatgcacagagaggcacaggcatgtggac
120
Sbjct: 1490104 1490045
Query: 121 tgttcaggcagaaacctgactacattaccacctggactgcaagagaacattatacattta 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
tgttcaggcagaaacctgactacattaccacctggactgcaagagaac-ttatacattta
180
Sbjct: 1490044 1489986
Query: 181 aacctgtcttataaccactttactgatctgcataaccagttaaccccttataccaatctg 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
aacctgtcttataaccactttactgatctgcataaccagttaaccccttataccaatctg
240
Sbjct: 1489985 1489926
Query: 241 aggaccctggatatttcaaacaacaggcttgaaagtctgcctgcccagttacctcggtct 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
aggaccctggatatttcaaacaacaggcttgaaagtctgcctgcccagttacctcggtct
300
Sbjct: 1489925 1489866
Query: 301 ctctggaacatgtctgctgctaacaacaacattaaactacttgacaaatctgatactgct 
1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 I 1111111111111111111111 1 1 1 1 I 1 II 1 1 1 II 1 1 1 II 1 1
ctctggaacatgtctgctgctaacaacaacattaaactacttgacaaatctgatactgct
360
Sbjct: 1489865 1489806
Query: 361 tatcagtggaaccttaaatacctggatgtttctaagaatatgttggaaaaggttgttctc 
11111II111 1 1 1 1 1 1 1 1 1 1 1 1 1 111111111111II 1 1 1 1 1 1 1 1 1 1 11111 1 1 1 1 1 1 1 1 
tatcagtggaaccttaaatacctggatgtttctaagaatatgttggaaaaggttgttctc
420
Sbjct: 1489805 1489746
Query: 421 attaaaaataccttaagaagtcttgaggttcttaacctcagcagtaataaactttggaca
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 1 1 1 1 1
attaaaaataccttaagaagtcttgaggttcttaacctcagcagtaataaactttggaca
480
Sbjct: 1489745 1489686
Query: 481 gttccaaccaacatgccttccaaactacatattgtgg-acctgtctaataactcactga-
1 111111 1 1 1 1 1 1 1 1 I 1 1111II11 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 111 111111 1 1 1 1 1 1 1 
gttccaaccaacatgccttccaaactacatattgtggnacctgtctaataactcactgan
538
Sbjct: 1489685 1489626
Query: 539 cacaaatccttccagggacattaataaacctgacaaatctcacacatctttacctgcaca
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 1
cacaaatccttccagggacattaataaacctgacaaatctcacacatctttacctgcaca
598
Sbjct: 1489625 1489566
Query: 599 acaataaattcacattcattccagatcagtcttttgaccaactcttgcagttgcaagaga 
1 1 II 11111111111 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 111111 111 111111 1 1 1 1 1 1 1 1 1 1 1
658
Sbjct: 1489585 acaataaattcacattcattccagatcagtcttttgaccaactcttgcagttgcaagaga 1489506
Query: 659 taactcttcataataacaggtggtcatgtgaccatacacaaaacattacttacttactga
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
718
Sbjct: 1489525 taactcttcataataacaggtggtcatgtgaccatacacaaaacattacttactjactga 1489446
Query: 719 agtggatgatggaaacaaaagcccatgtgatagggattccttgttctaagcaagtatcct 
1111111111 11 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1111111111 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
778
Sbjct: 1489465 agtggatgatggaaacaaaagcccatgtgatagggattccttgttctaagcaagtatcct 1489386
Query: 779 ctctgaaggaacagagcatgtaccccacgcctcccggatttacttcaagcttatttacta 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
838
Sbjct: 1489385 ctctgaaggaacagagcatgtaccccacgcctcccggatttacttcaagcttatttacta 1489326
Query: 839 tgagtgagatgcagacagtggacaccattaactctctgagtatggtaactcaacctaaag 
1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 111II11111111111111111111 II 1 1 1 1 1 1 1 1 1 1 1
898
Sbjct: 1489325 tgagtgagatgcagacagtggacaccattaactctctgagtatggtaactcaacctaaag 1489266
Query: 899 tgaccaatatacccaaacaatatcgaggaaaagacaccacatttggtgtcaccctaagca 
111111111111 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
958
Sbjct: 1489265 tgaccaatatacccaaacaatatcgaggaaaagacaccacatttggtgtcaccctaagca 1489206
236
Query: 959 aagacaccacttttagtagcactgatagggctctggagccctacccagaagacacaccca 
1111111111 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 11 1II1111111 1 1 1 1 1 1 1 1 1 I 
aagacaccacttttagtagcactgatagggctctggagccctacccagaagacacaccca
1018
Sbjct: 1489205 1489146
Query: 1019 caaaaatgaccagttcacgtgaagcagcagctgcaactctaactattcacctccaggatg 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1078
Sbjct: 1489145 cagaaatgaccagttcacgtgaagcagcagctgcaactctaactattcacctccaggatg 1489086
Query: 107 9 gaatgagttcaaatgcaagcctcaccagtgcagcaaaatcctccccagcacctgtgaccc 
1 1 1 1 111111111 1 I 1 1 1 1 1 1 1 II 1 1 1 1 111111111 1 1 1 1 1 1 111111 1 1 1 11 1 1 1 1 1 1
1138
Sbjct: 1489085 gaatgagttcaaatgcaagcctcaccagtgcagcaaaatcctccccagcacctgtgaccc 1489026
Query: 1139 tcagcataactagtggcatgccaaataatttctctgaaatgcctcaacagagcacaaccc 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1198
Sbjct: 1489025 tcagcataactagtggcatgccaaataatttctctgaaatgcctcaacagagcacaaccc 1488966
Query: 1199 ttaacttacggagggaagaaacaactgcaaatgtaaagactcagccaccttcctcggcta 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1258
Sbjct: 1488965 ttaacttacggagggaagaaacaactgcaaatgtaaagactcagccaccttcctcggcta 1488906
Query: 1259 gtgcttggaaagtaaatgcctcactccttttaatgctcaatgctgtggtcatgctggcag 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1318
Sbjct: 1488605 gtgcttggaaagtaaatgcctcactccttttaatgctcaatgctgtggtcatgctggcag 1488846
Query: 1319 gctga 1323 
1 1 1 1 1
gctga 1488841Sbjct: 1488545
237
Figure 6.4.
Alignment of the cloned rat omgp CDS against the latest build of the rat genome. The 
cloned omgp CDS is identical to that contained on contig NW 047336, which was 
released as part of the latest build of the rat genome. This confirms that the mismatch 
observed between position 713 (T) of the cloned CDS and the corresponding nucleotide 
(C) in the draft rat genomic contig, NW 042664, was the result of a genomic sequencing 
error.
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>ref|NW 047336.1|RnlO 1856 Rattus norvegicus chromosome 10 WGS supercontig
Length = 24143058
Score * 2544 bits (1323), Expect = 0 . 0  
Identities = 1323/1323 (100%)
Strand = Plus / Minus
Query: 1 atggaatatcagatattgaaaatgtcttcctgcctgttcatccttctgtttctcacgcct 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
60
Sbjct: 6689639 atggaatatcagatattgaaaatgtcttcctgcctgttcatccttctgtttctcacgcct 6689580
Query: 61 ggcattttatgcatttgtcctctccaatgtatatgcacagagaggcacaggcatgtggac 
111111II 1 1 1 1 1 1 1 1 1i 1 1 1 1 I 1 1 1 1 1 II 1 II 1 111111111 1 1 1 111111111 1 1 1 1 1
120
Sbjct: 6689579 ggcattttatgcatttgtcctctccaatgtatatgcacagagaggcacaggcatgtggac 6689520
Query: 121 tgttcaggcagaaacctgactacattaccacctggactgcaagagaacattatacattta 
1 II 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1
tgttcaggcagaaacctgactacattaccacctggactgcaagagaacattatacattta
180
Sbjct: 6689519 6689460
Query: 181 aacctgtcttataaccactttactgatctgcataaccagttaaccccttataccaatctg
1 111111 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 111111II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1111111 1 1 1
aacctgtcttataaccactttactgatctgcataaccagttaaccccttataccaatctg
240
Sbjct: 6689459 6689400
Query: 241 aggaccctggatatttcaaacaacaggcttgaaagtctgcctgcccagttacctcggtct 
1 1 1 1 111 1 1 1 1 1 1 1 1 1 1 1 1 1 11111 1 11111 1 II 1111 1 1 111 1 1 1 1 1 1 1 11111 1 1 1 1 1 
aggaccctggatatttcaaacaacaggcttgaaagtctgcctgcccagttacctcggtct
300
Sbjct: 6689399 6689340
Query: 301 ctctggaacatgtctgctgctaacaacaacattaaactacttgacaaatctgatactgct 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
ctctggaacatgtctgctgctaacaacaacattaaactacttgacaaatctgatactgct
360
Sbjct: 6689339 6689280
Query: 361 tatcagtggaaccttaaatacctggatgtttctaagaatatgttggaaaaggttgttctc 
I 1 ! 1 1 I 1 I I  1 1 1 1 1 1 1 I I  1 l 1 l 1 I I  1 l l 1 1 1 l l 1 1 1 1 1 1 I I  1 l 1 l 1 1 I 1 I 1 I I  1 I I  1 l l 1
420
Sbjct: 6689279
i i i i i  i i I I  m  i i  i i  i i  i i i i i i i i m  i m  i i  i t  m  i m i m  i i i i  i i  i i i i  i i i i  i i i i  
tatcagtggaaccttaaatacctggatgtttctaagaatatgttggaaaaggttgttctc 6689220
Query: 421 attaaaaataccttaagaagtcttgaggttcttaacctcagcagtaataaactttggaca 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
480
Sbjct: 6689219 attaaaaataccttaagaagtcttgaggttcttaacctcagcagtaataaactttggaca 6689160
Query: 481 gttccaaccaacatgccttccaaactacatattgtggacctgtctaataactcactgaca
111 I 11 1 1 1 1 1 1 1 1 1 1 1 1 1 11111111 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1111111 1 1 1 1 1 1 1 1
gttccaaccaacatgccttccaaactacatattgtggacctgtctaataactcactgaca
540
Sbjct: 6689159 6689100
Query: 541 caaatccttccagggacattaataaacctgacaaatctcacacatctttacctgcacaac
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 1 1 1 1 1 1 1 1 1 
caaatccttccagggacattaataaacctgacaaatctcacacatctttacctgcacaac
600
Sbjct: 6689099 6689040
Query: 601 aataaattcacattcattccagatcagtcttttgaccaactcttgcagttgcaagagata 
1 111111 1 1 1 1 1 1 1 1 1 1 11111 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 11 1 111 1 1 1 1 1 1 1 1 1 111 11 
aataaattcacattcattccagatcagtcttttgaccaactcttgcagttgcaagagata
660
Sbjct: 6689039 6688980
Query: 661 actcttcataataacaggtggtcatgtgaccatacacaaaacattacttacttactgaag 
1111I I 11111I I 111111111111111111111111111111111 1 1 1 1 1 1 1 1 1 1 1 1 1 1
720
Sbjct: 6688979 actcttcataataacaggtggtcatgtgaccatacacaaaacattacttacttactgaag 6688920
Query: 721 tggatgatggaaacaaaagcccatgtgatagggattccttgttctaagcaagtatcctct 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
780
Sbjct: 6688919 tggatgatggaaacaaaagcccatgtgatagggattccttgttctaagcaagtatcctct 6688860
Query: 781 ctgaaggaacagagcatgtaccccacgcctcccggatttacttcaagcttatttactatg 
11II 1111 1 1 II 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 
ctgaaggaacagagcatgtaccccacgcctcccggatttacttcaagcttatttactatg
840
Sbjct: 6688859 6688800
Query: 841 agtgagatgcagacagtggacaccattaactctctgagtatggtaactcaacctaaagtg 
111 1 1 1 1 1 1 1 1 1 1 1 1 1 111111 1 1 1 111111 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1111111 1 1 1 1 1 1 
agtgagatgcagacagtggacaccattaactctctgagtatggtaactcaacctaaagtg
900
Sbjct: 6688799 6688740
Query: 901 accaatatacccaaacaatatcgaggaaaagacaccacatttggtgtcaccctaagcaaa 
1 1 1 1 1 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
960
Sbjct: 6688739 accaatatacccaaacaatatcgaggaaaagacaccacatttggtgtcaccctaagcaaa 6688680
239
Query: 961 gacaccacttttagtagcactgatagggctctggagccctacccagaagacacacccaca 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1020
Sbjct: 6688679 gacaccacttttagtagcactgatagggctctggagccctacccagaagacacacccaca 6688620
Query: 1021 gaaatgaccagttcacgtgaagcagcagctgcaactctaactattcacctccaggatgga 
1 111 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1111111 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 111111 1 1 1 111 1 1 1 1 1
1080
Sbjct: 6688619 gaaatgaccagttcacgtgaagcagcagctgcaactctaactattcacctccaggatgga 6688560
Query: 1081 atgagttcaaatgcaagcctcaccagtgcagcaaaatcctccccagcacctgtgaccctc 
111111111 1 1 1 1 1 1 1 1 1 1 1 1 11111111 1 II 1 1 I 1 1 1 1 1 1 1 11111111111 1 1 1 1 1 1 1
1140
Sbjct: 6688559 atgagttcaaatgcaagcctcaccagtgcagcaaaatcctccccagcacctgtgaccctc 6688500
Query: 1141 agcataactagtggcatgccaaataatttctctgaaatgcctcaacagagcacaaccctt 
II 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
agcataactagtggcatgccaaataatttctctgaaatgcctcaacagagcacaaccctt
1200
Sbjct: 6688499 6688440
Query: 1201 aacttacggagggaagaaacaactgcaaatgtaaagactcagccaccttcctcggctagt 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1260
Sbjct: 6688439 aacttacggagggaagaaacaactgcaaatgtaaagactcagccaccttcctcggctagt 6688380
Query: 1261 gcttggaaagtaaatgcctcactccttttaatgctcaatgctgtggtcatgctggcaggc 
1 1 1 1 1 1 1 1 1 1 1 1 1111111111 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 111111111 1 II 1 1 1 1 1 1 1 1 1 1 1
1320
Sbjct: 6688379 gcttggaaagtaaatgcctcactccttttaatgctcaatgctgtggtcatgctggcaggc 6688320
Query: 1321 tga 1323
Sbjct: 6688319
1 1 1
tga 6688317
240
Figure 6.5.
Alignment of the predicted rat, mouse and human OMgp amino acid sequences. The 
predicted rat sequence is 95% identical to that of mouse, and 90% identical to that of 
human.
Rat : 1 MEYQILKMSSCLFILLFLTPGILCICPLQCICTERHRHVDCSGRNLTTLPPGLQENIIHL 60
Mouse: 1 MEYQILKMSSCLFILLFLTPGILCICPLQCTCTERHRHVDCSGRNLTTLPPGLQENIIHL 60
Human: 1 MEYQILKMSLCLFILLFLTPXILCICPLQCICTERHRHVDCSGRNLSTLPSGLQENIIHL 60
Rat : 61 NLSYNHFTDLHNQLTPYTNLRTLDISNNRLESLPAQLPRSLWNMSAANNNIKLLDKSDTA 120 
Mouse: 61 NL S YNH FTDLHNQLTPYTNLRTLDIS NNRL E S L PAQL P RS LWNMSAANNNIKLLDKSDTA 120 
Human: 61 NLSYNHFTDLHNQLTQYTNLRTLDISNNRLESLPAHLPRSLWNMSAANNNIKLLDKSDTA 120
Rat : 121 YQWNLKYLDVSKNMLEKWLIKNTLRSLEVLNLSSNKLWTVPTNMPSKLHIVDLSNNSLT 180 
Mouse: 121 YQWNLKYLDVSKNMLEKWLIKNTLRSLEVLNLSSNKLWTVPTNMPSKLHIVDLSNNSLT 180 
Human: 121 YQWNLKYLDVSKNMLEKWLIKNTLRSLEVLNLSSNKLWTVPTNMPSKLHIVDLSNNSLT 180
Rat : 181 QILPGTLINLTNLTHLYLHNNKFTFIPDQSFDQLLQLQEITLHNNRWSCDHTQNITYLLK 240 
Mouse: 181 QILPGTLINLTNLTHLYLHNNKFTFIPEQSFDQLLQLQEITLHNNRWSCDHKQNITYLLK 240 
Human: 181 QILPGTLINLTNLTHLYLHNNKFTFIPDQSFDQLFQLQEITLYNNRWSCDHKQNITYLLK 240
Rat : 241
Mouse: 241
Human: 241
Rat : 301
Mouse: 301
Human: 301
Rat : 361
Mouse: 361
Human: 361
Rat : 421 AWK 423 
Mouse: 421 AWK 423 
Human: 421 AWK 423
241
Figure 6.6.
Radioactive in situ hybridisation for omgp in the uninjured adult rodent nervous system.
or
A-F show negative images of the film exposed to slides hybridized with S-labelled 45- 
mer DNA oligonucleotide antisense probe. The top row shows sections reacted only with 
the radiolabelled antisense probe, and the bottom row shows the respective competitive 
control sections which were reacted with a mixture of radiolabelled antisense probe and 
excess unlabelled antisense probe. The lack of signal in the competitive control sections 
demonstrates the binding specificity of the antisense probe. A, strong signal was 
observed in the neocortex and pyriform cortex of the rostral forebrain. B and C, omgp 
was strongly expressed in the neocortex and hippocampal formation, and moderately in 
the habenular nucleus in B. D, moderate signal was detectable in the cerebellar cortex, 
and strong signal could be observed in discrete nuclei within the brainstem. E, strong 
expression of omgp was found in the grey matter of the spinal cord. F, DRGs expressed 
omgp mRNA at moderate/high levels.
242
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Figure 6.7.
Expression of mRNAs for myelin-associated inhibitors of neurite outgrowth, and ngr, in 
neocortex of adult rat. omgp is expressed by neurons in layers II-VI, but the large 
pyramidal neurons do not exhibit strong signal. Expression of nogo-a includes many 
large cells presumed to be neurons, and smaller cells which may include 
oligodendrocytes. Large, presumptive pyramidal projection neurons are particularly 
prominent, nogo-66 expression is similar to that of nogo-a, except that expression by glia 
is more difficult to identify (since neuronal signal is much stronger), ngr, is expressed by 
neurons (i.e. cortical neurons express both ngr and its ligands) but not by glia. M = 
molecular layer; W = white matter. Scale bar = 500pm.
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Figure 6.8.
Non-radioactive in situ hybridisation of the uninjured adult rodent nervous system. 
Sections were reacted with a DIG-labelled antisense riboprobe.
A. Moderate to strong signal for omgp was detectable in the dentate gyrus, and CA4 cells 
of the hippocampal formation. Neurons of the dentate hilus also strongly expressed the 
transcript. Scale bar = 200pm.
B. In the cerebellum, weak expression of omgp was found in the granule cell layer (G), 
and strong expression in the Purkinje cells (arrows). Moderate to strong signal for omgp 
was also present in neurons of the vestibular nuclei (V). Stronger expression was 
detectable in some larger neurons within the brainstem. Scale bar = 400pm.
C. Higher power image of cerebellar cortex showing strong expression of omgp by 
Purkinje cells (arrows), and moderate expression by cerebellar granule neurons (G). 
Scale bar = 100pm.
D. In the spinal cord, omgp was strongly expressed by neurons throughout the grey 
matter, but especially by the larger motor neurons of the ventral horn. Scale bar = 
400pm.
E. Moderate to strong omgp expression was observed in DRG neurons. Scale bar = 
100pm.
F. Similarly, SCG neurons were found to exhibit variable levels of omgp expression, 
from moderate to strong. Scale bar = 200pm.
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Figure 6.9.
In situ hybridisation for omgp in a section of thalamus, 16 days after grafting of a 
segment of autologous tibial nerve. The only sign of omgp regulation was found in the 
ventral blade of the dentate gyrus (arrowheads), ipsilateral to the graft (g), in which the 
expression of omgp appeared to have ceased. This was only observed in one of three 
animals, c = cortex. Scale bar = 500pm.
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CHAPTER 7
Construction of Replication-Incompetent HSV-1 for the 
Expression of the NgR Antagonist Peptide, NEP1-40
INTRODUCTION
Nogo extracellular peptide 1-40 (NEP1-40) is an antagonist peptide to the Nogo-66 
receptor (NgR) and comprises the first forty amino acids of the NgR ligand, Nogo-66 
(Grandpre et al., 2002). It was originally described following the process of identifying 
residues within Nogo-66 responsible for the binding and activation of NgR (Fournier et
al., 2001). Initially, Fournier et al. constructed five different overlapping 25-residue
)
alkaline-phosphatase fusion proteins of Nogo-66 in order to identify the region active in 
inducing growth cone collapse and inhibiting neurite outgrowth through NgR. 
Interestingly, only the Nogo-66(31-55) fusion protein exhibited any inhibitory effect, and 
this was three-fold lower than that observed for the entire Nogo-66 fusion protein. 
Binding assays showed that residues 31-33 (SEEL) are particularly important for high- 
affinity binding: Nogo-66(1-30) does not bind NgR; Nogo-66(l-31) possesses a 
dissociation constant (Kd) of 24 +/- 1 InM; and Nogo-66(l-33), or longer fusion proteins, 
possess an improved Kd of 1 l-14+/-3nM. Similarly, the first ten amino terminal residues 
of Nogo-66 (RIYKGVIQAI) were also shown to be important for binding to NgR; Nogo- 
66(6-40) was shown to bind with significantly reduced affinity, and Nogo-66(11-40) did 
not bind at all. Thus, it was established that Nogo-66(1-40), i.e. NEP1-40, possessed the 
highest binding affinity for NgR of these various truncated forms of Nogo-66. 
Assessment of the activity of NEP1-40 in vitro seemed to show that it did not cause 
growth cone collapse of E l2 chick DRG neurons at a dose of 20nM; however, it should 
be borne in mind that sample sizes were not reported and if this experiment were repeated 
on a larger scale there may be a statistically significant, but slight, increase in growth 
cone collapse in the presence of NEP1 -40.
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The addition of lpM NEP1-40 partially blocks the inhibitory activity of a substrate of 
CNS myelin on E12 chick DRG neurite outgrowth (Grandpre et al., 2002). This is in 
keeping with the finding that NEP1-40 is an antagonist of Nogo-66 induced neurite- 
outgrowth inhibition, but exhibits no antagonist activity against MAG, OMgp (Barton et 
al., 2003), or Nogo-A specific peptide (Grandpre et al., 2002). Nogo-A is a major 
inhibitory constituent of CNS myelin and the Nogo-A specific peptide is thought to act 
through an as yet unidentified receptor (or receptor complex). There are, of course, 
numerous inhibitory molecules which may be present within extracts of CNS, such as 
chondroitin sulphate proteoglycans and semaphorins, whose effects would not be 
expected to be neutralized by NEP1-40.
In vivo studies demonstrated that the intrathecal infusion of NEP1-40 (75pg per kg body 
weight per day) by osmotic minipump after midthoracic dorsal hemisection, over a period 
of four weeks, resulted in significantly enhanced growth of injured CST axons (Grandpre 
et al., 2002). Rostral to the lesion site, numerous ectopic CST fibres were identified, 
particularly in grey matter. Furthermore, there was a more than 10-fold increase in 
sprouting from the injured dorsal CST into adjacent tracts in NEP1-40 treated animals, 
compared to the PBS treated control animals. In the NEP1-40 treated rats, many sinuous 
fibres were found to by-pass the lesion within the intact ventral half of the spinal cord. 
Many of these ectopic fibres were found in both grey and white matter up to a distance of 
11-15mm caudal to the lesion site (20-30 axons per section per animal at this distance). 
There is some suggestion that these regenerating fibres may have been derived from the 
sprouting of intact collaterals or spared ventral CST fibres, induced by NEP1-40. 
However, the authors did not note any abnormal CST fibre sprouting in uninjured NEP1- 
40 treated rats, suggesting that the molecule’s activity is confined to injured axons. 
NEP1-40 has interesting effects on serotonergic fibres within the injured spinal cord. In 
PBS-treated control animals, the ventral hom caudal to the lesion exhibited a 40% 
reduction in 5-hydroxytryptamine (serotonin) density compared to that rostral to the 
lesion. However, in NEP1-40 treated animals, the density was similar caudally and 
rostrally. This is in agreement with the preliminary findings that sprouting of 
serotonergic fibres of the raphespinal tract is enhanced following spinal injury in the ngr
251
null mutant mouse (Kim et al., 2003a). In terms of functional recovery, locomotor 
activity -  as measured using the BBB scale -  was found to be significantly improved in 
the NEP1-40 treated animals compared to the PBS control treated animals after 28 days 
(-15 vs. -11).
NEP1-40 has yielded promising results both in vitro and in vivo. The administration of 
NEP1-40 to primary cultures of E l2 chick DRG neurons grown on a substrate of (i) 
Nogo-66, or (ii) CNS myelin, greatly enhances neurite outgrowth (Grandpre et al., 2002). 
Also, after midthoracic dorsal hemisection in rats, intrathecal infusion of NEP1-40 (75pg 
per kg body weight per day) by mini-osmotic pump has been claimed to elicit significant 
regeneration of lesioned CST axons (Grandpre et al., 2002). Even subcutaneous 
administration of the antagonist peptide (11.6mg per kg body weight per day) 
commencing 1 week after midthoracic dorsal hemisection of the spinal cord for a 
duration of 14 days has been reported to elicit significant regeneration of injured CST 
axons, sprouting of serotonergic fibres, synapse reformation and ultimately enhanced 
locomotor recovery (Li and Strittmatter, 2003). That intrathecal infusion or delayed 
systemic administration of the peptide have produced such results prompted the question 
of whether targeted viral delivery of a secreted form of the antagonist peptide would 
achieve a comparable, if not better, regenerative response.
SUMMARY OF METHODS 
Expression and Purification of Nogo-66-(His)6
Nogo-66 was amplified from adult rat brain cDNA. The forward primer, CCC ATA 
TGA GGA TAT ATA AGG GCG TGA TC, encoded an internal NdeI restriction site and 
in-frame start codon whilst the reverse primer, CTC CTC GAG TCA GTG GTG GTG 
GTG GTG GTG CTT CAT GGA ATC AAC TAA ATC, encoded an internal inframe 
(His)6-tag and stop codon followed by Xhol restriction endonuclease site. The PCR was 
undertaken with the proof-reading DNA polymerase, Pfu (Promega), with the first five 
annealing cycles at 42°C and the remaining 25 annealing cycles a 55°C.
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The PCR product was ligated into pET23a(+) (Novagen) between the NdeI and Xhol 
restriction sites, respectively. Chemically competent BL21 A.DE3 lysogen cells 
(Novagen) were transformed as described in Chapter 2. Bacterial expression of Nogo-66 
was induced by incubating the transformed bacteria, under standard bacterial growth 
conditions, with lOOmM IPTG for three hours.
Total cell protein samples were obtained from induced and uninduced transformed 
bacteria for analysis by SDS-PAGE. Fractionation of induced transformed bacteria was 
performed using the protocol provided in the pET system manual (Novagen). Media, 
periplasmic, soluble cytoplasmic and insoluble cytoplasmic fractions were isolated. 
Protein samples were resolved by SDS-PAGE against Rainbow molecular weight marker 
(Amersham), on a 20% polyacrylamide gel, and visualized with Coomassie stain.
For purification of Nogo-66-(His)6, the insoluble cytoplasmic fraction was solubilized in 
6M urea and passed through a nickel-primed HiTrap™ column (Amersham) using FPLC 
apparatus (Amersham), as per the manufacturer’s instructions. Protein was eluted from 
the column with 6M urea containing a rising concentration of imidazole (0->500mM) 
over the course of 10 minutes. Ten 1 minute fractions of eluent were captured, and 
placed at -20°C for longterm storage.
Samples of induced and uninduced transformed bacteria, as well as elution fractions 2-8 
were resolved by SDS-PAGE with MES buffer, on a pre-made 12% Bis-Tris NuPAGE® 
gel (Invitrogen), against a broadrange pre-stained SDS-PAGE molecular weight standard 
(Bio-rad). Bands of protein were visualized with Colloidal Coomassie® Stain 
(Invitrogen).
Construction of HSV-1 Expressing Secreted-Tagged NEP1-40
NEP1-40 was cloned by PCR from adult rat brain cDNA. The forward primer, ACT 
GAA GCT TGA GGA TAT ATA AGG GCG TGA TCC A, contained an internal 
Hiru&ll restriction and the reverse primer, ATC GCT CGA GAG AAT TAC TGT ATT 
TCT GAA CCA ATT CC, contained an internal Xhol restriction site. The PCR product
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was ligated inframe into pSecTagA (Invitrogen) between the Hindlll and Xhol restriction 
sites, respectively. A further round of PCR was performed using a forward primer 
against the T7 promoter, with an internal EcoR\ restriction site to facilitate clonal 
screening, and a reverse primer against pcDNA3.1 BGH reverse priming site. The primer 
sequences were ACT GGA ATT CTA ATA CGA CTC ACT ATA GGG and ACT GAT 
GCA TTA GAA GGC ACA GTC GAG G, respectively. This PCR product was ligated 
into the blunted Hindlll restriction sites of the pR19 hrGFP WPRE shuttle vector 
backbone, thus replacing hrGFP. Screening for the correct orientation of the insert was 
performed by plasmid digestion with the EcoRI restriction endonuclease.
The Seal-linearized shuttle vector, pR19 mNEPl-40 WPRE, was used in a co­
transfection of 27/12/M:4 cells with 1764/4-/27in/RLl+ viral DNA for the generation of 
recombinant HSV-1. EcoRI-digested viral DNA, from nine different purified plaques, 
was analysed by southern blotting. iscoRI-digested pR19 mNEPl-40 WPRE was used as 
a positive control, and £coRI-digested 1764/4-/27in/RLl+/pR19 hrGFP WPRE as a 
negative control. Hybridisation was performed with 32P-radiolabelled PCR product of 
mNEPl-40.
Western Blot of Virally Transduced BHKs
BHKs were cultured in 24-well plates, and transduced with 1764/4-/27in/RLl+/pR19 
mNEPl-40 WPRE at an MOI of 1 when 80% confluent. 1764/4-/27in/RLl+/pR19 
hrGFP WPRE (MOI=l) and mock transduction served as negative controls. After 48 
hours, growth media was removed and filtered using Microcon® columns (Millipore 
Corporation), with a 3KDa cut-off., as per the manufacturer’s instructions. The protein 
samples were resuspended in lxPBS containing a cocktail of protease inhibitors (Sigma). 
The transduced cells were harvested in boiling lysis buffer (1% w/v SDS, 0.1% Triton-X 
100, lOmM DTT in PBS). A lysate of stable cells expressing a myc-tagged protein of 
~60KDa served as a positive control (kindly provided by Emma Willoughby, Department 
of Immunology and Molecular Pathology, UCL). Protein concentrations were 
determined by spectrophotometry using RcDc reagent (Bio-Rad). Samples were resolved 
by SDS-PAGE on a 20% polyacrylamide gel, against Rainbow molecular weight marker
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(Amersham). Western blotting was performed as described in Chapter 2. The membrane 
was probed with a mouse monoclonal anti-myc antibody (Invitrogen) at a concentration 
of 1:500. HRP-conjugated goat anti-mouse antibody was applied at a concentration of 
1:2000. The membrane was reacted with ECL reagent (Amersham), as per the 
manufacturer’s instructions, and exposed to X-OMAT radiographic film (Kodak).
Immunocytochemistry of Virally Transduced BHKs
BHK cells were cultured on uncoated 13mm glass coverslips, transduced with 1764/4- 
/27in/RLl+/pR19 mNEPl-40 WPRE (MOIs of 1, 5 and 20) when 80% confluent, and 
fixed with 4% PFA after 48 hours. Transduction with 1764/4-/27in/RLl+/pR19 hrGFP 
WPRE (MOI=l), and mock transduction, served as negative controls. 
Immunocytochemistry was performed as described in Chapter 2, with a mouse 
monoclonal anti-myc primary antibody (Invitrogen) at a dilution of 1:500.
Injection of Cervical Spinal Cord with Replication-Incompetent HSV-1
Six uninjured adult Sprague-Dawley rats were injected with 2 x 106 pfu of virus at the 
level of the cervical spinal cord (as described in Chapter 2). Three rats received 1764/4- 
/27in/RLl+/pR19 mNEPl-40 WPRE, and the three control rats received 1764/4- 
/27in/RLl+/pR19 hrGFP WPRE. Animals were culled at 8 days post operation (dpo), 
and the tissue processed for mNEPl-40 expression by immunohistochemistry with anti- 
myc antibody (Invitrogen), or for hrGFP expression by fluorescence microscopy.
RESULTS
In order to construct a HSV-1 vector for targeted delivery of NEP1-40, it would first be 
necessary to modify the peptide such that it would be secreted, and detectable by 
immunohistochemistry. These modifications could potentially alter the activity of NEP1- 
40, so it was decided that an in vitro system should be established to determine whether a 
modified form of NEP1-40 is antagonistic to the effects of Nogo-66.
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Recombinant Nogo-66
Purified bacterially-expressed recombinant Nogo-66 has previously been reported to be 
active in inducing growth cone collapse, and neurite outgrowth inhibition (Fournier et al., 
2001). It was decided that a similar bacterial expression system should be used to 
produce Nogo-66 with a carboxy terminal (His)6-tag, for subsequent Nickel-based solid 
phase purification of the peptide. This was achieved by PCR amplification of Nogo-66 
from rat single-stranded DNA using a forward primer containing an in-frame start codon, 
and a reverse primer containing an in-frame (His)6-tag coding sequence and stop codon. 
This fragment was ligated into the bacterial inducible expression vector, pET23a(+) 
(Fig.7.1.A), and sequenced prior to the transformation of BL21 XDE3 lysogen E.coli. 
Expression of the peptide was induced with lOOmM IPTG, and fractionation was 
performed to identify the compartmentalisation of the peptide by SDS-PAGE (Fig.
7.1.C).
The majority of the 73 residue protein (Fig. 7.1.B), was detectable as a ~10KDa band in 
the insoluble cytoplasmic fraction (Fig. 7.1.C). This is indicative of inclusion body 
formation, which occurs commonly with highly expressed recombinant proteins in 
bacteria. For the purification of the recombinant protein, the insoluble cytoplasmic 
fraction was solubilized in 6M urea and passed through Nickel-primed HiTrap™ 
columns. The protein was eluted from the columns using a rising concentration of 
imidazole (0->500mM) over a 10 minute period on an automated FPLC machine (Figs
7.2.A and 7.2.B). Fractions of eluent were collected at 1 minute intervals. These were 
resolved by SDS-PAGE, and visualized with Colloidal Coomassie® stain (Fig. 7.2.C).
The absorbance data (280nm) obtained by spectrophotometry during FPLC revealed at 
least two overlapping peaks, suggesting some impurity of the eluted Nogo-66-(His)6, 
which formed the last of the peaks (Figs. 7.2.A and 7.2.B). A comparison of the pattern 
of protein expression in the induced and uninduced transformed bacteria indicated that at 
least four proteins were induced by the addition of IPTG (Fig 7.2.C, denoted by 
asterisks). By far the strongest of these bands was formed by a ~10KDa protein, 
consistent with being Nogo-66-(His)6, which eluted primarily in fractions 6 and 7;
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however, fraction 6 was contaminated with the three other unknown induced proteins 
(~7KDa, ~45KDa, and ~100KDa) as well as trace amounts of other proteins. Since 
fraction 7 contained a significant amount of the recombinant protein and appeared to be 
relatively pure, it was decided that this fraction should be renatured and used in the in 
vitro assay of growth cone collapse and neurite outgrowth inhibition.
Replication-Incompetent HSV-1 Expression of mNEPl-40
The modification of the peptide such that it would be secreted, and detectable by 
immunohistochemistry, was achieved by cloning the NEP1-40 coding sequence into 
pSecTagA (Invitrogen) (Figs 7.3.A and 7.3.B). In doing so, the peptide coding sequence 
acquired an in-frame amino terminal Ig k leader sequence, and carboxy terminal MycHis 
tag, for secretion and epitope detection, respectively. The coding sequence of the 
modified peptide (mNEPl-40), which was amplified by PCR (Fig. 7.3.C) and predicted 
to give rise to a 100 amino acid peptide (Fig. 7.3.D), was subcloned into a pR19 shuttle 
vector, between a CMV promoter and woodchuck postranscriptional regulatory element 
(WPRE) (Figs. 7.4.A and 7.4.B). The latter has been widely reported to enhance 
exogenous gene expression (Zufferey et al., 1999; Loeb et al., 1999), apparently by 
stabilising the mRNA. The correct DNA sequence was confirmed by automated 
fluorescent dye sequencing, before the pR19 shuttle vector -  which also contains flanking 
regions for homologous recombination into the latency associated transcript (LAT) 
region of the herpes virus genome - was used in a co-transfection of genetically modified 
complementing BHK cells (27/12/M:4) with mutant HSV-1 viral DNA to generate 
recombinant replication-incompetent HSV-1. This viral backbone is termed 1764/4- 
/27in/RLl+; it possesses a mutant form of the viral transactivator, VP 16, and is deleted 
for ICP4, thus rendering it incapable of replication without complementation for the 
wildtype forms of these genes. A southern blot was performed on the viral DNA 
obtained after plaque purification to confirm the presence of mNEPl-40 (Fig. 7.4.C).
In V i t r o  Assessment of mNEPl-40 Antagonist Activity
Since PC 12 cells have been reported to express NgR (Fournier et al., 2003), and can be 
readily induced to sprout axons using the pNGF subunit (Greene and Tischler, 1976), it
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was thought that these would make an ideal in vitro model to examine the growth cone 
collapsing activity of Nogo-66-(His)6, and the antagonist effect of mNEPl-40. However, 
it was first necessary to establish a protocol for the measurement of growth cone collapse. 
There were two potential ways of achieving this: (i) monitor growth cone collapse and 
neurite retraction in real-time, or (ii) counting collapsed growth cones after exposure.
Without having renatured the Nogo-66-(His)6, a feasibility study was performed for the 
first of these methods using ice-cold HBSS as a substitute. The growth media was 
replaced with ice-cold HBSS, and the effect on the growth cones monitored continuously 
by microscopy for 30 minutes, with images being captured at one minute intervals to 
form a time-lapse reel (Fig. 7.5). Although crude, the experiment clearly showed that 
growth cone collapse and neurite retraction was widespread and could be monitored in 
such a fashion.
As a feasibility study for the second of the two methods, the differentiated PC 12 cells 
were removed to a tissue culture hood where 10pl PBS was added per 500pl of growth 
media. The cells were immediately returned to the incubator, and pre-warmed 20% PFA 
was added to the growth media to give a final concentration of 4% PFA 15 minutes later. 
After a further 10 minutes, images were captured by microscopy to determine whether 
the growth cones had been successfully fixed, or whether they had collapsed in the 
processing. The result was that growth cones could be readily fixed and clearly 
visualized (Fig. 7.6).
On balance, the second of the two methods seemed most appropriate, given the ease with 
which growth cones could be fixed and visualized. In contrast, the first of the two 
methods requires specialized apparatus for incubating the cells whilst under microscopic 
observation, and would also have largely restricted assessment to a single microscopic 
field.
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Expression of mNEPl-40 from Virally Transduced BHKs
In order to (i) demonstrate that HSV-1 expressed mNEPl-40 is secreted and myc-tagged, 
and (ii) purify the peptide for assessment of antagonistic activity in an in vitro assay of 
growth cone collapse, it was necessary to transduce cultured cells with the virus and 
harvest the growth media. To this end, BHKs were transduced with 1764/4- 
/27in/RLl+/pR19 mNEPl-40 WPRE at a multiplicity of infection (MOI) of 1. Mock 
transduced BHKs, and those transduced with the equivalent virus expressing hrGFP 
(MOI=l), were employed as negative controls. After 48 hours the supernatant was 
harvested and concentrated using Microcon® columns, with a 3KDa cut-off. The protein 
samples were resuspended in PBS with a cocktail of protease inhibitors, and analysed by 
western blot. The only detectable band was that of the positive control myc-tagged 
protein at ~60KDa (not shown). A western blot of the cell lysates produced similar 
results (Fig. 7.7); only the ~60KDa positive control myc-tagged protein was detectable.
Expression of mNEPl-40 by virally transduced BHKs was subsequently assessed by 
immunocytochemistry. After 48 hours, no expression was detectable in cells transduced 
at an MOI of 1. However, sporadic expression (by <1% of cells) was evident at an MOI 
of 5 (Fig. 7.8.C). The number of cells expressing mNEPl-40 increased with increasing 
MOI, but even at an MOI of 20 the percentage of cells expressing the peptide remained 
low (Figs. 7.8.A and 7.8.B). This result was unexpected and remains to be explained.
Injection of HSV-1 Expressing mNEPl-40 into Adult Rat Cervical Spinal Cord
Three adult Sprague-Dawley rats received 5pi injections of 1764/4-/27in/RLl+/pR19 
mNEPl-40 WPRE (at a stock concentration of 4xl08 pfu/ml) into their cervical spinal 
cords. A further three rats were treated identically with 1764/4-/27in/RLl+/pR19 eGFP 
WPRE. The animals were culled at 8dpo, and the tissue processed for mNEPl-40 and 
eGFP expression, respectively.
Expression of mNEPl-40 could be detected in cells bordering the injection site, and 
sporadically by neurons and their processes up to several millimetres rostral and caudal 
from the injection site (Figs. 7.8.D-F). However, the extent of neuronal expression of
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mNEPl-40 was considerably lower than that observed for the eGFP-expressing virus 
(Fig. 7.8.G).
DISCUSSION
The original aims of the work reported herein were (i) to construct a tagged-secreted form 
of NEP1-40 which could be expressed by HSV-1, (ii) to develop an in vitro assay to 
determine whether such a modified form of NEP1-40 exhibited antagonistic activity to 
Nogo-66, and (iii) to establish whether targeted-delivery of such a peptide to the injured 
nervous system with a replication-incompetent HSV-1 vector was conducive to axonal 
regeneration.
Expression of Modified NEP1-40 from HSV-1
Unfortunately, although the construction of a HSV-1 vector for the expression of a 
modified form of NEP1-40 (termed mNEPl-40) was successful, the level of expression 
was unexpectedly low both in vitro and in vivo. Indeed, in BHK cells, an MOI of 5 was 
necessary for the peptide to be detectable by immunocytochemistry; and, even then, 
fewer than 1% of total cell population were immunopositive. In theory, and usually in 
practice, an MOI of 1 should be sufficient to achieve near 100% cell expression of a 
transgene (e.g. eGFP) in these cells. This is indicative of a problem with transcription 
and translation of the transgene, rather than viral transduction of the cell line -  since the 
HSV-1 vector backbone was not altered in the process of construction. One possible 
explanation for the poor expression of NEP1-40 is its relatively short coding sequence 
(303bp); there is at least some circumstantial evidence that small transgenes are not well 
expressed by HSV-1, although this usually relates to sequences considerably shorter than 
300bp (Dr. R.S. Coffin, personal communication).
Analysing the growth media of virally transduced BHKs for the expression of mNEPl-40 
was of two-fold importance: (i) to demonstrate that mNEPl-40 is secreted by virally 
transduced cells, and (ii) to concentrate the peptide in order to assess its antagonistic 
activity in an in vitro assay of Nogo-66 induced growth cone collapse. The failure to
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detect the peptide in the growth media of BHKs transduced at an MOI of 1 is probably a 
reflection of the high MOI required (minimum of 5) for detection of mNEPl-40 in the 
cytoplasm of BHKs by immunocytochemistry.
Bacterial Expression of Recombinant Nogo-66-(His)6
A carboxy terminal (His)6-tagged form of Nogo-66 was successfully purified by FPLC 
from a bacterial expression system, and a suitable protocol for analysing growth cone 
collapse in differentiated PC 12 cells was devised. However, due to the failure to detect 
and concentrate mNEPl-40 from the growth media of virally transduced BHKs, as well 
as the overall time constraints, the peptide was not renatured and its activity in inducing 
growth cone collapse or inhibiting neurite outgrowth was not assessed.
Summary
Ultimately, further work is required. If the time were available, it would first be 
necessary to renature the bacterial Nogo-66-(His)6 and demonstrate its activity in 
inducing growth cone collapse or inhibiting neurite outgrowth. This could be achieved 
using differentiated PC 12 cells, as previously suggested, or with primary cultures of 
embryonic neocortical neurons, for example. Assuming that the Nogo-66-(His)6 is 
active, then it would be desirable to express and purify mNEPl-40 -  ideally from a the 
growth media of a stable cell line -  in order to assess its antagonist activity against Nogo- 
66. This would also demonstrate that the peptide is secreted. Then, numerous 
approaches could be taken to optimise the level of HSV-1 mediated expression of NEP1- 
40. If these were successful, studies in spinal injury models would be warranted.
To date, all of the published in vivo data on NEP1-40 has been produced by Strittmatter’s 
laboratory (Grandpre et al., 2002; Li and Strittmatter, 2003). It is somewhat surprising 
that no independent reports of its activity in spinal injury models have yet emerged, given 
that more than two years has elapsed since the potent in vivo effects of NEP1-40 on 
axonal regeneration were first described. Nonetheless, it is reasonable to assume that 
these promising findings are the result of blocking Nogo-66 signalling through NgR, but 
not that of MAG or OMgp (Barton et al., 2003). Whether targeted viral delivery of a
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secreted form of NEP1-40 to a lesion site will achieve similar results to those obtained 
with continuous intrathecal or subcutaneous infusion of the peptide remains to be seen.
CONCLUSION
Owing to numerous technical difficulties and time constraints, it was not possible to see 
this project to completion. However, there is still potential for this virus; but, the 
demonstration of mNEPl-40 antagonism of Nogo-66 and the optimisation of viral 
transgene expression are inevitably necessary before any meaningful in vivo studies can 
be undertaken.
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Figure 7.1.
Bacterial Expression of Nogo-66-(His)6.
A, Schematic representation of the pET23a(+)-Nogo-66-(His)6 vector. B, The Nogo-66- 
(His)6 open reading frame and its translation to the Nogo-66-(His)6 peptide sequence. C, 
SDS-PAGE of total cell protein from uninduced (Un) and induced (In) pET23a(+)-Nogo- 
66-(His)6 transformed BL21 ADE3 lysogen E.coli. Adjacent lanes show the medium 
(M), periplasmic (P), soluble cytoplasmic (SC) and insoluble cytoplasmic (IC) fractions 
of IPTG-induced transformed bacteria. Protein samples were resolved on a 20% 
polyacrylamide gel against high molecular weight Rainbow marker (Amersham). Nogo- 
66-(His)6 is evident as an inducible ~10KDa band. It localizes primarily to the insoluble 
cytoplasmic fraction, presumably as inclusion bodies. Mw = molecular weight marker.
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Figure 7.2.
Purification of bacterial Nogo-66-(His)6- A, Spectrophotometric absorbance 
measurements of FPLC eluent, at a wavelength of 280nm (A280), with respect to time. 
B, A280 measurements of eluent with respect to the rising concentration of imidazole 
(0% = OmM, 100% = 500mM). C, SDS-PAGE of total cell protein from IPTG-induced 
(In), and uninduced (Un), pET23a(+)-Nogo-66-(His)6 transformed BL21 A.DE3 lysogen
E.coli. FPLC elution fractions 2-8 were analysed in the adjacent lanes. Protein samples 
were resolved on a 12% Bis-Tris NuPAGE® gel (Invitrogen) against a broadrange pre­
stained molecular weight marker (Amersham). Bands of protein were visualized with 
Colloidal Coomassie® Stain (Invitrogen). Asterisks denote the major differences in 
protein expression between IPTG-induced and uninduced pET23a(+)-Nogo-66-(His)6 
transformed bacteria. Nogo-66-(His)6 was found to elute predominantly in fractions 6 
and 7, and is represented by a ~10KDa band.
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Figure 7.3.
Construction of modified form of NEP1-40 antagonist peptide (mNEPl-40). A, 
schematic representation of the multiple cloning site of pSecTagA (Invitrogen). B, 
schematic representation of pSecTagA NEP1-40. C, schematic representation of 
mNEPl-40 PCR product for subcloning into the pR19 shuttle vector. D, coding sequence 
of mNEPl-40, and translated peptide sequence.
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(D) Translation of Modified NEP1-40 Antagonist Peptide (mNEP1-40)
Ig K-chain leader sequence
' a TG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACT GGT 
Met Glu Thr Aap Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro Gly Ser Thr Gly
GAC GCG GCC CAG CCG GCC AGG CGC GCC GTA CGA AGC TTG AGG ATA TAT AAG GGC GTG ATC 
Asp Ala Ala Gin Pro Ala Arg Arg Ala Val Arg Ser Leu Arg H e  Tyr Lys Gly Val lie
NEP1-40 sequence
CAG GCT ATC CAG AAA TCA GAT GAA GGC CAC CCA TTC AGG GCA TAT TTA GAA TC T GAA GTT 
Gin Ala lie Gin Lys Ser Asp Glu Gly His Pro Phe Arg Ala Tyr Leu Glu Ser Glu Val
GCT ATA TCA GAG GAA TTG GTT CAG AAA TAC AGT AAT TC T CTC GAG TCT AGA GGG CCC GAA
Ala lie Ser Glu Glu Leu Val Gin Lys Tyr Ser Asn Ser Arg Ala Ser Arg Gly Pro Glu
myc epitope Polyhistidine tag
CAA AAA CTC ATC TCA GAA GAG GAT CTG AA T1 AGC GCC GTC GAC 'CAT CAT CAT CAT CAT CA T1
Gin Lys Leu lie Ser Glu Glu Asp Leu Asn Ser Ala Val Asp His His His His His His
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Figure '7.1.
Constriucion of replication-incompetent HSV-1 for the expression of mNEPl-40. A, 
schem#ti* representation of pR19 hrGFP WPRE shuttle vector (Biovex Ltd.). B, 
schem#th representation of pR19 mNEPl-40 WPRE shuttle vector. C, Southern blot for 
recomlbir&tion of the pR19 mNEPl-40 WPRE cassette into 1764/4-/27in/RLl+ HSV-1 
vector 1ba±bone.
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All DNA samples were digested with EcoRI. The blot was probed with radiolabeled m N EPl-40 PCR product.
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Figure 7.5.
Microscopic capture of growth cone collapse and neurite retraction in cold-shocked 
differentiated PC 12 cells. The growth media was replaced with ice-cold lx  HBSS, after 
induction of differentiation and neurite outgrowth by incubation with lOOng pNGF/ml 
media for 48 hours. Images of a single field were captured at one minute intervals, for a 
duration of 30 minutes. A time course is presented, illustrating widespread neurite 
retraction from 1 to 30 minutes post cold-shock. Scale bar = 50pm.
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Figure 7.6.
Fixation of differentiated PC 12 cells. Growth cones are indicated by arrows. 
Scale bar = 50jxm.
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Figure 7.7.
Western blot for myc-tagged protein in the cell lysate of virally transduced BHKs. 
Cultured cells were transduced at an MOI of 1, and harvested at 48 hours post 
transduction. 20pg of protein were loaded per well, and resolved on a 20% 
polyacrylamide gel against high-molecular weight Rainbow marker (Amersham). The 
membrane was probed with anti-myc antibody (Invitrogen) at a dilution of 1:500, 
followed by HRP-conjugated goat anti-mouse antibody (Dako) at a dilution of 1:2000. 
The membrane was reacted with ECL reagent (Amersham), and exposed to film for 1 
minute. The only detectable band was that of the positive control protein at ~60KDa. 
mNEPl-40 should have been detectable as a ~10KDa band. No additional bands were 
visible on longer exposure.
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Figure 7.8.
HSV-1 mediated transgene expression in vitro and in vivo.
A, HSV-1 mediated expression of mNEPl-40 (red) by BHKs after 48 hours, following 
transduction at an MOI of 20. B, the same field as in A visualized with the nuclear stain, 
bisbenzimide (blue). C, HSV-1 mediated expression of mNEPl-40 (red) by BHKs after 
48 hours, following transduction at an MOI of 5. Perinuclear localization of mNEPl-40 
is visible. D, Horizontal section of adult Sprague-Dawley rat cervical spinal cord, caudal 
to the injection site, 8 days post injection of 2x106 pfu of 1764/4-/27in/RLl+/pR19 
mNEPl-40 WPRE. Numerous mNEPl-40 expressing cells, some of which exhibit a 
neuronal morphology, can be seen spread diffusely throughout the field. The spinal canal 
is denoted by an asterisk. E and F, mNEPl-40 expressing cells were also present rostral 
to the injection site. Some of these also exhibited a neuronal morphology. G, Horizontal 
section through the ventral hom, 8 days post injection of 2xl06 pfu of 1764/4- 
/27in/RLl+/pR19 eGFP WPRE. A considerably higher level of transgene expression 
(green) is evident, compared to that obtained with 1764/4-/27in/RLl+/pR19 mNEPl-40 
WPRE. eGFP, a non-secreted protein, clearly undergoes extensive axonal transport. 
(Scale bars A = 100pm, B = 100pm, C = 50pm, D = 100pm, E = 100pm, F = 50pm, G = 
50pm).
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CHAPTER 8
Development of an HSV-1 Platform for the Mediation
of RNA interference
INTRODUCTION
The discovery of short interfering RNAs (siRNAs), and the characterisation of their 
mechanism of action, has resulted in their widespread use in functional genomics over 
recent years. They suppress endogenous gene expression postranscriptionally by 
targeting short, and perfectly complementary, contiguous sequences of mRNA to those 
encoded in the antisense arm of the siRNA. This is achieved through the formation of a 
specialized complex of proteins, termed the RNA induced silencing complex (RISC) 
(Martinez et al., 2002). The controlled degradation of target mRNA is mediated by an as 
yet unidentified nuclease. If the target sequence is carefully selected, a single species of 
mRNA can be effectively targeted with greater than 90% downregulation of its normal 
level of protein expression (Elbashir et al., 2001c).
Traditionally, siRNAs were chemically synthesized and consisted of separate annealed 
sense and antisense strands of between 19-21 nucleotides, each with a 3' di-uridine 
overhang. These were typically used for in vitro functional genomic studies (reviewed by 
Bargmann, 2001), for example in the transfection of morphologically distinct
D.melangaster cell lines to rapidly screen for genes underlying the cellular appearance 
(Kiger et al., 2003). Relatively recently, it was discovered that RNA-polymerase type III 
dependent promoters, such as U6 and HI, could be harnessed to transcribe short hairpin 
forms of siRNA from DNA vectors (Yu et al., 2002a; Sui et al., 2002a; Paul et al., 2002b; 
Paddison et al., 2002b; Miyagishi and Taira, 2002b). The activity of short hairpin RNA 
(shRNA) was found to be almost comparable to that of siRNA.
279
In the past, gene therapy has been limited to the supplementation of host cell gene 
expression. However, the developments in shRNA technology have, in turn, lead to the 
construction of effective virus-based gene therapy systems for the suppression of host cell 
gene expression. Reports have now emerged of successful delivery of functionally active 
shRNAs, driven by RNA polymerase III dependent promoters, using lentivirus (Rubinson 
et al., 2003), retrovirus (Brummelkamp et al., 2002b) and adenovirus (Shen et al., 2003). 
Invariably, in the fullness of time, viral systems will permit many new lines of 
experimental enquiry, especially into (i) gene function in vivo, and (ii) the molecular 
treatment of diseases (such as cancers, heritable genetic disorders in which mutant 
proteins are expressed, as well as viral diseases). Of course, gene silencing systems that 
can be effectively applied in vivo to neurons, which are post-mitotic, will also have 
enormous value in the study of CNS injury.
Many different proteins are expressed in CNS injury states that have been shown to be 
inhibitory to axonal regeneration in vivo, or neurite outgrowth in vitro. In the past, 
attempts to neutralise the activity of such molecules have included the administration of 
function-blocking antibodies (Schnell and Schwab, 1990; Schnell and Schwab, 1993), 
peptide antagonists (Grandpre et al., 2002), dominant negative proteins (Fischer et al., 
2004) or chemical inhibitors of downstream signalling pathways (Dergham et al., 2002; 
Fournier et al., 2003). With any one of these methods, it is difficult to say with great 
certainty that the observed effects are the sole result of impeding the activity of the 
protein of interest. However, with the advent of RNAi technology, it should become 
increasingly less difficult to achieve transient, specific and effective knockdown of a 
given target protein -  and this should yield more accurate results.
The aim of the work reported herein was to determine whether a platform for the 
expression of functional shRNA could be established in HSV-1, which is neurotropic and 
is inherently suited to gene therapy applications within the CNS. As a proof of principle, 
eGFP was targeted. However, a vector expressing shRNA against ngr, which would be 
of particular interest in the study of spinal injury, was also constructed.
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Activation of the double-stranded RNA dependent protein kinase (PKR) in eukaryotic 
cells brings about absolute cellular shut-down of translation (Clemens and Elia, 1997), 
which is an obvious impediment to DNA-vector based attempts to specifically 
downregulate a target gene using a long-hairpin RNA approach. However, HSV-1 has 
evolved to overcome this host-cell activity through the function of ICP34.5 -  the 
neurovirulence factor -  which has been shown to prevent the PKR response to double­
stranded RNA (He et al., 1997; Randazzo et al., 1997; Leib et al., 2000). For this reason, 
HSV-1 is theoretically well-suited to both short- and long-hairpin approaches to post- 
transcriptional gene silencing (PTGS). Since it is already known that RNA polymerase II 
dependent promoters work well when flanked by the LAT promoters, whereas no data are 
yet available on the function of RNA polymerase III dependent promoters in this context, 
it was decided that a direct comparison of the two approaches should be made against 
eGFP in an in vitro assay.
SUMMARY OF METHODS
Construction of HSV-1 for the Expression of Short-Hairpin RNA (against eGFP or 
NgR)
First, the pBluescript II SK+ plasmid (Stratagene; Fig 1A) was digested with Apal, 
blunted with T4 DNA polymerase and re-ligated. This vector was termed pBS (Apal 
minus) (Fig IB). The human U6 snRNA promoter sequence (-265 to +1) was amplified 
by nested PCR from HT1080 cell line genomic DNA (extracted with DNAzol (Gibco), 
according to the manufacturer’s instructions), using the primer pairs: (i) CAA AAC GCA 
CCA CGT GAC and CAG GGG CCA TGC TAA TCT T, followed by (ii) AGT CAC 
TAG TCA AGG TCG GGC AGG AAG A and ACT GAA GCT TCA GTC TGG GCC 
CGG TGT TTC GTC CTT TCC AAG. The PCR product was digested with SpeI and 
Xhol, resolved on a 1% agarose gel, excised, purified with GFX columns (Amersham) 
and ligated between the Spe I and Xhol sites of pBS (Apal minus). This vector was 
termed pBS (Apal minus) U6 (Fig 1C). The promoter sequence was verified by 
automated fluorescent dye sequencing. Preparation of the vector backbone for ligation of 
the short-hairpin encoding oligonucleotide entailed digestion with Apal and Xhol, and
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subsequent gel-purification of the backbone fragment. The custom-made, FPLC-purified, 
5'-phosphorylated sense and antisense deoxyribonucleotides were mixed in equimolar 
ratio, heated to 65°C for lOmins in annealing buffer (lOnm Tris-HCl, lOOmM NaCl, 
ImM EDTA in DEPC water), and left to cool to room temperature overnight. These 
hybridized adaptor sequences were subsequently ligated into the Apal and Xhol digested 
backbone. GT116 cells (Invivogen), which have been genetically modified specifically 
for the propagation of DNA hairpin structures, were used in the transformation. These
E.coli lack the sbcC and sbcD proteins that are involved in recognition and cleavage of 
such structures (Connelly et al., 1998).
Originally, it was intended that a previously reported anti-eGFP shRNA sequence (Yu et 
al., 2002b) should be used in the construction of the HSV-1 U6 anti-eGFP shRNA vector. 
However, this was hindered by the fact that mutation/recombination of the custom-made 
adaptor sequence always arose during plasmid propagation. Ultimately, a new unverified 
target sequence within eGFP was selected, which did not produce any of these 
complications. Each shRNA encoding adaptor sequence consisted of annealed sense and 
antisense PAGE purified oligonucleotides. For the construction of HSV-1 anti-eGFP 
shRNA the sense and antisense oligonucleotides were A A G C T G A C C C T G A A G T T C A - 
TTC AAG AG A -TG  A A C T T C  A G G G T C  A G C T T -TTTTTTAG A TCTC and TCG AG/4 GA T C T A A A A A A -  
A A G C TG A C C C TG A A G TTC A -TC TC TTG A A -TG A A C TTC A G G G TC A G C TT-G G C C , 
respectively. The target sequence, AAGCTGACCCTGAAGTTCA, corresponds to bases 
124 to 142 of the eGFP coding sequence of peGFP-Nl (Clontech) (Genbank Accession 
No. U55762). For the construction of HSV-1 anti-NgR shRNA the sense and antisense 
oligonucleotides were A A TG A G CCC A AG G TCA CA A -TTC AA G A GA -
T T G T G A C C T T G G G C T C A T T -T T T T T T ^G ^rC 7G  and TCG AGL4 GA T C T A A A A A A -
A A TG A G C C C A A G G TC A C A A -TC TC TTG A A -TTG TG A C C TTG G G C TC A TT-G G C C , 
respectively. The target sequence, AATGAGCCCAAGGTCACAA, corresponds to 
bases 103 to 121 of the rat ngr reference sequence (Genbank Accession No. 
NM_053613). In both constructs, a previously reported loop sequence, TTCAAGAGA, 
was used (Brummelkamp et al., 2002a). Also, in each case, a BglII restriction site 
(AGATCT) was incorporated after the poly-thymidine transcription termination signal, so
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that a gain of sensitivity to the BgRl restriction endonuclease could be employed as 
screening method for positive clones. The shRNA encoding sequence in the pBS (Apal 
minus) U6 shRNA vector was verified by automated fluorescent dye sequencing, prior to 
the subcloning of the U6 shRNA cassette into the shuttle vector.
The pR19 shuttle vector into which the human U6 promoter, complete with hairpin 
sequence, were to be cloned had to be modified. pR19 IRES eGFP (Fig. 8.3.A) was 
digested with EcoKV to remove a small fragment (~200bp) from the upstream LAT 
flanking region, creating the vector pR19 (SpeI minus) IRES eGFP. This eliminated a 
superfluous Spe I site, which would have otherwise prevented the excision of the CMV 
promoter and IRES eGFP sequence using the Spel and Xhol restriction sites. These sites 
were required for the insertion of the human U6 shRNA cassette, which was excised from 
the relevant pBS (Apal minus) U6 shRNA vector with the Spel and Xhol restriction 
endonucleases. This final shuttle vector, termed pR19 (Spel minus) U6 shRNA, was 
linearized with Seal for co-transfection with 1764/4-/27in/RLl+ viral DNA to generate 
recombinant HSV-1.
Construction of HSV-1 for the Expression of Long-Hairpin RNA against eGFP
For the purpose of generating long hairpin RNAs, the RNA polymerase II dependent 
CMV promoter is suitable, meaning that the unmodified pR19 backbone vector was 
identified as an appropriate shuttle vector in which to construct the long hairpin sequence 
against eGFP. The first strand of the hairpin (antisense) was amplified by PCR using the 
primers GTC AAA GCT TAA GTC GTG CTG CTT CAT GTG and GTC ACT CGA 
GGT CAA TCG ATA CGT AAA CGG CCA CAA GTT C. This strand corresponds to 
bases 65-251 of the eGFP coding sequence within the template vector peGFP-Nl 
(Genbank accession No. U55762), and was ligated into the pR19 backbone between the 
Hindlll and Xhol restriction sites. The primers were designed such that the forward 
primer contained an internal Hindlll site and the reverse primer, both Xhol and Clal sites. 
The second strand of the hairpin (sense) was amplified by PCR using the primers GTC 
AAA GCT TGT CAA TCG ATA CGT AAA CGG CCA CAA GTT C and GTC ACT 
CGA GAA GTC GTG CTG CTT CAT GTG. The forward primer contained internal
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Hindlll and CM  restriction sites and the reverse primer a Xhol site. The intermediate 
‘pR19 AS eGFP strand’ vector was linearized with CM and Xhol and the second strand 
(sense) was ligated between these sites. Purpose-engineered GT116 E.coli (Invivogen), 
which have a AsbcCD genotype (Connelly et al., 1998), were transformed (as described 
in Chapter 2) for the propagation of the hairpin-containing plasmid. The shuttle vector 
was used to co-transfect 27/12/M:4 cells with 1764/4-/27in/RLl+/pR19 hrGFP WPRE 
viral DNA in order to generate recombinant HSV-1.
Lentivirus (LV)
All lentiviruses used in this study were kindly provided by Sam Wilson (Department of 
Immunology and Molecular Pathology, UCL). The viruses were replication-incompetent 
second generation HIV-1, pseudotyped with the vesicular stomatitis virus coat protein G 
(VSV-G) for enhanced transduction of non-dividing cells. A modified form of a 
previously reported vector genome, pHR-SIN-CSGW (Demaison et al., 2002), in which 
the U6-shRNA cassette had been incorporated and the eGFP gene replaced with PAC, 
was used in a three-plasmid transient transfection with pCMVR8.91 (the packaging 
plasmid) and pMD-G (the VSV-G expressing plasmid). The growth medium, which 
contained recombinant HIV-1, was collected and stored at -80°C.
The lentivirus cassette for the expression of shRNA contained the human U6 promoter (- 
315 to +1), followed by Sail and Xbal sites. The shRNA encoding adaptor sequence was 
ligated between the Sail site, which had first been blunted with mung bean nuclease, and 
the Xbal site. The shRNA had been designed such that sense strand of 23 nucleotides 
was transcribed first, followed by TTCG loop sequence, and then the 23 nucleotide 
antisense strand. A poly-thymidine transcription termination signal was incorporated 
immediately after the antisense strand sequence. The sense and antisense 
oligonucleotides used in the construction of the anti-eGFP shRNA encoding adaptor 
sequence for lentivirus were T T C A T C T G C A C C A C C G G C A A G C -TTC G - 
G C T T G C C G G T G G T G C A G A TG A A C -T TT T T  and CTAG-AAAAA-
G TTC A TC T G C A C C A C C G G C A A G C -C G A A -G C TT G C C G G T G G T G C A G A T G A A , respectively. 
The target sequence, GTTCATCTGCACCACCGGCAAGC, corresponds to residues 138-160
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of the eGFP coding sequence of peGFP-Nl (Clontech) (Genbank Accession No. 
U55762). The sense and antisense oligonucleotides used in the construction of anti-LacZ 
shRNA encoding adaptor sequence were C T G T G A T T G C G T C T G G G T T T G C -T T C G - 
G C A A G C C C G G G C G TA A TC A TA G C -TTTTT and CTAG-AAAAA-
G C TA TG A TTA C G C C C G G G C TT G C -C G A A -G C A A A C C C A G A C G C A A T C A C A G , respectively. 
The target sequence, CTATGATTACGCCCGGGCTTGC, corresponds to bases 5-26 of the P- 
galactosidase coding sequence (Genbank Accession No. M34519).
Construction of eGFP-Expressing Stable Cell Line
BHK cells were transfected with yf/?aLI-linearized peGFP-Nl (Clontech), and an eGFP- 
expressing stable cell line was generated as described in Chapter 2. Based on cellular 
fluorescence and morphology, clone 2B1 was selected for use in the experiments reported 
here. Analysis by flow cytometry revealed that the green fluorescence measurements 
(FL1-H) of the 2B1 clone was 103 fold higher than that of normal BHKs.
Viral Transduction of the 2B1 Cell Line
2B1 cells were transduced with 1764/4-/27in/RLl+/pR19 anti-eGFP shRNA, 1764/4- 
/27in/RLl+/pR19 anti-NgR shRNA, or 1764/4-/27in/RLl+/pR19 anti-eGFP lhRNA at an 
MOI of 5, or the cells were mock transduced. Alternatively, 2B1 cells were transduced 
with LV anti-eGFP shRNA or LV anti-LacZ shRNA, or the cells were mock transduced. 
Four days post infection, cellular fluorescence was analysed by flow cytometry, as 
described in Chapter 2.
Double Transduction of BHKs with HSV-1
BHKs were transduced with 1764/4-/27in/RLl+/pR19 anti-eGFP shRNA, 1764/4- 
/27in/RLl+/pR19 anti-NgR shRNA, or 1764/4-/27in/RLl+/pR19 anti-eGFP lhRNA at an 
MOI of 5, or the cells were mock transduced. 24 hours later, the cells were superinfected 
with 1764/4-/27in/RLl+/pR19 eGFP WPRE at an MOI of 1. After a further 48 hours, 
cellular fluorescence was analysed by flow cytometry.
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Transduction of Dissociated Cultures of Rat P8 Cerebellar Granule Neurons
Dissociated cultures of rat P8 cerebellar granule neurons were prepared as described in 
Chapter 2. After 2 days in culture, the cells were transduced with 1764/4- 
/27in/RLl+/pR19 anti-NgR shRNA, 1764/4-/27in/RLl+/pR19 anti-eGFP shRNA, or 
1764/4-/27in/RL l+/pRl 9 eGFP WPRE at an MOI of 1, or the cells were mock 
transduced. After a further 2 days in culture, total RNA was extracted using Trizol 
reagent (Gibco). These samples were treated with DNasel (DNA-free; Ambion) to 
eliminate any contaminating genomic DNA, as per the manufacturer’s instructions. 
cDNA was subsequently produced, as described in Chapter 2, for analysis by quantitative 
PCR.
Taqman® Quantitative PCR
Quantitative PCR was performed as described in Chapter 2. The forward (CGT GGC 
TTG CAC AGT CTT GA) and reverse (AGG TCC CGG AAG GCA TGT) rat ngr 
primers corresponded to bases 595-614 and 657-674 of NM 053613, respectively. The 
Probe (CGT CTC CTC TTG CAC CAG AAC CAT GTG) corresponded to bases 6lb- 
642, and possessed a 5' 6-FAM Fluor label. The concentration of primers and probe were 
optimized (Fig. 2.1), as recommended by the manufacturer, prior to use in sample 
analysis. The ribosomal 18S subunit was used as an endogenous control, i.e. for 
normalisation of sample values (Eukaryotic ribosomal 18S subunit; Pre-Developed 
Taqman® Assay Reagents; Applied Biosystems, UK.). The PCR of ngr and 18S was 
performed on an ABI7000 as singleplex reactions. The standard curves and ‘no template 
control’ reactions were included on the same plate as the respective samples. Each 
reaction was performed in triplicate.
RESULTS
Construction of HSV-1 for the Expression of Short-Hairpin RNA
The human U6 promoter (-265 to +1) was ligated into the Spe I and Xhol sites of an Apal 
minus version of pBluescript II SK+ (Figs. 8.1.A-C). The shRNA encoding adaptor 
sequence was ligated between the Apal site, within the U6 promoter fragment, and the
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vector Xhol site (Fig. 8.1.D). The shRNA encoding adaptor sequence for both the anti- 
eGFP and anti-NgR constructs followed a generic design (Fig. 8.1.E), in which the sense 
and antisense strands of the hairpin were each 19 nucleotides long, and separated by a 
standard nine-nucleotide loop sequence, with the sense strand being transcribed first 
(Brummelkamp et al., 2002a). A poly-thymidine transcription termination signal 
followed the antisense strand. This, in turn, was followed by a BgM restriction site, so 
that a gain of restriction endonuclease sensitivity could be used to identify positive 
clones. The adaptor sequence was designed such that it had an upstream Apal overhang, 
and downstream Xhol overhang, for ligation into the pBS (Apal minus) U6 vector (Fig. 
8.1.C). The generic shRNA derived from this U6 shRNA cassette would be expected to 
be processed by Dicer to form conventional siRNA (Fig. 8.2).
The U6 shRNA cassette was subcloned into the Spel and Xhol sites of a modified form of 
the pR19 IRES eGFP shuttle vector, which lacked a superfluous Spel site in the upstream 
LAT flanking region (Figs. 8.3.A-C). The shuttle vector was used in a co-transfection 
with 1764/4-/27in/RLl+ viral DNA in order to generate recombinant HSV-1, expressing 
shRNA from the LAT regions (Figs. 8.4.D and E). Southern blots were performed to 
detect recombinant viral plaques of HSV-1 anti-eGFP shRNA and HSV-1 anti-NgR 
shRNA (Figs. 8.4.A and B).
Construction of HSV-1 for the Expression of Long-Hairpin RNA against eGFP
The antisense strand of the long-hairpin encoding sequence, corresponding to bases 65- 
251 of the eGFP coding sequence, was ligated into the Hindlll and Xhol sites of the pR19 
IRES eGFP shuttle vector, thus replacing the IRES eGFP transgene (Figs. 8.5.A and B). 
The sense strand, corresponding to exactly the same region of the eGFP coding sequence, 
was subcloned between the Clal and Xhol sites (Fig. 8.5.C). This shuttle vector was 
termed pR19 anti-eGFP lhRNA and was used in a co-transfection with 1764/4- 
/27in/RLl+ viral DNA in order to generate recombinant HSV-1. A southern blot was 
performed to detect recombinant viral plaques (Fig. 8.5.D).
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Stable eGFP-Expressing BHK cells (clone 2B1)
A stable eGFP-expressing BHK cell line, termed clone 2B1, was generated for use in in 
vitro assays of anti-eGFP shRNA activity. These cells are fibroblasts, and are readily 
transducible with HSV-1. Fluorescence and bright field microscopy, as well as flow 
cytometry, were used to gauge the intensity and uniformity of eGFP expression (Fig.
8.6.A-C). By microscopy, most of the cells appeared to express eGFP at similar intensity 
(Fig. 8.6.A). However, when compared to BHKs by flow cytometry, it was apparent that 
7.6% of the 2B1 population was non-fluorescent according to FL1-H measurements. In 
contrast, 88.6% of 2B1 cells were highly fluorescent, and 3.8% weakly fluorescent (Fig.
8.6.C).
eGFP Expression by 2B1 Cells Transduced with HSV-1 anti-eGFP shRNA
2B1 cells were transduced with HSV-1 anti-eGFP shRNA, HSV-1 anti-NgR shRNA, or 
HSV-1 anti-eGFP lhRNA at an MOI of 5, or the cells were mock transduced. Four days 
post transduction, cellular fluorescence was assessed by microscopy and flow cytometry 
(Fig. 8.7.A and B). No difference in the level of fluorescence was discernible between 
mock transduced, HSV-1 anti-NgR shRNA or HSV-1 anti-eGFP lhRNA transduced cells 
by fluorescence microscopy. However, the HSV-1 anti-eGFP shRNA transduced cells 
appeared slightly less fluorescent (Fig. 8.7.A). By flow cytometry, 32.9% and 30.8% 
reduction in median fluorescence were detected in the HSV-1 anti-NgR shRNA and 
HSV-1 anti-eGFP lhRNA treated cells, compared to mock transduced cells. HSV-1 anti- 
eGFP shRNA transduction resulted in a 59.7% reduction in median fluorescence (Fig.
8.7.B and C).
eGFP Expression by 2B1 Cells Transduced with LV anti-eGFP shRNA
Another postgraduate research student, Sam Wilson, in the Department of Immunology 
and Molecular Pathology at UCL had also been constructing viruses expressing shRNA. 
However, he had made lentiviruses (VSV-G pseudotyped second generation replication- 
incompetent HIV-1) for the expression of shRNA against various targets, including 
eGFP. In the preliminary experiments, it had been shown that the LV anti-eGFP shRNA 
virus reduced eGFP expression by stable eGFP-expressing Hela cells by -90%. Having
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discussed the similarity of the two projects, it was decided that his LV anti-eGFP shRNA 
virus be assayed in the in vitro system reported here to (i) confirm the previous finding 
and, thus, validate the assay system, and (ii) make a crude comparison with the 
equivalent HSV-1 vector.
First, it was necessary to establish whether the BHK cells can be transduced with 
lentivirus. Using a lentivirus expressing eGFP, it appeared that these cells were readily 
amenable to transduction, with apparently all cells expressing eGFP after two days (Fig.
8.8.A). The lentivirus U6-shRNA cassette was slightly different to that used in HSV-1 
(Fig. 8.8.B). The shRNA encoding sequence had been blunt ligated into the transcription 
start site, consisted of longer 23-nucleotide sense and antisense hairpin strands, and 
contained a shorter four-nucleotide loop sequence than was used in HSV-1. Other 
differences are described in the summary of methods. LV anti-eGFP shRNA, or LV anti- 
LacZ shRNA, were used to transduce 2B1 cells. After four days, the fluorescence of 
virally-transduced and mock transduced cells was compared by microscopy and flow 
cytometry (Fig. 8.8.C-D). No difference between the cellular fluorescence of mock or 
LV anti-LacZ transduced 2B1 cells was obvious by microscopy. In comparison, LV anti- 
eGFP shRNA transduced cells were barely visible by fluorescence microscopy (Fig.
8.8.C). By flow cytometry, median fluorescence readings were reduced by 85.4% and 
4.4% in LV anti-eGFP shRNA and LV anti-LacZ shRNA samples, respectively, 
compared to mock transduced 2B1 cells (Figs. 8.8.D and E).
Effect of HSV-1 anti-eGFP shRNA on the Onset of eGFP Expression
BHKs were first transduced with HSV-1 anti-eGFP shRNA, HSV-1 anti-NgR shRNA, or 
HSV-1 anti-eGFP lhRNA at an MOI df 5, or the cells were mock transduced. 24 hours 
later, the cells were transduced with HSV-1 eGFP WPRE at an MOI of 1. Fluorescence 
microscopy and flow cytometry were performed to determine cellular fluorescence (Figs.
8.9.A-C). By microscopy, the level of fluorescence was similar in the HSV-1 eGFP-only 
and HSV-1 anti-eGFP shRNA samples, whereas it was considerably higher in the HSV-1 
anti-NgR shRNA and HSV-1 anti-eGFP lhRNA samples (Fig. 8.9.A). This was 
confirmed by flow cytometry (Figs. 8.9.B and C). The median fluorescence values were
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normalized against those of the HSV-1 eGFP-only sample. The median fluorescence of 
S the HSV-1 anti-eGFP shRNA, HSV-1 anti-NgR shRNA, and HSV-1 anti-eGFP lhRNA 
samples were 81.8%, 214.7% and 255.0% relative to that of the control HSV-1 eGFP- 
only sample, respectively (Fig. 8.9.D).
Expression of ngr by HSV-1 Transduced Rat P8 Cerebellar Granule Cells
Dissociated cultures of rat P8 cerebellar granule cells were transduced, after two days in 
culture, with HSV-1 anti-NgR shRNA, HSV-1 anti-eGFP shRNA, or HSV-1 eGFP 
WPRE at an MOI of 1, or the cells were mock transduced. After a further 2 days in 
culture, ngr transcript expression was analysed by quantitative PCR. Relative to the level 
of ngr mRNA detectable in mock transduced P8 CGCs, the HSV-1 anti-NgR shRNA 
sample contained 20.8% less of the transcript. This compared to a 9.3% and 6.9% 
reduction in transcript levels in the HSV-1 anti-eGFP shRNA and HSV-1 eGFP WPRE 
samples, respectively (Fig. 8.10).
DISCUSSION
The aim of the work reported here was to demonstrate, as a proof of principle, that HSV- 
1 can be successfully manipulated for the delivery of functional shRNA. To this end, 
recombinant HSV-1 was generated to drive transcription of shRNA against eGFP or NgR 
from the human U6 promoter. In addition, recombinant virus was constructed for the 
expression of long hairpin RNA. The rationale for this being that the viral protein 
ICP34.5 should block with the mammalian host cell PKR response, which otherwise 
occurs in the presence of long double stranded RNA and results in the absolute shut­
down of cellular translation. It was thought that, if successful, this approach would 
obviate the need to limit the RNA hairpin length to less than 30bp, and that it could 
potentially be more efficacious than shRNA owing to the longer target sequence.
HSV-1 Mediated Delivery of anti-eGFP shRNA and lhRNA
Of the two anti-eGFP viruses, only that expressing the shRNA against eGFP had any 
effect on the expression of eGFP by the 2B1 stable cell line. Flow cytometric analysis
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revealed a 59.7% reduction in fluorescence, which was also apparent by fluorescence 
microscopy, compared to mock transduced 2B1 cells. In contrast, the anti-eGFP lhRNA 
virus exhibited no more effect in reducing the fluorescence profile of the stable cells than 
did the anti-NgR shRNA virus. Therefore, this must be considered a non-specific effect 
resulting from the process of viral transduction.
Even in the experiment in which BHKS were first infected with viruses expressing 
hairpins, and then superinfected 24 hours later with a virus expressing eGFP, it appeared 
that the viral ly-expressed anti-eGFP hairpins had an effect on the resultant eGFP 
expression. Although, in absolute terms, there was only a marginal reduction in 
fluorescence compared to the eGFP only control sample, this must be considered in the 
context of viral gene dosage and the role of viral proteins, such as ICPO, which are known 
to effect a generalized upregulation in gene expression soon after transduction 
(Samaniego et al., 1997; Jordan and Schaffer, 1997; Kawaguchi et al., 1997a). For 
example, the anti-NgR shRNA and anti-eGFP lhRNA samples, like the anti-eGFP 
shRNA sample, were transduced on two occasions: first with the virus of interest at an 
MOI of 5, and 24 hours later with an eGFP-expressing virus at an MOI of 1. Whereas the 
eGFP only sample was first mock transduced, and 24 hours later transduced with an 
eGFP-expressing virus at an MOI of 1. In other words, the control sample contained only 
one sixth the number of copies of viral genome as the samples of interest. That the level 
of fluorescence observed in the anti-NgR shRNA and anti-eGFP lhRNA samples was 
greater than two-fold higher than the level of fluorescence observed in the eGFP only 
control sample is of considerable significance. It implies that the level of fluorescence of 
the anti-eGFP shRNA sample would have been equally as high if it did not have any 
effect on eGFP expression. The fact that the level of fluorescence in the anti-eGFP 
shRNA sample was only marginally lower than that of the eGFP only sample is 
somewhat irrelevant in this experimental model, since it has to be compared directly to 
the anti-NgR shRNA sample to account for the effect of viral gene dosage. In this light, 
it would appear that HSV-1 mediated delivery of anti-eGFP shRNA has a significant 
effect on eGFP gene expression, whereas HSV-1 mediated delivery of anti-eGFP lhRNA 
has none.
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The HSV-1 viral genome has a considerable propensity to rearrange itself by homologous 
recombination, and the complete lack of activity of the anti-eGFP lhRNA obviously 
raises the question of whether the lhRNA sequence might have been lost during the 
rounds of viral replication needed to produce a high-titre stock. If that were the case, 
there would be no conceivable future for HSV-1-mediated lhRNA delivery. The absence 
of anti-eGFP activity could potentially be explained by the selection of ineffectual target 
sequence. However, in this study, bases 65-251 of the eGFP coding sequence were 
targeted which, of course, includes sequences that were effectively targeted by the HSV-1 
and LV anti-eGFP shRNA vectors (bases 124-142, and 138-160, respectively). It is 
unlikely the difference in strand order (antisense-loop-sense in the long-hairpin construct 
vs. sense-loop-antisense in the short-hairpin constructs) would have had any bearing on 
the difference in effect, since the long double-stranded RNA should be endogenously 
processed to multiple different siRNAs of 21-23 nucleotides in length (Elbashir et al., 
2001b). Structurally, these siRNAs should have 180° of rotational symmetry -  thus, the 
initial strand order would be irrelevant. In any event, it is clear that there was no PKR 
response (which can elicit complete translational shut-down). Nonetheless, further work 
will be necessary before any definitive conclusions can be made about the value of this 
system in HSV-1, particularly in view of the recent description of additional measures 
that can be taken to enhance the silencing activity of long-hairpin systems (Shinagawa 
and Ishii, 2003); these entail the removal of both the 5' mRNA cap and 3' polyadenylate 
tail, such that the transcribed long-hairpin RNA is retained within the nucleus.
HSV-1 vs. Lentivirus
The median fluorescence of 2B1 cells was reduced by 85.4% or 4.4%, following 
transduction with lentivirus expressing anti-eGFP shRNA or anti-LacZ shRNA, 
respectively. The latter is a non-specific effect relating to the process of viral 
transduction. There are several potential explanations for the difference in effect between 
lentivirus and HSV-1 mediated delivery of anti-eGFP shRNA.
First, and probably most important, is the difference in eGFP target sequence. It is well 
documented that the selection of an appropriate target sequence within the transcript of
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interest is critical to the success of RNAi (Elbashir et al., 2001c). This is, in part, 
believed to be due to the fact that only one siRNA stand is assembled into the RNA 
induced silencing complex (RISC) (Martinez et al., 2002), and that this association is 
influenced by strand nucleotide composition (Schwarz et al., 2003; Khvorova et al.,
2003). Should the sense siRNA strand have the greater affinity for RISC than the 
antisense strand, then optimal silencing of the target will not be observed. Although 
algorithms have been devised for the selection of appropriate target sequence, this has not 
totally eliminated the trial-and-error element of the process. Ideally, numerous siRNAs 
should be synthesized and their effect on the target molecule characterized in vitro, in 
order to select the target sequence that produces optimal knock-down. Unfortunately, in 
this instance, there was insufficient time to undertake this screening process prior to the 
construction of recombinant HSV-1. Originally, a verified target sequence within eGFP 
was selected (Yu et al., 2002b) but, inexplicably, this was always found to mutate during 
plasmid amplification. Ultimately, a new target sequence within the eGFP coding 
sequence (bases 124-142) was selected using an algorithm (Elbashir et al., 2001c). This 
was unverified experimentally, but did not mutate during plasmid amplification. The 
target sequence used in the lentivirus construct, which was very effective in silencing 
eGFP expression, corresponded to bases 138-160 of the eGFP coding sequence.
It should also be noted that there are two commonly used lengths of human U6 promoter, 
-265 to +1 (Lee et al., 2002; Paddison et al., 2002a) and -315 to +1 (Sui et al., 2002b); the 
shorter form was used in HSV-1, and the longer form in the lentivirus. This is unlikely to 
account for much difference in effect between the two viruses, since both forms of the 
promoter have been used successfully in DNA vectors to dramatically reduce target gene 
expression (Lee et al., 2002; Paddison et al., 2002a; Sui et al., 2002b).
It is also possible, but unlikely, that some of the difference in effect could be attributed to 
alternative shRNA cloning strategies. In HSV-1, the shRNA coding sequence is cloned 
into an Apal overhang, the first base of which corresponds to the transcription start site. 
This would result in a 5' pentanucleotide overhang which, theoretically, should be 
degraded (Fig. 8.2). In lentivirus, the shRNA coding sequence was ligated blunt to the
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transcription start site, meaning that no 5' overhanging sequence would be present in the 
hairpin structure. Also, the sense and antisense strands of the hairpin were designed to be 
23 nucleotides in length, with a 4-nucleotide loop sequence. This compares with strand 
lengths of 19 nucleotides, and a loop sequence of 9 nucleotides, in the HSV-1 construct. 
It would be surprising if these differences had any major impact on the functional activity 
of the respective shRNA, but relatively little has so far been reported on such aspects of 
shRNA design.
HSV-1 Mediated Delivery of anti-NgR shRNA
Quantitative PCR of P8 rat cerebellar granule neurons revealed a 30% reduction in ngr 
mRNA levels, after transduction with the anti-NgR shRNA virus. However, this 
compared to 9.3% and 6.9% reduction in ngr mRNA levels following transduction with 
HSV-1 anti-eGFP shRNA or HSV-1 eGFP WPRE, respectively. Such a non-specific 
effect on mRNA expression is not uncommon following viral transduction (Malmgaard,
2004). By immunocytochemistry, no obvious difference in NgR expression could be 
observed between samples.
Summary
A convincing reduction in eGFP expression was achieved in two different experimental 
models using HSV-1 mediated delivery of anti-eGFP shRNA. However, no effect was 
apparent using HSV-1 for the expression of anti-eGFP lhRNA. Whether this virus is 
actually expressing lhRNA is not yet known, and requires further investigation. The 
HSV-1 mediated delivery of anti-NgR shRNA resulted in a slight reduction in ngr 
mRNA levels in primary cultures of postnatal rat cerebellar granule neurons, but this 
effect was considerably less convincing than the results obtained for the anti-eGFP 
shRNA HSV-1 virus and can probably can accounted for by the selection of poor target 
sequence within the ngr mRNA. The extent of silencing activity achieved with the anti- 
NgR shRNA HSV-1 vector was not sufficient to warrant any specific in vitro or in vivo 
studies of ngr gene function
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That lentivirus was so much better in reducing eGFP expression by a stable cell line, than 
was HSV-1, is probably indicative of a finer level of optimisation of the target sequence 
rather than inherent differences in the level of U6 promoter activity in a viral context. An 
ideal way to confirm this would be to construct an HSV-1 vector using the same U6-anti- 
eGFP shRNA cassette as that employed in the construction of the lentivirus. This would 
enable a direct comparison of HSV-1 and lentivirus, which was not permitted here due to 
numerous differences in U6-shRNA construct specification, and would yield important 
data regarding the inherent suitability of HSV-1 for the expression of functional shRNA.
CONCLUSION
As a proof of principle, it has been demonstrated that HSV-1 is capable of delivering 
functionally active shRNA in vitro. The degree of silencing activity was not as great as 
that which has been achieved using other types of virus, but there appears to be plenty of 
scope for optimisation -  not least, in the selection of target sequences and the verification 
of their susceptibility to the activity of shRNA.
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Figure 8.1.
Construction of the U6-shRNA cassette. A, Schematic representation of the multiple 
cloning site (MCS) of pBluescript II SK+. B, Schematic representation of the MCS after 
the vector was linearized with Apal, blunted with T4 DNA polymerase, and religated to 
generate the vector pBluescript (Apal minus). C, The human U6 promoter was ligated 
into pBluescript (Apal minus) between Spel and Xhol, to generate the vector termed pBS 
U6. D, The appropriate short-hairpin RNA coding sequence was ligated between the 
Apal sites and Xhol sites of pBS U6. E, Schematic illustration of the generic U6-shRNA 
cassette. The design of the hairpins is such that the antisense strand is transcribed first, 
followed by a loop sequence, and then the sense strand. A polythymine tract serves as 
the transcription stop signal. The Bgtll site was incorporated for screening purposes.
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Figure 8.2.
Illustration of the theoretical structure of generic pR19 U6 derived shRNA. Dicer- 
mediated processing of this shRNA should result in the formation of conventional 
siRNA.
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Figure 8.3.
Construction of HSV-1 for the expression of shRNA. A, Schematic representation of the 
pR19 IRES eGFP shuttle vector. B, Schematic representation of pR19 (Spel minus) 
IRES eGFP. The vector was digested with EcoRV, and the backbone purified and 
religated to remove the superfluous Spe I site. C, The appropriate U6-shRNA cassette 
was excised from pBS U6 shRNA vector using Spe I and Xhol, and ligated into the 
corresponding sites within pR19 (Spel minus), to replace the IRES eGFP. The final 
shuttle vector was termed pR19 (Spel minus) U6 shRNA. D, Schematic representation of 
1764/4-/27in/RLl+ HSV-1 genomic DNA. ICP4 and virion host shut-off (vhs) genes 
have been deleted. A 12bp function-blocking mutation is present in the transactivating 
domain of VMW65 (also known as VP 16). E, Schematic representation of homologous 
recombination of the pR19 U6 shRNA cassette into the LAT regions of 1764/4- 
/27in/RLl+ HSV-1 DNA.
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Figure 8.4.
Southern blots for the identification of recombinant HSV-1. A, Blot for 1764/4- 
/27in/RL 1 +/pRl9 anti-eGFP shRNA viral DNA. B, Blot for 1764/4-/27in/RLl+/pR19 
anti-NgR shRNA viral DNA. In both cases, 1764/4-/27in/RLl+/pR19 eGFP WPRE viral 
DNA served as the negative control. All samples were digested with SpeI and Xhol. The 
membranes were probed with 3 2P-labelled U6  PCR product, and exposed to film 
overnight.
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Figure 8.5.
Construction of HSV-1 for the expression of anti-eGFP long-hairpin RNA. A, Schematic 
representation of the pR19 IRES eGFP shuttle vector. B, The antisense strand against 
eGFP, containing a 3' Clal site, was ligated between the Hindlll and Xhol sites. C, The 
sense eGFP strand was subsequently ligated between the Clal and Xhol sites. D, 
Southern blot for the identification of recombinant 1764/4-/27in/RLl+/pR19 anti-eGFP 
lhRNA. All samples were digested with Hindlll and Xhol. The gel-purified Clal-Xhol 
fragment of pR19 anti-eGFP lhRNA, which had been radiolabelled with P, was used in 
probing the membrane. The hybridized blot was exposed to film overnight. In 
recombinant samples, a single band was present at ~0.3Kb. The negative control sample, 
1764/4-/27in/RLl+/pR19 eGFP WPRE, exhibited a single strong band at ~4.5Kb due to 
the presence of the full-length eGFP coding sequence within a larger fragment of Hindlll 
and Xhol digested viral DNA. Plaques 2 was selected for the generation high titre viral 
stocks.
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Figure 8 .6 .
Stable eGFP-expressing BHK cells (clone 2B1). A, 2B1 cells viewed by fluorescence 
microscopy. B, Same microscopic field as in A, viewed under bright field illumination. 
Scale bars in A and B = 100pm. C, Histogram, obtained by flow cytometry, indicating 
the difference in fluorescence (FL1-H) between 2B1 cells (green outline) and standard 
BHK cells (black outline). The median fluorescence exhibited by the 2B1 clone is 103 
times greater than that of standard BHK cells. However, although 8 8 .6 % of 2B1 cells 
were found to be highly fluorescent, 7.6% were in the same FL1-H range as standard 
BHK cells and were considered non-fluorescent. The remaining 3.8% of 2B1 cells were 
classed as lowly fluorescent.
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Figure 8.7.
Transduction of 2B1 cells by HSV-1 vectors expressing hairpin constructs. A, 
fluorescence and bright field microscopy of mock, HSV-1 anti-eGFP shRNA, HSV-1 
anti-NgR shRNA and HSV-1 anti-eGFP lhRNA transduced 2B1 cells, 96 hours post 
transduction. B, Histogram, obtained by flow cytometry, showing the fluorescence 
profile of mock (pink outline), HSV-1 anti-eGFP shRNA (green outline), HSV-1 anti- 
NgR shRNA (blue outline), and HSV-1 anti-eGFP lhRNA (brown outline) transduced 
2B1 cells. C, Graph showing the median fluorescence, and standard error, of each 
sample relative to that of mock transduced cells. A one-tailed Student’s t-test was 
performed on the virus-transduced samples vs. the mock transduced sample. *** = 
p<0.005.
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Figure 8 .8 .
Transduction of 2B1 cells by lentivirus expressing hairpin constructs. A, Fluorescence 
and bright field microscopy of standard BHK cells, 48 hours after transduction with 
lentivirus expressing eGFP. This was performed to ensure that this type of lentivirus is 
able to transduce the BHK cell type at high efficiency. B, Schematic representation of 
the U6 -shRNA cassette present in both the anti-eGFP shRNA and anti-lacZ shRNA 
lentiviruses. C, Fluorescence and bright field microscopy of mock, LV anti-eGFP 
shRNA and LV anti-LacZ shRNA transduced 2B1 cells. Almost no fluorescent signal is 
detectable in LV anti-eGFP shRNA treated cells. D, Histogram, obtained by flow 
cytometry, of the fluorescence profile of mock (pink outline), LV anti-eGFP shRNA 
(green outline), and LV anti-LacZ shRNA (blue outline) transduced 2B1 cells. E, Graph 
showing the median fluorescence, and standard error, of each sample relative to that of 
mock transduced cells. A one-tailed Student’s t-test was performed on the virus- 
transduced samples vs. the mock transduced sample. ** = p<0 .0 1 .
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Figure 8.9.
Double transduction of BHK cells with HSV-1 to assess the effect of hairpin constructs 
on the onset of eGFP expression. On day 1, BHK cells were transduced with HSV-1 
anti-eGFP shRNA, HSV-1 anti-NgR shRNA or HSV-1 anti-lhRNA, or cells were mock 
transduced. On day 2, all samples, except one previously mock transduced sample, were 
transduced with HSV-1 eGFP WPRE. After 48 hours, samples were viewed by 
fluorescence and bright field microscopy (A), and were analysed by flow cytometry for 
their fluorescence profile (B). A composite of the histograms (C), obtained by flow 
cytometry, illustrates the difference in fluorescence profile the samples. The HSV-1 anti- 
eGFP shRNA (green outline) and the HSV-1 eGFP only (black outline) samples have 
similar fluorescence profiles, whereas those of both the HSV-1 anti-NgR shRNA (blue 
outline) and the HSV-1 anti-eGFP lhRNA (pink outline) samples appear to have more 
fluorescent profiles. This was confirmed by analysis of the median fluorescence values 
of each sample, relative to that of the HSV-1 eGFP only sample. The standard error is 
indicated. Whilst a slight reduction in fluorescence was observed in the HSV-1 anti- 
eGFP shRNA sample compared to the HSV-1 eGFP sample, there was greater than two­
fold increase in median fluorescence values in the HSV-1 anti-NgR shRNA and HSV-1 
anti-lhRNA samples compared to the same sample. The median fluorescence values 
obtained from mock transduced cells were 23% that of the HSV-1 eGFP only treated 
cells. This shows that the level of fluorescence in the control HSV-1 eGFP only sample 
was considerably lower than that of the clone 2B1 stable eGFP-expressing BHK cell line, 
where the magnitude of difference between fluorescence profiles of standard BHK cells 
and 2B1 cells was of the order of 103. A two-tailed Student’s t-test was performed on the 
double virus-transduced, and mock transduced sample, vs. the HSV-1 eGFP only 
transduced sample. * = p<0.05. *** = p<0.005.
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Figure 8.10.
Quantitative PCR for ngr in HSV-1 transduced rat P8  CGCs. The level of ngr in HSV-1 
anti-NgR shRNA, HSV-1 anti-eGFP shRNA and HSV-1 eGFP WPRE transduced 
samples is shown relative to that of mock transduced rat P8  CGCs. For each sample, the 
standard error of the mean is indicated. The largest reduction in ngr transcript levels was 
achieved with HSV-1 anti-NgR shRNA (20.8%), whereas HSV-1 anti-eGFP shRNA 
(9.3%) and HSV-1 eGFP WPRE (6.9%) each brought about a smaller non-specific 
reduction. A one-tailed Student’s t-test was performed on the virus-transduced samples 
vs. the untransduced sample. * = p<0.05.
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CHAPTER 9
General Discussion
The work reported in this thesis was principally focussed on the expression patterns of 
NgR and some of its ligands in the healthy and injured nervous system, and the 
development of HSV-1 based methods for disrupting NgR signalling. Individual 
experiments are discussed at the end of each chapter. Here, the major findings of these 
studies, and their implications, are discussed.
THE EXPRESSION OF NgR AND ITS LIGANDS 
ngr mRNA is Differentially Expressed by CNS Neurons
The fact that ngr mRNA is difficult to detect in many types of neuron appears to suggest 
that NgR signalling cannot be a general mechanism for preventing axonal regeneration in 
the CNS. Whilst the levels of NgR expression required to transduce inhibitory signals 
into growth cones have not been quantified, it is difficult to believe that neurons in 
regions such as the neostriatum, which show minimal ngr mRNA expression, are 
prevented from regenerating axons by NgR signalling. Indeed, this consideration would 
also apply to the neurons which give rise to most ascending axons in the spinal cord. The 
receptors which allow postnatal DRG neurons in vitro to show growth cone collapse in 
response to CNS myelin, MAG and Nogo are unknown, but in vivo DRG neurons do not 
behave as if they are affected by NgR ligands: their axons do not respond to treatment 
with the IN-1 antibody (Oudega et al., 2000), and when DRG neurons are transplanted 
into the dorsal columns of the spinal cord their axons regenerate rapidly in the white 
matter (Davies et al., 1997; Davies et al., 1999). It is not known whether the DRG 
neurons that survive isolation and transplantation and successfully regenerate axons 
express NgR, but ngr transcript expression has not been found to be subject to regulation 
in response to mechanical CNS injury (Chapter 3; Hunt et al., 2002b). Nonetheless,
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chemical injury, achieved through the administration of kainic acid, has been reported to 
induce changes in ngr expression in the hippocampus (Josephson et al., 2002; 
Mingorance et al., 2004).
ngr mRNA Expression Does Not Correlate with Lack of Regenerative Ability
In experiments in which peripheral nerve grafts were placed in the thalamus or 
cerebellum to stimulate regeneration of axons from intrinsic CNS neurons, it was found 
that regenerating cells did not alter their expression of ngr mRNA (Chapter 3; Hunt et al., 
2002b). The neurons that regenerated axons into grafts in the thalamus, those in the 
thalamic reticular nucleus, did not express ngr mRNA, but the neurons that regenerated 
axons into grafts in the cerebellum, those of the deep cerebellar nuclei, remained strongly 
ngr mRNA positive in the grafted animals.
That ngr expression does not correlate with an inability to regenerate axons into 
peripheral nerve grafts is perhaps not surprising since NgR, alone, is insufficient to 
transduce intracellular signals. This finding needs to be considered in the context of 
P7 5 NTR an£j LfNGO- 1  expression, which are both believed to be necessary for successful 
axon-inhibitory signalling (Fig. 9.1.A). Neurons that regenerate axons into peripheral 
nerve grafts to thalamus or cerebellum are known to upregulate pTS^ 11 (Vaudano et al., 
1998). The expression of LINGO-1 by TRN or DCN is yet to be reported following 
peripheral nerve graft to thalamus and cerebellum, respectively; however, from the 
observations of ngr expression in this experimental model, one would assume that it may 
be absent in the regenerating DCN neurons.
Expression of Nogo by Neurons is Correlated with High Regenerative Capacity
Nogo mRNA is strongly expressed by many, but not all, neurons as well as by 
oligodendrocytes. Curiously, nogo-66 and/or nogo-a mRNA expression seems to be 
particularly strong in neurons with a pronounced capacity for axonal regeneration, e.g. 
motor neurons, DRG neurons (Chapter 3; Huber et al., 2002; Hunt et al., 2002b), and 
intrinsic CNS neurons such as those in the thalamic reticular nucleus (Chapter 3; Hunt et 
al., 2002b) and deep cerebellar nuclei (Huber et al., 2002; Hunt et al., 2002b), which
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have greater than normal ability to regenerate axons into nerve grafts in the brain 
(Morrow et al., 1993; Chaisuksunt et al., 2000b; reviewed by Anderson et al., 1998; 
Anderson and Lieberman, 1999). This correlation is not absolute, since neocortical 
projection neurons express nogo mRNA (Chapters 3 and 4; Hunt et al., 2002b; Hunt et 
al., 2003), but do not regenerate axons into nerve grafts in the spinal cord (Richardson et 
al., 1984) although they have shown greater ability than any other neurons to regenerate 
within the CNS in experiments using antibodies to Nogo (see Chapter 1).
Nogo-A has been consistently detected by immunohistochemistry in the perikarya and/or 
axons of various classes of neuron during development, as well as in adulthood. For 
example, it is expressed in the developing axons of embryonic rat sciatic nerve (Chapter 
4; Wang et al., 2002c) and some developing CNS fibre tracts (Chapter 4; Tozaki et al., 
2002), and also in the axons of mature DRG and spinal motor neurons (Chapter 4). 
Intriguingly, Nogo-A continues to be expressed in axons undergoing regeneration in the 
injured sciatic nerve. Similarly, Nogo-A immunoreactive fibres, consistent with being 
sprouting neurites, are detectable in dorsal column lesion sites following a concomitant 
conditioning lesion to the sciatic nerve. It is difficult to explain why a putatively axon- 
inhibitory molecule should be present in developing and regenerating axons, but at least 
one other member of the reticulon family of proteins exhibits a similar developmental 
expression pattern (Kumamaru et al., 2004). One theory is that Nogo-A may act by 
contact suppression of interstitial axonal sprouting, thereby driving axonal growth in 
longitudinal arrays (Raisman, 2004).
In dissociated cultures of adult rat DRG neurons, and embryonic mouse and rat 
neocortical neurons, Nogo-A localizes to the central domain of the growth cone, axonal 
varicosities and branch points. Its appearance is strikingly similar to that of SCG10, a 
growth-associated protein which is involved in controlling microtubule dynamics 
(Lutjens et al., 2000). These findings indicate that neuronal Nogo-A may play a role in 
axonal growth or guidance in the developing or regenerating nervous system. 
Unfortunately, however, it is still not known whether Nogo-A is found at the surface of 
neurons.
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nogo mRNA Expression in Peripheral Nerve
Whether nogo mRNA is present in peripheral nerve trunks is of particular relevance to 
axonal regeneration. In the original papers describing Nogo there was a difference of 
opinion: Nogo-B mRNA was detected by Chen et al. (2000) in sciatic nerve, but no form 
of Nogo was found by GrandPre et al.(2000). In a further study the Northern blot 
showing Nogo-B in peripheral nerve was published again (Huber et al., 2002), and Nogo- 
A protein was apparently detectable in nerve (i.e. in DRG axons) by 
immunohistochemistry but not in Western Blots. In one of the studies presented here, no 
evidence for nogo mRNA in intact sciatic nerve was found using a nogo-66 probe, but 
strong expression in scattered cells within the distal stumps of nerves 3 days after injury 
was detected (Chapter 3; Hunt et al., 2002b). Since motor neurons and some sensory and 
sympathetic neurons express NgR, although not strongly, and DRG neurons are sensitive 
to Nogo in vitro, it would obviously be of interest to know what form of Nogo is 
expressed in damaged nerves, by which cells it is expressed, whether the upregulation is 
transient or prolonged, and whether the protein is reaching the cell surface.
Neuronal Expression of omgp mRNA
Like Nogo, OMgp was first identified as a myelin protein but has subsequently been 
found to be expressed by neurons (Chapter 6 ; Habib et al., 1998c). There is also 
evidence to suggest that OMgp may be acting as receptor in its own right -  although, a 
co-receptor is yet to be identified. Both findings are frequently overlooked (Wang et al., 
2002b; Filbin, 2003), and yet are of great significance since they infer a role for OMgp 
in the function of neurons by which it is expressed. Curiously, there is not yet any 
credible evidence that OMgp is in fact inhibitory to axonal regeneration in vivo.
Neuronal Co-Expression of Nogo-A, OMgp and NgR
The fact that Nogo and OMgp are co-expressed with NgR in adult neurons is intriguing. 
Of the major Nogo isoforms, there is convincing evidence (Josephson et al., 2001; Huber 
et al., 2002; Tozaki et al., 2002; Hunt et al., 2003) that Nogo-A is expressed in 
neocortical neurons, cerebellar deep nucleus neurons, Purkinje cells, DRG neurons, 
spinal motor neurons and others. Neocortical neurons and Purkinje cells have been
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shown to be responsive to the monoclonal antibody IN-1 (Zagrebelsky et al., 1998), 
which raises the possibility that reverse signalling is occurring through Nogo-A acting as 
a receptor. In addition, the expression of Nogo-A in growing axons of developing 
neurons (Chapter 4; Tozaki et al., 2002) raises some interesting issues. Many or most 
fibre tracts in the developing CNS, including the corticospinal tracts, take the form of 
bundles of neurites with little intervening space or glial cytoplasm (Guillery and Walsh, 
1987; Gorgels et al., 1989; Joosten et al., 1989; Williams et al., 1991). It has been 
presumed that the axons are not mutually inhibited because they do not express NgR or 
other Nogo receptors at that stage of development (Wang et al., 2002c). A 
comprehensive study of the onset of NgR expression in different neurons would be 
important for interpreting the role of NgR ligands in axonal growth. However, the most 
convincing study suggests that NgR is more widely expressed in the nervous system 
during development than it is in the adult (Josephson et al., 2002). Nogo-A might 
mediate inhibitory interactions between different fibre tracts, assuming that the onset of 
expression of NgR or other receptors varies (Fig. 9.1.B). It has long been known that 
neurite outgrowth can be inhibited by contact with other neurites (Kapfhammer and 
Raper, 1987), particularly their growth cones (Ivins and Pittman, 1989). Further studies 
of the expression of NgR, Nogo-A and OMgp in developing neurons are clearly required. 
However, no pathfinding errors or other developmental abnormalities of the corticospinal 
tract have been reported in the ngr null mutant mouse.
Neurons which Respond to IN-1 mAb In Vivo Express nogo and omgp mRNA 
A curious observation relating to the ability of IN-1 to enhance axonal regeneration, 
sprouting and growth-related gene expression is that the neurons which respond best- 
cerebral cortical neurons, cerebellar Purkinje cells and retinal ganglion cells - strongly 
express mRNAs for nogo-66 and omgp. In the cerebellum, Purkinje cells express both 
nogo-66 and omgp much more strongly than granule cells, whereas ngr is more strongly 
expressed by granule cells. Thus, in CNS neurons nogo-66 and omgp expression 
correlates even better with their ability to respond to IN-1 than does ngr expression, 
although NgR is a major receptor for oligodendrocyte Nogo. The possibility exists that 
IN-1 acts in vivo by binding to neuronal Nogo and directly stimulating neurons, rather
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than by dis-inhibiting them. The best in vitro evidence for such a mechanism comes from 
the work by Mingorance et al. (2004), who showed that neurite outgrowth from mouse P4 
cerebellar granule neurons, cultured on poly-L-omithine coated glass coverslips, was 
significantly enhanced by treatment with the IN-1 antibody. However, in opposition to 
this, Huber et al. (2002) cite unpublished experiments showing that IN-1 does not 
enhance neurite outgrowth from DRG neurons grown on laminin, and 
immunohistochemical evidence that IN-1 binds mainly to white matter (Huber et al., 
2002). In any event, the environment, surrounding neurons in vivo is complex and could 
influence the effects of IN-1 binding to neuronal surfaces. For example, it has been 
shown that NGF downregulates RhoA in growth cones attached to laminin but not in 
growth cones attached to LI (Liu et al., 2002c). IN-1 was originally reported to bind 
both the large and small myelin inhibitory proteins, suggesting that it recognises a site 
common to at least two forms of Nogo (although the possibility that NI-35 is a 
degradation product of the larger protein has not been ruled out), and would be expected 
to bind neuronal Nogo. Furthermore, Fournier et al. (2002) claim that IN-1 recognises 
other myelin proteins. If this is the case, it would be interesting to see if IN-1 binds 
OMgp, which is also expressed by cortical neurons.
POTENTIAL FOR HSV-1 MEDIATED DISRUPTION OF NgR- 
LIGAND INTERACTIONS
Genetically modified HSV-1 has been shown to permit widespread and effective gene 
delivery to the central nervous system (Lilley et al., 2001). Whilst a high level of HSV-1 
transgene expression can be readily achieved in many classes of neuron in vivo, there are 
some classes of neuron, e.g. neocortical neurons, in which the expression of the transgene 
has been found to be dependent on the strain of HSV-1, as well as its transgene promoter 
type (Dr. R.S. Coffin, personal communication). However, neocortical neurons in 
particular appear to be much more amenable to expression from less disabled stains of 
HSV-1, such as the 1764/4-/27in/RLl+ strain of virus that was used in the studies 
reported here.
320
The successful establishment of a platform for the expression of functional shRNA in 
HSV-1 (Chapter 8 ), albeit in need of optimisation, should permit new lines of 
experimental enquiry in the injured nervous system. Admittedly, the activity of such 
viruses has not yet been demonstrated in vivo but, on the assumption that their effect in 
vivo would be comparable to that in vitro, these HSV-1 vectors could potentially be of 
considerable value in the study of the NgR-ligand interactions in the injured nervous 
system. In terms of NgR silencing, the obvious targets for viral transduction would be 
either the neocortical projection neurons which give rise to the corticospinal tract, or the 
retinal ganglion cells which give rise to the optic nerve. Both classes of neuron strongly 
express ngr transcripts in vivo, and there is already some evidence that disruption of 
NgR-ligand interactions enhances axonal regeneration in both systems (Grandpre et al., 
2002; Fischer et al., 2004).
There are, of course, means of disrupting the NgR-ligand interaction without having to 
silence expression of the respective proteins. These include the use of dominant negative 
NgR (Fischer et al., 2004) or antagonist peptides such as NEP1-40 (Grandpre et al., 
2 0 0 2 ); both of which can be modified, where necessary, to be expressed from a viral 
vector such as HSV-1. It is unfortunate that in the study presented in this thesis (Chapter 
7), the expression of a tagged-secreted form of NEP1-40 from HSV-1 was relatively 
poor, both in vitro and in vivo. Almost certainly this anomaly was specific to the NEP1- 
40 transgene cassette, which may not have been compatible with HSV-1, owing to the 
relatively short transgene sequence. Nonetheless, the premise for the study, that targeted 
viral delivery of a secreted form of NEP1-40 to a corticospinal tract lesion site should 
elicit comparable if not more extensive axonal regeneration than was previously reported 
(Grandpre et al., 2002), still stands.
CONCLUDING REMARKS
Because NgR is a common receptor for at least three inhibitory ligands present in the 
CNS it is tempting to believe that it plays a significant role in blocking CNS regeneration.
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Nonetheless, numerous factors suggest caution in interpreting the importance of NgR 
signalling as an explanation for the overwhelming failure of regeneration in the CNS of 
adult mammals: the differential expression of NgR; its apparent dependence on both 
p75NTR and LINGO-1 for the formation of a functional receptor complex; the existence of 
other receptors for NgR ligands (Niederost et al., 2002); the absence of myelin, MAG and 
Nogo from lesion sites which are, nonetheless, demonstrably inhibitory; the ability of 
transplanted and otherwise suitably stimulated neurons to grow axons in white matter; 
and, of course, the absence of enhanced CNS axonal regeneration in the ngr null mutant 
mouse (Kim et al., 2003a).
Ultimately, however, there is still sufficient evidence to suggest that NgR signalling plays 
an important part in preventing the sprouting and regeneration of the axons of some 
classes of neuron, including neocortical neurons and retinal ganglion cells, and it remains 
a valid target for the study of CNS axonal regeneration in those systems.
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Figure 9.1.
A. Diagram illustrating the known distribution, theoretical interactions and signalling 
pathways of molecules involved in NgR-mediated growth cone collapse/neurite 
outgrowth inhibition in response to contact with oligodendrocyte membranes. The 
p75NTR low-affinity neurotrophin receptor acts as a co-receptor mediating signalling from 
NgR (Yamashita et al., 2002; Wang et al., 2002a), as does LINGO-1 (Mi et al., 2004). 
Note that the schematic representation of the MAG interaction with NgR is not true to the 
physical interaction, since experiments using a mutant form of the MAG protein, 
consisting only of a solubilized form of the first three immunoglobulin domains, show 
that it fails to bind to NgR (Domeniconi et al., 2002). There may be a separate receptor 
to the Nogo-A specific N-terminal domain, which in some models of Nogo conformation 
is exposed at the surface of oligodendrocytes. Other receptors (not shown) for NgR 
ligands may be expressed by the many neurons that lack NgR. Activation of the Rho A 
GTPase is believed to be downstream of NgR and Nogo-A signalling. We have 
speculated that the LIM kinase may be downstream of Rho A, as it is known to alter the 
cytoskeleton in response to Serna 3A signalling via Rho A (Aizawa et al., 2001). 
Neuronal Nogo and OMgp could have functions unrelated to growth cone collapse (e.g. 
OMgp expression by fibroblasts suppresses mitogenesis; (Habib et al., 1998a)). That 
Nogo and OMgp act as receptors remains a possibility. PKA = protein kinase A.
B. Diagram illustrating the possible interactions between NgR and its ligands on the 
surfaces of adjacent neurons. Although OMgp and Nogo were originally identified as 
myelin proteins they are strongly expressed by neurons. NgR may also bind to NgR in 
apposing membranes or within the same membrane (in cis) (Liu et al., 2002; Fournier et 
al., 2002). The roles of neuronal Nogo and OMgp are obscure but they are presumably 
capable of acting as inhibitory ligands for NgR on other neurons. These interactions may 
take place between growing or regenerating axons. Nogo-A is present in growing axons 
(Huber et al., 2002; Tozaki et al., 2002) and ngr mRNA is widely expressed during 
development (Josephson et al., 2002). Inhibitory interactions between adjacent axonal 
sprouts following injury may limit regeneration. Another physiological function in the 
adult may be to suppress sprouting at synapses.
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